WO2018144605A1 - Compounds for the treatment of hepatitis b virus infection - Google Patents

Compounds for the treatment of hepatitis b virus infection Download PDF

Info

Publication number
WO2018144605A1
WO2018144605A1 PCT/US2018/016243 US2018016243W WO2018144605A1 WO 2018144605 A1 WO2018144605 A1 WO 2018144605A1 US 2018016243 W US2018016243 W US 2018016243W WO 2018144605 A1 WO2018144605 A1 WO 2018144605A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
pharmaceutically acceptable
cycloalkyl
acceptable salt
inhibitors
Prior art date
Application number
PCT/US2018/016243
Other languages
French (fr)
Inventor
Evangelos Aktoudianakis
Eda Canales
Kevin S. Currie
Darryl Kato
Jiayao Li
John O. Link
Samuel E. Metobo
Roland D. Saito
Scott D. Schroeder
Nathan Shapiro
Winston C. Tse
Qiaoyin Wu
Original Assignee
Gilead Sciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences, Inc. filed Critical Gilead Sciences, Inc.
Priority to ES18704797T priority Critical patent/ES2988184T3/en
Priority to EP18704797.2A priority patent/EP3577118B1/en
Publication of WO2018144605A1 publication Critical patent/WO2018144605A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Definitions

  • the present invention relates to novel small molecule and related pharmaceutical compositions useful in the treatment of hepatitis B virus (HBV) infection.
  • HBV hepatitis B virus
  • HBV hepatitis B virus
  • HBV is an enveloped, partially double-stranded DNA virus.
  • Initial symptoms of infection may include vomiting, jaundice, lethargy, dark urine, and abdominal pain.
  • Chronic HBV infection can result in cirrhosis and liver cancer.
  • therapies can inhibit replication of the virus and minimize liver damage; however, there are no currently available therapies that can clear an HBV infection.
  • HBV surface antigen (HBsAg) is a protein located in the HBV envelope. It allows
  • HBsAg may also function as a tolerogen, suppressing immune elimination of infected cells. Total HBsAg loss and seroconversion are rarely achieved in chronically infected patients. Inhibiting HBsAg secretion and/or production is thus believed to be a strategy for the treatment of HBV infection, including chronic HBV infection.
  • A is a 4-7 membered cycloalkyl or heterocyclyl ring substituted with 0-8 R 5 groups;
  • R 1 is H or halogen;
  • R 2 is selected from the group consisting of halogen, R 2a O, C 1-6 alkyl, C 3-lo cycloalkyl, 3- 7 membered heterocyclyl, -NR a R b , -S(0)o-2R a , or -CN, wherein each Ci- 6 alkyl, C 3-10 cycloalkyl or 3-7 membered heterocyclyl is optionally substituted with 1 -5 R 20 groups;
  • R 2a is selected from the group consisting of H, C 3 - 6 cycloalkyl or Ci- alkyl, wherein each C 3 -6 cycloalkyl or Ci- alkyl is optionally substituted with 1-5 R 20 groups;
  • R 3 is selected from the group consisting of R 3a O-, Ci- alkyl, 5-10 membered heteroaryl, 3-12 membered heterocyclyl, C 2 _6 alkenyl, C2-6 alkynyl, Ce-w aryl, C 3-lo cycloalkyl, -NR a R b , and -S(0)o-2R a , wherein each Ci- alkyl, 5-10 membered heteroaryl, 3-12 membered
  • heterocyclyl C2-6 alkenyl, C2-6 alkynyl, Ce-w aryl, or C 3-lo cycloalkyl is optionally substituted with 1-5 R 20 groups;
  • R 3a is selected from the group consisting of H, C 1-6 alkyl, Ci- 5-10 membered heteroaryl, 3- 12 membered heterocyclyl, Ce-w aryl and C 3-lo cycloalkyl, wherein each Ci-6 alkyl, Ci- alkoxyC ⁇ alkyl, 5-10 membered heteroaryl, 3-12 membered heterocyclyl, Ce-w aryl and C 3-lo cycloalkyl is optionally substituted with 1-5 R 20 groups;
  • R 4 is H or halogen
  • each R 5 is independently selected from the group consisting of Ci- alkyl, C 1-6 alkoxy, C 2- 6 alkenyl, C 2 ⁇ alkynyl, -NR a R b , halogen, -C(0)R a , -C(0)OR a , -C(0)NR a R b , -OC(0)NR a R b , - NR a C(0)R b , -NR a C(0)OR b , -S(O) 0-2 R a , -S(0) 2 NR a R b , -NR a S(0) 2 R b , -OR a , C 6 . 10 aryl, C 3 .
  • each R 20 is independently selected from the group consisting Ci ⁇ alkyl, C3-10 cycloalkyl, Ci_6 alkoxy, 3-12 membered heterocyclyl, C 6- io aryl, 5-10 membered heteroaryl, halogen, oxo, - OR a , -C(0)R a , -C(0)OR a , -C(0)NR a R b , -OC(0)NR a R b , -NR a R b , -NR a C(0)R b , -NR a C(0)OR b , -S(0)o -2 R a , -S(0) 2 NR a R b , -NR a S(0) 2 R b , -N 3 , -CN, or -N0 2 , or two R 20 groups appended to the same group can join together to form a fused, spiro or bridged C3-10 cylcloalkyl or 3-12 member
  • each R 21 is independently selected from the group consisting Ci_ 6 alkyl, C3-10 cycloalkyl, Ci-6 alkoxy, 3-12 membered heterocyclyl, C6-10 aryl, 5-10 membered heteroaryl, hydroxyl, amino, Ci ⁇ alkylamino, -CN or halogen.
  • Another embodiment provides a compound of Formula (II):
  • Z 1 is a bond, O, NR a or CR 5e R 5f ;
  • R 2 is selected from the group consisting of halogen, R 2a O, Ci-6 alkyl, or -CN, wherein alkyl is optionally substituted with 1-3 R 20 groups;
  • R a is selected from the group consisting of H, C3-6 cycloalkyl or Ci ⁇ alkyl, wherein each C3-6 cycloalkyl or Ci ⁇ alkyl is optionally substituted with 1-3 R 20 groups;
  • R 3 is selected from and C3- 8 cycloalkoxyCi ⁇ alkoxy, wherein each Ci-6 alkoxy, and C3- 8 cycloalkoxyCi- 6 alkoxy is optionally substituted with halo;
  • each of R 5a , R 5b , R 5c , R 5d , R 5e , R 5f R 5g and R 5h are independently selected from the group consisting of H, alkyl, alkoxy, C 2-6 alkenyl, C 2-6 alkynyl, -NR a R b , halogen, C(0)R a , - C(0)OR a , -C(0)NR a R b , -OC(0)NR a R b , -NR a C(0)R b , -NR a C(0)OR b , -S(O) 0-2 R a , - S(0) 2 NR a R b , -NR a S(0) 2 R b , -N 3 , -CN, -N0 2 , -OR a , C 6 .
  • each Ci ⁇ alkyl, Ci ⁇ alkoxy, C2-6 alkenyl, C2-6 alkynyl, Ce- ⁇ aryl, C3-1 0 cycloalkyl, 5-10 membered heteroaryl and 3-12 membered heterocyclyl is optionally substituted with 1-5 R 20 groups;
  • each R 20 is independently selected from the group consisting Ci ⁇ alkyl, C3-1 0 cycloalkyl, Ci_6 alkoxy, 3-12 membered heterocyclyl, C 6- io aryl, 5-10 membered heteroaryl, halogen, oxo, - OR a , -C(0)R a , -C(0)OR a , -C(0)NR a R b , -OC(0)NR a R b , -NR a R b , -NR a C(0)R b , -NR a C(0)OR b , -S(0)o -2 R a , -S(0) 2 NR a R b , -NR a S(0) 2 R b , -N 3 , -CN, or -N0 2 , wherein each d-s alkyl, C 3 -1 0 cycloalkyl, Ci ⁇ alkoxy, 3-12 membered heterocyclyl, C
  • each R 21 is independently selected from the group consisting Ci ⁇ alkyl, Ci- 6 haloalkyl, C 3 -1 0 cycloalkyl, Ci ⁇ alkoxy, 3-12 membered heterocyclyl, C6-1 0 aryl, 5-10 membered heteroaryl, hydroxyl, amino, Ci ⁇ alkylamino, -CN or halogen;
  • each R 21 is independently selected from the group consisting Ci_ 6 alkyl, C 3-10 cycloalkyl, C 1-6 alkoxy, 3-12 membered heterocyclyl, Ce-w aryl, 5-10 membered heteroaryl, hydroxyl, amino, Ci ⁇ alkylamino, -CN or halogen;
  • a pharmaceutical composition comprising a compound of Formula (I) or (II), or Formula (la), (lb) or (Ila) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
  • the pharmaceutical composition further comprises one or more additional therapeutic agents.
  • a method of inhibiting the production and/or secretion of HBsAg in an individual e.g. a human infected with HBV comprising
  • the human is chronically infected with HBV.
  • a method of treating or preventing a HBV infection comprising administering to an individual (e.g. a human) in need thereof a
  • the methods further comprise administering one or more additional therapeutic agents.
  • a compound of Formula (I) or (II), or Formula (la), (lb) or (Ila), or a pharmaceutically acceptable salt thereof, for use in medical therapy is provided.
  • a compound of Formula (I) or (II), or Formula (la), (lb) or (Ila), or a pharmaceutically acceptable salt thereof, for use in treating or preventing HBV infection is provided.
  • the use of a compound of Formula (I) or (II), or Formula (la), (lb) or (Ila), or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for treating or preventing HBV infection is provided.
  • Kits comprising a compound of Formula (I) or (II), or Formula (la), (lb) or (Ila), or pharmaceutically acceptable salts thereof, or pharmaceutical compositions of the foregoing are also provided.
  • Articles of manufacture comprising a unit dose of the compounds, or pharmaceutically acceptable salts thereof, of the foregoing are also provided.
  • Methods of preparing compounds of the present disclosure are also provided.
  • FIG. 1 is a series of graphs plotting mean branch point count per cell as a function of concentration of compound, where the compound is Vincristine, RG783/R07020332, and compound 73.
  • FIG. 2 is a series of graphs plotting mean neurite total length per cell as a function of concentration of compound, where the compound is Vincristine, RG783/R07020332, and compound 73.
  • alkyl is a linear or branched saturated monovalent hydrocarbon.
  • alkyl groups include, but are not limited to, methyl (Me, -CH 3 ), ethyl (Et,
  • Amino refers to -NH 2 . Amino groups may also be substituted as described herein, such as with alkyl, carbonyl or other amino groups.
  • alkylamino refers to an amino group substituted with one or two alkyl substituents (e.g. dimethylamino or propylamino).
  • halo'Or “halogen” as used herein refers to fluoro (-F), chloro (-C1), bromo (- Br) and iodo (-1).
  • haloalkyl refers to an alkyl as defined herein, wherein one or more hydrogen atoms of the alkyl are independently replaced by a halogen substituent, which may be the same or different. For example, is a Ci- 6 alkyl wherein one or more of the hydrogen atoms of the have been replaced by a halo substituent.
  • haloalkyl groups include, but are not limited to, fluoromethyl, fluorochloromethyl,
  • alkoxy refers to a radical of the formula -OR x where R x is an alkyl radical as defined above.
  • alkoxy include methoxy, ethoxy, propoxy, and butoxy.
  • haloalkoxy refers to a radical of the formula -OR x wherein R x is an alkyl radical as defined above, and wherein one or more hydrogens on the alkyl radical are replaced with halogen.
  • alkoxyalkoxy and “haloalkoxyalkoxy,” refer to an alkoxy radical that is substituted with alkoxy or haloalkoxy, respectively.
  • alkoxyalkoxy a non- limiting example of “alkoxyalkoxy”
  • Alkenyl refers to any group derived from a straight or branched hydrocarbon with at least one carbon-carbon double bond. Alkenyl groups include, but are not limited to, ethenyl (vinyl), propenyl (allyl), 1-butenyl, 1,3-butadienyl, and the like. Unless otherwise specified, an alkenyl group has from 2 to 10 carbon atoms, for example from 2 to 6 carbon atoms, for example from 2 to 4 carbon atoms.
  • Alkynyl refers to any group derived from a straight or branched hydrocarbon with at least one carbon-carbon triple bond and includes those groups having one triple bond and one double bond.
  • alkynyl groups include, but are not limited to, ethynyl (-C ⁇ CH), propargyl (-CH 2 C ⁇ CH), (£)-pent-3-en-l-ynyl, and the like.
  • an alkynyl group has from 2 to 10 carbon atoms, for example from 2 to 6 carbon atoms, for example from 2 to 4 carbon atoms.
  • Aryl refers to any group derived from one or more aromatic rings, that is, a single aromatic ring, a bicyclic or a multicyclic ring system.
  • Aryl groups include, but are not limited to, those groups derived from acenaphthylene, anthracene, azulene, benzene, chrysene, a cyclopentadienyl anion, naphthalene, fluoranthene, fluorene, indane, perylene, phenalene, phenanthrene, pyrene and the like. Unless otherwise specified, an aryl group has from 5 to 20 carbon atoms.
  • Arylalkyl refers to any combination aryl group and an alkyl group.
  • Arylalkyl groups include, but are not limited to, those groups derived from benzyl, tolyl, dimethylphenyl, 2-phenylethan-l-yl, 2-naphthylmethyl, and the like.
  • An arylalkyl group comprises from 6 to 30 carbon atoms, for example the alkyl group can comprise from 1 to 10 carbon atoms and the aryl group can comprise from 5 to 20 carbon atoms.
  • Bridged refers to a ring fusion wherein non-adjacent atoms on a ring are joined by a divalent substituent, such as an alkylenyl or heteroalkylenyl group or a single heteroatom.
  • Quinuclidinyl and admantanyl are examples of bridged ring systems.
  • cycloalkyl or “carbocycle” as used herein refers to a saturated or partially saturated all carbon ring radical.
  • a cycloalkyl group can have one or more cyclic rings and includes fused and bridged groups that are fully saturated or partially unsaturated. Examples include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, adamantyl, methylcycloproyl (cyclopropylmethyl), ethylcyclopropyl, cyclohexenyl and the like. Another example includes C 5-7 cycloakenyl.
  • cycloalkoxy refers to a cycloalkyl group as defined herein appended directly to an -O- or to an alkoxy group as defined herein.
  • examples of cycloalkoxy groups include cyclopropyloxy, cyclobutylmethoxy, and cyclopentyloxyethyl.
  • Heteroaryl refers to mono or multi cyclic aryl group in which one or more of the aromatic carbon atoms (and any associated hydrogen atoms) are independently replaced with the same or different heteroatom or heteroatomic group, as defined above. Multicyclic ring systems are included in heteroaryl and may be attached at the ring with the heteroatom or the aryl ring.
  • Heteroaryl groups include, but are not limited to, groups derived from acridine, benzoimidazole, benzothiophene, benzofuran, benzoxazole, benzothiazole, carbazole, carboline, cinnoline, furan, imidazole, imidazopyridine, indazole, indole, indoline, indolizine, isobenzofuran, isochromene, isoindole, isoindoline, isoquinoline, isothiazole, isoxazole, naphthyridine, oxadiazole, oxazole, perimidine, phenanthridine, phenanthroline, phenazine, phthalazine, pteridine, purine, pyran, pyrazine, pyrazole, pyridazine, pyridine, pyridone, pyrimidine, pyrrole, pyrrolizin
  • Heterocycle refers to a saturated or partially unsaturated non-aromatic ring or a partially non-aromatic multiple-ring system with at least one heteroatom or heteroatomic group, as defined above.
  • Heterocycles include, but are not limited to, groups derived from azetidine, aziridine, imidazolidine, morpholine, oxirane (epoxide), oxetane, piperazine, piperidine, pyrazolidine, piperidine, pyrrolidine, pyrrolidinone,
  • Heterocyclyl groups also include partially unsaturated ring systems containing one or more double bonds, including fused ring systems with one aromatic ring and one non-aromatic ring, but not fully aromatic ring systems. Examples include dihydroquinolines, e.g. 3,4- dihydroquinoline, dihydroisoquinolines, e.g.
  • Heterocycle groups may have 3-12 members, or 3-10 members, or 3-7 members, or 5-6 members.
  • substituent combinations used herein include: Ci ⁇ alkylamiocarbonyl (e.g. CH 3 CH 2 NHC(0)-) C w alkoxycarbonyl (e.g. CH 3 0-C(0)-), 5-7 membered alkyl (e.g. piperazinyl-CH 2 -), C 1-6 alkylsulfonyl-5-7 membered heterocyclyl (e.g. CH 3 S(0)2-morpholinyl-), 5-7 membered heterocyclyl Ci ⁇ alkoxy (e.g.
  • pyrrolidinyl-O- 5-7 membered heterocyclyloxy, (4-7 membered heterocyclyl)-4-7 membered heterocyclyl (e.g. oxetanyl-pyrrolidinyl-), C3-6 cycloalkylaminocarbonyl (e.g. cyclopropyl-NH- C(O)-), 5-7 membered heterocyclyl-C 2 -6 alkynyl (e.g. N-piperazinyl-CH 2 C ⁇ CCH 2- ), and C 6-1 o arylaminocarbonyl (e.g. phenyl-NH-C(O)-).
  • C3-6 cycloalkylaminocarbonyl e.g. cyclopropyl-NH- C(O)-
  • 5-7 membered heterocyclyl-C 2 -6 alkynyl e.g. N-piperazinyl-CH 2 C ⁇ CCH 2-
  • Spiro refers to a ring substituent which is j oined by two bonds at the same carbon atom.
  • examples of spiro groups include 1 ,1 -diethylcyclopentane, dimethyl-dioxolane, and 4- benzyl-4-methylpiperidine, wherein the cyclopentane and piperidine, respectively, are the spiro substituents.
  • substituents (R-groups) When substituents (R-groups) are taken together (e.g. when R 7 and R 8 are taken together) they may be taken from the same point of attachment to form a spiro ring.
  • “Fused” refers to a ring substituent which is j oined by two bonds at adj acent carbon atoms, such as decahydronaphthalene. "Bridged” refers to a ring substituent which is j oined by two bonds at the non-adj acent carbon atoms, such as a quinuclidine.
  • treatment is an approach for obtaining beneficial or desired results.
  • beneficial or desired results include, but are not limited to, alleviation of a symptom and/or diminishment of the extent of a symptom associated with a disease or condition.
  • treatment includes one or more of the following: a) inhibiting the disease or condition (e.g. , decreasing one or more symptoms resulting from the disease or condition, and/or diminishing the extent of the disease or condition); b) slowing or arresting the development of one or more symptoms associated with the disease or condition (e.g.
  • prevention refers to a regimen that protects against the onset of the disease or disorder such that the clinical symptoms of the disease do not develop.
  • prevention relates to administration of a therapy (e.g., administration of a therapeutic substance) to a subject before signs of the disease are detectable in the subject (e.g. , administration of a therapeutic substance to a subject in the absence of detectable infectious agent (e.g. , virus) in the subject).
  • the subject may be an individual at risk of developing the disease or disorder, such as an individual who has one or more risk factors known to be associated with development or onset of the disease or disorder.
  • the term "preventing HBV infection” refers to administering to a subj ect who does not have a detectable HBV infection an anti-HBV therapeutic substance. It is understood that the subject for anti-HBV preventative therapy may be an individual at risk of contracting the HBV virus.
  • the term "therapeutically effective amount” or “effective amount” refers to an amount that is effective to elicit the desired biological or medical response, including the amount of a compound that, when administered to a subject for treating a disease, is sufficient to effect such treatment for the disease.
  • the effective amount will vary depending on the particular compound, and characteristics of the subject to be treated, such as age, weight, etc.
  • the effective amount can include a range of amounts.
  • an effective amount may be in one or more doses, i.e. , a single dose or multiple doses may be required to achieve the desired treatment endpoint.
  • An effective amount may be considered in the context of administering one or more therapeutic agents, and a single agent may be considered to be given in an effective amount if, in conjunction with one or more other agents, a desirable or beneficial result may be or is achieved.
  • Suitable doses of any co-administered compounds may optionally be lowered due to the combined action (e.g. , additive or synergistic effects) of the compounds.
  • co-administration includes administration of unit dosages of the compounds disclosed herein before or after administration of unit dosages of one or more additional therapeutic agents, for example, administration of the compound disclosed herein within seconds, minutes, or hours of the administration of one or more additional therapeutic agents.
  • a unit dose of a compound of the present disclosure is administered first, followed within seconds or minutes by administration of a unit dose of one or more additional therapeutic agents.
  • a unit dose of one or more additional therapeutic agents is administered first, followed by administration of a unit dose of a compound of the present disclosure within seconds or minutes.
  • a unit dose of a compound of the present disclosure is administered first, followed, after a period of hours (e.g.
  • a unit dose of one or more additional therapeutic agents is administered first, followed, after a period of hours (e.g. , 1-12 hours), by administration of a unit dose of a compound of the present disclosure.
  • “Pharmaceutically acceptable” or “physiologically acceptable” refer to compounds, salts, compositions, dosage forms and other materials which are suitable for veterinary or human pharmaceutical use.
  • compositions described herein may be prepared and/or formulated as pharmaceutically acceptable salts.
  • Pharmaceutically acceptable salts are non-toxic salts of a free base form of a compound that possesses the desired pharmacological activity of the free base. These salts may be derived from inorganic or organic acids or bases. For example, a compound that contains a basic nitrogen may be prepared as a pharmaceutically acceptable salt by contacting the compound with an inorganic or organic acid.
  • Non-limiting examples of pharmaceutically acceptable salts include sulfates, pyrosulfates, bisulfates, sulfites, bisulfites, phosphates, monohydrogen-phosphates, dihydrogenphosphates, metaphosphates, pyrophosphates, chlorides, bromides, iodides, acetates, propionates, decanoates, caprylates, acrylates, formates, isobutyrates, caproates, heptanoates, propiolates, oxalates, malonates, succinates, suberates, sebacates, fumarates, maleates, butyne-l,4-dioates, hexyne-l,6-dioates, benzoates, chlorobenzoates, methylbenzoates, dinitrobenzoates, hydroxybenzoates, methoxybenzoates, phthalates, sulfonates, methylsulfonates, propylsulf
  • Non-limiting examples of "pharmaceutically acceptable salts” of the compounds disclosed herein also include salts derived from an appropriate base, such as an alkali metal (for example, sodium, potassium), an alkaline earth metal (for example, magnesium), ammonium and NX 4 + (wherein X is C 1-C4 alkyl). Also included are base addition salts, such as sodium or potassium salts.
  • an appropriate base such as an alkali metal (for example, sodium, potassium), an alkaline earth metal (for example, magnesium), ammonium and NX 4 + (wherein X is C 1-C4 alkyl).
  • base addition salts such as sodium or potassium salts.
  • stereoisomer refers to a compound made up of the same atoms bonded by the same bonds but having different three-dimensional structures, which are not interchangeable.
  • the present disclosure contemplates various stereoisomers and mixtures thereof and includes “enantiomers”, which refers to two stereoisomers whose molecules are non-superimposable mirror images of one another.
  • scalemic mixture is a mixture of stereoisomers at a ratio other than 1 : 1.
  • a “tautomer” refers to a proton shift from one atom of a molecule to another atom of the same molecule.
  • the present disclosure includes tautomers of any said compounds.
  • a “solvate” is formed by the interaction of a solvent and a compound. Solvates of salts of the compounds described herein are also provided. Hydrates of the compounds described herein are also provided.
  • prodrug as used herein is a biologically inactive derivative of a drug upon administration to the human body is converted to the biologically active parent drug according to some chemical or enzymatic pathway.
  • A is a 4-7 membered cycloalkyl or heterocyclyl ring substituted with 0-8 R 5 groups;
  • R 1 is H or halogen;
  • R 2 is selected from the group consisting of halogen, R 2a O, C 1-6 alkyl, C 3-lo cycloalkyl, 3- 7 membered heterocyclyl, -NR a R b , -S(O) 0- 2R a , or -CN, wherein each Ci -6 alkyl, C 3-10 cycloalkyl or 3-7 membered heterocyclyl is optionally substituted with 1 -5 R 20 groups;
  • R 2a is selected from the group consisting of H, C 3 - 6 cycloalkyl or Ci- alkyl, wherein each C 3 -6 cycloalkyl or Ci- alkyl is optionally substituted with 1-5 R 20 groups;
  • R 3 is selected from the group consisting of R 3a O-, Ci- alkyl, 5-10 membered heteroaryl, 3-12 membered heterocyclyl, C 2 _6 alkenyl, C2-6 alkynyl, Ce-w aryl, C 3-lo cycloalkyl, -NR a R b , and -S(0)o-2R a , wherein each Ci- alkyl, 5-10 membered heteroaryl, 3-12 membered
  • heterocyclyl C2-6 alkenyl, C2-6 alkynyl, Ce-w aryl, or C 3-lo cycloalkyl is optionally substituted with 1-5 R 20 groups;
  • R 3a is selected from the group consisting of H, C 1-6 alkyl, Ci- 5-10 membered heteroaryl, 3- 12 membered heterocyclyl, Ce-w aryl and C 3-lo cycloalkyl, wherein each Ci-6 alkyl, Ci- alkoxyC ⁇ alkyl, 5-10 membered heteroaryl, 3-12 membered heterocyclyl, Ce-w aryl and C 3-lo cycloalkyl is optionally substituted with 1-5 R 20 groups;
  • R 4 is H or halogen
  • each R 5 is independently selected from the group consisting of Ci- alkyl, C 1-6 alkoxy, C 2- 6 alkenyl, C 2 ⁇ alkynyl, -NR a R b , halogen, -C(0)R a , -C(0)OR a , -C(0)NR a R b , -OC(0)NR a R b , - NR a C(0)R b , -NR a C(0)OR b , -S(O) 0-2 R a , -S(0) 2 NR a R b , -NR a S(0) 2 R b , -OR a , C 6 . 10 aryl, C 3 .
  • each Ci ⁇ alkyl, Ci-6 alkoxy, C 2- 6 alkenyl, C2-6 alkynyl, Ce- ⁇ aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl and 3-12 membered heterocyclyl is optionally substituted with 1 -5 R 20 groups;
  • each R a and R b is independently selected from the group consisting H; or C i ⁇ alkyl, C 3- i 0 cycloalkyl, 3-12 membered heterocyclyl, C 6- io aryl, 5-10 membered heteroaryl, each of which is optionally substituted with from one to five R 21 groups; or R a and R b together with the atoms to which they are attached form a 3-12 membered heterocyclyl optionally substituted with one to five R 21 groups;
  • each R 20 is independently selected from the group consisting Ci ⁇ alkyl, C3-10 cycloalkyl, Ci-6 alkoxy, 3-12 membered heterocyclyl, C6-10 aryl, 5-10 membered heteroaryl, halogen, oxo, - OR a , -C(0)R a , -C(0)OR a , -C(0)NR a R b , -OC(0)NR a R b , -NR a R b , -NR a C(0)R b , -NR a C(0)OR b , -S(0)o- 2 R a , -S(0) 2 NR a R b , -NR a S(0) 2 R b , -N 3 , -CN, or -N0 2 , or two R 20 groups appended to the same group can j oin together to form a fused, spiro or bridged C3-10 cylcloalkyl or 3-12
  • each R 21 is independently selected from the group consisting Ci.
  • A is a 4-7 membered cycloalkyl or heterocyclyl ring substituted with 0-8 R 5 groups;
  • R 3 is selected from the group consisting of R 3a O-, Ci ⁇ alkyl, 5-10 membered heteroaryl, 3-12 membered heterocyclyl, C 2 _6 alkenyl, C2-6 alkynyl, Ce-w aryl, C3-10 cycloalkyl, -NR a R b , and -S(0)o-2R a , wherein each Ci ⁇ alkyl, 5-10 membered heteroaryl, 3-12 membered
  • heterocyclyl C2-6 alkenyl, C2-6 alkynyl, Ce-w aryl, or C 3-lo cycloalkyl is optionally substituted with 1-5 R 20 groups;
  • R 3a is selected from the group consisting of H, C 1-6 alkyl, 5-10 membered heteroaryl, 3- 12 membered heterocyclyl, Ce-w aryl and C 3-10 cycloalkyl, wherein each Ci_6 alkyl, alkoxyC ⁇ alkyl, 5-10 membered heteroaryl, 3-12 membered heterocyclyl, C 6-1 o aryl and C 3-lo cycloalkyl is optionally substituted with 1-5 R 20 groups;
  • each R a and R b is independently selected from the group consisting H; or alkyl, C 3-lo cycloalkyl, 3-12 membered heterocyclyl, Ce-w aryl, 5-10 membered heteroaryl, each of which is optionally substituted with from one to five R 21 groups; or R a and R b together with the atoms to which they are attached form a 3-12 membered heterocyclyl optionally substituted with one to five R 21 groups;
  • each R 20 is independently selected from the group consisting Ci ⁇ alkyl, C 3-lo cycloalkyl, Ci-6 alkoxy, 3-12 membered heterocyclyl, Ce-w aryl, 5-10 membered heteroaryl, halogen, oxo, - OR a , -C(0)R a , -C(0)OR a , -C(0)NR a R b , -OC(0)NR a R b , -NR a R b , -NR a C(0)R b , -NR a C(0)OR b , -S(0)o -2 R a , -S(0) 2 NR a R b , -NR a S(0) 2 R b , -N 3 , -CN, or -N0 2 , or two R 20 groups appended to the same group can j oin together to form a fused, spiro or bridged C 3-lo cylcloalkyl or
  • each R 21 is independently selected from the group consisting Ci_ 6 alkyl, C 3-lo cycloalkyl, C 1-6 alkoxy, 3-12 membered heterocyclyl, Ce-w aryl, 5-10 membered heteroaryl, hydroxyl, amino, Ci ⁇ alkylamino, -CN or halogen.
  • the present disclosure provides compounds of Formula (lb):
  • A is a 4-7 membered cycloalkyl or heterocyclyl ring substituted with 0-8 R 5 groups;
  • X is CH or N
  • R 1 is H or halogen
  • R 2 is selected from the group consisting of halogen, R 2a O, C 1-6 alkyl, C 3-lo cycloalkyl, 3- 7 membered heterocyclyl, -NR a R b , -S(0)o-2R a , or -CN, wherein each Ci- 6 alkyl, C 3-10 cycloalkyl or 3-7 membered heterocyclyl is optionally substituted with 1 -5 R 20 groups;
  • R 2a is selected from the group consisting of H, C 3 - 6 cycloalkyl or Ci ⁇ alkyl, wherein each C 3 -6 cycloalkyl or Ci ⁇ alkyl is optionally substituted with 1-5 R 20 groups;
  • R 3 is selected from the group consisting of R 3a O-, Ci ⁇ alkyl, 5-10 membered heteroaryl, 3-12 membered heterocyclyl, C 2 _6 alkenyl, C2-6 alkynyl, Ce- ⁇ aryl, C 3-lo cycloalkyl, -NR a R b , and -S(0)o-2R a , wherein each C -5 alkyl, 5-10 membered heteroaryl, 3-12 membered
  • heterocyclyl C2-6 alkenyl, C2-6 alkynyl, Ce- ⁇ aryl, or C 3-lo cycloalkyl is optionally substituted with 1-5 R 20 groups;
  • R 3a is selected from the group consisting of H, C 1-6 alkyl, C -5 5-10 membered heteroaryl, 3- 12 membered heterocyclyl, Ce- ⁇ aryl and C 3-lo cycloalkyl, wherein each Ci ⁇ 5 alkyl, alkoxyC ⁇ alkyl, 5-10 membered heteroaryl, 3-12 membered heterocyclyl, C 6- io aryl and C 3-lo cycloalkyl is optionally substituted with 1-5 R 20 groups;
  • R 4 is H or halogen
  • each R 5 is independently selected from the group consisting of Ci ⁇ alkyl, C 1-6 alkoxy, C 2- 6 alkenyl, C 2 ⁇ alkynyl, -NR a R b , halogen, -C(0)R a , -C(0)OR a , -C(0)NR a R b , -OC(0)NR a R b , - NR a C(0)R b , -NR a C(0)OR b , -S(O) 0-2 R a , -S(0) 2 NR a R b , -NR a S(0) 2 R b , -OR a , C 6 . 10 aryl, C 3 .
  • each R a and R b is independently selected from the group consisting H; or Ci ⁇ alkyl, C3 0 cycloalkyl, 3-12 membered heterocyclyl, C6-10 aryl, 5-10 membered heteroaryl, each of which is optionally substituted with from one to five R 21 groups; or R a and R b together with the atoms to which they are attached form a 3-12 membered heterocyclyl optionally substituted with one to five R 21 groups;
  • each R 20 is independently selected from the group consisting Ci ⁇ alkyl, C3-10 cycloalkyl, Ci-6 alkoxy, 3-12 membered heterocyclyl, C6-10 aryl, 5-10 membered heteroaryl, halogen, oxo, - OR a , -C(0)R a , -C(0)OR a , -C(0)NR a R b , -OC(0)NR a R b , -NR a R b , -NR a C(0)R b , -NR a C(0)OR b , -S(0)o -2 R a , -S(0) 2 NR a R b , -NR a S(0) 2 R b , -N 3 , -CN, or -N0 2 , or two R 20 groups appended to the same group can join together to form a fused, spiro or bridged C3-10 cylcloalkyl or 3-12 membered hetero
  • each R 21 is independently selected from the group consisting Ci. 6 alkyl, C3-10 cycloalkyl, Ci-6 alkoxy, 3-12 membered heterocyclyl, C6-10 aryl, 5-10 membered heteroaryl, hydroxyl, amino, Ci ⁇ alkylamino, -CN or halogen.
  • A is a 4-7 membered cycloalkyl or heterocyclyl ring substituted with 0-8 R groups;
  • R 1 is H or halogen;
  • R 3 is selected from the group consisting of R 3a O-, Ci ⁇ alkyl, 5-10 membered heteroaryl, 3-12 membered heterocyclyl, C 2 _6 alkenyl, C2-6 alkynyl, Ce-w aryl, C3-10 cycloalkyl, -NR a R b , and -S(0)o-2R a , wherein each C -5 alkyl, 5-10 membered heteroaryl, 3-12 membered
  • heterocyclyl C2-6 alkenyl, C2-6 alkynyl, Ce-w aryl, or C 3-lo cycloalkyl is optionally substituted with 1-5 R 20 groups;
  • R 3a is selected from the group consisting of H, C 1-6 alkyl, alkoxyC ⁇ alkyl, 5-10 membered heteroaryl, 3- 12 membered heterocyclyl, Ce-w aryl and C 3-10 cycloalkyl, wherein each Ci ⁇ alkyl, Ci ⁇ alkoxyC ⁇ alkyl, 5-10 membered heteroaryl, 3-12 membered heterocyclyl, Ce-w aryl and C 3-lo cycloalkyl is optionally substituted with 1-5 R 20 groups;
  • R 4 is H or halogen
  • each R 5 is independently selected from the group consisting of Ci ⁇ alkyl, C 1-6 alkoxy, C 2- 6 alkenyl, C 2 ⁇ alkynyl, -NR a R b , halogen, -C(0)R a , -C(0)OR a , -C(0)NR a R b , -OC(0)NR a R b , - NR a C(0)R b , -NR a C(0)OR b , -S(O) 0-2 R a , -S(0) 2 NR a R b , -NR a S(0) 2 R b , -OR a , C 6 .
  • each R a and R b is independently selected from the group consisting H; or alkyl, C 3-lo cycloalkyl, 3-12 membered heterocyclyl, Ce-w aryl, 5-10 membered heteroaryl, each of which is optionally substituted with from one to five R 21 groups; or R a and R b together with the atoms to which they are attached form a 3-12 membered heterocyclyl optionally substituted with one to five R 21 groups;
  • each R 20 is independently selected from the group consisting Ci ⁇ alkyl, C 3-lo cycloalkyl, Ci-6 alkoxy, 3-12 membered heterocyclyl, Ce-w aryl, 5-10 membered heteroaryl, halogen, oxo, - OR a , -C(0)R a , -C(0)OR a , -C(0)NR a R b , -OC(0)NR a R b , -NR a R b , -NR a C(0)R b , -NR a C(0)OR b , -S(0)o -2 R a , -S(0) 2 NR a R b , -NR a S(0) 2 R b , -N 3 , -CN, or -N0 2 , or two R 20 groups appended to the same group can j oin together to form a fused, spiro or bridged C 3-lo cylcloalkyl or
  • each R 21 is independently selected from the group consisting Ci. 6 alkyl, C 3- i 0 cycloalkyl, Ci -6 alkoxy, 3-12 membered heterocyclyl, C 6- io aryl, 5-10 membered heteroaryl, hydroxyl, amino, Ci ⁇ alkylamino, -CN or halogen;
  • X is N. In another embodiment, X is CH.
  • R 2 is selected from the group consisting of halogen, C 3- i 0 cycloalkyl, C3-10 cycloalkoxy, Ci-6 alkyl, or -CN, wherein each C3-10 cycloalkyl, C4-10 cycloalkoxy, Ci ⁇ alkyl, d ⁇ alkoxy is optionally substituted with halo.
  • R 2 is selected from the group consisting of chloro, methoxy, ethoxy, -OCH(CH 3 ) 2 OC(CH 3 ) 3 cyclopropyl, -OCHF 2 and 0 ° .
  • R is halogen.
  • R 2 is chloro.
  • R 2 is methoxy.
  • R 2 is C 3 - 6 cycloalkyl. In another embodiment, R 2 is cyclopropyl, or a pharmaceutically acceptable salt thereof. In another embodiment, R 2 is 3-7 membered heterocyclyl. In another embodiment, R 2 is oxetanyl. In another embodiment, R 2 is oxetan-3-yl.
  • R 2 is R 2a O-. In another embodiment, R 2a is C 3 _6 cycloalkyl optionally substituted with 1 -2 R 20 groups. In another embodiment, R 2a is cyclopropyl. In another embodiment, R 2a is
  • R 2a is C6-10 In another embodiment, R 2a is 3-7 membered heterocyclylCi- 6 alkyl. In another embodiment, R 2a is 5-7 membered heteroarylCi- 6 alkyl. In another embodiment, R 2a is Ci ⁇ haloalkyl. In another embodiment, R 2a is -CF 3 .
  • R 2 is -CH 2 OCH 3 (methoxymethyl). In another embodiment, R 2 is Ci -3 alkoxymethyl. In another embodiment, R 2 is C3-6 cycloalkyl substituted with 1-3 fluoro groups. More particularly, 2 fluoro groups. More parpticularly, 2 fluoro groups on the same carbon.
  • R 3 is selected from C -5 alkoxy, and C3- haloCi- 3 alkylC 3 - 6 cycloalkylaminocarbonyloxyC2- 6 alkoxy, wherein each Ci-6 alkoxy, and C3- 8 cycloalkoxyCi ⁇ alkoxy is optionally substituted with halo.
  • R 3 is Ci- 6 alkoxyCi- 6 alkoxy or
  • R 3 is C3 ⁇ halocycloalkyloxyC 3 ⁇ alkyoxy. In another embodiment, R 3 is haloCi- 3 alkylC 3 ⁇ cycloalkylaminocarbonyloxyC2- 6 alkoxy.
  • R 3 is selected from the group consisting of C2-6 alkenyl, Ce-w aryl, 3-7 membered heterocyclyl, C3-6 cycloalkyl, C 1-6 alkoxyCi- 6 alkyl, C3-6
  • R 3 is C3-6 cycloalkyl. In another embodiment, R 3 is C3-6 cycloalkoxy.
  • R 3 is Ci- alkoxyCi- 6 alkyl. In another embodiment, R 3 is C3-6 cycloalkylCi- 6 alkyl. In another embodiment, R 3 is C2-6 alkynyl optionally substituted with 1-3 R 20 groups.
  • C2-6 alkynyl group is substituted with heteroaryl or
  • R 3 is R 3a O-, wherein R 3a is optionally substituted with 1-3 R 20 groups.
  • R 3a is C3-6 cycloalkyl.
  • R 3a is C3-6 cycloalkylCi-6 alkyl, wherein the C3-6 cycloalkyl is optionally substituted with oxo or 1-3 fluoro groups.
  • R 3a is 5-10 membered heteroaryl.
  • R 3a is 3-7 membered heterocyclylCi- 6 alkyl.
  • R 3a is In another embodiment, R 3a is Ci- alkyl substituted with R 20 selected from C3-6 cycloalkyl, Ce-w aryl, 3-7 membered heterocyclyl, 5-7 membered heteroaryl. In another embodiment R 3a is 5-10 membered heteroaryl, 3- 12 membered heterocyclyl or Ce-w aryl.
  • R 3 is selected from the group consisting of: embodiment, R .3 :- A O . In another embodiment, R 3 is not
  • R is selected from the group consisting of:
  • R is
  • R is selected from a group consisting of:
  • R 1 and R 4 are both H.
  • R 4 is bromo.
  • R 1 is bromo.
  • R 1 is H.
  • R 4 is H.
  • one of R 1 or R 4 is halo.
  • at least one of R is C 1-3 alkyl optionally substituted with halo.
  • at least two R 5 groups are C 1-3 alkyl.
  • at least two R 5 groups are methyl, or a pharmaceutically acceptable salt thereof.
  • at least two R 5 groups are methyl bound at the same carbon atom, or a pharmaceutically acceptable salt thereof.
  • two R 5 groups j oin together at the same carbon atom to form a cyclopropyl, or a pharmaceutically acceptable salt thereof.
  • the compound of Formula (I) or (II), or Formula (la), (lb) or (Ila) is/are substituted with 0-7, 0-6, 0-5, 0-4, 0-3 or 0-2 R 5 groups.
  • R 1 and R 4 are both H. In another embodiment, R 1 and R 4 are both H and R 2 is cyclopropyl.
  • two R 5 groups j oin together at the same carbon atom to form a C 3 _6 cycloalkyl or 3-6 membered heterocyclyl ring, each optionally substituted with 1-3 R 20 groups.
  • each R 20 is independently selected from the group consisting Ci_ 6 alkyl, C 3-10 cycloalkyl, C 1-6 alkoxy, 3-12 membered heterocyclyl, Ce-w aryl, 5-10 membered heteroaryl, halogen, oxo, -OR a , -C(0)R a , -C(0)OR a , -C(0)NR a R b , -OC(0)NR a R b , -NR a R b , - NR a C(0)R b , -NR a C(0)OR b , -S(O) 0-2 R a , -S(0) 2 NR a R b , -NR a S(0) 2 R b , -N 3 , -CN, or -N0 2 , wherein each C 1-6 alkyl, C 3-lo cycloalkyl, C 1-6 alkoxy, 3-12 membered heterocyclyl,
  • each of R 2 , R 2a , R 3 , R 3a and R 5 are substituted with 0-5, 0-4, 0-3, 0-2 or 0-1 R 20 groups.
  • each R a or R b group is substituted with 0-5, 0-4, 0-3, 0-2 or 0-1 R 21 groups.
  • ring A is selected from the group consisting of:
  • ring A from Formula (I) or Formula (la) or Forumula (lb) is:
  • Z 1 is a bond, O, NR a or CR 5e R 5f ;
  • Z 2 is a bond, O, NR a or CR 5g R 5h ;
  • Z x and Z 2 are O or NR a ;
  • each of R 5a , R 5b , R 5c , R 5d , R 5e , R 5f R 5g and R 5h are independently selected from the group consisting of H, C w alkyl, C w alkoxy, C 2-6 alkenyl, C 2-6 alkynyl, -NR a R b , halogen, C(0)R a , - C(0)OR a , -C(0)NR a R b , -OC(0)NR a R b , -NR a C(0)R b , -NR a C(0)OR b , -S(O) 0-2 R a , -
  • each R a and R b is independently selected from the group consisting H; or C i ⁇ alkyl, C3 0 cycloalkyl, 3-12 membered heterocyclyl, C6-10 aryl, 5-10 membered heteroaryl, each of which is optionally substituted with from one to five R 21 groups; or R a and R b together with the atoms to which they are attached form a 3-12 membered heterocyclyl optionally substituted with one to five R 21 groups;
  • each R 20 is independently selected from the group consisting Ci ⁇ alkyl, C3-10 cycloalkyl, Ci-6 alkoxy, 3-12 membered heterocyclyl, C6-10 aryl, 5-10 membered heteroaryl, halogen, oxo, - OR a , -C(0)R a , -C(0)OR a , -C(0)NR a R b , -OC(0)NR a R b , -NR a R b , -NR a C(0)R b , -NR a C(0)OR b , -S(0)o -2 R a , -S(0) 2 NR a R b , -NR a S(0) 2 R b , -N 3 , -CN, or -N0 2 , or two R 20 groups appended to the same group can j oin together to form a fused, spiro or bridged C3-10 cylcloalkyl or 3-12
  • each R 21 is independently selected from the group consisting Ci. 6 alkyl, C 3- i 0 cycloalkyl, Ci -6 alkoxy, 3-12 membered heterocyclyl, C 6- io aryl, 5-10 membered heteroaryl, hydroxyl, amino, Ci ⁇ alkylamino, -CN or halogen.
  • Z 2 is CR 5g R 5h .
  • R 5g and R 5h are H or
  • Another embodiment of the present invention provides a compound of Formula (II):
  • Z 1 is a bond, O, NR a or CR 5e R 5f ;
  • R 2 is selected from the group consisting of halogen, R 2a O, Ci-6 alkyl, or -CN, wherein is optionally substituted with 1-3 R 20 groups;
  • R 2a is selected from the group consisting of H, C 3-6 cycloalkyl or Ci ⁇ alkyl, wherein each C 3 _6 cycloalkyl or Ci ⁇ alkyl is optionally substituted with 1-3 R 20 groups;
  • R 3 is selected from and C 3 -8cycloalkoxyCi ⁇ alkoxy, wherein each Ci-6 alkoxy, and C 3 -8cycloalkoxyCi-6alkoxy is optionally substituted with halo;
  • each of R 5a , R 5b , R 5c , R 5d , R 5e , R 5f R 5g and R 5h are independently selected from the group consisting of H, C w alkyl, C w alkoxy, C 2-6 alkenyl, C 2-6 alkynyl, -NR a R b , halogen, C(0)R a , - C(0)OR a , -C(0)NR a R b , -OC(0)NR a R b , -NR a C(0)R b , -NR a C(0)OR b , -S(O) 0-2 R a , - S(0) 2 NR a R b , -NR a S(0) 2 R b , -N 3 , -CN, -N0 2 , -OR a , C 6 .
  • each Ci ⁇ alkyl, Ci ⁇ alkoxy, C 2 _6 alkenyl, C2-6 alkynyl, Ce- ⁇ aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl and 3-12 membered heterocyclyl is optionally substituted with 1 -5 R 20 groups;
  • each R 20 is independently selected from the group consisting Ci ⁇ alkyl, C 3-lo cycloalkyl, Ci-6 alkoxy, 3-12 membered heterocyclyl, Ce-w aryl, 5-10 membered heteroaryl, halogen, oxo, - OR a , -C(0)R a , -C(0)OR a , -C(0)NR a R b , -OC(0)NR a R b , -NR a R b , -NR a C(0)R b , -NR a C(0)OR b , -S(0)o- 2 R a , -S(0) 2 NR a R b , -NR a S(0) 2 R b , -N 3 , -CN, or -N0 2 , wherein each d-s alkyl, C 3 .
  • each R 21 is independently selected from the group consisting Ci ⁇ alkyl, C 1-6 haloalkyl, C 3- io cycloalkyl, Ci ⁇ alkoxy, 3-12 membered heterocyclyl, Ce-w aryl, 5-10 membered heteroaryl, hydroxyl, amino, Ci ⁇ alkylamino, -CN or halogen;
  • each R 21 is independently selected from the group consisting Ci_ 6 alkyl, C 3-10 cycloalkyl, C 1-6 alkoxy, 3-12 membered heterocyclyl, Ce-w aryl, 5-10 membered heteroaryl, hydroxyl, amino, alkylamino, -CN or halogen.
  • Z 1 is O.
  • Another embodiment provides a compound of Formula (Ila):
  • B is a 3-6 membered cycloalkyl or 3-6 membered heterocyclyl ring each substituted with 0-2 R 21 groups;
  • Z 1 is a bond, O, NR a or CR 5e R 5f ;
  • R 2 is selected from the group consisting of halogen, R 2a O, C 1-6 alkyl, or -CN, wherein is optionally substituted with 1 -3 R 20 groups;
  • R 2a is selected from the group consisting of H, C3-6 cycloalkyl or Ci ⁇ alkyl, wherein each C3-6 cycloalkyl or Ci ⁇ alkyl is optionally substituted with 1-3 R 20 groups;
  • R 3 is selected from C -5 alkoxy, and C3- 8 cycloalkoxyCi ⁇ alkoxy, wherein each C 1-6 alkoxy, and C 3-8 cycloalkoxyCi. 6 alkoxy is optionally substituted with halo;
  • each of R 5a , R 5b R 5e , R 5f R 5g and R 5h are independently selected from the group consisting of H, Ci-s alkyl, d-s alkoxy, C 2 ⁇ alkenyl, C 2-6 alkynyl, -NR a R b , halogen, C(0)R a , -C(0)OR a , - C(0)NR a R b , -OC(0)NR a R b , -NR a C(0)R b , -NR a C(0)OR b , -S(O) 0-2 R a , -S(0) 2 NR a R b , -
  • each R a and R b is independently selected from the group consisting H; or C i ⁇ alkyl, C3 0 cycloalkyl, 3-12 membered heterocyclyl, Ce-w aryl, 5-10 membered heteroaryl, each of which is optionally substituted with from one to five R 21 groups; or R a and R b together with the atoms to which they are attached form a 3-12 membered heterocyclyl optionally substituted with one to five R 21 groups;
  • each R 20 is independently selected from the group consisting Ci ⁇ alkyl, C 3 -10 cycloalkyl, Ci-6 alkoxy, 3-12 membered heterocyclyl, Ce-w aryl, 5-10 membered heteroaryl, halogen, oxo, - OR a , -C(0)R a , -C(0)OR a , -C(0)NR a R b , -OC(0)NR a R b , -NR a R b , -NR a C(0)R b , -NR a C(0)OR b , -S(0)o -2 R a , -S(0) 2 NR a R b , -NR a S(0) 2 R b , -N 3 , -CN, or -N0 2 , wherein each C w alkyl, C 3 -10 cycloalkyl, Ci ⁇ alkoxy, 3-12 membered heterocyclyl, Ce-w aryl, 5
  • each R 21 is independently selected from the group consisting Ci ⁇ alkyl, Ci-6 haloalkyl, C3-1 0 cycloalkyl, Ci ⁇ alkoxy, 3-12 membered heterocyclyl, Ce- ⁇ aryl, 5-10 membered heteroaryl, hydroxyl, amino, Ci ⁇ alkylamino, -CN or halogen;
  • each R 21 is independently selected from the group consisting Ci. 6 alkyl, C 3- i 0 cycloalkyl, Ci -6 alkoxy, 3-12 membered heterocyclyl, C 6- io aryl, 5-10 membered heteroaryl, hydroxyl, amino, Ci ⁇ alkylamino, -CN or halogen.
  • B is selected from the group consisting of oxetanyl, 2,2- dimethyl-l ,3-dioxanyl, or cyclopropyl.
  • Z 1 is O.
  • Z 1 is a bond. In another embodiment, Z 1 is CR 5e R 5f . In another embodiment, Z 1 is O.
  • R 5e and R 5f are H, halo, or C1-3 alkyl.
  • R 5c and R 5d are H.
  • R 5c and R 5 are C1-3 alkyl.
  • R 5c and R 5d are CH 3 .
  • R 5c is H and R 5d is CH 3 .
  • R 5c and R 5d are taken together to form cyclopropyl,.
  • R 5a and R 5 are H.
  • R 5a and R 5b are CH 3 .
  • R 5g and R 5h are H.
  • R 5g and R 5h are CH 3 , or a pharmaceutically acceptable salt thereof.
  • R 5c and R 5d are taken together to form a C 3 -6 cycloalkyl or 3-6 membered heterocyclyl ring. In another embodiment, R 5c and R 5d are taken together to form a C 3 -6 cycloalkyl. In another embodiment, R 5c and R 5d are taken together to form cyclopropyl or cyclobutyl.
  • R 5a and R 5b are taken together to form a ring selected from the group consisting of oxetanyl, 2,2-dimethyl-l,3-dioxanyl, or cyclopropyl.
  • R 5a and R 5b are both methoxy methyl.
  • the compounds are selected from the group consisting of:
  • the compounds are selected from the group consisting of:
  • the compound is selected from:
  • the compound is selected from a group consisting of:
  • Another embodiment provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound or pharmaceutically acceptable salt as described herein, and a pharmaceutically acceptable excipient.
  • Another embodiment further comprises one or more additional therapeutic agents. More particularly, the one or more additional therapeutic agents are selected from the group consisting of HBV DNA polymerase inhibitors, toll-like receptor 7 modulators, toll -like receptor 8 modulators, toll-like receptor 7 and 8 modulators, toll-like receptor 3 modulators, interferon alpha ligands, HBsAg inhibitors, compounds targeting HBcAg, cyclophilin inhibitors, HBV therapeutic vaccines, HBV prophylactic vaccines, HBV viral entry inhibitors, NTCP inhibitors, antisense oligonucleotide targeting viral mRNA, short interfering RNAs (siRNA), HBeAg inhibitors, HBx inhibitors, cccDNA inhibitors, HBV antibodies including HBV antibodies targeting the surface antigens of the hepatitis B virus, thymosin agonists, cytokines, nucleoprotein inhibitors (HBV core or capsid protein inhibitors), stimulators of retinoic acid- inducible
  • the one or more additional therapeutic agents are selected from the group consisting of adefovir (Hepsera®), tenofovir disoproxil fumarate + emtricitabine (Truvada®), tenofovir disoproxil fumarate (Viread®), entecavir (Baraclude®), lamivudine (Epivir-HBV®), tenofovir alafenamide, tenofovir, tenofovir disoproxil, tenofovir alafenamide fumarate, tenofovir alafenamide hemifumarate, telbivudine (Tyzeka®), Clevudine®, emtricitabine (Emtriva®), peginterferon alfa-2b (PEG-Intron®), Multiferon®, interferon alpha lb (Hapgen®), interferon alpha-2b (Intron A®), pegylated interferon
  • the one or more additional therapeutic agents are selected from the group consisting of entecavir, adefovir, tenofovir disoproxil fumarate, tenofovir alafenamide, tenofovir, tenofovir disoproxil, tenofovir alafenamide fumarate, tenofovir alafenamide hemifumarate, telbivudine and lamivudine.
  • Another embodiment provides a method of inhibiting the production and/or secretion of HBsAg in an individual infected with HBV comprising administering a therapeutically effective amount of a compound as described herein to the individual.
  • Another embodiment provides a method of treating or preventing an HBV infection comprising administering to an individual in need thereof a therapeutically effective amount of a compound as described herein to the individual.
  • the individual is chronically infected with HBV.
  • Another embodiment provides an article of manufacture comprising a unit dosage of a compound as described herein.
  • Another embodiment provides a compound as described herein for use in medical therapy.
  • Another embodiment provides a compound as described herein for use in treating or preventing an HBV infection in an individual. Another embodiment provides use of a compound as described herein for the manufacture of a medicament for use in medical therapy.
  • Another embodiment provides a compound as described herein for use in inhibiting the production or secretion of HBsAg in vitro.
  • Any of the compounds described herein is optionally comprises a pharmaceutically acceptable salt.
  • the deuterium atom is a non-radioactive isotope of the hydrogen atom.
  • Such compounds may increase resistance to metabolism, and thus may be useful for increasing the half-life of the compounds described herein or pharmaceutically acceptable salts, isomers, or mixtures thereof when administered to a mammal. See, e.g., Foster, "Deuterium Isotope Effects in Studies of Drug Metabolism", Trends Pharmacol. Sci., 5(12):524-527 (1984).
  • Such compounds are synthesized by means known in the art, for example by employing starting materials in which one or more hydrogen atoms have been replaced by deuterium.
  • isotopes that can be incorporated into the disclosed compounds also include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, chlorine, and iodine, such as 2 H, 3 H, n C, 13 C, 14 C, 13 N, 15 N, 15 0, 17 0, 18 0, 31 P, 32 P, 35 S, 18 F, 36 C1, 123 I, and 125 I, respectively.
  • isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, chlorine, and iodine such as 2 H, 3 H, n C, 13 C, 14 C, 13 N, 15 N, 15 0, 17 0, 18 0, 31 P, 32 P, 35 S, 18 F, 36 C1, 123 I, and 125 I, respectively.
  • Substitution with positron emitting isotopes, such as n C, 18 F, 15 0 and 13 N can be useful in Positron Emission Topography (PET) studies for examining substrate receptor occupancy.
  • PET Positron Emission Top
  • Isotopically-labeled compounds of Formula (I) or (II), or Formula (la), (lb) or (Ila), can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the Examples as set out below using an appropriate isotopically-labeled reagent in place of the non-labeled reagent previously employed. Additionally, in one embodiment, the compounds described herein are pegylated at a substituent or functional group (i.e. a polyethylene glycol moiety is appended thereto).
  • the compounds disclosed herein may contain one or more asymmetric centers and may thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that may be defined, in terms of absolute stereochemistry, as (R)- or (S)- or, as (D)- or (L)- for amino acids.
  • the present disclosure is meant to include all such possible isomers, as well as their racemic and optically pure forms.
  • Optically active (+) and (-), (R)- and (S)-, or (D)- and (L)- isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques, for example, chromatography and fractional crystallization.
  • the present disclosure provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
  • the pharmaceutical composition comprises one or more additional therapeutic agents, as described in more detail below.
  • compositions comprising the compounds disclosed herein, or pharmaceutically acceptable salts thereof, may be prepared with one or more pharmaceutically acceptable excipients which may be selected in accord with ordinary practice.
  • “Pharmaceutically acceptable excipient” includes without limitation any adjuvant, carrier, excipient, glidant, sweetening agent, diluent, preservative, dye/colorant, flavor enhancer, surfactant, wetting agent, dispersing agent, suspending agent, stabilizer, isotonic agent, solvent, or emulsifier which has been approved by the United States Food and Drug Administration as being acceptable for use in humans or domestic animals.
  • compositions are provided as a solid dosage form, including a solid oral dosage form, such as a tablet.
  • Tablets may contain excipients including glidants, fillers, binders and the like.
  • Aqueous compositions may be prepared in sterile form, and when intended for delivery by other than oral administration generally may be isotonic. All compositions may optionally contain excipients such as those set forth in the Rowe et al, Handbook of Pharmaceutical Excipients, 6 th edition, American Pharmacists Association, 2009. Excipients can include ascorbic acid and other antioxidants, chelating agents such as EDTA, carbohydrates such as dextrin, hydroxyalkylcellulose, hydroxyalkylmethylcellulose, stearic acid and the like.
  • compositions disclosed herein include those suitable for various administration routes, including oral administration.
  • the compositions may be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. Such methods include the step of bringing into association the active ingredient (e.g. , a compound of the present disclosure or a pharmaceutical salt thereof) with one or more pharmaceutically acceptable excipients.
  • the compositions may be prepared by uniformly and intimately bringing into association the active ingredient with liquid excipients or finely divided solid excipients or both, and then, if necessary, shaping the product. Techniques and
  • compositions described herein that are suitable for oral administration may be presented as discrete units (a unit dosage form) including but not limited to capsules, cachets or tablets each containing a predetermined amount of the active ingredient.
  • the pharmaceutical composition is a tablet.
  • compositions disclosed herein comprise one or more compounds disclosed herein, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable excipient and optionally other therapeutic agents.
  • Pharmaceutical compositions containing the active ingredient may be in any form suitable for the intended method of administration. When used for oral use for example, tablets, troches, lozenges, aqueous or oil suspensions, dispersible powders or granules, emulsions, hard or soft capsules, syrups or elixirs may be prepared.
  • Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more excipients including sweetening agents, flavoring agents, coloring agents and preserving agents, in order to provide a palatable preparation.
  • excipients which are suitable for manufacture of tablets are acceptable.
  • excipients may be, for example, inert diluents, such as calcium or sodium carbonate, lactose, lactose monohydrate, croscarmellose sodium, povidone, calcium or sodium phosphate; granulating and disintegrating agents, such as maize starch, or alginic acid; binding agents, such as cellulose, microcrystalline cellulose, starch, gelatin or acacia; and lubricating agents, such as magnesium stearate, stearic acid or talc.
  • inert diluents such as calcium or sodium carbonate, lactose, lactose monohydrate, croscarmellose sodium, povidone, calcium or sodium phosphate
  • granulating and disintegrating agents such as maize starch, or alginic acid
  • binding agents such as cellulose, microcrystalline cellulose, starch, gelatin or acacia
  • lubricating agents such as magnesium
  • Tablets may be uncoated or may be coated by known techniques including microencapsulation to delay disintegration and adsorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.
  • a time delay material such as glyceryl monostearate or glyceryl distearate alone or with a wax may be employed.
  • a dosage form for oral administration to humans may contain approximately 1 to 1000 mg of active material formulated with an appropriate and convenient amount of a pharmaceutically acceptable excipient.
  • the pharmaceutically acceptable excipient varies from about 5 to about 95% of the total compositions (weigh weight).
  • the present disclosure provides methods of treating or preventing an HBV infection.
  • a method of treating or preventing an HBV infection comprises administering to an individual (e.g. a human) a therapeutically effective amount a compound disclosed herein, or a pharmaceutically acceptable salt thereof.
  • the present disclosure also provides methods for treating an HBV infection comprising administering to an individual (e.g. a human) infected with HBV a therapeutically effective amount a compound disclosed herein or a pharmaceutically acceptable salt thereof.
  • the individual is chronically infected with HBV.
  • the individual is acutely infected with HBV.
  • a method of treating an individual e.g.
  • a human infected with HBV comprises inhibiting HBsAg secretion and/or production.
  • a compound disclosed herein or a pharmaceutically acceptable salt thereof for use in medical therapy is provided.
  • the disease or condition is an HBV infection.
  • a compound disclosed herein for use in treating or preventing an HBV infection is provided.
  • a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for treating or preventing HBV infection is provided.
  • a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for treating or preventing an HBV infection is provided.
  • compounds of the present disclosure can be administered with one or more additional therapeutic agent(s) to an individual (e.g. a human) infected with HBV.
  • the additional therapeutic agent(s) can be administered to the infected individual (e.g. a human) at the same time as a compound disclosed herein or before or after administration of a compound disclosed herein.
  • a compound disclosed herein when used to treat or prevent a HBV infection, is administered with one or more additional therapeutic agent(s) selected from the group consisting of HBV DNA polymerase inhibitors, toll-like receptor 7 modulators, toll-like receptor 8 modulators, Toll-like receptor 7 and 8 modulators, Toll-like receptor 3 modulators, interferon alpha ligands, HBsAg inhibitors, compounds targeting HBcAg, cyclophilin inhibitors, HBV therapeutic vaccines, HBV prophylactic vaccines, HBV viral entry inhibitors, NTCP inhibitors, antisense oligonucleotide targeting viral mRNA, short interfering RNAs (siRNA), hepatitis B virus E antigen inhibitors, HBx inhibitors, cccDNA inhibitors, HBV antibodies including HBV antibodies targeting the surface antigens of the hepatitis B virus, thymosin agonists, cytokines, nucleoprotein inhibitors (HBV core), HBV DNA polymerase
  • the present disclosure provides a method for ameliorating a symptom associated with an HBV infection, wherein the method comprises administering to an individual (e.g. a human) infected with hepatitis B virus a therapeutically effective amount of a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, wherein the therapeutically effective amount is sufficient to ameliorate a symptom associated with the HBV infection.
  • an individual e.g. a human
  • hepatitis B virus e.g. a human
  • a therapeutically effective amount of a compound of the present disclosure e.g. a human
  • a pharmaceutically acceptable salt thereof e.g. a pharmaceutically acceptable salt thereof
  • the present disclosure provides a method for reducing the rate of progression of a hepatitis B viral infection in an individual (e.g. a human), wherein the method comprises administering to an individual (e.g. a human) infected with hepatitis B virus a therapeutically effective amount of a compound disclosed herein, or a pharmaceutically acceptable salt thereof, wherein the therapeutically effective amount is sufficient to reduce the rate of progression of the hepatitis B viral infection.
  • the rate of progression of the infection can be followed by measuring the amount of HBV virus particles in the blood.
  • the present disclosure provides a method for reducing the viral load associated with HBV infection, wherein the method comprises administering to an individual (e.g. a human) infected with HBV a therapeutically effective amount of a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, wherein the individual (e.g. a human) infected with HBV a therapeutically effective amount of a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, wherein the
  • a method of treating an individual comprises reducing the viral load associated with HBV infection as measured by PCR testing.
  • Compounds disclosed herein can be administered by any route appropriate for use in a method described herein. Suitable routes include oral, rectal, nasal, topical (including buccal and sublingual), transdermal, vaginal and parenteral (including subcutaneous, intramuscular, intravenous, intradermal, intrathecal and epidural), and the like. Compounds disclosed herein may be administered to an individual in accordance with an effective dosing regimen for a desired period of time or duration, such as at least one week, at least about one month, at least about 2 months, at least about 3 months, at least about 6 months, or at least about 12 months or longer. In one variation, the compound is administered on a daily or intermittent schedule for the duration of the individual's life. The dosage or dosing frequency of a compound of the present disclosure may be adjusted over the course of the treatment, based on the judgment of the administering physician.
  • Therapeutically effective amounts of compounds disclosed herein are from about 0.00001 mg/kg body weight per day to about 10 mg/kg body weight per day, such as from about 0.0001 mg/kg body weight per day to about 10 mg/kg body weight per day, or such as from about 0.001 mg/kg body weight per day to about 1 mg/kg body weight per day, or such as from about 0.01 mg/kg body weight per day to about 1 mg/kg body weight per day, or such as from about 0.05 mg/kg body weight per day to about 0.5 mg/kg body weight per day, or such as from about 0.3 ⁇ g to about 30 mg per day, or such as from about 30 ⁇ g to about 300 ⁇ g per day.
  • a compound of the present disclosure may be combined with one or more additional therapeutic agents in any dosage amount of the compound of the present disclosure (e.g. , from 1 mg to 1000 mg of compound).
  • Therapeutically effective amounts of the compound of Formula (I) or (II), or Formula (la), (lb) or (Ila) can range from about 0.01 mg per dose to about 1000 mg per dose, such as from about 0.01 mg per dose to about 100 mg per dose, or such as from about 0.1 mg per dose to about 100 mg per dose, or such as from about 1 mg per dose to about 100 mg per dose, or such as from about 1 mg per dose to about 10 mg per dose.
  • Other therapeutically effective amounts of the compound of Formula (I) or (II), or Formula (la), (lb) or (Ila) are about 1 mg per dose, or about 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or about 100 mg per dose.
  • Other therapeutically effective amounts of the compound of Formula (I) or (II), or Formula (la), (lb) or (Ila) are about 100 mg per dose, or about 125, 150, 175, 200, 225, 250, 275, 300, 350, 400, 450, or about 500 mg per dose.
  • a single dose can be administered hourly, daily, or weekly. For example, a single dose can be administered once every 1 hour, 2, 3, 4, 6, 8, 12, 16 or once every 24 hours. A single dose can also be administered once every 1 day, 2, 3, 4, 5, 6, or once every 7 days. A single dose can also be administered once every 1 week, 2, 3, or once every 4 weeks. In certain embodiments, a single dose can be administered once every week. A single dose can also be administered once every month. In some embodiments, a compound disclosed herein is administered once daily in a method disclosed herein. In some embodiments, a compound disclosed herein is administered twice daily in a method disclosed herein.
  • the frequency of dosage of a compound disclosed herein will be determined by the needs of the individual patient and can be, for example, once per day or twice, or more times, per day.
  • Administration of a compound continues for as long as necessary to treat an HBV infection.
  • a compound disclosed herein can be administered to a human being infected with HBV for a period of from 20 days to 180 days or, for example, for a period of from 20 days to 90 days or, for example, for a period of from 30 days to 60 days.
  • Administration can be intermittent, with a period of several or more days during which a patient receives a daily dose of a compound disclosed herein, followed by a period of several or more days during which a patient does not receive a daily dose of the compound.
  • a patient can receive a dose of a compound every other day, or three times per week.
  • a patient can receive a dose of a compound each day for a period of from 1 to 14 days, followed by a period of 7 to 21 days during which the patient does not receive a dose of the compound, followed by a subsequent period (e.g. , from 1 to 14 days) during which the patient again receives a daily dose of the compound.
  • Alternating periods of administration of the compound, followed by non-administration of the compound can be repeated as clinically required to treat the patient.
  • compositions comprising a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, in combination with one or more (e.g., one, two, three, four, one or two, one to three, or one to four) additional therapeutic agents, and a pharmaceutically acceptable excipient are provided.
  • kits comprising a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, in combination with one or more (e.g., one, two, three, four, one or two, one to three, or one to four) additional therapeutic agents are provided.
  • a compound of the present disclosure, or a pharmaceutically acceptable salt thereof is combined with one, two, three, four or more additional therapeutic agents.
  • a compound of the present disclosure, or a pharmaceutically acceptable salt thereof is combined with one additional therapeutic agent.
  • a compound of the present disclosure, or a pharmaceutically acceptable salt thereof is combined with two additional therapeutic agents.
  • a compound of the present disclosure, or a pharmaceutically acceptable salt thereof is combined with three additional therapeutic agents.
  • a compound of the present disclosure, or a pharmaceutically acceptable salt thereof is combined with four additional therapeutic agents.
  • the one, two, three, four or more additional therapeutic agents can be different therapeutic agents selected from the same class of therapeutic agents, and/or they can be selected from different classes of therapeutic agents.
  • the components of the composition are administered as a simultaneous or sequential regimen.
  • the combination may be administered in two or more administrations.
  • a compound of the present disclosure is combined with one or more additional therapeutic agents in a unitary dosage form for simultaneous administration to a patient, for example as a solid dosage form for oral administration.
  • a compound of the present disclosure is administered with one or more additional therapeutic agents.
  • Co-administration of a compound of the present disclosure with one or more additional therapeutic agents generally refers to simultaneous or sequential administration of a compound of the present disclosure and one or more additional therapeutic agents, such that therapeutically effective amounts of the compound disclosed herein and one or more additional therapeutic agents are both present in the body of the patient.
  • Co-administration includes administration of unit dosages of the compounds disclosed herein before or after administration of unit dosages of one or more additional therapeutic agents, for example, administration of the compound disclosed herein within seconds, minutes, or hours of the administration of one or more additional therapeutic agents.
  • a unit dose of a compound of the present disclosure is administered first, followed within seconds or minutes by administration of a unit dose of one or more additional therapeutic agents.
  • a unit dose of one or more additional therapeutic agents is administered first, followed by administration of a unit dose of a compound of the present disclosure within seconds or minutes.
  • a unit dose of a compound of the present disclosure is administered first, followed, after a period of hours (e.g.
  • a unit dose of one or more additional therapeutic agents is administered first, followed, after a period of hours (e.g., 1-12 hours), by administration of a unit dose of a compound of the present disclosure.
  • a method for treating or preventing an HBV infection in an individual comprising administering to the individual a therapeutically effective amount of a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective amount of one or more (e.g., one, two, three, four, one or two, one to three or one to four) additional therapeutic agents.
  • a method for treating an HBV infection in an individual e.g.
  • a human having or at risk of having the infection
  • administering comprising administering to the individual a therapeutically effective amount of a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective amount of one or more (e.g. , one, two, three, four, one or two, one to three or one to four) additional therapeutic agents.
  • a therapeutically effective amount of a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, and one or more additional therapeutic agents are administered in a "fixed dose combination," also termed a "combined dosage form," wherein the active agents are combined in a solid (e.g. tablet or capsule), liquid (e.g. IV), or vaporized formulation.
  • the present disclosure provides a method for treating an HBV infection, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective amount of one or more (e.g., one, two, three, four, one or two, one to three or one to four) additional therapeutic agents which are suitable for treating an HBV infection.
  • one or more additional therapeutic agents includes, for example, one, two, three, four, one or two, one to three or one to four additional therapeutic agents.
  • the additional therapeutic agent may be an anti-HBV agent.
  • the additional therapeutic agent is selected from the group consisting of HBV combination drugs, HBV DNA polymerase inhibitors, immunomodulators, toll-like receptor modulators (modulators of TLR-1, TLR-2, TLR-3, TLR-4, TLR-5, TLR-6, TLR-7, TLR-8, TLR-9, TLR-10, TLR-11, TLR-12 and TLR-13), interferon alpha receptor ligands, hyaluronidase inhibitors, recombinant IL-7, hepatitis B surface antigen (HBsAg) inhibitors, compounds targeting hepatitis B core antigen (HBcAg), cyclophilin inhibitors , HBV therapeutic vaccines, HBV prophylactic vaccines, HBV viral entry inhibitors, NTCP (Na+- taurocholate cotransporting polypeptide) inhibitors, antisense oligonucleotide targeting viral mRNA, short
  • HEVEM modulators of CD161, modulators of Axl, modulators of Mer, modulators of Tyro, gene modifiers or editors such as CRISPR (including CRISPR Cas9), zinc finger nucleases or synthetic nucleases (TALENs), Hepatitis B virus replication inhibitors, compounds such as those disclosed in U.S. Publication No. 2010/0143301 (Gilead Sciences), U.S. Publication No.
  • the additional therapeutic agent is further selected from hepatitis B surface antigen (HBsAg) secretion or assembly inhibitors, TCR-like antibodies, IDO inhibitors, cccDNA epigenetic modifiers, IAPs inhibitors, SMAC mimetics, and compounds such as those disclosed in US20100015178 (Incyte),
  • the additional therapeutic agent may be an anti-HBV agent.
  • the additional therapeutic agent may be selected from the group consisting of HBV combination drugs, other drugs for treating HBV, 3-dioxygenase (IDO) inhibitors, antisense oligonucleotide targeting viral mRNA, Apolipoprotein Al modulator, arginase inhibitors, B- and T-lymphocyte attenuator inhibitors, Bruton's tyrosine kinase (BTK) inhibitors, CCR2 chemokine antagonist, CD137 inhibitors, CD160 inhibitors, CD305 inhibitors, CD4 agonist and modulator, compounds targeting HBcAg, compounds targeting hepatitis B core antigen
  • HBcAg covalently closed circular DNA (cccDNA) inhibitors, cyclophilin inhibitors, cytokines, cytotoxic T-lymphocyte-associated protein 4 (ipi4) inhibitors, DNA polymerase inhibitor, Endonuclease modulator, epigenetic modifiers, Famesoid X receptor agonist, gene modifiers or editors, HBsAg inhibitors, HBsAg secretion or assembly inhibitors, HBV antibodies, HBV DNA polymerase inhibitors, HBV replication inhibitors, HBV RNAse inhibitors, HBV vaccines, HBV viral entry inhibitors, HBx inhibitors, Hepatitis B large envelope protein modulator, Hepatitis B large envelope protein stimulator, Hepatitis B structural protein modulator, hepatitis B surface antigen (HBsAg) inhibitors, hepatitis B surface antigen (HBsAg) secretion or assembly inhibitors, hepatitis B virus E antigen inhibitors, hepatitis B virus replication inhibitors
  • the additional therapeutic agent is selected from the group consisting of HBV combination drugs, HBV DNA polymerase inhibitors, toll-like receptor 7 modulators, toll-like receptor 8 modulators, Toll-like receptor 7 and 8 modulators, Toll-like receptor 3 modulators, interferon alpha receptor ligands, HBsAg inhibitors, compounds targeting HBcAg, cyclophilin inhibitors, HBV therapeutic vaccines, HBV prophylactic vaccines, HBV viral entry inhibitors, NTCP inhibitors, antisense oligonucleotide targeting viral mRNA, short interfering RNAs (siRNA), hepatitis B virus E antigen (HBeAg) inhibitors, HBx inhibitors, cccDNA inhibitors, HBV antibodies including HBV antibodies targeting the surface antigens of the hepatitis B virus, thymosin agonists, cytokines, nucleoprotein inhibitors (HBV core or capsid protein inhibitors), stimulators of retinoic acid
  • the additional therapeutic agent is selected from the group consisting of HBV combination drugs, HBV DNA polymerase inhibitors, toll-like receptor 7 modulators, toll-like receptor 8 modulators, Toll-like receptor 7 and 8 modulators, Toll-like receptor 3 modulators, interferon alpha receptor ligands, HBsAg inhibitors, compounds targeting HBcAg, cyclophilin inhibitors, HBV therapeutic vaccines, HBV prophylactic vaccines, HBV viral entry inhibitors, NTCP inhibitors, antisense oligonucleotide targeting viral mRNA, short interfering RNAs (siRNA), hepatitis B virus E antigen (HBeAg) inhibitors, HBx inhibitors, cccDNA inhibitors, HBV antibodies including HBV antibodies targeting the surface antigens of the hepatitis B virus, thymosin agonists, cytokines, nucleoprotein inhibitors (HBV core or capsid protein inhibitors), stimulators of retinoic acid
  • a compound of the present disclosure ⁇ is formulated as a tablet, which may optionally contain one or more other compounds useful for treating HBV.
  • the tablet can contain another active ingredient for treating HBV, such as HBV DNA polymerase inhibitors, immunomodulators, toll-like receptor modulators (modulators of TLR-1, TLR-2, TLR-3, TLR-4, TLR-5, TLR-6, TLR-7, TLR-8, TLR-9, TLR-10, TLR-11, TLR- 12 and TLR-13), modulators of tlr7, modulators of tlr8, modulators of tlr7 and tlr8, interferon alpha receptor ligands, hyaluronidase inhibitors, hepatitis B surface antigen (HBsAg) inhibitors, compounds targeting hepatitis B core antigen (HBcAg), cyclophilin inhibitors , HBV viral entry inhibitors, NTCP (Na+-taurocholate cotransporting polypeptide
  • the tablet can contain another active ingredient for treating HBV, such as hepatitis B surface antigen (HBsAg) secretion or assembly inhibitors, cccDNA epigenetic modifiers, IAPs inhibitors, SMAC mimetics, and IDO inhibitors.
  • HBV hepatitis B surface antigen
  • such tablets are suitable for once daily dosing.
  • the additional therapeutic agent is selected from one or more of: (1) Combination drugs selected from the group consisting of tenofovir disoproxil fumarate + emtricitabine (TRUVADA®); adefovir + clevudine and GBV-015, as well as combination drugs selected from ABX-203+lamivudine+PEG-IFNalpha, ABX-203+adefovir+PEG- IFNalpha, and INO-9112 + RG7944 (INO-1800);
  • Combination drugs selected from the group consisting of tenofovir disoproxil fumarate + emtricitabine (TRUVADA®); adefovir + clevudine and GBV-015, as well as combination drugs selected from ABX-203+lamivudine+PEG-IFNalpha, ABX-203+adefovir+PEG- IFNalpha, and INO-91
  • HBV DNA polymerase inhibitors selected from the group consisting of besifovir, entecavir
  • Immunomodulators selected from the group consisting of rintatolimod, imidol
  • hydrochloride ingaron, dermaVir, plaquenil (hydroxychloroquine), proleukin, hydroxyurea, mycophenolate mofetil (MP A) and its ester derivative mycophenolate mofetil (MMF), WF- 10, ribavirin, IL-12, polymer polyethyleneimine (PEI), Gepon, VGV-1, MOR-22, BMS- 936559 and IR-103, as well as immunomodulators selected from INO-9112, polymer polyethyleneimine (PEI), Gepon, VGV-1, MOR-22, BMS-936559, RO-7011785, RO- 6871765 and IR-103;
  • Toll-like receptor 7 modulators selected from the group consisting of GS-9620, GSK-
  • Toll-like receptor 8 modulators selected from the group consisting of motolimod,
  • Toll-like receptor 3 modulators selected from the group consisting of rintatolimod, poly-
  • Interferon alpha receptor ligands selected from the group consisting of interferon alpha-2b
  • Hyaluronidase inhibitors selected from the group consisting of astodrimer;
  • HBsAg inhibitors selected from the group consisting of HBF-0259, PBHBV-001, PBHBV - 2-15, PBHBV-2-1, REP 9AC, REP-9C and REP 9 AC, as well as HBsAg inhibitors selected from REP-9, REP-2139, REP-2139-Ca, REP-2165, REP-2055, REP-2163, REP- 2165, REP-2053, REP-2031 and REP-006 and REP-9AC
  • Toll like receptor 9 modulators selected from CYT003, as well as Toll like receptor 9
  • modulators selected from CYT-003, IMO-2055, IMO-2125, IMO-3100, IMO-8400, IMO- 9200, agatolimod, DIMS-9054, DV-1179, AZD-1419, MGN-1703, and CYT-003-QbG10;
  • Cyclophilin inhibitors selected from the group consisting of OCB-030, SCY-635 and NVP- 018;
  • HBV Prophylactic vaccines selected from the group consisting of Hexaxim, Heplisav,
  • Mosquirix DTwP-HBV vaccine, Bio-Hep-B, D/T/P/HBV/M (LBVP-0101; LBVW-0101), DTwP-Hepb-Hib-IPV vaccine, Hebe enta L, DTwP-HepB-Hib, V-419, CVI-HBV-001, Tetrabhay, hepatitis B prophylactic vaccine (Advax Super D), Hepatrol-07, GSK-223192A, Engerix B®, recombinant hepatitis B vaccine (intramuscular, Kangtai Biological Products), recombinant hepatitis B vaccine (Hansenual polymorpha yeast, intramuscular, Hualan
  • HBV Therapeutic vaccines selected from the group consisting of HBsAG-HBIG complex, Bio-Hep-B, NASVAC, abi-HB (intravenous), ABX-203, Tetrabhay, GX-110E, GS-4774, peptide vaccine (epsilonPA-44), Hepatrol-07, NASVAC (NASTERAP), IMP-321, BEVAC, Revac B mcf, Revac B+, MGN-1333, KW-2, CVI-HBV-002, AltraHepB, VGX-6200, FP- 02, TG-1050, NU-500, HBVax, im/TriGrid/antigen vaccine, Mega-CD40L-adjuvanted vaccine, HepB-v, NO- 1800, recombinant VLP -based therapeutic vaccine (HBV infection, VLP Biotech), AdTG-17909, AdTG-17910 AdTG-18202, ChronVac-B, and Lm HBV, as well as HBV Therapeutic vaccine
  • HBV viral entry inhibitor selected from the group consisting of Myrcludex B;
  • Antisense oligonucleotide targeting viral mRNA selected from the group consisting of ISIS-HBVRx;
  • short interfering RNAs selected from the group consisting of TKM-HBV (TKM- HepB), ALN-HBV, SR-008, ddRNAi and ARC-520;
  • Endonuclease modulators selected from the group consisting of PGN-514;
  • Hepatitis B virus E antigen inhibitors selected from the group consisting of wogonin;
  • HBV antibodies including monoclonal antibodies and polyclonal antibodies selected from the group consisting of Zutectra, Shang Sheng Gan Di, Uman Big (Hepatitis B
  • Thymosin agonists selected from the group consisting of Thymalfasin;
  • Cytokines selected from the group consisting of recombinant IL-7, CYT-107, interleukin-2 (IL-2, Immunex); recombinant human interleukin-2 (Shenzhen Neptunus) and celmoleukin, as well as cytokines selected from IL-15, IL-21, IL-24;
  • Nucleoprotein inhibitors selected from the group consisting of NVR-1221, NVR-3778, BAY 41-4109, morphothiadine mesilate and DVR- 23;
  • Stimulators of retinoic acid-inducible gene 1 selected from the group consisting of SB- 9200, SB-40, SB-44, ORI-7246, ORI-9350, ORI-7537, ORI-9020, ORI-9198 and ORI- 7170;
  • Hepatitis B virus replication inhibitors selected from the group consisting of isothiafludine, IQP-HBV, RM-5038 and Xingantie;
  • PI3K inhibitors selected from the group consisting of idelalisib, AZD-8186, buparlisib, CLR-457, pictilisib, neratinib, rigosertib, rigosertib sodium, EN-3342, TGR-1202, alpelisib, duvelisib, UCB-5857, taselisib, XL-765, gedatolisib, VS-5584, copanlisib, CAI orotate, perifosine, RG-7666, GSK-2636771, DS-7423, panulisib, GSK-2269557, GSK-2126458, CUDC-907, PQR-309, INCB-040093, pilaralisib, BAY-1082439, puquitinib mesylate, SAR-245409, AMG-319, RP-6530, ZSTK-474,
  • cccDNA inhibitors selected from the group consisting of BSBI-25;
  • PD-Ll inhibitors selected from the group consisting of MEDI-0680, RG-7446, durvalumab, KY-1003, KD-033, MSB-0010718C, TSR-042, ALN-PDL, STI-A1014 and BMS-936559;
  • PD-1 inhibitors selected from the group consisting of nivolumab, pembrolizumab,
  • BTK inhibitors selected from the group consisting of ACP-196, dasatinib, ibrutinib, PRN- 1008, SNS-062, ONO-4059, BGB-3111, MSC-2364447, X-022, spebrutinib, TP-4207, HM-71224, KBP-7536, AC-0025;
  • WO2014033176 (Janssen), WO2014033170 (Janssen), WO2014033167 (Janssen), US20140330015 (Ono pharmaceutical), US20130079327 (Ono pharmaceutical), and US20130217880 (Ono pharmaceutical), and the compounds disclosed in US20100015178 (Incyte);
  • IDO inhibitors selected from the group consisting of epacadostat (INCB24360), F-001287, resminostat (4SC-201), SN-35837, NLG-919, GDC-0919, and indoximod;
  • Arginase inhibitors selected from CB-1158, C-201, and resminostat;
  • Cytotoxic T-lymphocyte-associated protein 4 (ipi4) inhibitors selected from ipilumimab, belatacept, PSI-001, PRS-010, tremelimumab, and JHL-1155; and
  • KDM5 inhibitors include the compounds disclosed in WO2016057924
  • a compound of the present disclosure, or a pharmaceutically acceptable salt thereof is combined with one, two, three, four or more additional therapeutic agents. In certain embodiments, a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, is combined with two additional therapeutic agents. In other embodiments, a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, is combined with three additional therapeutic agents. In further embodiments, a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, is combined with four additional therapeutic agents.
  • the one, two, three, four or more additional therapeutic agents can be different therapeutic agents selected from the same class of therapeutic agents, and/or they can be selected from different classes of therapeutic agents.
  • a compound of the present disclosure, or a pharmaceutically acceptable salt thereof is combined with an HBV DNA polymerase inhibitor.
  • a compound of the present disclosure, or a pharmaceutically acceptable salt thereof is combined with an HBV DNA polymerase inhibitor and at least one additional therapeutic agent selected from the group consisting of: immunomodulators, toll-like receptor modulators (modulators of TLR-1, TLR-2, TLR-3, TLR-4, TLR-5, TLR-6, TLR-7, TLR-8, TLR-9, TLR-10, TLR-11, TLR-12 and TLR-13), interferon alpha receptor ligands,
  • hyaluronidase inhibitors recombinant IL-7, HBsAg inhibitors, compounds targeting HBcAg, cyclophilin inhibitors , HBV therapeutic vaccines, HBV prophylactic vaccines HBV viral entry inhibitors, NTCP inhibitors, antisense oligonucleotide targeting viral mRNA, short interfering RNAs (siRNA), miRNA gene therapy agents, endonuclease modulators, inhibitors of ribonucleotide reductase, Hepatitis B virus E antigen inhibitors, recombinant scavenger receptor A (SRA) proteins, src kinase inhibitors, HBx inhibitors, cccDNA inhibitors, short synthetic hairpin RNAs (sshRNAs), HBV antibodies including HBV antibodies targeting the surface antigens of the hepatitis B virus and bispecific antibodies and "antibody-like" therapeutic proteins (such as DARTs®, Duobodies®, Bites®,
  • the at least one additional therapeutic agent is further selected from hepatitis B surface antigen (HBsAg) secretion or assembly inhibitors, TCR-like antibodies, cccDNA epigenetic modifiers, IAPs inhibitors, SMAC mimetics, and IDO inhibitors.
  • HBsAg hepatitis B surface antigen
  • a compound of the present disclosure is combined with an HBV DNA polymerase inhibitor and at least one additional therapeutic agent selected from the group consisting of: HBV viral entry inhibitors, NTCP inhibitors, HBx inhibitors, cccDNA inhibitors, HBV antibodies targeting the surface antigens of the hepatitis B virus, short interfering RNAs (siRNA), miRNA gene therapy agents, short synthetic hairpin RNAs (sshRNAs), and nucleoprotein inhibitors (HBV core or capsid protein inhibitors).
  • HBV viral entry inhibitors NTCP inhibitors, HBx inhibitors, cccDNA inhibitors
  • HBV antibodies targeting the surface antigens of the hepatitis B virus short interfering RNAs (siRNA), miRNA gene therapy agents, short synthetic hairpin RNAs (sshRNAs), and nucleoprotein inhibitors (HBV core or capsid protein inhibitors).
  • a compound of the present disclosure, or a pharmaceutically acceptable salt thereof is combined with an HBV DNA polymerase inhibitor, one or two additional therapeutic agents selected from the group consisting of: immunomodulators, toll-like receptor modulators (modulators of TLR-1, TLR-2, TLR-3, TLR-4, TLR-5, TLR-6, TLR-7, TLR-8, TLR-9, TLR-10, TLR-11, TLR-12 and TLR-13), HBsAg inhibitors, HBV therapeutic vaccines, HBV antibodies including HBV antibodies targeting the surface antigens of the hepatitis B virus and bispecific antibodies and "antibody-like" therapeutic proteins (such as DARTs®, Duobodies®, Bites®, XmAbs®, TandAbs ®, Fab derivatives), cyclophilin inhibitors, stimulators of retinoic acid-inducible gene 1, PD-1 inhibitors, PD-L1 inhibitors, Arginase-1 inhibitors, PI3K inhibitors and stimulators of NOD
  • a compound of the present disclosure or a
  • adefovir Hepsera®
  • tenofovir disoproxil fumarate + emtricitabine TRUVADA®
  • tenofovir disoproxil fumarate Viread®
  • entecavir Baraclude®
  • lamivudine Epivir-HBV®
  • tenofovir alafenamide tenofovir
  • tenofovir disoproxil tenofovir alafenamide fumarate
  • tenofovir alafenamide hemifumarate telbivudine
  • alfainterferona 2b Kalferon, Pegnano, Feronsure, PegiHep, interferon alfa 2b (Zydus-Cadila), Optipeg A, Realfa 2B, Reliferon, interferon alfa-2b (Amega), interferon alfa-2b (Virchow), peginterferon alfa-2b (Amega), Reaferon-EC, Proquiferon, Uniferon, Urifron, interferon alfa-2b (Changchun Institute of Biological Products), Anterferon, Shanferon, MOR-22, interleukin-2 (IL-2, Immunex), recombinant human interleukin-2
  • a compound of the present disclosure or a
  • entecavir Baraclude®
  • Hepsera® adefovir
  • Viread® tenofovir disoproxil fumarate
  • tenofovir alafenamide tenofovir
  • tenofovir disoproxil tenofovir alafenamide fumarate
  • tenofovir alafenamide hemifumarate telbivudine
  • Tyzeka® telbivudine
  • Epivir-HBV® lamivudine
  • a compound of the present disclosure or a
  • entecavir Baraclude®
  • Hepsera® adefovir
  • Viread® tenofovir disoproxil fumarate
  • telbivudine Tyzeka®
  • lamivudine Epivir-HBV®
  • a pharmaceutically acceptable salt thereof is combined with a PD-1 inhibitor.
  • a compound of the present disclosure, or a pharmaceutically acceptable salt thereof is combined with a PD-L1 inhibitor.
  • a compound of the present disclosure, or a pharmaceutically acceptable salt thereof is combined with an IDO inhibitor.
  • a compound of the present disclosure, or a pharmaceutically acceptable salt thereof is combined with an IDO inhibitor and a PD-1 inhibitor.
  • a compound of the present disclosure, or a pharmaceutically acceptable salt thereof is combined with an IDO inhibitor and a PD-Ll inhibitor.
  • a compound of the present disclosure, or a pharmaceutically acceptable salt thereof is combined with a TLR7 modulator, such as GS-9620.
  • GS-9620 (4-amino-2-butoxy-8-( ⁇ 3- [(pyrrolidin-l-yl)methyl]phenyl ⁇ methyl)-7,8-dihydropteridin-6(5H)-one), includes
  • a compound of the present disclosure or a
  • a first additional therapeutic agent selected from the group consisting of: entecavir (Baraclude®), adefovir (Hepsera®), tenofovir disoproxil fumarate (Viread®), tenofovir alafenamide, tenofovir, tenofovir disoproxil, tenofovir alafenamide fumarate, tenofovir alafenamide hemifumarate, telbivudine (Tyzeka®) or lamivudine (Epivir-HBV®) and at least one additional therapeutic agent selected from the group consisting of immunomodulators, toll-like receptor modulators (modulators of TLR-1, TLR-2, TLR-3, TLR-4, TLR-5, TLR-6, TLR-7, TLR-8, TLR-9, TLR-10, TLR-11, TLR-12 and TLR- 13), interferon alpha receptor ligands, hyaluronidas
  • oligonucleotide targeting viral mRNA short interfering RNAs (siRNA), miRNA gene therapy agents, endonuclease modulators, inhibitors of ribonucleotide reductase, Hepatitis B virus E antigen inhibitors, recombinant scavenger receptor A (SRA) proteins, src kinase inhibitors, HBx inhibitors, cccDNA inhibitors, short synthetic hairpin RNAs (sshRNAs), HBV antibodies including HBV antibodies targeting the surface antigens of the hepatitis B virus and bispecific antibodies and "antibody-like" therapeutic proteins (such as DARTs®, Duobodies®, Bites®, XmAbs®, TandAbs ®, Fab derivatives), CCR2 chemokine antagonists, thymosin agonists, cytokines, nucleoprotein inhibitors (HBV core or capsid protein inhibitors), stimulators of retinoic acid-inducible
  • the at least one additional therapeutic agent is further selected from hepatitis B surface antigen (HBsAg) secretion or assembly inhibitors, TCR-like antibodies, IDO inhibitors, cccDNA epigenetic modifiers, IAPs inhibitors, and SMAC mimetics.
  • HBsAg hepatitis B surface antigen
  • a compound of the present disclosure or a
  • a first additional therapeutic agent selected from the group consisting of: entecavir (Baraclude®), adefovir (Hepsera®), tenofovir disoproxil fumarate (Viread®), tenofovir alafenamide, tenofovir, tenofovir disoproxil, tenofovir alafenamide fumarate, tenofovir alafenamide hemifumarate, telbivudine (Tyzeka®) or lamivudine (Epivir-HBV®) and at least a one additional therapeutic agent selected from the group consisting of peginterferon alfa-2b (PEG-Intron®), Multiferon®, interferon alpha lb (Hapgen®), interferon alpha-2b (Intron A®), pegylated interferon alpha-2a (Pegasys®), interferon alfa-nl(Humo
  • a compound of the present disclosure or a
  • a first additional therapeutic agent selected from the group consisting of: entecavir (Baraclude®), adefovir (Hepsera®), tenofovir disoproxil fumarate (Viread®), tenofovir alafenamide, tenofovir, tenofovir disoproxil, tenofovir alafenamide fumarate, tenofovir alafenamide hemifumarate, telbivudine (Tyzeka®) or lamivudine (Epivir-HBV®) and at least one additional therapeutic agent selected from the group consisting of HBV viral entry inhibitors, NTCP inhibitors, HBx inhibitors, cccDNA inhibitors, HBV antibodies targeting the surface antigens of the hepatitis B virus, short interfering RNAs (siRNA), miRNA gene therapy agents, short synthetic hairpin RNAs (sshRNAs), and nucleoprotein inhibitors (siRNA), miRNA gene therapy
  • a compound of the present disclosure or a
  • a first additional therapeutic agent selected from the group consisting of: entecavir (Baraclude®), adefovir (Hepsera®), tenofovir disoproxil fumarate (Viread®), tenofovir alafenamide, tenofovir, tenofovir disoproxil, tenofovir alafenamide fumarate, tenofovir alafenamide hemifumarate, telbivudine (Tyzeka®) or lamivudine (Epivir-HBV®), one or two additional therapeutic agents selected from the group consisting of: immunomodulators, toll-like receptor modulators (modulators of TLR-1, TLR-2, TLR-3, TLR-4, TLR-5, TLR-6, TLR-7, TLR-8, TLR-9, TLR-10, TLR-11, TLR-12 and TLR- 13), HBsAg inhibitors, HBV therapeutic vaccines, HBV antibodies including
  • a compound of the present disclosure or a
  • a pharmaceutically acceptable salt thereof is combined with a first additional therapeutic agent selected from the group consisting of: tenofovir disoproxil fumarate (Viread®), tenofovir alafenamide, tenofovir, tenofovir disoproxil, tenofovir alafenamide fumarate, and tenofovir alafenamide hemifumarate; and a second therapeutic agent selected from the group consisting of: modulators of TLR-7 and modulators of TLR-8.
  • a compound of the present disclosure, or a pharmaceutically acceptable salt thereof is combined with 5-30 mg tenofovir alafenamide fumarate, tenofovir alafenamide hemifumarate, or tenofovir alafenamide. In certain embodiments, a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, is combined with 5-10; 5- 15; 5-20; 5-25; 25-30; 20-30; 15-30; or 10-30 mg tenofovir alafenamide fumarate, tenofovir alafenamide hemifumarate, or tenofovir alafenamide.
  • a compound of the present disclosure, or a pharmaceutically acceptable salt thereof is combined with 10 mg tenofovir alafenamide fumarate, tenofovir alafenamide hemifumarate, or tenofovir alafenamide. In certain embodiments, a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, is combined with 25 mg tenofovir alafenamide fumarate, tenofovir alafenamide hemifumarate, or tenofovir alafenamide.
  • a compound of the present disclosure e.g.
  • a compound of Formula (I) or (II), or Formula (la), (lb) or (Ila) may be combined with the agents provided herein in any dosage amount of the compound (e.g. , from 50 mg to 500 mg of compound) the same as if each combination of dosages were specifically and individually listed.
  • a compound of the present disclosure e.g. , a compound of Formula (I) or (II), or Formula (la), (lb) or (Ila)
  • may be combined with the agents provided herein in any dosage amount of the compound e.g. from about 1 mg to about 150 mg of compound) the same as if each
  • a compound of the present disclosure, or a pharmaceutically acceptable salt thereof is combined with 100-400 mg tenofovir disoproxil fumarate, tenofovir disoproxil hemifumarate, or tenofovir disoproxil.
  • a compound of the present disclosure, or a pharmaceutically acceptable salt thereof is combined with 100-150; 100-200, 100-250; 100-300; 100-350; 150-200; 150-250; 150-300; 150-350; 150-400; 200-250; 200-300; 200-350; 200-400; 250-350; 250-400; 350-400 or 300-400 mg tenofovir disoproxil fumarate, tenofovir disoproxil hemifumarate, or tenofovir disoproxil.
  • a compound of the present disclosure, or a pharmaceutically acceptable salt thereof is combined with 300 mg tenofovir disoproxil fumarate, tenofovir disoproxil hemifumarate, or tenofovir disoproxil. In certain embodiments, a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, is combined with 250 mg tenofovir disoproxil fumarate, tenofovir disoproxil hemifumarate, or tenofovir disoproxil.
  • a compound of the present disclosure is combined with 150 mg tenofovir disoproxil fumarate, tenofovir disoproxil hemifumarate, or tenofovir disoproxil.
  • a compound of the present disclosure e.g., a compound of Formula (I) or (II), or Formula (la), (lb) or (Ila)
  • may be combined with the agents provided herein in any dosage amount of the compound e.g. , from 50 mg to 500 mg of compound) the same as if each combination of dosages were specifically and individually listed.
  • a compound of the present disclosure e.g.
  • a compound of Formula (I) or (II), or Formula (la), (lb) or (Ila)) may be combined with the agents provided herein in any dosage amount of the compound (e.g., from about 1 mg to about 150 mg of compound) the same as if each combination of dosages were specifically and individually listed.
  • a compound of the present disclosure e.g., a compound of Formula (I) or (II), or Formula (la), (lb) or (Ila)
  • a pharmaceutically acceptable salt thereof e.g., a compound of Formula (I) or (II), or Formula (la), (lb) or (Ila)
  • additional active ingredients for treating HBV for use in a method of treating or preventing HBV.
  • a compound of the present disclosure e.g., a compound of Formula (I) or (II), or Formula (la), (lb) or (Ila)
  • a pharmaceutically acceptable salt thereof for use in a method of treating or preventing HBV, wherein the compounder a pharmaceutically acceptable salt thereof is administered simultaneously, separately or sequentially with one or more additional therapeutic agents fort for treating HBV.
  • the present disclosure provides a kit comprising a compound of the present disclosure or a pharmaceutically acceptable salt thereof.
  • the kit may further comprise instructions for use in treating an HBV infection.
  • the instructions may be written instructions or electronic storage media (e.g., magnetic diskette or optical disk) containing instructions.
  • kits comprising one or more containers comprising a compound of the present disclosure or a pharmaceutically acceptable salt thereof.
  • Optionally associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals, which notice reflects approval by the agency for the manufacture, use or sale for human administration.
  • Each component if there is more than one component
  • kits may be in unit dosage forms, bulk packages (e.g., multi-dose packages) or sub- unit doses. Kits may also include multiple unit doses of the compounds and instructions for use and be packaged in quantities sufficient for storage and use in pharmacies (e.g., hospital pharmacies and compounding pharmacies).
  • articles of manufacture comprising a unit dosage of a compound of the present disclosure or a pharmaceutically acceptable salt thereof, in suitable packaging for use in the methods described herein.
  • suitable packaging is known in the art and includes, for example, vials, vessels, ampules, bottles, jars, flexible packaging and the like.
  • An article of manufacture may further be sterilized and/or sealed.
  • Compounds as described herein can be purified by any of the means known in the art, including chromatographic means, such as high performance liquid chromatography (HPLC), preparative thin layer chromatography, flash column chromatography and ion exchange chromatography. Any suitable stationary phase can be used, including normal and reversed phases as well as ionic resins. Most typically the disclosed compounds are purified via silica gel and/or alumina chromatography.
  • any of the processes for preparation of the subject compounds it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by means of conventional protecting groups as described in standard works, such as T. W. Greene and P. G. M. Wuts, "Protective Groups in Organic Synthesis," 4 th ed., Wiley, New York 2006.
  • the protecting groups may be removed at a convenient subsequent stage using methods known from the art.
  • Example 1 ll-chloro-12-(3-methoxypropoxy)-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l- a] pyrrolo [ 1,2-c] phthalazine-7-carboxylic acid
  • Example 2 (R) -ll-chloro-12-(3-methoxypropoxy)-8-oxo-2,3,8,13b-tetrahydro-lH- pyrido[2,l-fl]pyrrolo[l,2-c]phthalazine-7-carboxylic acid and (S -ll-chloro-12-(3- methoxypropoxy)-8-oxo-2,3,8,13b-tetrahydro- lH-pyrido [2,1-a] pyrrolo [ 1,2-c] phthalazine- 7-carboxylic acid
  • Ethyl 1 l-chloro-12-(3-methoxypropoxy)-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH- pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate was separated into its enantiomers by chiral SFC chromatography using AD-H 4.6X100mm columns with 30% methanol as the co- solvent. The faster eluting peak with a retention time of 2.1 min was taken up in in EtOH (1 ml) and 2M LiOH (0.3 ml) then stirred at room temperature until hydrolysis was complete.
  • Ethyl l l-chloro-12-(3-methoxypropoxy)-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH- pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate was separated into its enantiomers by chiral SFC chromatography using AD-H 4.6X100mm columns with 30% methanol as the co- solvent. The slower eluting peak with a retention time of 3.45 min was taken up in in EtOH (1 ml) and 2M Li OH (0.3 ml) then stirred at room temperature until hydrolysis was complete.
  • the cis/trans mixture was separated by reverse phase HPLC using ACN / H20 with 0.1% TFA as the eluent on a Gemini CI 8 column.
  • the cis isomer was assigned to be the faster eluting peak and the trans the slower.
  • Ethyl l-(6-(2-bromo-4-chloro-5-(3-methoxypropoxy)phenyl)-2,2-dimethylpiperidin-l-yl)-4- oxo-l,4-dihydropyridine-3-carboxylate was prepared similarly to example 4 using 2,2- dimethyl-2,3,4,5-tetrahydropyridine 1 -oxide in place of 2,2-dimethyl-3,4-dihydro-2H-pyrrole 1- oxide. MS (m/z) 555.2 [M+H]+.
  • Example 12 (i?)-13-chloro-12-(3-methoxypropoxy)-7,7-dimethyl-2-oxo-2,7,8,9,10,10a- hexahydrodipyrido[2,l-a:l',2'-c]phthalazine-3-carboxylic acid
  • Example 13 (.S)-13-chloro-12-(3-methoxypropoxy)-7,7-dimethyl-2-oxo-2,7,8,9,10,10a- hexahydrodipyrido[2,l-a:l',2'-c]phthalazine-3-carboxylic acid
  • 5-(5-(benzyloxy)-2-bromo-4-methoxyphenyl)-2,2-dimethylpyrrolidin-l-amine 5-(5- (benzyloxy)-2-bromo-4-methoxyphenyl)-2,2-dimethylpyrrolidin-l-ol (5.65 g, 13.9 mmol) was suspended in trifluoroacetic acid (6.3 mL) and water (3 mL). Zinc powder (2.6 g, 40 mmol) was added and the mixture was stirred at 40 °C for 15 minutes.
  • the reaction mixture was cooled to room temperature, diluted with ethyl acetate, rinsed with aqueous sodium bicarbonate and brine, dried over sodium sulfated, filtered, and concentrated in vacuo.
  • the resulting crude 5-(5-(benzyloxy)-2-bromo-4-methoxyphenyl)-2,2-dimethyl-l-nitrosopyrrolidine was dissolved in trifluoroacetic acid (6.3 mL) and water (3 mL). Zinc powder (2.6 g, 40 mmol) was added. A rapid exotherm to boiling was observed, and the reaction was cooled on ice. After cooling, the reaction was warmed to 40 °C.
  • Ethyl 12-(benzyloxy)-ll-methoxy-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l- a]pyrrolo[l,2-c]phthalazine-7-carboxylate Ethyl l-(5-(5-(benzyloxy)-2-bromo-4- methoxyphenyl)-2,2-dimethylpyrrolidin- 1 -yl)-4-oxo- 1 ,4-dihy dropy ridine-3 -carboxylate (3.67 g, 6.6 mmol) was dissolved in DMA (20 mL) with potassium propionate (1.9g, 17 mmol) under argon.
  • the mixture was purified by flash column chromatography (hexanes / ethyl acetate / ethanol) to provide ethyl 12- (benzyloxy)-l l-methoxy-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2- c]phthalazine-7-carboxylate.
  • Ethyl (i?)-12-(benzyloxy)-ll-methoxy-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH- pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate Ethyl 12-(benzyloxy)-l 1-methoxy- 3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7- carboxylate was separated into its enantiomers by SFC using an OJ-H column with methanol as the co-solvent. Retention time of 1.1 min.
  • Example 17 13-chloro-12-(3-methoxypropoxy)-8,8-dimethyl-2-oxo-2,7,8,9,10,10a- hexahydrodipyrido[2,l-a:l',2'-c]phthalazine-3-carboxylic acid
  • Example 18 ll-(difluoromethoxy)-12-(3-methoxypropoxy)-3,3-dimethyl-8-oxo-2,3,8,13b- tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid
  • the reaction was heated at 70°C for 2h.
  • the reaction was cooled to ambient temperature and 2M LiOH(aq) (0.15 ml) was added.
  • the reaction was stirred for lh, acidified with 2M HCl (300uL), and the product was purified by prep HPLC using acetonitrile in water with 0.1% TFA.
  • Example 22 (i?)-ll-isopropoxy-12-(3-methoxypropoxy)-3,3-dimethyl-8-oxo-2,3,8,13b- tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid
  • the mixture was heated for 45 minutes, concentrated under vacuum, and the resulting mixture was diluted with ethanol (0.5 ml) and treated with 2M LiOH(aq) (0.15 ml). After stirring for lh, the mixture was acidified with 2M HC1 (0.2 ml). The product was purified by prep HPLC using acetonitrile in water with 0.1% TFA.
  • Example 28 (i?)-ll-cyclopropyl-12-(3-methoxypropoxy)-3,3-dimethyl-8-oxo-2,3,8,13b- tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid oxo- ne-7-
  • the mixture was degassed by pulling vacuum and back filling with Ar 5x. After heating to reflux for 1.5 h, the reaction mixture was cooled to RT, diluted with EtOAc and washed with H 2 0 and brine. The organic layer was dried over MgSC>4, filtered and concentrated under reduced pressure.
  • Ethyl l l-chloro-12-(3-methoxypropoxy)-2,2-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH- pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate was separated into its enantiomers by chiral SFC chromatography using IA 5uM-4.6X150mm columns with 30% isopropanol as the co-solvent. The slower eluting peak with a retention time of 4.99 min was taken up in in EtOH (1 ml) and 2M LiOH (0.3 ml) then stirred at room temperature until hydrolysis was complete.
  • Example 31 ira «s-10-Chloro-ll-(3-methoxypropoxy)-3,3-dimethyl-7-oxo-l,2,3,3a,7,12b- hexahydrocyclopenta[c]pyrido[2,l-a]isoquinoline-6-carboxylic acid (racemate) and
  • Example 32 cis-10-chloro-ll-(3-methoxypropoxy)-3,3-dimethyl-7-oxo-l,2,3,3a,7,12b- hexahydrocyclopenta[c]pyrido[2,l-a]isoquinoline-6-carboxylic acid (racemate)
  • hexahydrocyclopenta[c]pyrido[2,l-a]isoquinoline-6-carboxylic acid was prepared analogously to 1 l-chloro-12-(3-methoxypropoxy)-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l- a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid (Example 11) using cis-ethyl l-(5-(2-bromo-4- chloro-5-(3-methoxypropoxy)phenyl)-2,2-dimethylcyclopentyl)-4-oxo-l,4-dihydropyridine-3- carboxylate.
  • Example 33 (3aS ⁇ 2bi?)-10-Chloro-ll-(3-methoxypropoxy)-3 ⁇ -dimethyl-7-oxo- l,2,3,3a,7,12b-hexahydrocyclopenta[c]pyrido[2,l-a]isoquinoline-6-carboxylic acid
  • hexahydrocyclopenta[c]pyrido[2,l-a]isoquinoline-6-carboxylic acid (31) was separated into its enantiomers by chiral SFC chromatography using OD-H 4.6X100mm columns with 30% isopropanol as the co-solvent.
  • Compound 33 is the slower eluting peak retention time of 4.47 min.
  • Example 34 (3a ?,12bS)-10-Chloro-ll-(3-methoxypropoxy)-3,3-dimethyl-7-oxo- l,2,3,3a,7,12b-hexahydrocyclopenta[c]pyrido[2,l-a]isoquinoline-6-carboxylic acid
  • hexahydrocyclopenta[c]pyrido[2,l-a]isoquinoline-6-carboxylic acid (31) was separated into its enantiomers by chiral SFC chromatography using OD-H 4.6X100mm columns with 30% isopropanol as the co-solvent.
  • Compound 34 is the faster eluting peak retention time of 3.52 min.
  • Example 35 ((3aS,12bS)-10-Chloro-ll-(3-methoxypropoxy)-3,3-dimethyl-7-oxo- l,2,3,3a,7,12b-hexahydrocyclopenta[c]pyrido[2,l-a]isoquinoline-6-carboxylic acid
  • trans-10-chloro-l l-(3-methoxypropoxy)-3,3-dimethyl-7-oxo-l,2,3,3a,7,12b- hexahydrocyclopenta[c]pyrido[2,l-a]isoquinoline-6-carboxylic acid (32) was separated into its enantiomers by chiral SFC chromatography using AD-H 4.6X100mm columns with 30% isopropanol as the co-solvent.
  • Compound 35 is the slower eluting peak retention time of 4.72 min.
  • Example 36 ((3aR,12bi?)-10-chloro-ll-(3-methoxypropoxy)-3,3-dimethyl-7-oxo- l,2,3,3a,7,12b-hexahydrocyclopenta[c]pyrido[2,l-a]isoquinoline-6-carboxylic acid
  • trans-10-chloro-l l-(3-methoxypropoxy)-3,3-dimethyl-7-oxo-l,2,3,3a,7,12b- hexahydrocyclopenta[c]pyrido[2,l-a]isoquinoline-6-carboxylic acid (32) was separated into its enantiomers by chiral SFC chromatography using AD-H 4.6X100mm columns with 30% isopropanol as the co-solvent.
  • Compound 36 is the faster eluting peak retention time of 4.06 min.
  • the mixture was stirred for 16 h at rt, concentrated under vacuum, and the resulting mixture was diluted with ethanol (0.5 ml) and treated with 2M LiOH (aq) (0.15 ml). After stirring for 2h, the mixture was acidified with TFA. The product was purified by prep HPLC using acetonitrile in water with 0.1% TFA.
  • Example 38 13-chloro-12-(3-methoxypropoxy)-10,10-dimethyl-2-oxo-2,7 ,8,9,10,10a- hexahydrodipyrido[2,l-a:l',2'- d
  • Example 40 (i?)-13-bromo- 11-methoxy- 12-(3-methoxypropoxy)-3,3-dimethyl-8-oxo- 2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid
  • Ethyl (R)-13-bromo-12-hydroxy-ll-methoxy-3,3-dimethyl-8-oxo-2,3,8,13b- tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate Ethyl (R)-12- hydroxy-l l-methoxy-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2- c]phthalazine-7-carboxylate (48 mg, 0.12 mmol) was dissolved in a mixture of 0.4 mL acetic acid and 0.4 mL THF.
  • reaction mixture was stirred at 70 °C for 30 minutes after which time LCMS analysis showed complete conversion of the starting material.
  • the reaction was cooled to room temperature.
  • Aqueous lithium hydroxide (1 M, 0.07 mL, 0.07 mmol) was added and the mixture was stirred at for 25 minutes after which time LCMS analysis showed complete ester hydrolysis.
  • Ethyl (R)-ll-methoxy-3,3-dimethyl-8-oxo-12-(((trifluoromethyl)sulfonyl)oxy)- 2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate Ethyl (R)- 12-hydroxy-l l-methoxy-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2- c]phthalazine-7-carboxylate (100 mg, 0.26 mmol) was combined with N-Phenyl- bis(trifluoromethanesulfonimide) (167 mg, 0.47 mmol) in DCM (2 mL) at room temperature.
  • N,N-diisopropylethylamine (0.44 mL, 2.6 mmol) was added and the reaction was stirred at room temperature. After 20 minutes, LCMS analysis showed complete conversion. Aqueous NaHC03 was added, the DCM layer was removed, dried over Na 2 SC>4, filtered, and concentrated in vacuo.
  • the mixture was purified by flash column chromatography (ethyl acetate / hexanes/ ethanol) to provide ethyl (R)-l l-methoxy-3,3-dimethyl-8-oxo-12-(((trifluoromethyl)sulfonyl)oxy)- 2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate.
  • the mixture was placed under argon and heated at 80 °C for 35 minutes after which time LCMS analysis showed complete conversion.
  • the reaction was cooled to room temperature and 1M aqueous lithium hydroxide (0.06 ml) was added. The reaction was stirred at 40 °C for 50 minutes after which time LCMS analysis showed complete conversion.
  • reaction was cooled to room temperature, diluted with TFA and purified by preparative HPLC to provide(R)-12-(l-(difluoromethyl)-lH-pyrazol-4-yl)-l l- methoxy-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7- carboxylic acid as a TFA salt.
  • Example 45 10-Chloro-ll-(3-methoxypropoxy)-2,2-dimethyl-7-oxo- tetrahydroazeto[2,l-a]pyrido[l,2-c]phthalazine-6-carboxylic acid
  • Racemic 10-chloro-l l-(3-methoxypropoxy)-2,2-dimethyl-7-oxo-l,2,7,12b-tetrahydroazeto[2,l- a]pyrido[l,2-c]phthalazine-6-carboxylic acid was purified by SFC on an OD-H column with isopropanol as the co-solvent.
  • Ethyl l l-chloro-12-(3-methoxypropoxy)-l,l-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH- pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate was separated into its enantiomers by chiral SFC chromatography using IA 5uM-4.6X150mm columns with 30% isopropanol as the co-solvent. The faster eluting peak was taken up in in EtOH (1 ml) and 2M LiOH (0.3 ml) then stirred at room temperature until hydrolysis was complete.
  • Example 52 (R)-13-methoxy-12-(3-methoxypropoxy)-7,7-dimethyl-2-oxo-2,7,8,9,10,10a- hexahydrodipyrido[2,l-a:l',2'-c]phthalazine-3-carboxylic acid and
  • Example 53 (S)-13- methoxy-12-(3-methoxypropoxy)-7,7-dimethyl-2-oxo-2,7,8 ,9,10,10a- hexahydrodipyrido[2,l-a:l',2'-c]phthalazine-3-carboxylic acid
  • Example 54 (R)-ll-chloro-12-((3,3-difluorocyclobutyl)methoxy)-3,3-dimethyl-8-oxo- 2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid
  • lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid was prepared similarly to example 55 using (3,3-difluorocyclobutyl)methanol in place of 3-(trifluoromethoxy)propan-l-ol.
  • Methyl (R)-12-(benzyloxy)-ll-chloro-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH- pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate Ethyl 12-(benzyloxy)-l l-chloro-3,3- dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate was separated into its enantiomers by chiral SFC using an IA column with 30% methanol as the co-solvent.
  • the R isomer has a Retention time of 3.81 min. Under the chiral separation conditions and concentration most of the ethyl ester was exchanged to the methyl ester.
  • ⁇ ⁇ NMR 400 MHz, Chloroform-i ) ⁇ 8.30 (s, 1H), 7.76 (s, 1H), 7.47 - 7.37 (m, 4H), 7.37 - 7.30 (m, 1H), 6.90 (s, 1H), 6.81 (s, 1H), 5.23 (s, 2H), 4.70 (d, 1H), 3.91 (s, 3H), 2.46 - 2.30 (m, 1H), 2.24 - 2.12 (m, 1H), 1.85 - 1.76 (m, 1H), 1.52 - 1.41 (m, 1H), 1.32 (s, 3H), 0.66 (s, 3H). MS (m/z) 465.4 [M+H]+.
  • Example 56 (R)-ll'-chloro-12'-(3-methoxypropoxy)-8'-oxo-l',2',8',13b'- tetrahydrospiro[cyclopropane-l,3'-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine]-7'-carboxylic acid
  • Ethyl l l-chloro-12-(3-methoxypropoxy)-l,l-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH- pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate was separated into its enantiomers by chiral SFC chromatography using IA 5uM-4.6X150mm columns with 30% isopropanol as the co-solvent. The faster eluting peak was taken up in in EtOH (1 ml) and 2M LiOH (0.3 ml) then stirred at room temperature until hydrolysis was complete.
  • Diisopropyl azodicarboxylate (28 ⁇ , 0.14 mmol) was added and the mixture was stirred at room temperature for 4 hours. After this time additional reagents were added: 3-(trifluoromethoxy)propan-l-ol (10 mg, 72 ⁇ ), polymer-bound triphenylphosphine (100-200 mesh, 3 mmol/g 10 mg), and diisopropyl azodicarboxylate (10 ⁇ , 51 ⁇ ). The mixture was stirred at room temperature for 1 hour. 1M LiOH (200 ⁇ ) was added and the mixture was stirred at 45 °C for 10 minutes.
  • Example 59 ll'-chloro-12'-(3-methoxypropoxy)-8'-oxo-l',2',8',13b'- tetrahydrospiro[cyclopropane-l,3'-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine]-7'-carboxylic acid
  • Example 60 (R)-ll-methoxy-3,3-dimethyl-8-oxo-12-(3-(2,2,2-trifluoroethoxy)propoxy)- 2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid:

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present disclosure generally relates to compounds and pharmaceutical compositions which may be used in methods of treating a hepatitis B virus infection.

Description

COMPOUNDS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION
CROSS-REFERENCE TO RELATED APPLICATIONS
This application claims priority benefit to U.S. Provisional Application Serial No.
62/453,982, filed on February 2, 2017, U. S. Provisional Application Serial No. 62/506,921, filed on May 16, 2017, and U.S. Provisional Application Serial No. 62/536,777, filed on July 25, 2017, the disclosures of which are incorporated by reference in their entirety.
FIELD
The present invention relates to novel small molecule and related pharmaceutical compositions useful in the treatment of hepatitis B virus (HBV) infection.
BACKGROUND
The hepatitis B virus (HBV) is an enveloped, partially double-stranded DNA virus. HBV is an infectious disease that affects the liver. Initial symptoms of infection may include vomiting, jaundice, lethargy, dark urine, and abdominal pain. Chronic HBV infection can result in cirrhosis and liver cancer. Currently available therapies can inhibit replication of the virus and minimize liver damage; however, there are no currently available therapies that can clear an HBV infection. HBV surface antigen (HBsAg) is a protein located in the HBV envelope. It allows
HBV virion entry into host cells by binding to the hepatocyte sodium-taurocholate
cotransporting polypeptide (NTCP) receptor. HBsAg may also function as a tolerogen, suppressing immune elimination of infected cells. Total HBsAg loss and seroconversion are rarely achieved in chronically infected patients. Inhibiting HBsAg secretion and/or production is thus believed to be a strategy for the treatment of HBV infection, including chronic HBV infection. (Wieland, S.F. & F.V. Chisari, J. Virol. (2005), 79, 9369-80; Woltman et al. PLoS One (2011), 6, el5324; Op den Brouw et al. Immunology (2009b), 126, 280-89).
BRIEF SUMMARY
The present disclosure provides compounds of Formula (I):
Figure imgf000003_0001
(I)
wherein:
A is a 4-7 membered cycloalkyl or heterocyclyl ring substituted with 0-8 R5 groups; R1 is H or halogen;
R2 is selected from the group consisting of halogen, R2aO, C1-6 alkyl, C3-lo cycloalkyl, 3- 7 membered heterocyclyl, -NRaRb, -S(0)o-2Ra, or -CN, wherein each Ci-6alkyl, C3-10 cycloalkyl or 3-7 membered heterocyclyl is optionally substituted with 1 -5 R20 groups;
R2a is selected from the group consisting of H, C3 -6 cycloalkyl or Ci- alkyl, wherein each C3-6 cycloalkyl or Ci- alkyl is optionally substituted with 1-5 R20 groups;
R3 is selected from the group consisting of R3aO-, Ci- alkyl, 5-10 membered heteroaryl, 3-12 membered heterocyclyl, C2_6 alkenyl, C2-6 alkynyl, Ce-w aryl, C3-lo cycloalkyl, -NRaRb, and -S(0)o-2Ra, wherein each Ci- alkyl, 5-10 membered heteroaryl, 3-12 membered
heterocyclyl, C2-6 alkenyl, C2-6 alkynyl, Ce-w aryl, or C3-lo cycloalkyl is optionally substituted with 1-5 R20 groups;
R3a is selected from the group consisting of H, C1-6 alkyl, Ci-
Figure imgf000003_0002
5-10 membered heteroaryl, 3- 12 membered heterocyclyl, Ce-w aryl and C3-lo cycloalkyl, wherein each Ci-6 alkyl, Ci- alkoxyC^alkyl, 5-10 membered heteroaryl, 3-12 membered heterocyclyl, Ce-w aryl and C3-lo cycloalkyl is optionally substituted with 1-5 R20 groups;
R4 is H or halogen;
each R5 is independently selected from the group consisting of Ci- alkyl, C1-6 alkoxy, C2- 6 alkenyl, C2^ alkynyl, -NRaRb, halogen, -C(0)Ra, -C(0)ORa, -C(0)NRaRb, -OC(0)NRaRb, - NRaC(0)Rb, -NRaC(0)ORb, -S(O)0-2Ra, -S(0)2NRaRb, -NRaS(0)2Rb, -ORa, C6.10 aryl, C3.10 cycloalkyl, 5-10 membered heteroaryl and 3-12 membered heterocyclyl, wherein each Ci- alkyl, Ci-6 alkoxy, C2-6 alkenyl, C2_6 alkynyl, Ce-w aryl, C3-lo cycloalkyl, 5-10 membered heteroaryl and 3-12 membered heterocyclyl is optionally substituted with 1 -5 R20 groups;
wherein any two R5 groups on the same carbon atom can optionally form a =0; and any two R5 groups can optionally j oin together to form a C3_6 cycloalkyl or 3-6 membered heterocyclyl ring optionally substituted with 1-3 R21 groups; each Ra and Rb is independently selected from the group consisting H; or Ci^ alkyl, C3-10 cycloalkyl, 3-12 membered heterocyclyl, C6-10 aryl, 5-10 membered heteroaryl, each of which is optionally substituted with from one to five R21 groups; or Ra and Rb together with the atoms to which they are attached form a 3-12 membered heterocyclyl optionally substituted with one to five R21 groups;
each R20 is independently selected from the group consisting Ci^ alkyl, C3-10 cycloalkyl, Ci_6 alkoxy, 3-12 membered heterocyclyl, C6-io aryl, 5-10 membered heteroaryl, halogen, oxo, - ORa, -C(0)Ra, -C(0)ORa, -C(0)NRaRb, -OC(0)NRaRb, -NRaRb, -NRaC(0)Rb, -NRaC(0)ORb, -S(0)o-2Ra, -S(0)2NRaRb, -NRaS(0)2Rb, -N3, -CN, or -N02, or two R20 groups appended to the same group can join together to form a fused, spiro or bridged C3-10 cylcloalkyl or 3-12 membered heterocyclyl ring, wherein each Ci^ alkyl, C3-10 cycloalkyl, Ci^ alkoxy, 3-12 membered heterocyclyl, C6-10 aryl, 5-10 membered heteroaryl is optionally substituted with from one to five halogen, oxo, -ORa, -C(0)Ra, -C(0)ORa, -C(0)NRaRb, -OC(0)NRaRb, -NRaRb, - NRaC(0)Rb, -NRaC(0)ORb, -S(O)0-2Ra, -S(0)2NRaRb, -NRaS(0)2Rb, -N3, -CN, or -N02; and each R21 is independently selected from the group consisting Ci^ alkyl, Ci-6haloalkyl,
C3-10 cycloalkyl, Ci^ alkoxy, 3-12 membered heterocyclyl, C6-10 aryl, 5-10 membered heteroaryl, hydroxyl, amino, Ci^ alkylamino, -CN or halogen;
or a pharmaceutically acceptable salt thereof.
In another embodiment, each R21 is independently selected from the group consisting Ci_ 6 alkyl, C3-10 cycloalkyl, Ci-6 alkoxy, 3-12 membered heterocyclyl, C6-10 aryl, 5-10 membered heteroaryl, hydroxyl, amino, Ci^ alkylamino, -CN or halogen.
Another embodiment provides a compound of Formula (II):
Figure imgf000004_0001
II
wherein:
Z1 is a bond, O, NRa or CR5eR5f;
R2 is selected from the group consisting of halogen, R2aO, Ci-6 alkyl, or -CN, wherein alkyl is optionally substituted with 1-3 R20 groups; R a is selected from the group consisting of H, C3-6 cycloalkyl or Ci^ alkyl, wherein each C3-6 cycloalkyl or Ci^ alkyl is optionally substituted with 1-3 R20 groups;
R3 is selected from
Figure imgf000005_0001
and C3-8cycloalkoxyCi^alkoxy, wherein each Ci-6 alkoxy,
Figure imgf000005_0002
and C3-8cycloalkoxyCi-6alkoxy is optionally substituted with halo;
each of R5a, R5b, R5c, R5d, R5e, R5f R5g and R5h are independently selected from the group consisting of H, alkyl, alkoxy, C2-6 alkenyl, C2-6 alkynyl, -NRaRb, halogen, C(0)Ra, - C(0)ORa, -C(0)NRaRb, -OC(0)NRaRb, -NRaC(0)Rb, -NRaC(0)ORb, -S(O)0-2Ra, - S(0)2NRaRb, -NRaS(0)2Rb, -N3, -CN, -N02, -ORa, C6.10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl and 3-12 membered heterocyclyl wherein each Ci^ alkyl, Ci^ alkoxy, C2-6 alkenyl, C2-6 alkynyl, Ce-ιο aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl and 3-12 membered heterocyclyl is optionally substituted with 1-5 R20 groups;
wherein up to two of R5a and R5b, R5c and R5d, R5e and R5f, or R5g and R5h can optionally form a =0; and wherein any two of R5a, R5b, R5c, R5d, R5e, R5f R5g and R5h can optionally j oin together to form a cycloalkyl or heterocyclyl ring optionally substituted with 1-3 R21 groups; each Ra and Rb is independently selected from the group consisting H; or Ci^ alkyl, C3-10 cycloalkyl, 3-12 membered heterocyclyl, C6-10 aryl, 5-10 membered heteroaryl, each of which is optionally substituted with from one to five R21 groups; or Ra and Rb together with the atoms to which they are attached form a 3-12 membered heterocyclyl optionally substituted with one to five R21 groups;
each R20 is independently selected from the group consisting Ci^ alkyl, C3-10 cycloalkyl, Ci_6 alkoxy, 3-12 membered heterocyclyl, C6-io aryl, 5-10 membered heteroaryl, halogen, oxo, - ORa, -C(0)Ra, -C(0)ORa, -C(0)NRaRb, -OC(0)NRaRb, -NRaRb, -NRaC(0)Rb, -NRaC(0)ORb, -S(0)o-2Ra, -S(0)2NRaRb, -NRaS(0)2Rb, -N3, -CN, or -N02, wherein each d-s alkyl, C3-10 cycloalkyl, Ci^ alkoxy, 3-12 membered heterocyclyl, C6-io aryl, 5-10 membered heteroaryl is optionally substituted with from one to five halogen, oxo, -ORa, -C(0)Ra, -C(0)ORa, - C(0)NRaRb, -OC(0)NRaRb, -NRaRb, -NRaC(0)Rb, -NRaC(0)ORb, -S(O)0-2Ra, -S(0)2NRaRb, -NRaS(0)2Rb, -N3, -CN, or -N02; and
each R21 is independently selected from the group consisting Ci^ alkyl, Ci-6haloalkyl, C3-10 cycloalkyl, Ci^ alkoxy, 3-12 membered heterocyclyl, C6-10 aryl, 5-10 membered heteroaryl, hydroxyl, amino, Ci^ alkylamino, -CN or halogen;
or a pharmaceutically acceptable salt thereof. In another embodiment, each R21 is independently selected from the group consisting Ci_ 6 alkyl, C3-10 cycloalkyl, C1-6 alkoxy, 3-12 membered heterocyclyl, Ce-w aryl, 5-10 membered heteroaryl, hydroxyl, amino, Ci^ alkylamino, -CN or halogen;
In some embodiments provided herein is a pharmaceutical composition comprising a compound of Formula (I) or (II), or Formula (la), (lb) or (Ila) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient. In some embodiments, the pharmaceutical composition further comprises one or more additional therapeutic agents.
In some embodiments provided herein is a method of inhibiting the production and/or secretion of HBsAg in an individual (e.g. a human) infected with HBV comprising
administering a therapeutically effective amount of a compound of Formula (I) or (II), or
Formula (la), (lb) or (Ila), or a pharmaceutically acceptable salt thereof, to the individual. In some embodiments, the human is chronically infected with HBV.
In some embodiments provided herein is a method of treating or preventing a HBV infection comprising administering to an individual (e.g. a human) in need thereof a
therapeutically effective amount of a compound of Formula (I) or (II), or Formula (la), (lb) or (Ila), or a pharmaceutically acceptable salt thereof. In some embodiments, the individual is chronically infected with HBV. In some embodiments, the methods further comprise administering one or more additional therapeutic agents.
In certain embodiments, a compound of Formula (I) or (II), or Formula (la), (lb) or (Ila), or a pharmaceutically acceptable salt thereof, for use in medical therapy is provided.
In certain embodiments, a compound of Formula (I) or (II), or Formula (la), (lb) or (Ila), or a pharmaceutically acceptable salt thereof, for use in treating or preventing HBV infection is provided
In certain embodiments, the use of a compound of Formula (I) or (II), or Formula (la), (lb) or (Ila), or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for treating or preventing HBV infection is provided.
Kits comprising a compound of Formula (I) or (II), or Formula (la), (lb) or (Ila), or pharmaceutically acceptable salts thereof, or pharmaceutical compositions of the foregoing are also provided. Articles of manufacture comprising a unit dose of the compounds, or pharmaceutically acceptable salts thereof, of the foregoing are also provided. Methods of preparing compounds of the present disclosure are also provided. BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 is a series of graphs plotting mean branch point count per cell as a function of concentration of compound, where the compound is Vincristine, RG783/R07020332, and compound 73. FIG. 2 is a series of graphs plotting mean neurite total length per cell as a function of concentration of compound, where the compound is Vincristine, RG783/R07020332, and compound 73.
DETAILED DESCRIPTION
The description below is made with the understanding that the present disclosure is to be considered as an exemplification of the claimed subject matter, and is not intended to limit the appended claims to the specific embodiments illustrated. The resent disclosure provides reference to various embodiments and techniques. However, it should be understood that many variations and modifications may be made while remaining within the spirit and scope of the present disclosure. The headings used throughout this disclosure are provided for convenience and are not to be construed to limit the claims in any way. Embodiments illustrated under any heading may be combined with embodiments illustrated under any other heading.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. A dash at the front or end of a chemical group is a matter of convenience to indicate the point of attachment to a parent moiety; chemical groups may be depicted with or without one or more dashes without losing their ordinary meaning. A prefix such as "Cu-V" or (Cu-Cv) indicates that the following group has from u to v carbon atoms, where u and v are integers. For example, "Ci-6alkyl" indicates that the alkyl group has from 1 to 6 carbon atoms.
Unless the context requires otherwise, throughout the present specification and claims, the word "comprise" and variations thereof, such as, "comprises" and "comprising" are to be construed in an open, inclusive sense, that is as "including, but not limited to".
As used herein, "alkyl" is a linear or branched saturated monovalent hydrocarbon. Examples of alkyl groups include, but are not limited to, methyl (Me, -CH3), ethyl (Et,
-CH2CH3), 1 -propyl (w-Pr, ^-propyl, -CH2CH2CH3), 2-propyl (z-Pr, /-propyl, -CH(CH3)2), 1- butyl (77-Bu, 77-butyl, -CH2CH2CH2CH3), 2-methyl-l -propyl (z-Bu, /-butyl, -CH2CH(CH3)2), 2-butyl (s-Bu, s-butyl, -CH(CH3)CH2CH3), 2-methyl-2-propyl (Y-Bu, i-butyl, -C(CH3)3), 1- pentyl («-pentyl, -CH2CH2CH2CH2CH3), 2-pentyl (-CH(CH3)CH2CH2CH3), 3-pentyl
(-CH(CH2CH3)2), 2-methyl-2-butyl (-C(CH3)2CH2CH3), 3-methyl-2-butyl
(-CH(CH3)CH(CH3)2), 3-methyl-l -butyl (-CH2CH2CH(CH3)2), 2-methyl-l -butyl
(-CH2CH(CH3)CH2CH3), 1-hexyl (-CH2CH2CH2CH2CH2CH3), 2-hexyl
(-CH(CH3)CH2CH2CH2CH3), 3-hexyl (-CH(CH2CH3)(CH2CH2CH3)), 2-methyl-2-pentyl
(-C(CH3)2CH2CH2CH3), 3-methyl-2-pentyl (-CH(CH3)CH(CH3)CH2CH3), 4-methyl-2-pentyl (-CH(CH3)CH2CH(CH3)2), 3-methyl-3-pentyl (-C(CH3)(CH2CH3)2), 2-methyl-3-pentyl (- CH(CH2CH3)CH(CH3)2), and 2,3-dimethyl-2-butyl (-C(CH3)2CH(CH3)2), 3,3-dimethyl-2-butyl (-CH(CH3)C(CH3)3. "Amino" refers to -NH2. Amino groups may also be substituted as described herein, such as with alkyl, carbonyl or other amino groups. The term "alkylamino" refers to an amino group substituted with one or two alkyl substituents (e.g. dimethylamino or propylamino).
The term "halo'Or "halogen" as used herein refers to fluoro (-F), chloro (-C1), bromo (- Br) and iodo (-1). The term "haloalkyl" as used herein refers to an alkyl as defined herein, wherein one or more hydrogen atoms of the alkyl are independently replaced by a halogen substituent, which may be the same or different. For example,
Figure imgf000008_0001
is a Ci-6alkyl wherein one or more of the hydrogen atoms of the
Figure imgf000008_0002
have been replaced by a halo substituent. Examples of haloalkyl groups include, but are not limited to, fluoromethyl, fluorochloromethyl,
difluoromethyl, difluorochloromethyl, trifluoromethyl, 1,1,1-trifluoroethyl, and
pentafluoroethyl.
The term "alkoxy" as used herein refers to a radical of the formula -ORx where Rx is an alkyl radical as defined above. Non-limiting examples of alkoxy include methoxy, ethoxy, propoxy, and butoxy. The term "haloalkoxy" as used herein refers to a radical of the formula -ORx wherein Rx is an alkyl radical as defined above, and wherein one or more hydrogens on the alkyl radical are replaced with halogen.
The terms "alkoxyalkoxy" and "haloalkoxyalkoxy," refer to an alkoxy radical that is substituted with alkoxy or haloalkoxy, respectively. For illustrative purposes only, a non- limiting example of "alkoxyalkoxy"
Figure imgf000008_0003
"Alkenyl" refers to any group derived from a straight or branched hydrocarbon with at least one carbon-carbon double bond. Alkenyl groups include, but are not limited to, ethenyl (vinyl), propenyl (allyl), 1-butenyl, 1,3-butadienyl, and the like. Unless otherwise specified, an alkenyl group has from 2 to 10 carbon atoms, for example from 2 to 6 carbon atoms, for example from 2 to 4 carbon atoms.
"Alkynyl" refers to any group derived from a straight or branched hydrocarbon with at least one carbon-carbon triple bond and includes those groups having one triple bond and one double bond. Examples of alkynyl groups include, but are not limited to, ethynyl (-C≡CH), propargyl (-CH2C≡CH), (£)-pent-3-en-l-ynyl, and the like. Unless otherwise specified, an alkynyl group has from 2 to 10 carbon atoms, for example from 2 to 6 carbon atoms, for example from 2 to 4 carbon atoms.
"Aryl" refers to any group derived from one or more aromatic rings, that is, a single aromatic ring, a bicyclic or a multicyclic ring system. Aryl groups include, but are not limited to, those groups derived from acenaphthylene, anthracene, azulene, benzene, chrysene, a cyclopentadienyl anion, naphthalene, fluoranthene, fluorene, indane, perylene, phenalene, phenanthrene, pyrene and the like. Unless otherwise specified, an aryl group has from 5 to 20 carbon atoms.
"Arylalkyl" (also "aralkyl") refers to any combination aryl group and an alkyl group. Arylalkyl groups include, but are not limited to, those groups derived from benzyl, tolyl, dimethylphenyl, 2-phenylethan-l-yl, 2-naphthylmethyl, and the like. An arylalkyl group comprises from 6 to 30 carbon atoms, for example the alkyl group can comprise from 1 to 10 carbon atoms and the aryl group can comprise from 5 to 20 carbon atoms.
"Bridged" refers to a ring fusion wherein non-adjacent atoms on a ring are joined by a divalent substituent, such as an alkylenyl or heteroalkylenyl group or a single heteroatom. Quinuclidinyl and admantanyl are examples of bridged ring systems.
The term "cycloalkyl" or "carbocycle" as used herein refers to a saturated or partially saturated all carbon ring radical. A cycloalkyl group can have one or more cyclic rings and includes fused and bridged groups that are fully saturated or partially unsaturated. Examples include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, adamantyl, methylcycloproyl (cyclopropylmethyl), ethylcyclopropyl, cyclohexenyl and the like. Another example includes C5-7 cycloakenyl. The term "cycloalkoxy" as used herein refers to a cycloalkyl group as defined herein appended directly to an -O- or to an alkoxy group as defined herein. Examples of cycloalkoxy groups include cyclopropyloxy, cyclobutylmethoxy, and cyclopentyloxyethyl.
"Heteroaryl" refers to mono or multi cyclic aryl group in which one or more of the aromatic carbon atoms (and any associated hydrogen atoms) are independently replaced with the same or different heteroatom or heteroatomic group, as defined above. Multicyclic ring systems are included in heteroaryl and may be attached at the ring with the heteroatom or the aryl ring. Heteroaryl groups include, but are not limited to, groups derived from acridine, benzoimidazole, benzothiophene, benzofuran, benzoxazole, benzothiazole, carbazole, carboline, cinnoline, furan, imidazole, imidazopyridine, indazole, indole, indoline, indolizine, isobenzofuran, isochromene, isoindole, isoindoline, isoquinoline, isothiazole, isoxazole, naphthyridine, oxadiazole, oxazole, perimidine, phenanthridine, phenanthroline, phenazine, phthalazine, pteridine, purine, pyran, pyrazine, pyrazole, pyridazine, pyridine, pyridone, pyrimidine, pyrrole, pyrrolizine, quinazoline, quinoline, quinolizine, quinoxaline, tetrazole, thiadiazole, thiazole, thiophene, triazole, xanthene, and the like. Heteroaryl groups may have 5-14 members, 5-10 members, or 5-6 members.
"Heterocycle," "heterocyclic," and "heterocyclyl" refer to a saturated or partially unsaturated non-aromatic ring or a partially non-aromatic multiple-ring system with at least one heteroatom or heteroatomic group, as defined above. Heterocycles include, but are not limited to, groups derived from azetidine, aziridine, imidazolidine, morpholine, oxirane (epoxide), oxetane, piperazine, piperidine, pyrazolidine, piperidine, pyrrolidine, pyrrolidinone,
tetrahydrofuran, tetrahydrothiophene, dihydropyridine, tetrahydropyridine, tetrahydro-2H- thiopyran 1 , 1 -dioxide, quinuclidine, N-bromopyrrolidine, N-chloropiperidine, and the like. Heterocyclyl groups also include partially unsaturated ring systems containing one or more double bonds, including fused ring systems with one aromatic ring and one non-aromatic ring, but not fully aromatic ring systems. Examples include dihydroquinolines, e.g. 3,4- dihydroquinoline, dihydroisoquinolines, e.g. 1 ,2-dihydroisoquinoline, dihydroimidazole, tetrahydroimidazole, etc., indoline, isoindoline, isoindolones (e.g. isoindolin-l -one), isatin, dihydrophthalazine, quinolinone, spiro[cyclopropane-l, -isoindolin]-3'-one, and the like.
Heterocycle groups may have 3-12 members, or 3-10 members, or 3-7 members, or 5-6 members.
"Hydroxyl" and "hydroxy" are used interchangeably and refer to -OH. "Oxo" refers to =0. Where tautomeric forms of the compound exist, hydroxyl and oxo groups are interchangeable.
It is understood that combinations of chemical groups may be used and will be recognized by persons of ordinary skill in the art. For instance, the group "hydroxyalkyl" would refer to a hydroxyl group attached to an alkyl group. A great number of such combinations may be readily envisaged. Additional examples of substituent combinations used herein include: Ci^ alkylamiocarbonyl (e.g. CH3CH2NHC(0)-) Cw alkoxycarbonyl (e.g. CH30-C(0)-), 5-7 membered
Figure imgf000011_0001
alkyl (e.g. piperazinyl-CH2-), C1-6 alkylsulfonyl-5-7 membered heterocyclyl (e.g. CH3S(0)2-morpholinyl-), 5-7 membered heterocyclyl Ci^ alkoxy (e.g.
pyrrolidinyl-O-), 5-7 membered heterocyclyloxy, (4-7 membered heterocyclyl)-4-7 membered heterocyclyl (e.g. oxetanyl-pyrrolidinyl-), C3-6 cycloalkylaminocarbonyl (e.g. cyclopropyl-NH- C(O)-), 5-7 membered heterocyclyl-C2-6 alkynyl (e.g. N-piperazinyl-CH2C≡CCH2-), and C6-1o arylaminocarbonyl (e.g. phenyl-NH-C(O)-).
As used herein, "appended to the same group" indicates that multiple substituents or R- groups are bound to the same base group and cannot be bound or fused with other groups from different parts of the molecule. For example, "two R20 groups appended to the same group j oin together to form a fused, spiro or bridged C3-10 cylcloalkyl or 3-12 membered heterocyclyl ring," indicates that the R20 groups capable of being fused, spiroed or bridged are bound together only with atoms from the group with which they were derived (e.g. R2 exclusively) and not R20 groups on different substituents (i.e. not R2 and R3). Reference to the rings "A" and "B" are made by the letter designation. It is understood that "A" can be replaced with "ring A" or "B" can be replaced with "ring B"
"Spiro" refers to a ring substituent which is j oined by two bonds at the same carbon atom. Examples of spiro groups include 1 ,1 -diethylcyclopentane, dimethyl-dioxolane, and 4- benzyl-4-methylpiperidine, wherein the cyclopentane and piperidine, respectively, are the spiro substituents. When substituents (R-groups) are taken together (e.g. when R7 and R8 are taken together) they may be taken from the same point of attachment to form a spiro ring. "Fused" refers to a ring substituent which is j oined by two bonds at adj acent carbon atoms, such as decahydronaphthalene. "Bridged" refers to a ring substituent which is j oined by two bonds at the non-adj acent carbon atoms, such as a quinuclidine.
The nomenclature used herein to name the subj ect compounds is illustrated in the
Examples and elsewhere herein. As used herein, "treatment" or "treating" is an approach for obtaining beneficial or desired results. For purposes of the present disclosure, beneficial or desired results include, but are not limited to, alleviation of a symptom and/or diminishment of the extent of a symptom associated with a disease or condition. In one embodiment, "treatment" or "treating" includes one or more of the following: a) inhibiting the disease or condition (e.g. , decreasing one or more symptoms resulting from the disease or condition, and/or diminishing the extent of the disease or condition); b) slowing or arresting the development of one or more symptoms associated with the disease or condition (e.g. , stabilizing the disease or condition, delaying the worsening or progression of the disease or condition); and c) relieving the disease or condition, e.g. , causing the regression of clinical symptoms, ameliorating the disease state, delaying the progression of the disease, increasing the quality of life, and/or prolonging survival.
As used herein, "prevention" or "preventing" refers to a regimen that protects against the onset of the disease or disorder such that the clinical symptoms of the disease do not develop. Thus, "prevention" relates to administration of a therapy (e.g., administration of a therapeutic substance) to a subject before signs of the disease are detectable in the subject (e.g. , administration of a therapeutic substance to a subject in the absence of detectable infectious agent (e.g. , virus) in the subject). The subject may be an individual at risk of developing the disease or disorder, such as an individual who has one or more risk factors known to be associated with development or onset of the disease or disorder. Thus, in certain embodiments, the term "preventing HBV infection" refers to administering to a subj ect who does not have a detectable HBV infection an anti-HBV therapeutic substance. It is understood that the subject for anti-HBV preventative therapy may be an individual at risk of contracting the HBV virus.
As used herein, the term "therapeutically effective amount" or "effective amount" refers to an amount that is effective to elicit the desired biological or medical response, including the amount of a compound that, when administered to a subject for treating a disease, is sufficient to effect such treatment for the disease. The effective amount will vary depending on the particular compound, and characteristics of the subject to be treated, such as age, weight, etc. The effective amount can include a range of amounts. As is understood in the art, an effective amount may be in one or more doses, i.e. , a single dose or multiple doses may be required to achieve the desired treatment endpoint. An effective amount may be considered in the context of administering one or more therapeutic agents, and a single agent may be considered to be given in an effective amount if, in conjunction with one or more other agents, a desirable or beneficial result may be or is achieved. Suitable doses of any co-administered compounds may optionally be lowered due to the combined action (e.g. , additive or synergistic effects) of the compounds.
As used herein, "co-administration" includes administration of unit dosages of the compounds disclosed herein before or after administration of unit dosages of one or more additional therapeutic agents, for example, administration of the compound disclosed herein within seconds, minutes, or hours of the administration of one or more additional therapeutic agents. For example, in some embodiments, a unit dose of a compound of the present disclosure is administered first, followed within seconds or minutes by administration of a unit dose of one or more additional therapeutic agents. Alternatively, in other embodiments, a unit dose of one or more additional therapeutic agents is administered first, followed by administration of a unit dose of a compound of the present disclosure within seconds or minutes. In some embodiments, a unit dose of a compound of the present disclosure is administered first, followed, after a period of hours (e.g. , 1-12 hours), by administration of a unit dose of one or more additional therapeutic agents. In other embodiments, a unit dose of one or more additional therapeutic agents is administered first, followed, after a period of hours (e.g. , 1-12 hours), by administration of a unit dose of a compound of the present disclosure.
Also provided herein are pharmaceutically acceptable salts, hydrates, solvates, tautomeric forms, polymorphs, and prodrugs of the compounds described herein.
"Pharmaceutically acceptable" or "physiologically acceptable" refer to compounds, salts, compositions, dosage forms and other materials which are suitable for veterinary or human pharmaceutical use.
Compounds described herein may be prepared and/or formulated as pharmaceutically acceptable salts. Pharmaceutically acceptable salts are non-toxic salts of a free base form of a compound that possesses the desired pharmacological activity of the free base. These salts may be derived from inorganic or organic acids or bases. For example, a compound that contains a basic nitrogen may be prepared as a pharmaceutically acceptable salt by contacting the compound with an inorganic or organic acid. Non-limiting examples of pharmaceutically acceptable salts include sulfates, pyrosulfates, bisulfates, sulfites, bisulfites, phosphates, monohydrogen-phosphates, dihydrogenphosphates, metaphosphates, pyrophosphates, chlorides, bromides, iodides, acetates, propionates, decanoates, caprylates, acrylates, formates, isobutyrates, caproates, heptanoates, propiolates, oxalates, malonates, succinates, suberates, sebacates, fumarates, maleates, butyne-l,4-dioates, hexyne-l,6-dioates, benzoates, chlorobenzoates, methylbenzoates, dinitrobenzoates, hydroxybenzoates, methoxybenzoates, phthalates, sulfonates, methylsulfonates, propylsulfonates, besylates, xylenesulfonates, naphthalene- 1 -sulfonates, naphthalene-2-sulfonates, phenyl acetates, phenylpropionates, phenylbutyrates, citrates, lactates, γ-hydroxybutyrates, glycolates, tartrates, and mandelates. Lists of other suitable pharmaceutically acceptable salts are found in Remington: The Science and Practice of Pharmacy, 21 st Edition, Lippincott Wiliams and Wilkins, Philadelphia, Pa., 2006.
Non-limiting examples of "pharmaceutically acceptable salts" of the compounds disclosed herein also include salts derived from an appropriate base, such as an alkali metal (for example, sodium, potassium), an alkaline earth metal (for example, magnesium), ammonium and NX4 + (wherein X is C 1-C4 alkyl). Also included are base addition salts, such as sodium or potassium salts.
A "stereoisomer" refers to a compound made up of the same atoms bonded by the same bonds but having different three-dimensional structures, which are not interchangeable. The present disclosure contemplates various stereoisomers and mixtures thereof and includes "enantiomers", which refers to two stereoisomers whose molecules are non-superimposable mirror images of one another.
Compounds described herein may have chiral centers and/or geometric isomeric centers (E- and Z- isomers), and it is to be understood that the invention encompasses all such optical, enantiomeric, diastereoisomeric and geometric isomers. Where compounds are represented in their chiral form, it is understood that the embodiment encompasses, but is not limited to, the specific diastereomerically or enantiomerically enriched form. Where chirality is not specified but is present, it is understood that the embodiment is directed to either the specific
diastereomerically or enantiomerically enriched form; or a racemic or scalemic mixture of such compound(s). As used herein, "scalemic mixture" is a mixture of stereoisomers at a ratio other than 1 : 1.
A "tautomer" refers to a proton shift from one atom of a molecule to another atom of the same molecule. The present disclosure includes tautomers of any said compounds.
A "solvate" is formed by the interaction of a solvent and a compound. Solvates of salts of the compounds described herein are also provided. Hydrates of the compounds described herein are also provided. The term "prodrug" as used herein is a biologically inactive derivative of a drug upon administration to the human body is converted to the biologically active parent drug according to some chemical or enzymatic pathway.
Compounds
The present disclosure provides compounds of Formula (I):
Figure imgf000015_0001
(I)
wherein:
A is a 4-7 membered cycloalkyl or heterocyclyl ring substituted with 0-8 R5 groups; R1 is H or halogen;
R2 is selected from the group consisting of halogen, R2aO, C1-6 alkyl, C3-lo cycloalkyl, 3- 7 membered heterocyclyl, -NRaRb, -S(O)0-2Ra, or -CN, wherein each Ci-6alkyl, C3-10 cycloalkyl or 3-7 membered heterocyclyl is optionally substituted with 1 -5 R20 groups;
R2a is selected from the group consisting of H, C3 -6 cycloalkyl or Ci- alkyl, wherein each C3-6 cycloalkyl or Ci- alkyl is optionally substituted with 1-5 R20 groups;
R3 is selected from the group consisting of R3aO-, Ci- alkyl, 5-10 membered heteroaryl, 3-12 membered heterocyclyl, C2_6 alkenyl, C2-6 alkynyl, Ce-w aryl, C3-lo cycloalkyl, -NRaRb, and -S(0)o-2Ra, wherein each Ci- alkyl, 5-10 membered heteroaryl, 3-12 membered
heterocyclyl, C2-6 alkenyl, C2-6 alkynyl, Ce-w aryl, or C3-lo cycloalkyl is optionally substituted with 1-5 R20 groups;
R3a is selected from the group consisting of H, C1-6 alkyl, Ci-
Figure imgf000015_0002
5-10 membered heteroaryl, 3- 12 membered heterocyclyl, Ce-w aryl and C3-lo cycloalkyl, wherein each Ci-6 alkyl, Ci- alkoxyC^alkyl, 5-10 membered heteroaryl, 3-12 membered heterocyclyl, Ce-w aryl and C3-lo cycloalkyl is optionally substituted with 1-5 R20 groups;
R4 is H or halogen;
each R5 is independently selected from the group consisting of Ci- alkyl, C1-6 alkoxy, C2- 6 alkenyl, C2^ alkynyl, -NRaRb, halogen, -C(0)Ra, -C(0)ORa, -C(0)NRaRb, -OC(0)NRaRb, - NRaC(0)Rb, -NRaC(0)ORb, -S(O)0-2Ra, -S(0)2NRaRb, -NRaS(0)2Rb, -ORa, C6.10 aryl, C3.10 cycloalkyl, 5-10 membered heteroaryl and 3-12 membered heterocyclyl, wherein each Ci^ alkyl, Ci-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl, Ce-ιο aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl and 3-12 membered heterocyclyl is optionally substituted with 1 -5 R20 groups;
wherein any two R5 groups on the same carbon atom can optionally form a =0; and any two R5 groups can optionally j oin together to form a C3-6 cycloalkyl or 3-6 membered heterocyclyl ring optionally substituted with 1-3 R21 groups;
each Ra and Rb is independently selected from the group consisting H; or C i^ alkyl, C3-i0 cycloalkyl, 3-12 membered heterocyclyl, C6-io aryl, 5-10 membered heteroaryl, each of which is optionally substituted with from one to five R21 groups; or Ra and Rb together with the atoms to which they are attached form a 3-12 membered heterocyclyl optionally substituted with one to five R21 groups;
each R20 is independently selected from the group consisting Ci^ alkyl, C3-10 cycloalkyl, Ci-6 alkoxy, 3-12 membered heterocyclyl, C6-10 aryl, 5-10 membered heteroaryl, halogen, oxo, - ORa, -C(0)Ra, -C(0)ORa, -C(0)NRaRb, -OC(0)NRaRb, -NRaRb, -NRaC(0)Rb, -NRaC(0)ORb, -S(0)o-2Ra, -S(0)2NRaRb, -NRaS(0)2Rb, -N3, -CN, or -N02, or two R20 groups appended to the same group can j oin together to form a fused, spiro or bridged C3-10 cylcloalkyl or 3-12 membered heterocyclyl ring, wherein each Ci^ alkyl, C3-10 cycloalkyl, Ci^ alkoxy, 3-12 membered heterocyclyl, C6-10 aryl, 5-10 membered heteroaryl is optionally substituted with from one to five halogen, oxo, -ORa, -C(0)Ra, -C(0)ORa, -C(0)NRaRb, -OC(0)NRaRb, -NRaRb, - NRaC(0)Rb, -NRaC(0)ORb, -S(O)0-2Ra, -S(0)2NRaRb, -NRaS(0)2Rb, -N3, -CN, or -N02; and each R21 is independently selected from the group consisting Ci^ alkyl, Ci-6haloalkyl, C3-io cycloalkyl, Ci^ alkoxy, 3-12 membered heterocyclyl, C6-io aryl, 5-10 membered heteroaryl, hydroxyl, amino, Ci^ alkylamino, -CN or halogen;
or a pharmaceutically acceptable salt thereof.
In another embodiment, each R21 is independently selected from the group consisting Ci.
6 alkyl, C3-10 cycloalkyl, Ci-6 alkoxy, 3-12 membered heterocyclyl, C6-10 aryl, 5-10 membered heteroaryl, hydroxyl, amino, Ci^ alkylamino, -CN or halogen.
The present disclosure provides compounds of Formula (la):
Figure imgf000016_0001
wherein:
A is a 4-7 membered cycloalkyl or heterocyclyl ring substituted with 0-8 R5 groups;
R3 is selected from the group consisting of R3aO-, Ci^ alkyl, 5-10 membered heteroaryl, 3-12 membered heterocyclyl, C2_6 alkenyl, C2-6 alkynyl, Ce-w aryl, C3-10 cycloalkyl, -NRaRb, and -S(0)o-2Ra, wherein each Ci^ alkyl, 5-10 membered heteroaryl, 3-12 membered
heterocyclyl, C2-6 alkenyl, C2-6 alkynyl, Ce-w aryl, or C3-lo cycloalkyl is optionally substituted with 1-5 R20 groups;
R3a is selected from the group consisting of H, C1-6 alkyl,
Figure imgf000017_0001
5-10 membered heteroaryl, 3- 12 membered heterocyclyl, Ce-w aryl and C3-10 cycloalkyl, wherein each Ci_6 alkyl, alkoxyC^alkyl, 5-10 membered heteroaryl, 3-12 membered heterocyclyl, C6-1o aryl and C3-lo cycloalkyl is optionally substituted with 1-5 R20 groups;
each Ra and Rb is independently selected from the group consisting H; or alkyl, C3-lo cycloalkyl, 3-12 membered heterocyclyl, Ce-w aryl, 5-10 membered heteroaryl, each of which is optionally substituted with from one to five R21 groups; or Ra and Rb together with the atoms to which they are attached form a 3-12 membered heterocyclyl optionally substituted with one to five R21 groups;
each R20 is independently selected from the group consisting Ci^ alkyl, C3-lo cycloalkyl, Ci-6 alkoxy, 3-12 membered heterocyclyl, Ce-w aryl, 5-10 membered heteroaryl, halogen, oxo, - ORa, -C(0)Ra, -C(0)ORa, -C(0)NRaRb, -OC(0)NRaRb, -NRaRb, -NRaC(0)Rb, -NRaC(0)ORb, -S(0)o-2Ra, -S(0)2NRaRb, -NRaS(0)2Rb, -N3, -CN, or -N02, or two R20 groups appended to the same group can j oin together to form a fused, spiro or bridged C3-lo cylcloalkyl or 3-12 membered heterocyclyl ring, wherein each C -5 alkyl, C3-lo cycloalkyl, Ci^ alkoxy, 3-12 membered heterocyclyl, Ce-w aryl, 5-10 membered heteroaryl is optionally substituted with from one to five halogen, oxo, -ORa, -C(0)Ra, -C(0)ORa, -C(0)NRaRb, -OC(0)NRaRb, -NRaRb, - NRaC(0)Rb, -NRaC(0)ORb, -S(O)0-2Ra, -S(0)2NRaRb, -NRaS(0)2Rb, -N3, -CN, or -N02; and each R21 is independently selected from the group consisting alkyl, Ci-6haloalkyl, C3-io cycloalkyl, Ci^ alkoxy, 3-12 membered heterocyclyl, Ce-w aryl, 5-10 membered heteroaryl, hydroxyl, amino, Ci^ alkylamino, -CN or halogen;
or a pharmaceutically acceptable salt thereof.
In another embodiment, each R21 is independently selected from the group consisting Ci_ 6 alkyl, C3-lo cycloalkyl, C1-6 alkoxy, 3-12 membered heterocyclyl, Ce-w aryl, 5-10 membered heteroaryl, hydroxyl, amino, Ci^ alkylamino, -CN or halogen. The present disclosure provides compounds of Formula (lb):
Figure imgf000018_0001
wherein:
A is a 4-7 membered cycloalkyl or heterocyclyl ring substituted with 0-8 R5 groups;
X is CH or N;
R1 is H or halogen;
R2 is selected from the group consisting of halogen, R2aO, C1-6 alkyl, C3-lo cycloalkyl, 3- 7 membered heterocyclyl, -NRaRb, -S(0)o-2Ra, or -CN, wherein each Ci-6alkyl, C3-10 cycloalkyl or 3-7 membered heterocyclyl is optionally substituted with 1 -5 R20 groups;
R2a is selected from the group consisting of H, C3 -6 cycloalkyl or Ci^ alkyl, wherein each C3-6 cycloalkyl or Ci^ alkyl is optionally substituted with 1-5 R20 groups;
R3 is selected from the group consisting of R3aO-, Ci^ alkyl, 5-10 membered heteroaryl, 3-12 membered heterocyclyl, C2_6 alkenyl, C2-6 alkynyl, Ce-ιο aryl, C3-lo cycloalkyl, -NRaRb, and -S(0)o-2Ra, wherein each C -5 alkyl, 5-10 membered heteroaryl, 3-12 membered
heterocyclyl, C2-6 alkenyl, C2-6 alkynyl, Ce-ιο aryl, or C3-lo cycloalkyl is optionally substituted with 1-5 R20 groups;
R3a is selected from the group consisting of H, C1-6 alkyl, C -5
Figure imgf000018_0002
5-10 membered heteroaryl, 3- 12 membered heterocyclyl, Ce-ιο aryl and C3-lo cycloalkyl, wherein each Ci^5 alkyl, alkoxyC^alkyl, 5-10 membered heteroaryl, 3-12 membered heterocyclyl, C6-io aryl and C3-lo cycloalkyl is optionally substituted with 1-5 R20 groups;
R4 is H or halogen;
each R5 is independently selected from the group consisting of Ci^ alkyl, C1-6 alkoxy, C2- 6 alkenyl, C2^ alkynyl, -NRaRb, halogen, -C(0)Ra, -C(0)ORa, -C(0)NRaRb, -OC(0)NRaRb, - NRaC(0)Rb, -NRaC(0)ORb, -S(O)0-2Ra, -S(0)2NRaRb, -NRaS(0)2Rb, -ORa, C6.10 aryl, C3.10 cycloalkyl, 5-10 membered heteroaryl and 3-12 membered heterocyclyl, wherein each C -5 alkyl, Ci-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl, Ce-ιο aryl, C3-lo cycloalkyl, 5-10 membered heteroaryl and 3-12 membered heterocyclyl is optionally substituted with 1 -5 R20 groups; wherein any two R groups on the same carbon atom can optionally form a =0; and any two R5 groups can optionally j oin together to form a C3-6 cycloalkyl or 3-6 membered heterocyclyl ring optionally substituted with 1-3 R21 groups;
each Ra and Rb is independently selected from the group consisting H; or Ci^ alkyl, C3 0 cycloalkyl, 3-12 membered heterocyclyl, C6-10 aryl, 5-10 membered heteroaryl, each of which is optionally substituted with from one to five R21 groups; or Ra and Rb together with the atoms to which they are attached form a 3-12 membered heterocyclyl optionally substituted with one to five R21 groups;
each R20 is independently selected from the group consisting Ci^ alkyl, C3-10 cycloalkyl, Ci-6 alkoxy, 3-12 membered heterocyclyl, C6-10 aryl, 5-10 membered heteroaryl, halogen, oxo, - ORa, -C(0)Ra, -C(0)ORa, -C(0)NRaRb, -OC(0)NRaRb, -NRaRb, -NRaC(0)Rb, -NRaC(0)ORb, -S(0)o-2Ra, -S(0)2NRaRb, -NRaS(0)2Rb, -N3, -CN, or -N02, or two R20 groups appended to the same group can join together to form a fused, spiro or bridged C3-10 cylcloalkyl or 3-12 membered heterocyclyl ring, wherein each Ci^ alkyl, C3-10 cycloalkyl, Ci^ alkoxy, 3-12 membered heterocyclyl, C6-10 aryl, 5-10 membered heteroaryl is optionally substituted with from one to five halogen, oxo, -ORa, -C(0)Ra, -C(0)ORa, -C(0)NRaRb, -OC(0)NRaRb, -NRaRb, - NRaC(0)Rb, -NRaC(0)ORb, -S(O)0-2Ra, -S(0)2NRaRb, -NRaS(0)2Rb, -N3, -CN, or -N02; and each R21 is independently selected from the group consisting Ci^ alkyl, Ci-6haloalkyl, C3-10 cycloalkyl, Ci^ alkoxy, 3-12 membered heterocyclyl, C6-10 aryl, 5-10 membered heteroaryl, hydroxyl, amino, Ci^ alkylamino, -CN or halogen;
or a pharmaceutically acceptable salt thereof.
In another embodiment, each R21 is independently selected from the group consisting Ci. 6 alkyl, C3-10 cycloalkyl, Ci-6 alkoxy, 3-12 membered heterocyclyl, C6-10 aryl, 5-10 membered heteroaryl, hydroxyl, amino, Ci^ alkylamino, -CN or halogen.
The present disclosure provides compounds of Formula (Ic):
Figure imgf000019_0001
Ic wherein: A is a 4-7 membered cycloalkyl or heterocyclyl ring substituted with 0-8 R groups; R1 is H or halogen;
R3 is selected from the group consisting of R3aO-, Ci^ alkyl, 5-10 membered heteroaryl, 3-12 membered heterocyclyl, C2_6 alkenyl, C2-6 alkynyl, Ce-w aryl, C3-10 cycloalkyl, -NRaRb, and -S(0)o-2Ra, wherein each C -5 alkyl, 5-10 membered heteroaryl, 3-12 membered
heterocyclyl, C2-6 alkenyl, C2-6 alkynyl, Ce-w aryl, or C3-lo cycloalkyl is optionally substituted with 1-5 R20 groups;
R3a is selected from the group consisting of H, C1-6 alkyl, alkoxyC^alkyl, 5-10 membered heteroaryl, 3- 12 membered heterocyclyl, Ce-w aryl and C3-10 cycloalkyl, wherein each Ci^ alkyl, Ci^ alkoxyC^alkyl, 5-10 membered heteroaryl, 3-12 membered heterocyclyl, Ce-w aryl and C3-lo cycloalkyl is optionally substituted with 1-5 R20 groups;
R4 is H or halogen;
each R5 is independently selected from the group consisting of Ci^ alkyl, C1-6 alkoxy, C2- 6 alkenyl, C2^ alkynyl, -NRaRb, halogen, -C(0)Ra, -C(0)ORa, -C(0)NRaRb, -OC(0)NRaRb, - NRaC(0)Rb, -NRaC(0)ORb, -S(O)0-2Ra, -S(0)2NRaRb, -NRaS(0)2Rb, -ORa, C6.10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl and 3-12 membered heterocyclyl, wherein each C -5 alkyl, Ci^5 alkoxy, C2-6 alkenyl, C2-6 alkynyl, Ce-w aryl, C3-lo cycloalkyl, 5-10 membered heteroaryl and 3-12 membered heterocyclyl is optionally substituted with 1 -5 R20 groups;
wherein any two R5 groups on the same carbon atom can optionally form a =0; and any two R5 groups can optionally j oin together to form a C3-6 cycloalkyl or 3-6 membered heterocyclyl ring optionally substituted with 1-3 R21 groups;
each Ra and Rb is independently selected from the group consisting H; or alkyl, C3-lo cycloalkyl, 3-12 membered heterocyclyl, Ce-w aryl, 5-10 membered heteroaryl, each of which is optionally substituted with from one to five R21 groups; or Ra and Rb together with the atoms to which they are attached form a 3-12 membered heterocyclyl optionally substituted with one to five R21 groups;
each R20 is independently selected from the group consisting Ci^ alkyl, C3-lo cycloalkyl, Ci-6 alkoxy, 3-12 membered heterocyclyl, Ce-w aryl, 5-10 membered heteroaryl, halogen, oxo, - ORa, -C(0)Ra, -C(0)ORa, -C(0)NRaRb, -OC(0)NRaRb, -NRaRb, -NRaC(0)Rb, -NRaC(0)ORb, -S(0)o-2Ra, -S(0)2NRaRb, -NRaS(0)2Rb, -N3, -CN, or -N02, or two R20 groups appended to the same group can j oin together to form a fused, spiro or bridged C3-lo cylcloalkyl or 3-12 membered heterocyclyl ring, wherein each C -5 alkyl, C3-lo cycloalkyl, Ci^ alkoxy, 3-12 membered heterocyclyl, Ce-w aryl, 5-10 membered heteroaryl is optionally substituted with from one to five halogen, oxo, -ORa, -C(0)Ra, -C(0)ORa, -C(0)NRaRb, -OC(0)NRaRb, -NRaRb, - NRaC(0)Rb, -NRaC(0)ORb, -S(O)0-2Ra, -S(0)2NRaRb, -NRaS(0)2Rb, -N3, -CN, or -N02; and each R21 is independently selected from the group consisting Ci^ alkyl, Ci-6haloalkyl, C3-10 cycloalkyl, Ci^ alkoxy, 3-12 membered heterocyclyl, C6-10 aryl, 5-10 membered heteroaryl, hydroxyl, amino, Ci^ alkylamino, -CN or halogen;
or a pharmaceutically acceptable salt thereof.
In another embodiment, each R21 is independently selected from the group consisting Ci. 6 alkyl, C3-i0 cycloalkyl, Ci-6 alkoxy, 3-12 membered heterocyclyl, C6-io aryl, 5-10 membered heteroaryl, hydroxyl, amino, Ci^ alkylamino, -CN or halogen;
In another embodiment, X is N. In another embodiment, X is CH.
The following embodiments are inclusive of definitions for Formula (I), Formula (la), Formula (lb), Formula (II) and/or Formula (Ila).
In one embodiment, R2 is selected from the group consisting of halogen, C3-i0 cycloalkyl, C3-10 cycloalkoxy, Ci-6 alkyl,
Figure imgf000021_0001
or -CN, wherein each C3-10 cycloalkyl, C4-10 cycloalkoxy, Ci^ alkyl, d^alkoxy is optionally substituted with halo. In another embodiment, R2 is selected from the group consisting of chloro, methoxy, ethoxy, -OCH(CH3)2 OC(CH3)3 cyclopropyl, -OCHF2 and 0 ° . In another embodiment, R is halogen. In another embodiment, R2 is chloro. In another embodiment, R2 is methoxy. In another embodiment, R2 is C3-6cycloalkyl. In another embodiment, R2 is cyclopropyl, or a pharmaceutically acceptable salt thereof. In another embodiment, R2 is 3-7 membered heterocyclyl. In another embodiment, R2 is oxetanyl. In another embodiment, R2 is oxetan-3-yl.
In another embodiment, R2 is R2aO-. In another embodiment, R2a is C3_6 cycloalkyl optionally substituted with 1 -2 R20 groups. In another embodiment, R2a is cyclopropyl. In another embodiment, R2a is
Figure imgf000021_0002
In another embodiment, R2a is C6-10
Figure imgf000021_0003
In another embodiment, R2a is 3-7 membered heterocyclylCi-6alkyl. In another embodiment, R2a is 5-7 membered heteroarylCi-6alkyl. In another embodiment, R2a is Ci^ haloalkyl. In another embodiment, R2a is -CF3.
In another embodiment, R2 is -CH2OCH3 (methoxymethyl). In another embodiment, R2 is Ci-3 alkoxymethyl. In another embodiment, R2 is C3-6 cycloalkyl substituted with 1-3 fluoro groups. More particularly, 2 fluoro groups. More parpticularly, 2 fluoro groups on the same carbon.
In another embodiment, R3 is selected from C -5 alkoxy,
Figure imgf000022_0001
and C3-
Figure imgf000022_0002
haloCi-3alkylC3-6cycloalkylaminocarbonyloxyC2-6alkoxy, wherein each Ci-6 alkoxy,
Figure imgf000022_0003
and C3-8cycloalkoxyCi^alkoxy is optionally substituted with halo. In another embodiment, R3 is Ci-6alkoxyCi-6alkoxy or
Figure imgf000022_0004
In another embodiment, R3 is C3^halocycloalkyloxyC3^alkyoxy. In another embodiment, R3 is haloCi-3alkylC3^cycloalkylaminocarbonyloxyC2-6alkoxy.
In another embodiment, R3 is selected from the group consisting of C2-6 alkenyl, Ce-w aryl, 3-7 membered heterocyclyl, C3-6 cycloalkyl, C1-6 alkoxyCi-6alkyl, C3-6
Figure imgf000022_0005
5-10 membered heteroaryl, C2-6 alkynyl, each optionally substituted with 1 -3 R20 groups. In another embodiment, R3 is C3-6 cycloalkyl. In another embodiment, R3 is C3-6 cycloalkoxy.
In another embodiment, R3 is Ci- alkoxyCi-6alkyl. In another embodiment, R3 is C3-6 cycloalkylCi-6alkyl. In another embodiment, R3 is C2-6 alkynyl optionally substituted with 1-3 R20 groups.
More particularly, the C2-6 alkynyl group is substituted with heteroaryl or
Figure imgf000022_0006
each optionally substituted with 1 -3 methyl groups.
In another embodiment R3 is R3aO-, wherein R3a is optionally substituted with 1-3 R20 groups. In another embodiment, R3a is C3-6 cycloalkyl. In another embodiment, R3a is C3-6 cycloalkylCi-6 alkyl, wherein the C3-6 cycloalkyl is optionally substituted with oxo or 1-3 fluoro groups. In another embodiment, R3a is 5-10 membered heteroaryl. In another embodiment, R3a is 3-7 membered heterocyclylCi-6alkyl. In another embodiment, R3a is
Figure imgf000022_0007
In another embodiment, R3a is Ci- alkyl substituted with R20 selected from C3-6 cycloalkyl, Ce-w aryl, 3-7 membered heterocyclyl, 5-7 membered heteroaryl. In another embodiment R3a is 5-10 membered heteroaryl, 3- 12 membered heterocyclyl or Ce-w aryl.
In another embodiment, R3 is selected from the group consisting of:
Figure imgf000023_0001
embodiment, R .3 :- A O . In another embodiment, R3 is not
Figure imgf000023_0002
In another embodiment, R is selected from the group consisting of:
Figure imgf000023_0003
In another embodiment, R is
Figure imgf000023_0004
In another embodiment, R is selected from a group consisting of:
Figure imgf000023_0005
In another embodiment, R1 and R4 are both H. In another embodiment, R4 is bromo. In another embodiment, R1 is bromo. In another embodiment, R1 is H. In another embodiment, R4 is H. In another embodiment, one of R1 or R4 is halo. In another embodiment, at least one of R is C1-3 alkyl optionally substituted with halo. In another embodiment, at least two R5 groups are C1-3 alkyl. In another embodiment, at least two R5 groups are methyl, or a pharmaceutically acceptable salt thereof. In another embodiment, at least two R5 groups are methyl bound at the same carbon atom, or a pharmaceutically acceptable salt thereof. In another embodiment, two R5 groups j oin together at the same carbon atom to form a cyclopropyl, or a pharmaceutically acceptable salt thereof. In another embodiment, the compound of Formula (I) or (II), or Formula (la), (lb) or (Ila), is/are substituted with 0-7, 0-6, 0-5, 0-4, 0-3 or 0-2 R5 groups.
In another embodiment, R1 and R4 are both H. In another embodiment, R1 and R4 are both H and R2 is cyclopropyl.
In another embodiment, two R5 groups j oin together at the same carbon atom to form a C3_6 cycloalkyl or 3-6 membered heterocyclyl ring, each optionally substituted with 1-3 R20 groups.
In another embodiment, each R20 is independently selected from the group consisting Ci_ 6 alkyl, C3-10 cycloalkyl, C1-6 alkoxy, 3-12 membered heterocyclyl, Ce-w aryl, 5-10 membered heteroaryl, halogen, oxo, -ORa, -C(0)Ra, -C(0)ORa, -C(0)NRaRb, -OC(0)NRaRb, -NRaRb, - NRaC(0)Rb, -NRaC(0)ORb, -S(O)0-2Ra, -S(0)2NRaRb, -NRaS(0)2Rb, -N3, -CN, or -N02, wherein each C1-6 alkyl, C3-lo cycloalkyl, C1-6 alkoxy, 3-12 membered heterocyclyl, C6-1o aryl, 5- 10 membered heteroaryl is optionally substituted with from one to five halogen, oxo, -ORa, - C(0)Ra, -C(0)ORa, -C(0)NRaRb, -OC(0)NRaRb, -NRaRb, -NRaC(0)Rb, -NRaC(0)ORb, - S(0)o-2Ra, -S(0)2NRaRb, -NRaS(0)2Rb, -N3, -CN, or -N02.
In another embodiment, each of R2, R2a, R3, R3a and R5 are substituted with 0-5, 0-4, 0-3, 0-2 or 0-1 R20 groups. In another embodiment, each Ra or Rb group is substituted with 0-5, 0-4, 0-3, 0-2 or 0-1 R21 groups. In another embodiment, d
Figure imgf000024_0001
In certain embodiments, ring A is selected from the group consisting of:
Figure imgf000025_0001
In another embodiment, ring A from Formula (I) or Formula (la) or Forumula (lb) is:
Figure imgf000025_0002
wherein:
Z1 is a bond, O, NRa or CR5eR5f;
Z2 is a bond, O, NRa or CR5gR5h;
provided only one of Zxand Z2 is O or NRa;
each of R5a, R5b, R5c, R5d, R5e, R5f R5g and R5h are independently selected from the group consisting of H, Cw alkyl, Cw alkoxy, C2-6 alkenyl, C2-6 alkynyl, -NRaRb, halogen, C(0)Ra, - C(0)ORa, -C(0)NRaRb, -OC(0)NRaRb, -NRaC(0)Rb, -NRaC(0)ORb, -S(O)0-2Ra, -
S(0)2NRaRb, -NRaS(0)2Rb, -N3, -CN, -N02, -ORa, C6.10 aryl, C3-io cycloalkyl, 5-10 membered heteroaryl and 3-12 membered heterocyclyl wherein each Ci^ alkyl, Ci^ alkoxy, C2_6 alkenyl, C2-6 alkynyl, Ce-w aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl and 3-12 membered heterocyclyl is optionally substituted with 1 -5 R20 groups;
wherein up to two of R5a and R5b, R5c and R5d, R5e and R5f, or R5g and R5h can form a =0; wherein any two of R5a, R5b, R5c, R5d, R5e, R5f R5g and R5h can join together to form a cycloalkyl or heterocyclyl ring optionally substituted with 1 -3 R21 groups;
each Ra and Rb is independently selected from the group consisting H; or C i^ alkyl, C3 0 cycloalkyl, 3-12 membered heterocyclyl, C6-10 aryl, 5-10 membered heteroaryl, each of which is optionally substituted with from one to five R21 groups; or Ra and Rb together with the atoms to which they are attached form a 3-12 membered heterocyclyl optionally substituted with one to five R21 groups;
each R20 is independently selected from the group consisting Ci^ alkyl, C3-10 cycloalkyl, Ci-6 alkoxy, 3-12 membered heterocyclyl, C6-10 aryl, 5-10 membered heteroaryl, halogen, oxo, - ORa, -C(0)Ra, -C(0)ORa, -C(0)NRaRb, -OC(0)NRaRb, -NRaRb, -NRaC(0)Rb, -NRaC(0)ORb, -S(0)o-2Ra, -S(0)2NRaRb, -NRaS(0)2Rb, -N3, -CN, or -N02, or two R20 groups appended to the same group can j oin together to form a fused, spiro or bridged C3-10 cylcloalkyl or 3-12 membered heterocyclyl ring, wherein each Ci^ alkyl, C3-10 cycloalkyl, Ci^ alkoxy, 3-12 membered heterocyclyl, C6-10 aryl, 5-10 membered heteroaryl is optionally substituted with from one to five halogen, oxo, -ORa, -C(0)Ra, -C(0)ORa, -C(0)NRaRb, -OC(0)NRaRb, -NRaRb, - NRaC(0)Rb, -NRaC(0)ORb, -S(O)0-2Ra, -S(0)2NRaRb, -NRaS(0)2Rb, -N3, -CN, or -N02; and each R21 is independently selected from the group consisting Ci^ alkyl, Ci-6haloalkyl, C3-10 cycloalkyl, Ci^ alkoxy, 3-12 membered heterocyclyl, C6-10 aryl, 5-10 membered heteroaryl, hydroxyl, amino, Ci^ alkylamino, -CN or halogen;
or a pharmaceutically acceptable salt thereof.
In another embodiment, each R21 is independently selected from the group consisting Ci. 6 alkyl, C3-i0 cycloalkyl, Ci-6 alkoxy, 3-12 membered heterocyclyl, C6-io aryl, 5-10 membered heteroaryl, hydroxyl, amino, Ci^ alkylamino, -CN or halogen.
In another embodiment, Z2 is CR5gR5h. In another embodiment, R5g and R5h are H or
CH3
Another embodiment of the present invention provides a compound of Formula (II):
Figure imgf000026_0001
II
wherein:
Z1 is a bond, O, NRa or CR5eR5f;
R2 is selected from the group consisting of halogen, R2aO, Ci-6 alkyl, or -CN, wherein is optionally substituted with 1-3 R20 groups;
R2a is selected from the group consisting of H, C3-6 cycloalkyl or Ci^ alkyl, wherein each C3_6 cycloalkyl or Ci^ alkyl is optionally substituted with 1-3 R20 groups;
R3 is selected from
Figure imgf000026_0002
and C3-8cycloalkoxyCi^alkoxy, wherein each Ci-6 alkoxy,
Figure imgf000026_0003
and C3-8cycloalkoxyCi-6alkoxy is optionally substituted with halo;
each of R5a, R5b, R5c, R5d, R5e, R5f R5g and R5h are independently selected from the group consisting of H, Cw alkyl, Cw alkoxy, C2-6 alkenyl, C2-6 alkynyl, -NRaRb, halogen, C(0)Ra, - C(0)ORa, -C(0)NRaRb, -OC(0)NRaRb, -NRaC(0)Rb, -NRaC(0)ORb, -S(O)0-2Ra, - S(0)2NRaRb, -NRaS(0)2Rb, -N3, -CN, -N02, -ORa, C6.10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl and 3-12 membered heterocyclyl wherein each Ci^ alkyl, Ci^ alkoxy, C2_6 alkenyl, C2-6 alkynyl, Ce-ιο aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl and 3-12 membered heterocyclyl is optionally substituted with 1 -5 R20 groups;
wherein up to two of R5a and R5b, R5c and R5d, R5e and R5f, or R5g and R5h can optionally form a =0; and wherein any two of R5a, R5b, R5c, R5d, R5e, R5f R5g and R5h can optionally j oin together to form a cycloalkyl or heterocyclyl ring optionally substituted with 1-3 R21 groups; each Ra and Rb is independently selected from the group consisting H; or C i^ alkyl, C3-lo cycloalkyl, 3-12 membered heterocyclyl, C6-1o aryl, 5-10 membered heteroaryl, each of which is optionally substituted with from one to five R21 groups; or Ra and Rb together with the atoms to which they are attached form a 3-12 membered heterocyclyl optionally substituted with one to five R21 groups;
each R20 is independently selected from the group consisting Ci^ alkyl, C3-lo cycloalkyl, Ci-6 alkoxy, 3-12 membered heterocyclyl, Ce-w aryl, 5-10 membered heteroaryl, halogen, oxo, - ORa, -C(0)Ra, -C(0)ORa, -C(0)NRaRb, -OC(0)NRaRb, -NRaRb, -NRaC(0)Rb, -NRaC(0)ORb, -S(0)o-2Ra, -S(0)2NRaRb, -NRaS(0)2Rb, -N3, -CN, or -N02, wherein each d-s alkyl, C3.10 cycloalkyl, Ci^ alkoxy, 3-12 membered heterocyclyl, Ce-w aryl, 5-10 membered heteroaryl is optionally substituted with from one to five halogen, oxo, -ORa, -C(0)Ra, -C(0)ORa, - C(0)NRaRb, -OC(0)NRaRb, -NRaRb, -NRaC(0)Rb, -NRaC(0)ORb, -S(O)0-2Ra, -S(0)2NRaRb, -NRaS(0)2Rb, -N3, -CN, or -N02; and
each R21 is independently selected from the group consisting Ci^ alkyl, C1-6 haloalkyl, C3-io cycloalkyl, Ci^ alkoxy, 3-12 membered heterocyclyl, Ce-w aryl, 5-10 membered heteroaryl, hydroxyl, amino, Ci^ alkylamino, -CN or halogen;
or a pharmaceutically acceptable salt thereof.
In another embodiment, each R21 is independently selected from the group consisting Ci_ 6 alkyl, C3-10 cycloalkyl, C1-6 alkoxy, 3-12 membered heterocyclyl, Ce-w aryl, 5-10 membered heteroaryl, hydroxyl, amino, alkylamino, -CN or halogen.
In another embodiment, Z1 is O.
Another embodiment provides a compound of Formula (Ila):
Figure imgf000027_0001
Ila wherein:
B is a 3-6 membered cycloalkyl or 3-6 membered heterocyclyl ring each substituted with 0-2 R21 groups;
Z1 is a bond, O, NRa or CR5eR5f;
R2 is selected from the group consisting of halogen, R2aO, C1-6 alkyl, or -CN, wherein is optionally substituted with 1 -3 R20 groups;
R2a is selected from the group consisting of H, C3-6 cycloalkyl or Ci^ alkyl, wherein each C3-6 cycloalkyl or Ci^ alkyl is optionally substituted with 1-3 R20 groups;
R3 is selected from C -5 alkoxy,
Figure imgf000028_0001
and C3-8cycloalkoxyCi^alkoxy, wherein each C1-6 alkoxy,
Figure imgf000028_0002
and C3-8cycloalkoxyCi.6alkoxy is optionally substituted with halo;
each of R5a, R5bR5e, R5f R5g and R5h are independently selected from the group consisting of H, Ci-s alkyl, d-s alkoxy, C2^ alkenyl, C2-6 alkynyl, -NRaRb, halogen, C(0)Ra, -C(0)ORa, - C(0)NRaRb, -OC(0)NRaRb, -NRaC(0)Rb, -NRaC(0)ORb, -S(O)0-2Ra, -S(0)2NRaRb, -
NRaS(0)2Rb, -N3, -CN, -NO2, -ORa, C6.10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl and 3-12 membered heterocyclyl wherein each C1-6 alkyl, Ci^ alkoxy, C2-6 alkenyl, C2-6 alkynyl, C6- 10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl and 3-12 membered heterocyclyl is optionally substituted with 1 -5 R20 groups;
wherein up to two of R5a and R5b, R5e and R5f, or R5g and R5h can optionally form a =0; and wherein any two of R5a, R5b, R5e, R5f R5g and R5h can optionally j oin together to form a cycloalkyl or heterocyclyl ring optionally substituted with 1 -3 R21 groups;
each Ra and Rb is independently selected from the group consisting H; or C i^ alkyl, C3 0 cycloalkyl, 3-12 membered heterocyclyl, Ce-w aryl, 5-10 membered heteroaryl, each of which is optionally substituted with from one to five R21 groups; or Ra and Rb together with the atoms to which they are attached form a 3-12 membered heterocyclyl optionally substituted with one to five R21 groups;
each R20 is independently selected from the group consisting Ci^ alkyl, C3-10 cycloalkyl, Ci-6 alkoxy, 3-12 membered heterocyclyl, Ce-w aryl, 5-10 membered heteroaryl, halogen, oxo, - ORa, -C(0)Ra, -C(0)ORa, -C(0)NRaRb, -OC(0)NRaRb, -NRaRb, -NRaC(0)Rb, -NRaC(0)ORb, -S(0)o-2Ra, -S(0)2NRaRb, -NRaS(0)2Rb, -N3, -CN, or -N02, wherein each Cw alkyl, C3-10 cycloalkyl, Ci^ alkoxy, 3-12 membered heterocyclyl, Ce-w aryl, 5-10 membered heteroaryl is optionally substituted with from one to five halogen, oxo, -ORa, -C(0)Ra, -C(0)ORa, - C(0)NRaRb, -OC(0)NRaRb, -NRaRb, -NRaC(0)Rb, -NRaC(0)ORb, -S(O)0-2Ra, -S(0)2NRaRb, -NRaS(0)2Rb, -N3, -CN, or -N02; and
each R21 is independently selected from the group consisting Ci^ alkyl, Ci-6 haloalkyl, C3-10 cycloalkyl, Ci^ alkoxy, 3-12 membered heterocyclyl, Ce-ιο aryl, 5-10 membered heteroaryl, hydroxyl, amino, Ci^ alkylamino, -CN or halogen;
or a pharmaceutically acceptable salt thereof.
In another embodiment, each R21 is independently selected from the group consisting Ci. 6 alkyl, C3-i0 cycloalkyl, Ci-6 alkoxy, 3-12 membered heterocyclyl, C6-io aryl, 5-10 membered heteroaryl, hydroxyl, amino, Ci^ alkylamino, -CN or halogen.
In another embodiment, B is selected from the group consisting of oxetanyl, 2,2- dimethyl-l ,3-dioxanyl, or cyclopropyl.
In another embodiment, Z1 is O.
The following embodiments are inclusive of definitions for Formula (I), (la), (lb), and/or (II) or (Ila).
In another embodiment, Z1 is a bond. In another embodiment, Z1 is CR5eR5f. In another embodiment, Z1 is O.
In another embodiment, R5e and R5f are H, halo, or C1-3 alkyl. In another embodiment, R5c and R5d are H. In another embodiment, R5c and R5 are C1-3 alkyl. In another embodiment, R5c and R5d are CH3. In another embodiment, R5c is H and R5d is CH3. In another embodiment, R5c and R5d are taken together to form cyclopropyl,. In another embodiment, R5a and R5 are H. In another embodiment, R5a and R5b are CH3. In another embodiment, R5g and R5h are H. In another embodiment, R5g and R5h are CH3, or a pharmaceutically acceptable salt thereof.
In another embodiment, R5c and R5d are taken together to form a C3-6 cycloalkyl or 3-6 membered heterocyclyl ring. In another embodiment, R5c and R5d are taken together to form a C3-6 cycloalkyl. In another embodiment, R5c and R5d are taken together to form cyclopropyl or cyclobutyl.
In another embodiment, R5a and R5b are taken together to form a ring selected from the group consisting of oxetanyl, 2,2-dimethyl-l,3-dioxanyl, or cyclopropyl.
In another embodiment, R5a and R5b are both methoxy methyl.
In one embodiment, the compounds are selected from the group consisting of:
Figure imgf000030_0001
Figure imgf000031_0001
It is understood that the compounds depicted without stereochemistry encompas all such optical, enantiomeric, diastereoisomeric and geometric isomers as well as scalemic and racemic mixtures thereof.
In another embodiment, the compounds are selected from the group consisting of:
Figure imgf000032_0001
Figure imgf000033_0001
Figure imgf000034_0001
Figure imgf000035_0001

Figure imgf000036_0001
or a pharmaceutically acceptable salt thereof.
In another embodiment, the compound is selected from:
Figure imgf000037_0001

Figure imgf000038_0001
or a pharmaceutically acceptable salt thereof.
Another embodiment provides a compound of the formula:
Figure imgf000038_0002
or a pharmaceutically acceptable salt thereof.
Another embodiment provides a compound of the formula:
Figure imgf000038_0003
or a pharmaceutically acceptable salt thereof.
Another embodiment provides a compound of the formula:
Figure imgf000038_0004
or a pharmaceutically acceptable salt thereof.
In another embodiment, the compound is selected from a group consisting of:
Figure imgf000039_0001
Another embodiment provides a pharmaceutical composition comprising a compound or pharmaceutically acceptable salt as described herein, and a pharmaceutically acceptable excipient.
Another embodiment further comprises one or more additional therapeutic agents. More particularly, the one or more additional therapeutic agents are selected from the group consisting of HBV DNA polymerase inhibitors, toll-like receptor 7 modulators, toll -like receptor 8 modulators, toll-like receptor 7 and 8 modulators, toll-like receptor 3 modulators, interferon alpha ligands, HBsAg inhibitors, compounds targeting HBcAg, cyclophilin inhibitors, HBV therapeutic vaccines, HBV prophylactic vaccines, HBV viral entry inhibitors, NTCP inhibitors, antisense oligonucleotide targeting viral mRNA, short interfering RNAs (siRNA), HBeAg inhibitors, HBx inhibitors, cccDNA inhibitors, HBV antibodies including HBV antibodies targeting the surface antigens of the hepatitis B virus, thymosin agonists, cytokines, nucleoprotein inhibitors (HBV core or capsid protein inhibitors), stimulators of retinoic acid- inducible gene 1 , stimulators of NOD2, recombinant thymosin alpha- 1 and hepatitis B virus replication inhibitors, hepatitis B surface antigen (HBsAg) secretion or assembly inhibitors, IDO inhibitors, KDM5 inhibitors, and combinations thereof. In another embodiment, the one or more additional therapeutic agents are selected from the group consisting of adefovir (Hepsera®), tenofovir disoproxil fumarate + emtricitabine (Truvada®), tenofovir disoproxil fumarate (Viread®), entecavir (Baraclude®), lamivudine (Epivir-HBV®), tenofovir alafenamide, tenofovir, tenofovir disoproxil, tenofovir alafenamide fumarate, tenofovir alafenamide hemifumarate, telbivudine (Tyzeka®), Clevudine®, emtricitabine (Emtriva®), peginterferon alfa-2b (PEG-Intron®), Multiferon®, interferon alpha lb (Hapgen®), interferon alpha-2b (Intron A®), pegylated interferon alpha-2a (Pegasys®), interferon alfa-nl(Humoferon®), ribavirin, interferon beta-la (Avonex®), Bioferon, Ingaron, Inmutag (Inferon), Algeron, Roferon-A, Oligotide, Zutectra, Shaferon, interferon alfa-2b (Axxo), Alfaferone, interferon alfa-2b (BioGeneric Pharma), Feron, interferon-alpha 2 (CJ), Bevac, Laferonum, Vipeg, Blauferon-B, Blauferon-A, Intermax Alpha, Realdiron, Lanstion, Pegaferon, PDferon-B, interferon alfa-2b (IFN, Laboratories Bioprofarma), alfainterferona 2b, Kalferon, Pegnano, Feronsure, PegiHep, interferon alfa 2b (Zydus-Cadila), Optipeg A, Realfa 2B, Reliferon, interferon alfa-2b (Amega), interferon alfa-2b (Virchow), peginterferon alfa-2b (Amega), Reaferon-EC, Proquiferon, Uniferon, Urifron, interferon alfa-2b (Changchun Institute of Biological Products), Anterferon, Shanferon, MOR-22, interleukin-2 (IL-2), recombinant human interleukin-2, Layfferon, Ka Shu Ning, Shang Sheng Lei Tai, Intefen, Sinogen,
Fukangtai, Alloferon, and celmoleukin, and combinations thereof. In another embodiment, the one or more additional therapeutic agents are selected from the group consisting of entecavir, adefovir, tenofovir disoproxil fumarate, tenofovir alafenamide, tenofovir, tenofovir disoproxil, tenofovir alafenamide fumarate, tenofovir alafenamide hemifumarate, telbivudine and lamivudine.
Another embodiment provides a method of inhibiting the production and/or secretion of HBsAg in an individual infected with HBV comprising administering a therapeutically effective amount of a compound as described herein to the individual.
Another embodiment provides a method of treating or preventing an HBV infection comprising administering to an individual in need thereof a therapeutically effective amount of a compound as described herein to the individual. In another embodiment, the individual is chronically infected with HBV. Another embodiment provides an article of manufacture comprising a unit dosage of a compound as described herein. Another embodiment provides a compound as described herein for use in medical therapy.
Another embodiment provides a compound as described herein for use in treating or preventing an HBV infection in an individual. Another embodiment provides use of a compound as described herein for the manufacture of a medicament for use in medical therapy.
Another embodiment provides a compound as described herein for use in inhibiting the production or secretion of HBsAg in vitro.
Any of the compounds described herein is optionally comprises a pharmaceutically acceptable salt.
Also provided herein are compounds of Formula (I) or (II), or Formula (la), (lb) or (Ila) in which from 1 to n hydrogen atoms attached to a carbon atom may be replaced by a deuterium atom or D, in which n is the number of hydrogen atoms in the molecule. As known in the art, the deuterium atom is a non-radioactive isotope of the hydrogen atom. Such compounds may increase resistance to metabolism, and thus may be useful for increasing the half-life of the compounds described herein or pharmaceutically acceptable salts, isomers, or mixtures thereof when administered to a mammal. See, e.g., Foster, "Deuterium Isotope Effects in Studies of Drug Metabolism", Trends Pharmacol. Sci., 5(12):524-527 (1984). Such compounds are synthesized by means known in the art, for example by employing starting materials in which one or more hydrogen atoms have been replaced by deuterium.
Examples of isotopes that can be incorporated into the disclosed compounds also include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, chlorine, and iodine, such as 2H, 3H, nC, 13C, 14C, 13N, 15N, 150, 170, 180, 31P, 32P, 35S, 18F, 36C1, 123I, and 125I, respectively. Substitution with positron emitting isotopes, such as nC, 18F, 150 and 13N, can be useful in Positron Emission Topography (PET) studies for examining substrate receptor occupancy. Isotopically-labeled compounds of Formula (I) or (II), or Formula (la), (lb) or (Ila), can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the Examples as set out below using an appropriate isotopically-labeled reagent in place of the non-labeled reagent previously employed. Additionally, in one embodiment, the compounds described herein are pegylated at a substituent or functional group (i.e. a polyethylene glycol moiety is appended thereto).
The compounds disclosed herein may contain one or more asymmetric centers and may thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that may be defined, in terms of absolute stereochemistry, as (R)- or (S)- or, as (D)- or (L)- for amino acids. The present disclosure is meant to include all such possible isomers, as well as their racemic and optically pure forms. Optically active (+) and (-), (R)- and (S)-, or (D)- and (L)- isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques, for example, chromatography and fractional crystallization. Conventional techniques for the preparation/isolation of individual enantiomers include chiral synthesis from a suitable optically pure precursor or resolution of the racemate (or the racemate of a salt or derivative) using, for example, chiral high pressure liquid chromatography (HPLC). Likewise, all tautomeric forms are also intended to be included.
In certain embodiments, the present disclosure provides a pharmaceutical composition comprising a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient. In certain embodiments, the pharmaceutical composition comprises one or more additional therapeutic agents, as described in more detail below.
Pharmaceutical compositions comprising the compounds disclosed herein, or pharmaceutically acceptable salts thereof, may be prepared with one or more pharmaceutically acceptable excipients which may be selected in accord with ordinary practice.
"Pharmaceutically acceptable excipient" includes without limitation any adjuvant, carrier, excipient, glidant, sweetening agent, diluent, preservative, dye/colorant, flavor enhancer, surfactant, wetting agent, dispersing agent, suspending agent, stabilizer, isotonic agent, solvent, or emulsifier which has been approved by the United States Food and Drug Administration as being acceptable for use in humans or domestic animals.
In certain embodiments, pharmaceutical compositions are provided as a solid dosage form, including a solid oral dosage form, such as a tablet. Tablets may contain excipients including glidants, fillers, binders and the like. Aqueous compositions may be prepared in sterile form, and when intended for delivery by other than oral administration generally may be isotonic. All compositions may optionally contain excipients such as those set forth in the Rowe et al, Handbook of Pharmaceutical Excipients, 6th edition, American Pharmacists Association, 2009. Excipients can include ascorbic acid and other antioxidants, chelating agents such as EDTA, carbohydrates such as dextrin, hydroxyalkylcellulose, hydroxyalkylmethylcellulose, stearic acid and the like.
Pharmaceutical compositions disclosed herein include those suitable for various administration routes, including oral administration. The compositions may be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. Such methods include the step of bringing into association the active ingredient (e.g. , a compound of the present disclosure or a pharmaceutical salt thereof) with one or more pharmaceutically acceptable excipients. The compositions may be prepared by uniformly and intimately bringing into association the active ingredient with liquid excipients or finely divided solid excipients or both, and then, if necessary, shaping the product. Techniques and
formulations generally are found in Remington: The Science and Practice of Pharmacy, 21st Edition, Lippincott Wiliams and Wilkins, Philadelphia, Pa., 2006.
Compositions described herein that are suitable for oral administration may be presented as discrete units (a unit dosage form) including but not limited to capsules, cachets or tablets each containing a predetermined amount of the active ingredient. In one embodiment, the pharmaceutical composition is a tablet.
Pharmaceutical compositions disclosed herein comprise one or more compounds disclosed herein, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable excipient and optionally other therapeutic agents. Pharmaceutical compositions containing the active ingredient may be in any form suitable for the intended method of administration. When used for oral use for example, tablets, troches, lozenges, aqueous or oil suspensions, dispersible powders or granules, emulsions, hard or soft capsules, syrups or elixirs may be prepared. Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more excipients including sweetening agents, flavoring agents, coloring agents and preserving agents, in order to provide a palatable preparation. Tablets containing the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for manufacture of tablets are acceptable. These excipients may be, for example, inert diluents, such as calcium or sodium carbonate, lactose, lactose monohydrate, croscarmellose sodium, povidone, calcium or sodium phosphate; granulating and disintegrating agents, such as maize starch, or alginic acid; binding agents, such as cellulose, microcrystalline cellulose, starch, gelatin or acacia; and lubricating agents, such as magnesium stearate, stearic acid or talc.
Tablets may be uncoated or may be coated by known techniques including microencapsulation to delay disintegration and adsorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate alone or with a wax may be employed.
The amount of active ingredient that may be combined with the inactive ingredients to produce a dosage form may vary depending upon the intended treatment subject and the particular mode of administration. For example, in some embodiments, a dosage form for oral administration to humans may contain approximately 1 to 1000 mg of active material formulated with an appropriate and convenient amount of a pharmaceutically acceptable excipient. In certain embodiments, the pharmaceutically acceptable excipient varies from about 5 to about 95% of the total compositions (weigh weight).
Methods
In certain embodiments, the present disclosure provides methods of treating or preventing an HBV infection. In certain embodiments, a method of treating or preventing an HBV infection comprises administering to an individual (e.g. a human) a therapeutically effective amount a compound disclosed herein, or a pharmaceutically acceptable salt thereof. In certain embodiments, the present disclosure also provides methods for treating an HBV infection comprising administering to an individual (e.g. a human) infected with HBV a therapeutically effective amount a compound disclosed herein or a pharmaceutically acceptable salt thereof. In some embodiments, the individual is chronically infected with HBV. In some embodiments, the individual is acutely infected with HBV. In some embodiments, a method of treating an individual (e.g. a human) infected with HBV comprises inhibiting HBsAg secretion and/or production. In certain embodiments, a compound disclosed herein or a pharmaceutically acceptable salt thereof for use in medical therapy is provided. In certain embodiments, the disease or condition is an HBV infection. In certain embodiments, a compound disclosed herein for use in treating or preventing an HBV infection is provided.
In certain embodiments, the use of a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for treating or preventing HBV infection is provided. In certain embodiments, a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for treating or preventing an HBV infection is provided.
As described more fully herein, compounds of the present disclosure can be administered with one or more additional therapeutic agent(s) to an individual (e.g. a human) infected with HBV. The additional therapeutic agent(s) can be administered to the infected individual (e.g. a human) at the same time as a compound disclosed herein or before or after administration of a compound disclosed herein. For example, in certain embodiments, when used to treat or prevent a HBV infection, a compound disclosed herein is administered with one or more additional therapeutic agent(s) selected from the group consisting of HBV DNA polymerase inhibitors, toll-like receptor 7 modulators, toll-like receptor 8 modulators, Toll-like receptor 7 and 8 modulators, Toll-like receptor 3 modulators, interferon alpha ligands, HBsAg inhibitors, compounds targeting HBcAg, cyclophilin inhibitors, HBV therapeutic vaccines, HBV prophylactic vaccines, HBV viral entry inhibitors, NTCP inhibitors, antisense oligonucleotide targeting viral mRNA, short interfering RNAs (siRNA), hepatitis B virus E antigen inhibitors, HBx inhibitors, cccDNA inhibitors, HBV antibodies including HBV antibodies targeting the surface antigens of the hepatitis B virus, thymosin agonists, cytokines, nucleoprotein inhibitors (HBV core or capsid protein inhibitors), stimulators of retinoic acid-inducible gene 1, stimulators of NOD2, recombinant thymosin alpha-1 and hepatitis B virus replication inhibitors, and combinations thereof. Specific examples are more fully described below. In certain embodiments, the present disclosure provides a method for ameliorating a symptom associated with an HBV infection, wherein the method comprises administering to an individual (e.g. a human) infected with hepatitis B virus a therapeutically effective amount of a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, wherein the therapeutically effective amount is sufficient to ameliorate a symptom associated with the HBV infection. Such symptoms include the presence of HBV virus particles in the blood, liver inflammation, jaundice, muscle aches, weakness and tiredness.
In certain embodiments, the present disclosure provides a method for reducing the rate of progression of a hepatitis B viral infection in an individual (e.g. a human), wherein the method comprises administering to an individual (e.g. a human) infected with hepatitis B virus a therapeutically effective amount of a compound disclosed herein, or a pharmaceutically acceptable salt thereof, wherein the therapeutically effective amount is sufficient to reduce the rate of progression of the hepatitis B viral infection. The rate of progression of the infection can be followed by measuring the amount of HBV virus particles in the blood.
In certain embodiments, the present disclosure provides a method for reducing the viral load associated with HBV infection, wherein the method comprises administering to an individual (e.g. a human) infected with HBV a therapeutically effective amount of a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, wherein the
therapeutically effective amount is sufficient to reduce the HBV viral load in the individual. In some embodiments, a method of treating an individual (e.g. a human) infected with hepatitis B virus comprises reducing the viral load associated with HBV infection as measured by PCR testing.
Compounds disclosed herein can be administered by any route appropriate for use in a method described herein. Suitable routes include oral, rectal, nasal, topical (including buccal and sublingual), transdermal, vaginal and parenteral (including subcutaneous, intramuscular, intravenous, intradermal, intrathecal and epidural), and the like. Compounds disclosed herein may be administered to an individual in accordance with an effective dosing regimen for a desired period of time or duration, such as at least one week, at least about one month, at least about 2 months, at least about 3 months, at least about 6 months, or at least about 12 months or longer. In one variation, the compound is administered on a daily or intermittent schedule for the duration of the individual's life. The dosage or dosing frequency of a compound of the present disclosure may be adjusted over the course of the treatment, based on the judgment of the administering physician.
Therapeutically effective amounts of compounds disclosed herein are from about 0.00001 mg/kg body weight per day to about 10 mg/kg body weight per day, such as from about 0.0001 mg/kg body weight per day to about 10 mg/kg body weight per day, or such as from about 0.001 mg/kg body weight per day to about 1 mg/kg body weight per day, or such as from about 0.01 mg/kg body weight per day to about 1 mg/kg body weight per day, or such as from about 0.05 mg/kg body weight per day to about 0.5 mg/kg body weight per day, or such as from about 0.3 μg to about 30 mg per day, or such as from about 30 μg to about 300 μg per day.
A compound of the present disclosure (e.g., any compound of Formula (I) or (II), or Formula (la), (lb) or (Ila)) may be combined with one or more additional therapeutic agents in any dosage amount of the compound of the present disclosure (e.g. , from 1 mg to 1000 mg of compound). Therapeutically effective amounts of the compound of Formula (I) or (II), or Formula (la), (lb) or (Ila) can range from about 0.01 mg per dose to about 1000 mg per dose, such as from about 0.01 mg per dose to about 100 mg per dose, or such as from about 0.1 mg per dose to about 100 mg per dose, or such as from about 1 mg per dose to about 100 mg per dose, or such as from about 1 mg per dose to about 10 mg per dose. Other therapeutically effective amounts of the compound of Formula (I) or (II), or Formula (la), (lb) or (Ila) are about 1 mg per dose, or about 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or about 100 mg per dose. Other therapeutically effective amounts of the compound of Formula (I) or (II), or Formula (la), (lb) or (Ila) are about 100 mg per dose, or about 125, 150, 175, 200, 225, 250, 275, 300, 350, 400, 450, or about 500 mg per dose.
A single dose can be administered hourly, daily, or weekly. For example, a single dose can be administered once every 1 hour, 2, 3, 4, 6, 8, 12, 16 or once every 24 hours. A single dose can also be administered once every 1 day, 2, 3, 4, 5, 6, or once every 7 days. A single dose can also be administered once every 1 week, 2, 3, or once every 4 weeks. In certain embodiments, a single dose can be administered once every week. A single dose can also be administered once every month. In some embodiments, a compound disclosed herein is administered once daily in a method disclosed herein. In some embodiments, a compound disclosed herein is administered twice daily in a method disclosed herein.
The frequency of dosage of a compound disclosed herein will be determined by the needs of the individual patient and can be, for example, once per day or twice, or more times, per day. Administration of a compound continues for as long as necessary to treat an HBV infection. For example, a compound disclosed herein can be administered to a human being infected with HBV for a period of from 20 days to 180 days or, for example, for a period of from 20 days to 90 days or, for example, for a period of from 30 days to 60 days. Administration can be intermittent, with a period of several or more days during which a patient receives a daily dose of a compound disclosed herein, followed by a period of several or more days during which a patient does not receive a daily dose of the compound. For example, a patient can receive a dose of a compound every other day, or three times per week. Again by way of non-limiting example, a patient can receive a dose of a compound each day for a period of from 1 to 14 days, followed by a period of 7 to 21 days during which the patient does not receive a dose of the compound, followed by a subsequent period (e.g. , from 1 to 14 days) during which the patient again receives a daily dose of the compound. Alternating periods of administration of the compound, followed by non-administration of the compound, can be repeated as clinically required to treat the patient.
In one embodiment, pharmaceutical compositions comprising a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, in combination with one or more (e.g., one, two, three, four, one or two, one to three, or one to four) additional therapeutic agents, and a pharmaceutically acceptable excipient are provided.
In one embodiment, kits comprising a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, in combination with one or more (e.g., one, two, three, four, one or two, one to three, or one to four) additional therapeutic agents are provided. In certain embodiments, a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, is combined with one, two, three, four or more additional therapeutic agents. In certain embodiments, a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, is combined with one additional therapeutic agent. In certain
embodiments, a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, is combined with two additional therapeutic agents. In other embodiments, a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, is combined with three additional therapeutic agents. In further embodiments, a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, is combined with four additional therapeutic agents. The one, two, three, four or more additional therapeutic agents can be different therapeutic agents selected from the same class of therapeutic agents, and/or they can be selected from different classes of therapeutic agents.
In certain embodiments, when a compound of the present disclosure is combined with one or more additional therapeutic agents as described herein, the components of the composition are administered as a simultaneous or sequential regimen. When administered sequentially, the combination may be administered in two or more administrations.
In certain embodiments, a compound of the present disclosure is combined with one or more additional therapeutic agents in a unitary dosage form for simultaneous administration to a patient, for example as a solid dosage form for oral administration.
In certain embodiments, a compound of the present disclosure is administered with one or more additional therapeutic agents. Co-administration of a compound of the present disclosure with one or more additional therapeutic agents generally refers to simultaneous or sequential administration of a compound of the present disclosure and one or more additional therapeutic agents, such that therapeutically effective amounts of the compound disclosed herein and one or more additional therapeutic agents are both present in the body of the patient.
Co-administration includes administration of unit dosages of the compounds disclosed herein before or after administration of unit dosages of one or more additional therapeutic agents, for example, administration of the compound disclosed herein within seconds, minutes, or hours of the administration of one or more additional therapeutic agents. For example, in some embodiments, a unit dose of a compound of the present disclosure is administered first, followed within seconds or minutes by administration of a unit dose of one or more additional therapeutic agents. Alternatively, in other embodiments, a unit dose of one or more additional therapeutic agents is administered first, followed by administration of a unit dose of a compound of the present disclosure within seconds or minutes. In some embodiments, a unit dose of a compound of the present disclosure is administered first, followed, after a period of hours (e.g. , 1-12 hours), by administration of a unit dose of one or more additional therapeutic agents. In other embodiments, a unit dose of one or more additional therapeutic agents is administered first, followed, after a period of hours (e.g., 1-12 hours), by administration of a unit dose of a compound of the present disclosure.
Combination Therapy
In certain embodiments, a method for treating or preventing an HBV infection in an individual (e.g. a human) having or at risk of having the infection is provided, comprising administering to the individual a therapeutically effective amount of a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective amount of one or more (e.g., one, two, three, four, one or two, one to three or one to four) additional therapeutic agents. In one embodiment, a method for treating an HBV infection in an individual (e.g. a human) having or at risk of having the infection is provided, comprising administering to the individual a therapeutically effective amount of a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective amount of one or more (e.g. , one, two, three, four, one or two, one to three or one to four) additional therapeutic agents. In some embodiments, a therapeutically effective amount of a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, and one or more additional therapeutic agents are administered in a "fixed dose combination," also termed a "combined dosage form," wherein the active agents are combined in a solid (e.g. tablet or capsule), liquid (e.g. IV), or vaporized formulation.
In certain embodiments, the present disclosure provides a method for treating an HBV infection, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective amount of one or more (e.g., one, two, three, four, one or two, one to three or one to four) additional therapeutic agents which are suitable for treating an HBV infection. In certain embodiments, one or more additional therapeutic agents includes, for example, one, two, three, four, one or two, one to three or one to four additional therapeutic agents.
In the above embodiments, the additional therapeutic agent may be an anti-HBV agent. For example, in some embodiments, the additional therapeutic agent is selected from the group consisting of HBV combination drugs, HBV DNA polymerase inhibitors, immunomodulators, toll-like receptor modulators (modulators of TLR-1, TLR-2, TLR-3, TLR-4, TLR-5, TLR-6, TLR-7, TLR-8, TLR-9, TLR-10, TLR-11, TLR-12 and TLR-13), interferon alpha receptor ligands, hyaluronidase inhibitors, recombinant IL-7, hepatitis B surface antigen (HBsAg) inhibitors, compounds targeting hepatitis B core antigen (HBcAg), cyclophilin inhibitors , HBV therapeutic vaccines, HBV prophylactic vaccines, HBV viral entry inhibitors, NTCP (Na+- taurocholate cotransporting polypeptide) inhibitors, antisense oligonucleotide targeting viral mRNA, short interfering RNAs (siRNA), miRNA gene therapy agents, endonuclease modulators, inhibitors of ribonucleotide reductase, hepatitis B virus E antigen inhibitors, recombinant scavenger receptor A (SRA) proteins, Src kinase inhibitors, HBx inhibitors, cccDNA inhibitors, short synthetic hairpin RNAs (sshRNAs), HBV antibodies including HBV antibodies targeting the surface antigens of the hepatitis B virus and bispecific antibodies and "antibody-like" therapeutic proteins (such as DARTs®, Duobodies®, Bites®, XmAbs®, TandAbs ®, Fab derivatives), CCR2 chemokine antagonists, thymosin agonists, cytokines, nucleoprotein inhibitors (HBV core or capsid protein inhibitors), stimulators of retinoic acid- inducible gene 1, stimulators of NOD2, stimulators of NODI, Arginase-1 inhibitors, STING agonists, PI3K inhibitors, lymphotoxin beta receptor activators, Natural Killer Cell Receptor 2B4 inhibitors, Lymphocyte-activation gene 3 inhibitors, CD160 inhibitors, cytotoxic T- lymphocyte-associated protein 4 inhibitors, CD137 inhibitors, Killer cell lectin-like receptor subfamily G member 1 inhibitors, TIM-3 inhibitors, B- and T-lymphocyte attenuator inhibitors, CD305 inhibitors, PD-1 inhibitors, PD-L1 inhibitors, PEG-Interferon Lambda, recombinant thymosin alpha-1, BTK inhibitors, modulators of TIGIT, modulators of CD47, modulators of SIRPalpha , modulators of ICOS, modulators of CD27, modulators of CD70, modulators of OX40, modulators of NKG2D, modulators of Tim-4, modulators of B7-H4, modulators of B7- H3, modulators of NKG2A, modulators of GITR, modulators of CD 160, modulators of
HEVEM, modulators of CD161, modulators of Axl, modulators of Mer, modulators of Tyro, gene modifiers or editors such as CRISPR (including CRISPR Cas9), zinc finger nucleases or synthetic nucleases (TALENs), Hepatitis B virus replication inhibitors, compounds such as those disclosed in U.S. Publication No. 2010/0143301 (Gilead Sciences), U.S. Publication No.
2011/0098248 (Gilead Sciences), U.S. Publication No. 2009/0047249 (Gilead Sciences), U.S. Patent No. 8722054 (Gilead Sciences), U.S. Publication No. 2014/0045849 (Janssen), U.S. Publication No. 2014/0073642 (Janssen), WO2014/056953 (Janssen), WO2014/076221 (Janssen), WO2014/128189 (Janssen), U.S. Publication No. 2014/0350031 (Janssen),
WO2014/023813 (Janssen), U.S. Publication No. 2008/0234251 (Array Biopharma), U.S.
Publication No. 2008/0306050 (Array Biopharma), U.S. Publication No. 2010/0029585 (Ventirx Pharma), U.S. Publication No. 2011/0092485 (Ventirx Pharma), US2011/0118235 (Ventirx Pharma), U.S. Publication No. 2012/0082658 (Ventirx Pharma), U.S. Publication No.
2012/0219615 (Ventirx Pharma), U.S. Publication No. 2014/0066432 (Ventirx Pharma), U.S. Publication No. 2014/0088085 (Ventirx Pharma), U.S. Publication No. 2014/0275167 (Novira Therapeutics), U.S. Publication No. 2013/0251673 (Novira Therapeutics) , U.S. Patent No. 8513184 (Gilead Sciences), U.S. Publication No. 2014/0030221 (Gilead Sciences), U.S.
Publication No. 2013/0344030 (Gilead Sciences), U.S. Publication No. 2013/0344029 (Gilead Sciences), U.S. Publication No. 2014/0343032 (Roche), WO2014037480 (Roche), U.S.
Publication No. 2013/0267517 (Roche), WO2014131847 (Janssen), WO2014033176 (Janssen), WO2014033170 (Janssen), WO2014033167 (Janssen), U.S. Publication No. 2014/0330015 (Ono Pharmaceutical), U. S. Publication No. 2013/0079327 (Ono Pharmaceutical), U. S.
Publication No. 2013/0217880 (Ono pharmaceutical), and other drugs for treating HBV, and combinations thereof. In some embodiments, the additional therapeutic agent is further selected from hepatitis B surface antigen (HBsAg) secretion or assembly inhibitors, TCR-like antibodies, IDO inhibitors, cccDNA epigenetic modifiers, IAPs inhibitors, SMAC mimetics, and compounds such as those disclosed in US20100015178 (Incyte),
In the above embodiments, the additional therapeutic agent may be an anti-HBV agent. For example, the additional therapeutic agent may be selected from the group consisting of HBV combination drugs, other drugs for treating HBV, 3-dioxygenase (IDO) inhibitors, antisense oligonucleotide targeting viral mRNA, Apolipoprotein Al modulator, arginase inhibitors, B- and T-lymphocyte attenuator inhibitors, Bruton's tyrosine kinase (BTK) inhibitors, CCR2 chemokine antagonist, CD137 inhibitors, CD160 inhibitors, CD305 inhibitors, CD4 agonist and modulator, compounds targeting HBcAg, compounds targeting hepatitis B core antigen
(HBcAg), covalently closed circular DNA (cccDNA) inhibitors, cyclophilin inhibitors, cytokines, cytotoxic T-lymphocyte-associated protein 4 (ipi4) inhibitors, DNA polymerase inhibitor, Endonuclease modulator, epigenetic modifiers, Famesoid X receptor agonist, gene modifiers or editors, HBsAg inhibitors, HBsAg secretion or assembly inhibitors, HBV antibodies, HBV DNA polymerase inhibitors, HBV replication inhibitors, HBV RNAse inhibitors, HBV vaccines, HBV viral entry inhibitors, HBx inhibitors, Hepatitis B large envelope protein modulator, Hepatitis B large envelope protein stimulator, Hepatitis B structural protein modulator, hepatitis B surface antigen (HBsAg) inhibitors, hepatitis B surface antigen (HBsAg) secretion or assembly inhibitors, hepatitis B virus E antigen inhibitors, hepatitis B virus replication inhibitors, Hepatitis virus structural protein inhibitor, HIV-1 reverse transcriptase inhibitor, Hyaluronidase inhibitor, IAPs inhibitors, IL-2 agonist, IL-7 agonist, Immunoglobulin agonist, Immunoglobulin G modulator, immunomodulators, indoleamine-2, inhibitors of ribonucleotide reductase, Interferon agonist, Interferon alpha 1 ligand, Interferon alpha 2 ligand, Interferon alpha 5 ligand modulator, Interferon alpha ligand, Interferon alpha ligand modulator, interferon alpha receptor ligands, Interferon beta ligand, Interferon ligand, Interferon receptor modulator, Interleukin-2 ligand, ipi4 inhibitors, lysine demethylase inhibitors, histone demethylase inhibitors, KDM5 inhibitors, KDM1 inhibitors, killer cell lectin- like receptor subfamily G member 1 inhibitors, lymphocyte-activation gene 3 inhibitors, lymphotoxin beta receptor activators, microRNA (miRNA) gene therapy agents, modulators of Axl, modulators of B7-H3, modulators of B7-H4, modulators of CD160, modulators of CD161, modulators of CD27, modulators of CD47, modulators of CD70, modulators of GITR, modulators of HEVEM, modulators of ICOS, modulators of Mer, modulators of NKG2A, modulators of NKG2D, modulators of OX40, modulators of SIRP alpha, modulators of TIGIT, modulators of Tim-4, modulators of Tyro, Na+-taurocholate cotransporting polypeptide (NTCP) inhibitors, natural killer cell receptor 2B4 inhibitors, NOD2 gene stimulator, Nucleoprotein inhibitor, nucleoprotein modulators, PD-1 inhibitors, PD-Ll inhibitors, PEG-Interferon Lambda, Peptidylprolyl isomerase inhibitor, phosphatidylinositol-3 kinase (PI3K) inhibitors, recombinant scavenger receptor A (SRA) proteins, recombinant thymosin alpha-1, Retinoic acid-inducible gene 1 stimulator, Reverse transcriptase inhibitor, Ribonuclease inhibitor, RNA DNA polymerase inhibitor, short interfering RNAs (siRNA), short synthetic hairpin RNAs (sshRNAs), SLC10A1 gene inhibitor, SMAC mimetics, Src tyrosine kinase inhibitor, stimulator of interferon gene (STING) agonists, stimulators of NODI, T cell surface glycoprotein CD28 inhibitor, T-cell surface glycoprotein CD8 modulator, Thymosin agonist, Thymosin alpha 1 ligand, Tim-3 inhibitors, TLR-3 agonist, TLR-7 agonist, TLR-9 agonist, TLR9 gene stimulator, toll-like receptor (TLR) modulators, Viral ribonucleotide reductase inhibitor, zinc finger nucleases or synthetic nucleases (TALENs), and combinations thereof.
In certain embodiments, the additional therapeutic agent is selected from the group consisting of HBV combination drugs, HBV DNA polymerase inhibitors, toll-like receptor 7 modulators, toll-like receptor 8 modulators, Toll-like receptor 7 and 8 modulators, Toll-like receptor 3 modulators, interferon alpha receptor ligands, HBsAg inhibitors, compounds targeting HBcAg, cyclophilin inhibitors, HBV therapeutic vaccines, HBV prophylactic vaccines, HBV viral entry inhibitors, NTCP inhibitors, antisense oligonucleotide targeting viral mRNA, short interfering RNAs (siRNA), hepatitis B virus E antigen (HBeAg) inhibitors, HBx inhibitors, cccDNA inhibitors, HBV antibodies including HBV antibodies targeting the surface antigens of the hepatitis B virus, thymosin agonists, cytokines, nucleoprotein inhibitors (HBV core or capsid protein inhibitors), stimulators of retinoic acid-inducible gene 1, stimulators of NOD2, stimulators of NODI, recombinant thymosin alpha-1, BTK inhibitors, and hepatitis B virus replication inhibitors, and combinations thereof. In certain embodiments, the additional therapeutic is selected from hepatitis B surface antigen (HBsAg) secretion or assembly inhibitors, IDO inhibitors, and combinations thereof.
In certain embodiments, the additional therapeutic agent is selected from the group consisting of HBV combination drugs, HBV DNA polymerase inhibitors, toll-like receptor 7 modulators, toll-like receptor 8 modulators, Toll-like receptor 7 and 8 modulators, Toll-like receptor 3 modulators, interferon alpha receptor ligands, HBsAg inhibitors, compounds targeting HBcAg, cyclophilin inhibitors, HBV therapeutic vaccines, HBV prophylactic vaccines, HBV viral entry inhibitors, NTCP inhibitors, antisense oligonucleotide targeting viral mRNA, short interfering RNAs (siRNA), hepatitis B virus E antigen (HBeAg) inhibitors, HBx inhibitors, cccDNA inhibitors, HBV antibodies including HBV antibodies targeting the surface antigens of the hepatitis B virus, thymosin agonists, cytokines, nucleoprotein inhibitors (HBV core or capsid protein inhibitors), stimulators of retinoic acid-inducible gene 1, stimulators of NOD2, stimulators of NODI, recombinant thymosin alpha-1, BTK inhibitors, and hepatitis B virus replication inhibitors, and combinations thereof. In certain embodiments, the additional therapeutic is selected from hepatitis B surface antigen (HBsAg) secretion or assembly inhibitors, IDO inhibitors, KDM5 inhibitors, and combinations thereof.
In certain embodiments a compound of the present disclosure \is formulated as a tablet, which may optionally contain one or more other compounds useful for treating HBV. In certain embodiments, the tablet can contain another active ingredient for treating HBV, such as HBV DNA polymerase inhibitors, immunomodulators, toll-like receptor modulators (modulators of TLR-1, TLR-2, TLR-3, TLR-4, TLR-5, TLR-6, TLR-7, TLR-8, TLR-9, TLR-10, TLR-11, TLR- 12 and TLR-13), modulators of tlr7, modulators of tlr8, modulators of tlr7 and tlr8, interferon alpha receptor ligands, hyaluronidase inhibitors, hepatitis B surface antigen (HBsAg) inhibitors, compounds targeting hepatitis B core antigen (HBcAg), cyclophilin inhibitors , HBV viral entry inhibitors, NTCP (Na+-taurocholate cotransporting polypeptide) inhibitors, endonuclease modulators, inhibitors of ribonucleotide reductase, hepatitis B virus E antigen inhibitors, Src kinase inhibitors, HBx inhibitors, cccDNA inhibitors, CCR2 chemokine antagonists, thymosin agonists, nucleoprotein inhibitors (HBV core or capsid protein inhibitors), stimulators of retinoic acid-inducible gene 1, stimulators of NOD2, stimulators of NODI, Arginase-1 inhibitors, STING agonists, PI3K inhibitors, lymphotoxin beta receptor activators, Natural Killer Cell Receptor 2B4 inhibitors, Lymphocyte-activation gene 3 inhibitors, CD 160 inhibitors, cytotoxic T-lymphocyte-associated protein 4 inhibitors, CD 137 inhibitors, Killer cell lectin-like receptor subfamily G member 1 inhibitors, TIM-3 inhibitors, B- and T-lymphocyte attenuator inhibitors, CD305 inhibitors, PD-1 inhibitors, PD-L1 inhibitors, BTK inhibitors, modulators of TIGIT, modulators of CD47, modulators of SIRP alpha , modulators of ICOS, modulators of CD27, modulators of CD70, modulators of OX40, modulators of NKG2D, modulators of Tim-4, modulators of B7-H4, modulators of B7-H3, modulators of NKG2A, modulators of GITR, modulators of CD 160, modulators of HEVEM, modulators of CD161, modulators of Axl, modulators of Mer, modulators of Tyro, and Hepatitis B virus replication inhibitors, and combinations thereof. In certain embodiments, the tablet can contain another active ingredient for treating HBV, such as hepatitis B surface antigen (HBsAg) secretion or assembly inhibitors, cccDNA epigenetic modifiers, IAPs inhibitors, SMAC mimetics, and IDO inhibitors.
In certain embodiments, such tablets are suitable for once daily dosing. In certain embodiments, the additional therapeutic agent is selected from one or more of: (1) Combination drugs selected from the group consisting of tenofovir disoproxil fumarate + emtricitabine (TRUVADA®); adefovir + clevudine and GBV-015, as well as combination drugs selected from ABX-203+lamivudine+PEG-IFNalpha, ABX-203+adefovir+PEG- IFNalpha, and INO-9112 + RG7944 (INO-1800);
(2) HBV DNA polymerase inhibitors selected from the group consisting of besifovir, entecavir
(Baraclude®), adefovir (Hepsera®), tenofovir disoproxil fumarate (Viread®), tenofovir alafenamide, tenofovir, tenofovir disoproxil, tenofovir alafenamide fumarate, tenofovir alafenamide hemifumarate, tenofovir dipivoxil , tenofovir dipivoxil fumarate, tenofovir octadecyloxyethyl ester, telbivudine (Tyzeka®), pradefovir, Clevudine, emtricitabine (Emtriva®), ribavirin, lamivudine (Epivir-HBV®), phosphazide, famciclovir, SNC-019754, FMCA, fusolin, AGX-1009 and metacavir, as well as HBV DNA polymerase inhibitors selected from AR-II-04-26 and HS-10234;
(3) Immunomodulators selected from the group consisting of rintatolimod, imidol
hydrochloride, ingaron, dermaVir, plaquenil (hydroxychloroquine), proleukin, hydroxyurea, mycophenolate mofetil (MP A) and its ester derivative mycophenolate mofetil (MMF), WF- 10, ribavirin, IL-12, polymer polyethyleneimine (PEI), Gepon, VGV-1, MOR-22, BMS- 936559 and IR-103, as well as immunomodulators selected from INO-9112, polymer polyethyleneimine (PEI), Gepon, VGV-1, MOR-22, BMS-936559, RO-7011785, RO- 6871765 and IR-103;
(4) Toll-like receptor 7 modulators selected from the group consisting of GS-9620, GSK-
2245035, imiquimod, resiquimod, DSR-6434, DSP-3025, IMO-4200, MCT-465, 3M-051, SB-9922, 3M-052, Limtop, TMX-30X, TMX-202 RG-7863 and RG-7795;
(5) Toll-like receptor 8 modulators selected from the group consisting of motolimod,
resiquimod, 3M-051, 3M-052, MCT-465, IMO-4200, VTX-763, VTX-1463;
(6) Toll-like receptor 3 modulators selected from the group consisting of rintatolimod, poly-
ICLC, MCT-465, MCT-475, Riboxxon, Riboxxim and ND-1.1 ;
(7) Interferon alpha receptor ligands selected from the group consisting of interferon alpha-2b
(Intron A®), pegylated interferon alpha-2a (Pegasys®), interferon alpha lb (Hapgen®), Veldona, Infradure, Roferon-A, YPEG-interferon alfa-2a (YPEG-rhIFNalpha-2a), P-1101, Algeron, Alfarona, Ingaron (interferon gamma), rSIFN-co (recombinant super compound interferon), Ypeginterferon alfa-2b (YPEG-rhIFNalpha-2b), MOR-22, peginterferon alfa-2b (PEG-Intron®), Bioferon, Novaferon, Inmutag (Inferon), Multiferon®, interferon alfa- nl(Humoferon®), interferon beta- la (Avonex®), Shaferon, interferon alfa-2b (AXXO), Alfaferone, interferon alfa-2b (BioGeneric Pharma), interferon-alpha 2 (CJ), Laferonum, VIPEG, BLAUFERON-B, BLAUFERON-A, Intermax Alpha, Realdiron, Lanstion, Pegaferon, PDferon-B PDferon-B, interferon alfa-2b (IFN, Laboratories Bioprofarma), alfainterferona 2b, Kalferon, Pegnano, Feronsure, PegiHep, interferon alfa 2b (Zydus- Cadila), Optipeg A, Realfa 2B, Reliferon, interferon alfa-2b (Amega), interferon alfa-2b (Virchow), peginterferon alfa-2b (Amega), Reaferon-EC, Proquiferon, Uniferon, Urifron, interferon alfa-2b (Changchun Institute of Biological Products), Anterferon, Shanferon, Layfferon, Shang Sheng Lei Tai, INTEFEN, SINOGEN, Fukangtai, Pegstat, rHSA-IFN alpha-2b and Interapo (Interapa);
(8) Hyaluronidase inhibitors selected from the group consisting of astodrimer;
(9) Modulators of IL- 10;
(10) HBsAg inhibitors selected from the group consisting of HBF-0259, PBHBV-001, PBHBV - 2-15, PBHBV-2-1, REP 9AC, REP-9C and REP 9 AC, as well as HBsAg inhibitors selected from REP-9, REP-2139, REP-2139-Ca, REP-2165, REP-2055, REP-2163, REP- 2165, REP-2053, REP-2031 and REP-006 and REP-9AC
(11) Toll like receptor 9 modulators selected from CYT003, as well as Toll like receptor 9
modulators selected from CYT-003, IMO-2055, IMO-2125, IMO-3100, IMO-8400, IMO- 9200, agatolimod, DIMS-9054, DV-1179, AZD-1419, MGN-1703, and CYT-003-QbG10;
(12) Cyclophilin inhibitors selected from the group consisting of OCB-030, SCY-635 and NVP- 018;
(13) HBV Prophylactic vaccines selected from the group consisting of Hexaxim, Heplisav,
Mosquirix, DTwP-HBV vaccine, Bio-Hep-B, D/T/P/HBV/M (LBVP-0101; LBVW-0101), DTwP-Hepb-Hib-IPV vaccine, Hebe enta L, DTwP-HepB-Hib, V-419, CVI-HBV-001, Tetrabhay, hepatitis B prophylactic vaccine (Advax Super D), Hepatrol-07, GSK-223192A, Engerix B®, recombinant hepatitis B vaccine (intramuscular, Kangtai Biological Products), recombinant hepatitis B vaccine (Hansenual polymorpha yeast, intramuscular, Hualan
Biological Engineering ), Bimmugen, Euforavac, Eutravac, anrix-DTaP-IPV-Hep B, Infanrix-DTaP-IPV-Hep B-Hib, Pentabio Vaksin DTP-HB-Hib, Comvac 4, Twinrix, Euvax-B, Tritanrix HB, Infanrix Hep B, Comvax, DTP-Hib-HBV vaccine, DTP-HBV vaccine, Yi Tai, Heberbiovac HB, Trivac HB, GerVax, DTwP-Hep B-Hib vaccine, Bilive, Hepavax-Gene, SUPERVAX, Comvac5, Shanvac-B, Hebsulin, Recombivax HB, Revac B mcf, Revac B+, Fendrix, DTwP-HepB-Hib, DNA-001, Shan6, rhHBsAG vaccine, and DTaP-rHB-Hib vaccine;
(14) HBV Therapeutic vaccines selected from the group consisting of HBsAG-HBIG complex, Bio-Hep-B, NASVAC, abi-HB (intravenous), ABX-203, Tetrabhay, GX-110E, GS-4774, peptide vaccine (epsilonPA-44), Hepatrol-07, NASVAC (NASTERAP), IMP-321, BEVAC, Revac B mcf, Revac B+, MGN-1333, KW-2, CVI-HBV-002, AltraHepB, VGX-6200, FP- 02, TG-1050, NU-500, HBVax, im/TriGrid/antigen vaccine, Mega-CD40L-adjuvanted vaccine, HepB-v, NO- 1800, recombinant VLP -based therapeutic vaccine (HBV infection, VLP Biotech), AdTG-17909, AdTG-17910 AdTG-18202, ChronVac-B, and Lm HBV, as well as HBV Therapeutic vaccines selected from FP-02.2 and RG7944 (INO-1800);
(15) HBV viral entry inhibitor selected from the group consisting of Myrcludex B;
(16) Antisense oligonucleotide targeting viral mRNA selected from the group consisting of ISIS-HBVRx;
(17) short interfering RNAs (siRNA) selected from the group consisting of TKM-HBV (TKM- HepB), ALN-HBV, SR-008, ddRNAi and ARC-520;
(18) Endonuclease modulators selected from the group consisting of PGN-514;
(19) Inhibitors of ribonucleotide reductase selected from the group consisting of Trimidox;
(20) Hepatitis B virus E antigen inhibitors selected from the group consisting of wogonin;
(21) HBV antibodies targeting the surface antigens of the hepatitis B virus selected from the group consisting of GC-1102, XTL-17, XTL-19, XTL-001, KN-003 and fully human monoclonal antibody therapy (hepatitis B virus infection, Humabs BioMed) , as well as HBV antibodies targeting the surface antigens of the hepatitis B virus selected from IV Hepabulin SN;
(22) HBV antibodies including monoclonal antibodies and polyclonal antibodies selected from the group consisting of Zutectra, Shang Sheng Gan Di, Uman Big (Hepatitis B
Hyperimmune), Omri-Hep-B, Nabi-HB, Hepatect CP, HepaGam B, igantibe, Niuliva, CT- P24, hepatitis B immunoglobulin (intravenous, pH4, HBV infection, Shanghai RAAS Blood Products) and Fovepta (BT-088);
(23) CCR2 chemokine antagonists selected from the group consisting of propagermanium;
(24) Thymosin agonists selected from the group consisting of Thymalfasin;
(25) Cytokines selected from the group consisting of recombinant IL-7, CYT-107, interleukin-2 (IL-2, Immunex); recombinant human interleukin-2 (Shenzhen Neptunus) and celmoleukin, as well as cytokines selected from IL-15, IL-21, IL-24;
(26) Nucleoprotein inhibitors (HBV core or capsid protein inhibitors) selected from the group consisting of NVR-1221, NVR-3778, BAY 41-4109, morphothiadine mesilate and DVR- 23; (27) Stimulators of retinoic acid-inducible gene 1 selected from the group consisting of SB- 9200, SB-40, SB-44, ORI-7246, ORI-9350, ORI-7537, ORI-9020, ORI-9198 and ORI- 7170;
(28) Stimulators of NOD2 selected from the group consisting of SB-9200;
(29) Recombinant thymosin alpha- 1 selected from the group consisting of NL-004 and
PEGylated thymosin alpha 1;
(30) Hepatitis B virus replication inhibitors selected from the group consisting of isothiafludine, IQP-HBV, RM-5038 and Xingantie;
(31) PI3K inhibitors selected from the group consisting of idelalisib, AZD-8186, buparlisib, CLR-457, pictilisib, neratinib, rigosertib, rigosertib sodium, EN-3342, TGR-1202, alpelisib, duvelisib, UCB-5857, taselisib, XL-765, gedatolisib, VS-5584, copanlisib, CAI orotate, perifosine, RG-7666, GSK-2636771, DS-7423, panulisib, GSK-2269557, GSK-2126458, CUDC-907, PQR-309, INCB-040093, pilaralisib, BAY-1082439, puquitinib mesylate, SAR-245409, AMG-319, RP-6530, ZSTK-474, MLN-1117, SF-1126, RV-1729, sonolisib, LY-3023414, SAR-260301 and CLR-1401;
(32) cccDNA inhibitors selected from the group consisting of BSBI-25;
(33) PD-Ll inhibitors selected from the group consisting of MEDI-0680, RG-7446, durvalumab, KY-1003, KD-033, MSB-0010718C, TSR-042, ALN-PDL, STI-A1014 and BMS-936559;
(34) PD-1 inhibitors selected from the group consisting of nivolumab, pembrolizumab,
pidilizumab, BGB-108 and mDX-400;
(35) BTK inhibitors selected from the group consisting of ACP-196, dasatinib, ibrutinib, PRN- 1008, SNS-062, ONO-4059, BGB-3111, MSC-2364447, X-022, spebrutinib, TP-4207, HM-71224, KBP-7536, AC-0025;
(36) Other drugs for treating HBV selected from the group consisting of gentiopicrin
(gentiopicroside), nitazoxanide, birinapant, NOV -205 (Molixan; BAM-205), Oligotide,
Mivotilate, Feron, levamisole, Ka ShuNing, Alloferon, WS-007, Y-101 (Ti Fen Tai), rSIFN-co, PEG-IIFNm, KW-3, BP-Inter-014, oleanolic acid, HepB-nRNA, cTP-5 (rTP-5), HSK-II-2, HEISCO-106-1, HEISCO-106, Hepbarna, IBPB-006IA, Hepuyinfen, DasKloster 0014-01, Jiangantai (Ganxikang), picroside, GA5 NM-HBV, DasKloster-0039, hepulantai, IMB-2613, TCM-800B and ZH-2N, as well as other drugs for treating HBV selected from reduced glutathione, and RO-6864018; and
(37) The compounds disclosed in US20100143301 (Gilead Sciences), US20110098248 (Gilead Sciences), US20090047249 (Gilead Sciences), US8722054 (Gilead Sciences),
US20140045849 (Janssen), US20140073642 (Janssen), WO2014/056953 (Janssen), WO2014/076221 (Janssen), WO2014/128189 (Janssen), US20140350031 (Janssen), WO2014/023813 (Janssen), US20080234251 (Array Biopharma), US20080306050 (Array Biopharma), US20100029585 (Ventirx Pharma), US20110092485 (Ventirx Pharma), US20110118235 (Ventirx Pharma), US20120082658 (Ventirx Pharma), US20120219615 (Ventirx Pharma), US20140066432 (Ventirx Pharma), US20140088085 (VentirxPharma), US20140275167 (Novira therapeutics), US20130251673 (Novira therapeutics) ,
US8513184 (Gilead Sciences), US20140030221 (Gilead Sciences), US20130344030 (Gilead Sciences), US20130344029 (Gilead Sciences), US20140343032 (Roche), WO2014037480 (Roche), US20130267517 (Roche), WO2014131847 (Janssen),
WO2014033176 (Janssen), WO2014033170 (Janssen), WO2014033167 (Janssen), US20140330015 (Ono pharmaceutical), US20130079327 (Ono pharmaceutical), and US20130217880 (Ono pharmaceutical), and the compounds disclosed in US20100015178 (Incyte);
(38) IDO inhibitors selected from the group consisting of epacadostat (INCB24360), F-001287, resminostat (4SC-201), SN-35837, NLG-919, GDC-0919, and indoximod;
(39) Arginase inhibitors selected from CB-1158, C-201, and resminostat;
(40) Cytotoxic T-lymphocyte-associated protein 4 (ipi4) inhibitors selected from ipilumimab, belatacept, PSI-001, PRS-010, tremelimumab, and JHL-1155; and
(41) KDM5 inhibitors include the compounds disclosed in WO2016057924
(Genentech/Constellation Pharmaceuticals), US20140275092 (Genentech/Constellation Pharmaceuticals), US20140371195 (Epitherapeutics) and US20140371214
(Epitherapeutics). , US20160102096 (Epitherapeutics), US20140194469 (Quanticel), US20140171432, US20140213591 (Quanticel), US20160039808 (Quanticel),
US20140275084 (Quanticel), WO2014164708 (Quanticel).
In certain embodiments, a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, is combined with one, two, three, four or more additional therapeutic agents. In certain embodiments, a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, is combined with two additional therapeutic agents. In other embodiments, a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, is combined with three additional therapeutic agents. In further embodiments, a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, is combined with four additional therapeutic agents. The one, two, three, four or more additional therapeutic agents can be different therapeutic agents selected from the same class of therapeutic agents, and/or they can be selected from different classes of therapeutic agents.
In one embodiment, a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, is combined with an HBV DNA polymerase inhibitor. In another embodiment, a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, is combined with an HBV DNA polymerase inhibitor and at least one additional therapeutic agent selected from the group consisting of: immunomodulators, toll-like receptor modulators (modulators of TLR-1, TLR-2, TLR-3, TLR-4, TLR-5, TLR-6, TLR-7, TLR-8, TLR-9, TLR-10, TLR-11, TLR-12 and TLR-13), interferon alpha receptor ligands,
hyaluronidase inhibitors, recombinant IL-7, HBsAg inhibitors, compounds targeting HBcAg, cyclophilin inhibitors , HBV therapeutic vaccines, HBV prophylactic vaccines HBV viral entry inhibitors, NTCP inhibitors, antisense oligonucleotide targeting viral mRNA, short interfering RNAs (siRNA), miRNA gene therapy agents, endonuclease modulators, inhibitors of ribonucleotide reductase, Hepatitis B virus E antigen inhibitors, recombinant scavenger receptor A (SRA) proteins, src kinase inhibitors, HBx inhibitors, cccDNA inhibitors, short synthetic hairpin RNAs (sshRNAs), HBV antibodies including HBV antibodies targeting the surface antigens of the hepatitis B virus and bispecific antibodies and "antibody-like" therapeutic proteins (such as DARTs®, Duobodies®, Bites®, XmAbs®, TandAbs ®, Fab derivatives), CCR2 chemokine antagonists, thymosin agonists, cytokines, nucleoprotein inhibitors (HBV core or capsid protein inhibitors), stimulators of retinoic acid-inducible gene 1, stimulators of NOD2, stimulators of NODI, Arginase-1 inhibitors, STING agonists, PI3K inhibitors, lymphotoxin beta receptor activators, Natural Killer Cell Receptor 2B4 inhibitors, Lymphocyte-activation gene 3 inhibitors, CD 160 inhibitors, cytotoxic T-lymphocyte-associated protein 4 inhibitors, CD 137 inhibitors, Killer cell lectin-like receptor subfamily G member 1 inhibitors, TIM-3 inhibitors, B- and T-lymphocyte attenuator inhibitors, CD305 inhibitors, PD-1 inhibitors, PD-L1 inhibitors, PEG-Interferon Lambda, recombinant thymosin alpha- 1, BTK inhibitors, modulators of TIGIT, modulators of CD47, modulators of SIRPalpha , modulators of ICOS, modulators of CD27, modulators of CD70, modulators of OX40, modulators of NKG2D, modulators of Tim-4, modulators of B7-H4, modulators of B7-H3, modulators of NKG2A, modulators of GITR, modulators of CD 160, modulators of HEVEM, modulators of CD161, modulators of Axl, modulators of Mer, modulators of Tyro, gene modifiers or editors such as CRISPR (including CRISPR Cas9), zinc finger nucleases or synthetic nucleases (TALENs), and Hepatitis B virus replication inhibitors. In certain embodiments the at least one additional therapeutic agent is further selected from hepatitis B surface antigen (HBsAg) secretion or assembly inhibitors, TCR-like antibodies, cccDNA epigenetic modifiers, IAPs inhibitors, SMAC mimetics, and IDO inhibitors.
In another embodiment, a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, is combined with an HBV DNA polymerase inhibitor and at least one additional therapeutic agent selected from the group consisting of: HBV viral entry inhibitors, NTCP inhibitors, HBx inhibitors, cccDNA inhibitors, HBV antibodies targeting the surface antigens of the hepatitis B virus, short interfering RNAs (siRNA), miRNA gene therapy agents, short synthetic hairpin RNAs (sshRNAs), and nucleoprotein inhibitors (HBV core or capsid protein inhibitors).
In another embodiment, a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, is combined with an HBV DNA polymerase inhibitor, one or two additional therapeutic agents selected from the group consisting of: immunomodulators, toll-like receptor modulators (modulators of TLR-1, TLR-2, TLR-3, TLR-4, TLR-5, TLR-6, TLR-7, TLR-8, TLR-9, TLR-10, TLR-11, TLR-12 and TLR-13), HBsAg inhibitors, HBV therapeutic vaccines, HBV antibodies including HBV antibodies targeting the surface antigens of the hepatitis B virus and bispecific antibodies and "antibody-like" therapeutic proteins (such as DARTs®, Duobodies®, Bites®, XmAbs®, TandAbs ®, Fab derivatives), cyclophilin inhibitors, stimulators of retinoic acid-inducible gene 1, PD-1 inhibitors, PD-L1 inhibitors, Arginase-1 inhibitors, PI3K inhibitors and stimulators of NOD2, and one or two additional therapeutic agents selected from the group consisting of: HBV viral entry inhibitors, NTCP inhibitors, HBx inhibitors, cccDNA inhibitors, HBV antibodies targeting the surface antigens of the hepatitis B virus, short interfering RNAs (siRNA), miRNA gene therapy agents, short synthetic hairpin RNAs (sshRNAs), and nucleoprotein inhibitors (HBV core or capsid protein inhibitors). In certain embodiments one or two additional therapeutic agents is further selected from hepatitis B surface antigen (HBsAg) secretion or assembly inhibitors, TCR-like antibodies, and IDO inhibitors.
In a particular embodiment, a compound of the present disclosure, or a
pharmaceutically acceptable salt thereof, is combined with one, two, three, four or more additional therapeutic agents selected from adefovir (Hepsera®), tenofovir disoproxil fumarate + emtricitabine (TRUVADA®), tenofovir disoproxil fumarate (Viread®), entecavir (Baraclude®), lamivudine (Epivir-HBV®), tenofovir alafenamide, tenofovir, tenofovir disoproxil, tenofovir alafenamide fumarate, tenofovir alafenamide hemifumarate, telbivudine (Tyzeka®),
Clevudine®, emtricitabine (Emtriva®), peginterferon alfa-2b (PEG-Intron®), Multiferon®, interferon alpha lb (Hapgen®), interferon alpha-2b (Intron A®), pegylated interferon alpha-2a (Pegasys®), interferon alfa-nl(Humoferon®), ribavirin, interferon beta- la (Avonex®), Bioferon, Ingaron, Inmutag (Inferon), Algeron, Roferon-A, Oligotide, Zutectra, Shaferon, interferon alfa-2b (AXXO), Alfaferone, interferon alfa-2b (BioGeneric Pharma), Feron, interferon-alpha 2 (CJ), BEVAC, Laferonum, VIPEG, BLAUFERON-B, BLAUFERON-A, Intermax Alpha, Realdiron, Lanstion, Pegaferon, PDferon-B, interferon alfa-2b (IFN,
Laboratorios Bioprofarma), alfainterferona 2b, Kalferon, Pegnano, Feronsure, PegiHep, interferon alfa 2b (Zydus-Cadila), Optipeg A, Realfa 2B, Reliferon, interferon alfa-2b (Amega), interferon alfa-2b (Virchow), peginterferon alfa-2b (Amega), Reaferon-EC, Proquiferon, Uniferon, Urifron, interferon alfa-2b (Changchun Institute of Biological Products), Anterferon, Shanferon, MOR-22, interleukin-2 (IL-2, Immunex), recombinant human interleukin-2
(Shenzhen Neptunus), Layfferon, Ka Shu Ning, Shang Sheng Lei Tai, INTEFEN, SINOGEN, Fukangtai, Alloferon and celmoleukin
In a particular embodiment, a compound of the present disclosure, or a
pharmaceutically acceptable salt thereof, is combined with entecavir (Baraclude®), adefovir (Hepsera®), tenofovir disoproxil fumarate (Viread®), tenofovir alafenamide, tenofovir, tenofovir disoproxil, tenofovir alafenamide fumarate, tenofovir alafenamide hemifumarate, telbivudine (Tyzeka®) or lamivudine (Epivir-HBV®)
In a particular embodiment, a compound of the present disclosure, or a
pharmaceutically acceptable salt thereof, is combined with entecavir (Baraclude®), adefovir (Hepsera®), tenofovir disoproxil fumarate (Viread®), tenofovir alafenamide hemifumarate, telbivudine (Tyzeka®) or lamivudine (Epivir-HBV®). In a particular embodiment, a compound of the present disclosure, or a
pharmaceutically acceptable salt thereof is combined with a PD-1 inhibitor. In a particular embodiment, a compound of the present disclosure, or a pharmaceutically acceptable salt thereof is combined with a PD-L1 inhibitor. In a particular embodiment, a compound of the present disclosure, or a pharmaceutically acceptable salt thereof is combined with an IDO inhibitor. In a particular embodiment, a compound of the present disclosure, or a pharmaceutically acceptable salt thereof is combined with an IDO inhibitor and a PD-1 inhibitor. In a particular
embodiment, a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, is combined with an IDO inhibitor and a PD-Ll inhibitor. In a particular embodiment, a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, is combined with a TLR7 modulator, such as GS-9620. As used herein, GS-9620 (4-amino-2-butoxy-8-({3- [(pyrrolidin-l-yl)methyl]phenyl}methyl)-7,8-dihydropteridin-6(5H)-one), includes
pharmaceutically acceptable salts thereof.
In a particular embodiment, a compound of the present disclosure, or a
pharmaceutically acceptable salt thereof, is combined with a first additional therapeutic agent selected from the group consisting of: entecavir (Baraclude®), adefovir (Hepsera®), tenofovir disoproxil fumarate (Viread®), tenofovir alafenamide, tenofovir, tenofovir disoproxil, tenofovir alafenamide fumarate, tenofovir alafenamide hemifumarate, telbivudine (Tyzeka®) or lamivudine (Epivir-HBV®) and at least one additional therapeutic agent selected from the group consisting of immunomodulators, toll-like receptor modulators (modulators of TLR-1, TLR-2, TLR-3, TLR-4, TLR-5, TLR-6, TLR-7, TLR-8, TLR-9, TLR-10, TLR-11, TLR-12 and TLR- 13), interferon alpha receptor ligands, hyaluronidase inhibitors, recombinant IL-7, HBsAg inhibitors, compounds targeting HBcAg, cyclophilin inhibitors , HBV Therapeutic vaccines, HBV prophylactic vaccines, HBV viral entry inhibitors, NTCP inhibitors, antisense
oligonucleotide targeting viral mRNA, short interfering RNAs (siRNA), miRNA gene therapy agents, endonuclease modulators, inhibitors of ribonucleotide reductase, Hepatitis B virus E antigen inhibitors, recombinant scavenger receptor A (SRA) proteins, src kinase inhibitors, HBx inhibitors, cccDNA inhibitors, short synthetic hairpin RNAs (sshRNAs), HBV antibodies including HBV antibodies targeting the surface antigens of the hepatitis B virus and bispecific antibodies and "antibody-like" therapeutic proteins (such as DARTs®, Duobodies®, Bites®, XmAbs®, TandAbs ®, Fab derivatives), CCR2 chemokine antagonists, thymosin agonists, cytokines, nucleoprotein inhibitors (HBV core or capsid protein inhibitors), stimulators of retinoic acid-inducible gene 1, stimulators of NOD2, stimulators of NODI, recombinant thymosin alpha-1, Arginase-1 inhibitors, STING agonists, PI3K inhibitors, lymphotoxin beta receptor activators, Natural Killer Cell Receptor 2B4 inhibitors, Lymphocyte-activation gene 3 inhibitors, CD 160 inhibitors, cytotoxic T-lymphocyte-associated protein 4 inhibitors, CD 137 inhibitors, Killer cell lectin-like receptor subfamily G member 1 inhibitors, TIM-3 inhibitors, B- and T-lymphocyte attenuator inhibitors, CD305 inhibitors, PD-1 inhibitors, PD-Ll inhibitors, PEG-Interferon Lambd, BTK inhibitors, modulators of TIGIT, modulators of CD47, modulators of SIRPalpha , modulators of ICOS, modulators of CD27, modulators of CD70, modulators of OX40, modulators of NKG2D, modulators of Tim-4, modulators of B7-H4, modulators of B7- H3, modulators of NKG2A, modulators of GITR, modulators of CD 160, modulators of HEVEM, modulators of CD161, modulators of Axl, modulators of Mer, modulators of Tyro, gene modifiers or editors such as CRISPR (including CRISPR Cas9), zinc finger nucleases or synthetic nucleases (TALENs), a and Hepatitis B virus replication inhibitors. In certain embodiments, the at least one additional therapeutic agent is further selected from hepatitis B surface antigen (HBsAg) secretion or assembly inhibitors, TCR-like antibodies, IDO inhibitors, cccDNA epigenetic modifiers, IAPs inhibitors, and SMAC mimetics.
In a particular embodiment, a compound of the present disclosure, or a
pharmaceutically acceptable salt thereof, is combined with a first additional therapeutic agent selected from the group consisting of: entecavir (Baraclude®), adefovir (Hepsera®), tenofovir disoproxil fumarate (Viread®), tenofovir alafenamide, tenofovir, tenofovir disoproxil, tenofovir alafenamide fumarate, tenofovir alafenamide hemifumarate, telbivudine (Tyzeka®) or lamivudine (Epivir-HBV®) and at least a one additional therapeutic agent selected from the group consisting of peginterferon alfa-2b (PEG-Intron®), Multiferon®, interferon alpha lb (Hapgen®), interferon alpha-2b (Intron A®), pegylated interferon alpha-2a (Pegasys®), interferon alfa-nl(Humoferon®), ribavirin, interferon beta-la (Avonex®), Bioferon, Ingaron, Inmutag (Inferon), Algeron, Roferon-A, Oligotide, Zutectra, Shaferon, interferon alfa-2b (AXXO), Alfaferone, interferon alfa-2b (BioGeneric Pharma), Feron, interferon-alpha 2 (CJ), BEVAC, Laferonum, VIPEG, BLAUFERON-B, BLAUFERON-A, Intermax Alpha, Realdiron, Lanstion, Pegaferon, PDferon-B, interferon alfa-2b (IFN, Laboratorios Bioprofarma), alfainterferona 2b, Kalferon, Pegnano, Feronsure, PegiHep, interferon alfa 2b (Zydus-Cadila), Optipeg A, Realfa 2B, Reliferon, interferon alfa-2b (Amega), interferon alfa-2b (Virchow), peginterferon alfa-2b (Amega), Reaferon-EC, Proquiferon, Uniferon, Urifron, interferon alfa-2b (Changchun Institute of Biological Products), Anterferon, Shanferon, MOR-22, interleukin-2 (IL-2, Immunex), recombinant human interleukin-2 (Shenzhen Neptunus), Layfferon, Ka Shu Ning, Shang Sheng Lei Tai, INTEFEN, SINOGEN, Fukangtai, Alloferon and celmoleukin.
In a particular embodiment, a compound of the present disclosure, or a
pharmaceutically acceptable salt thereof, is combined with a first additional therapeutic agent selected from the group consisting of: entecavir (Baraclude®), adefovir (Hepsera®), tenofovir disoproxil fumarate (Viread®), tenofovir alafenamide, tenofovir, tenofovir disoproxil, tenofovir alafenamide fumarate, tenofovir alafenamide hemifumarate, telbivudine (Tyzeka®) or lamivudine (Epivir-HBV®) and at least one additional therapeutic agent selected from the group consisting of HBV viral entry inhibitors, NTCP inhibitors, HBx inhibitors, cccDNA inhibitors, HBV antibodies targeting the surface antigens of the hepatitis B virus, short interfering RNAs (siRNA), miRNA gene therapy agents, short synthetic hairpin RNAs (sshRNAs), and nucleoprotein inhibitors (HBV core or capsid protein inhibitors).
In a particular embodiment, a compound of the present disclosure, or a
pharmaceutically acceptable salt thereof, is combined with a first additional therapeutic agent selected from the group consisting of: entecavir (Baraclude®), adefovir (Hepsera®), tenofovir disoproxil fumarate (Viread®), tenofovir alafenamide, tenofovir, tenofovir disoproxil, tenofovir alafenamide fumarate, tenofovir alafenamide hemifumarate, telbivudine (Tyzeka®) or lamivudine (Epivir-HBV®), one or two additional therapeutic agents selected from the group consisting of: immunomodulators, toll-like receptor modulators (modulators of TLR-1, TLR-2, TLR-3, TLR-4, TLR-5, TLR-6, TLR-7, TLR-8, TLR-9, TLR-10, TLR-11, TLR-12 and TLR- 13), HBsAg inhibitors, HBV therapeutic vaccines, HBV antibodies including HBV antibodies targeting the surface antigens of the hepatitis B virus and bispecific antibodies and "antibodylike" therapeutic proteins (such as DARTs®, Duobodies®, Bites®, XmAbs®, TandAbs ®, Fab derivatives), cyclophilin inhibitors, stimulators of retinoic acid-inducible gene 1, PD-1 inhibitors, PD-L1 inhibitors, Arginase-1 inhibitors, PI3K inhibitors and stimulators ofNOD2, and one or two additional therapeutic agents selected from the group consisting of: HBV viral entry inhibitors, NTCP inhibitors, HBx inhibitors, cccDNA inhibitors, HBV antibodies targeting the surface antigens of the hepatitis B virus, short interfering RNAs (siRNA), miRNA gene therapy agents, short synthetic hairpin RNAs (sshRNAs), and nucleoprotein inhibitors (HBV core or capsid protein inhibitors). In certain embodiments, the one or two additional therapeutic agents is further selected from hepatitis B surface antigen (HBsAg) secretion or assembly inhibitors, TCR-like antibodies, and IDO inhibitors.
In a particular embodiment, a compound of the present disclosure, or a
pharmaceutically acceptable salt thereof, is combined with a first additional therapeutic agent selected from the group consisting of: tenofovir disoproxil fumarate (Viread®), tenofovir alafenamide, tenofovir, tenofovir disoproxil, tenofovir alafenamide fumarate, and tenofovir alafenamide hemifumarate; and a second therapeutic agent selected from the group consisting of: modulators of TLR-7 and modulators of TLR-8. In certain embodiments, a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, is combined with 5-30 mg tenofovir alafenamide fumarate, tenofovir alafenamide hemifumarate, or tenofovir alafenamide. In certain embodiments, a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, is combined with 5-10; 5- 15; 5-20; 5-25; 25-30; 20-30; 15-30; or 10-30 mg tenofovir alafenamide fumarate, tenofovir alafenamide hemifumarate, or tenofovir alafenamide. In certain embodiments, a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, is combined with 10 mg tenofovir alafenamide fumarate, tenofovir alafenamide hemifumarate, or tenofovir alafenamide. In certain embodiments, a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, is combined with 25 mg tenofovir alafenamide fumarate, tenofovir alafenamide hemifumarate, or tenofovir alafenamide. A compound of the present disclosure (e.g. , a compound of Formula (I) or (II), or Formula (la), (lb) or (Ila)) may be combined with the agents provided herein in any dosage amount of the compound (e.g. , from 50 mg to 500 mg of compound) the same as if each combination of dosages were specifically and individually listed. A compound of the present disclosure (e.g. , a compound of Formula (I) or (II), or Formula (la), (lb) or (Ila)) may be combined with the agents provided herein in any dosage amount of the compound (e.g. from about 1 mg to about 150 mg of compound) the same as if each
combination of dosages were specifically and individually listed.
In certain embodiments, a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, is combined with 100-400 mg tenofovir disoproxil fumarate, tenofovir disoproxil hemifumarate, or tenofovir disoproxil. In certain embodiments, a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, is combined with 100-150; 100-200, 100-250; 100-300; 100-350; 150-200; 150-250; 150-300; 150-350; 150-400; 200-250; 200-300; 200-350; 200-400; 250-350; 250-400; 350-400 or 300-400 mg tenofovir disoproxil fumarate, tenofovir disoproxil hemifumarate, or tenofovir disoproxil. In certain embodiments, a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, is combined with 300 mg tenofovir disoproxil fumarate, tenofovir disoproxil hemifumarate, or tenofovir disoproxil. In certain embodiments, a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, is combined with 250 mg tenofovir disoproxil fumarate, tenofovir disoproxil hemifumarate, or tenofovir disoproxil. In certain embodiments, a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, is combined with 150 mg tenofovir disoproxil fumarate, tenofovir disoproxil hemifumarate, or tenofovir disoproxil. A compound of the present disclosure (e.g., a compound of Formula (I) or (II), or Formula (la), (lb) or (Ila)) may be combined with the agents provided herein in any dosage amount of the compound (e.g. , from 50 mg to 500 mg of compound) the same as if each combination of dosages were specifically and individually listed. A compound of the present disclosure (e.g. , a compound of Formula (I) or (II), or Formula (la), (lb) or (Ila)) may be combined with the agents provided herein in any dosage amount of the compound (e.g., from about 1 mg to about 150 mg of compound) the same as if each combination of dosages were specifically and individually listed.
Also provided herein is a compound of the present disclosure (e.g., a compound of Formula (I) or (II), or Formula (la), (lb) or (Ila)), or a pharmaceutically acceptable salt thereof, and one or more additional active ingredients for treating HBV, for use in a method of treating or preventing HBV.
Also provided herein is a compound of the present disclosure (e.g., a compound of Formula (I) or (II), or Formula (la), (lb) or (Ila)), or a pharmaceutically acceptable salt thereof, for use in a method of treating or preventing HBV, wherein the compounder a pharmaceutically acceptable salt thereof is administered simultaneously, separately or sequentially with one or more additional therapeutic agents fort for treating HBV.
Kits
The present disclosure provides a kit comprising a compound of the present disclosure or a pharmaceutically acceptable salt thereof. The kit may further comprise instructions for use in treating an HBV infection. The instructions may be written instructions or electronic storage media (e.g., magnetic diskette or optical disk) containing instructions.
The present disclosure also provides a pharmaceutical kit comprising one or more containers comprising a compound of the present disclosure or a pharmaceutically acceptable salt thereof. Optionally associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals, which notice reflects approval by the agency for the manufacture, use or sale for human administration. Each component (if there is more than one component) can be packaged in separate containers or some components can be combined in one container where cross-reactivity and shelf life permit. The kits may be in unit dosage forms, bulk packages (e.g., multi-dose packages) or sub- unit doses. Kits may also include multiple unit doses of the compounds and instructions for use and be packaged in quantities sufficient for storage and use in pharmacies (e.g., hospital pharmacies and compounding pharmacies). Compound Preparation
Also provided are articles of manufacture comprising a unit dosage of a compound of the present disclosure or a pharmaceutically acceptable salt thereof, in suitable packaging for use in the methods described herein. Suitable packaging is known in the art and includes, for example, vials, vessels, ampules, bottles, jars, flexible packaging and the like. An article of manufacture may further be sterilized and/or sealed.
Some embodiments of the instant disclosure are directed to processes and
intermediates useful for preparing the subject compounds or pharmaceutically acceptable salts thereof.
Many general references providing commonly known chemical synthetic schemes and conditions useful for synthesizing the disclosed compounds are available (see, e.g. , Smith, March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, 7th edition, Wiley-Interscience, 2013.)
Compounds as described herein can be purified by any of the means known in the art, including chromatographic means, such as high performance liquid chromatography (HPLC), preparative thin layer chromatography, flash column chromatography and ion exchange chromatography. Any suitable stationary phase can be used, including normal and reversed phases as well as ionic resins. Most typically the disclosed compounds are purified via silica gel and/or alumina chromatography.
During any of the processes for preparation of the subject compounds, it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by means of conventional protecting groups as described in standard works, such as T. W. Greene and P. G. M. Wuts, "Protective Groups in Organic Synthesis," 4th ed., Wiley, New York 2006. The protecting groups may be removed at a convenient subsequent stage using methods known from the art.
EXAMPLES
Exemplary chemical entities of the present disclosure are provided in the specific examples that follow. Those skilled in the art will recognize that, to obtain the various compounds herein, starting materials may be suitably selected so that the ultimately desired substituents will be carried through the reaction scheme with or without protection as appropriate to yield the desired product. Alternatively, it may be necessary or desirable to employ, in the place of the ultimately desired substituent, a suitable group that may be carried through the reaction scheme and replaced as appropriate with the desired substituent.
Furthermore, one of skill in the art will recognize that the transformations shown in the schemes below may be performed in any order that is compatible with the functionality of the particular pendant groups.
The Examples provided herein describe the synthesis of compounds disclosed herein as well as intermediates used to prepare the compounds. It is to be understood that individual steps described herein may be combined. It is also to be understood that separate batches of a compound may be combined and then carried forth in the next synthetic step.
In the following description of the Examples, specific embodiments are described. These embodiments are described in sufficient detail to enable those skilled in the art to practice certain embodiments of the present disclosure. Other embodiments may be utilized and logical and other changes may be made without departing from the scope of the disclosure. The following description is, therefore, not intended to limit the scope of the present disclosure.
Example 1: ll-chloro-12-(3-methoxypropoxy)-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l- a] pyrrolo [ 1,2-c] phthalazine-7-carboxylic acid
O v Br
CI Br, CI
HO ^ Ί rB' K2C03, DMF
HO
2-chloro-5-iodophenol 4-bromo- 1 -bromo-5-chloroC-2X-iodo,-4- 2-chloro-5-iodophenol (3-methoxypropoxy)benzene
1 - (3- (3- ihydro-2H-
Figure imgf000070_0001
5-(2-bromo-4-chloro-5-(3-
2-(2-bromo-4-chloro-5-(3- methoxypropoxy)phenyl)- methoxypropoxy)phenyl)pyrroli
3,4-dihydro-2H-pyrrole
dine
Figure imgf000070_0002
methoxypropoxy)phenyl)pyrroli
dine 2-(2-bromo-4-chloro-5- (3-methoxypropoxy)
phenyl)-1 - nitrosopyrrolidine
Figure imgf000071_0001
2-(2-bromo-4-c loro-5- (3- 2-(2-bromo-4-c loro-5-(3- met oxypropoxy)p enyl) met oxypropoxy)p enyl)pyrro
-1-nitrosopyrrolidine lidin-1 -amine
Figure imgf000071_0002
2-(2-bromo-4-c loro-5-(3- ((dimethylamino)m
met oxypropoxy)p enyl)pyrro ethylene)-5,5- ethyl 1-(2-(2-bromo-4-chloro-5-(3- lidin-1-amine diethoxy-3- methoxypropoxy)phenyl)pyrrolidin-1 - oxopentanoate yl)-4-oxo-1 ,4-dihydropyridine-3- carboxylate
Figure imgf000071_0003
ethyl 1 -(2-(2-bromo-4-chloro-5-(3- methoxypropoxy)phenyl)pyrrolidin-1 - ethyl 11 -chloro-12-(3- yl)-4-oxo-1 ,4-dihydropyridine-3- methoxypropoxy)-8-oxo-2,3,8,13b- carboxylate tetrahydro-1 H-pyrido[2,1 - a]pyrrolo[1 ,2-c]phthalazine-7- carboxylate
Figure imgf000071_0004
ethyl 11-chloro-12-(3- methoxypropoxy)-8-oxo-2,3,8,13b- tetrahydro-1 H-pyrido[2,1- a]pyrrolo[1 ,2-c]phthalazine-7- carboxylate
Synthesis of 4-bromo-2-chloro-5-iodophenol: To a solution of 2-chloro-5-iodophenol (10 g, 39.3 mmol) in AcOH (20 ml) was added dropwise bromine (2.22 ml, 43.23 mmol) maintaining an internal temperature less than 30 °C. After stirring for 20 min, additional bromine (200 μί) was added the reaction was stirred for 20 min. To the reaction was added water (10 mL) followed by 40% NaHS03 (4 mL). The precipitates were filtered, washed with 50% AcOH (20 mL), followed by water (30 mL). The solids in the filtrate were filtered, washed, combined, and air dried. XH NMR (400 MHz, Chloroform-c δ 7.55 (d, J = 0.7 Hz, 1H), 7.53 (d, J = 0.7 Hz, 1H), 5.46 (s, 1H). MS (m/z) 333.1 [M-H]-. Synthesis of l-bromo-5-chloro-2-iodo-4-(3-methoxypropoxy) benzene: To a solution of 4- bromo-2-chloro-5-iodophenol (3 g, 9 mmol) in DMF (9 ml) was added CS2CO3 (3.81 g, 11.7 mmol) followed by dropwise addition of l-bromo-3-methoxypropane (1.06 ml, 9.45
mmol). The mixture was stirred overnight at ambient temperature. The mixture was diluted with 10% hexane in EtOAc (40 mL) and washed with water (2 x 40 mL). The organic layer was dried with Na2SC>4, filtered, and concentrated. Product was purified by silica chromatography using EtOAc in hexane (0-10%). Rf~0.45 w/ 10% EtOAc/hexanes. lH NMR (400 MHz, Chloroform-ύ δ 7.56 (s, 1H), 7.36 (s, 1H), 4.08 (t, J = 6.2 Hz, 2H), 3.57 (t, J = 6.0 Hz, 2H), 3.36 (s, 3H), 2.08 (p, J = 6.1 Hz, 2H).
Synthesis of 5-(2-bromo-4-chloro-5-(3-methoxypropoxy)phenyl)-3,4-dihydro-2H-pyrrole: l-bromo-5-chloro-2-iodo-4-(3-methoxypropoxy)benzene (2.5 g, 6.17 mmol) was taken up in THF (25 mL) under an atmosphere or argon and cooled to 0°C. To this was slowly added 1.3M Isopropylmagnesium chloride - Lithium chloride complex (6.17 ml, 8.02 mmol) and the reaction stirred for an additional 15 minutes. To this was then added l-(tert-Butoxycarbonyl)-2- pyrrolidinone 97% (1.05 ml, 6.17 mmol) and the reaction stirred for 15 minutes. Reaction was diluted in EtOAc / aq. ammonium chloride and extracted with EtOAc (3x). Organics were then washed with aq. ammonium chloride (lx), water( lx), brine, then dried over sodium sulfate before filtering and evaporating organics under reduced pressure to afford crude residue. Crude residue was taken up in DCM (10 mL) and to this was added TFA (10 mL) and stirred at room temperature for 1 hour. At this point reaction was complete and solvents were removed under reduced pressure to afford crude residue. Crude residue was diluted in EtOAc then washed with dilute aq. sodium bicarbonate (3x), water (lx), brine, then dried over sodium sulfate before filtering and evaporating organics under reduced pressure to afford crude residue. MS (m/z) 348.2 [M+H]+.
Synthesis of 2-(2-bromo-4-chloro-5-(3-methoxypropoxy)phenyl)pyrrolidine: Crude residue was then taken up in 20 mL EtOH and cooled to 0°C under an argon atmosphere. To this was then added in portions sodium borohydride (0.65 g, 20 mmol) and reaction allowed to stir for 15 minutes. Reaction was quenched with slow addition of aq. ammonium chloride, then reaction was diluted in EtOAc / H20 and EtOAc (3x). Organics were then washed with IN aq HC1 (3x). Acid aqueous extracts were then basified with aqueous sodium hydroxide and extracted EtOAc (3x). Organics were washed with water and brine then dried over sodium sulfate, filtered and evaporated to dryness to afford the desired product as a light colored oil. MS (m/z) 350.2 [M+H]+. Synthesis of 2-(2-bromo-4-chloro-5-(3-methoxypropoxy)phenyl)-l-nitrosopyrrolidine: To
2-(2-bromo-4-chloro-5-(3-methoxypropoxy)phenyl)pyrrolidine (930 mg, 2.67 mmol) in 16 mL 3: 1 THF :water was added Sodium nitrite (544.09 mg, 7.9 mmol), followed by acetic acid (0.38 ml, 6.67 mmol) and the reaction stirred at 50°C for 1 hour. Reaction was diluted in EtOAc / H20 and extracted with EtOAc (3x). Organics were then washed with water (2x), brine, then dried over sodium sulfate before filtering and evaporating organics under reduced pressure to afford crude residue. MS (m/z) 379.0 [M+H]+.
Synthesis of 2-(2-bromo-4-chloro-5-(3-methoxypropoxy)phenyl)pyrrolidin-l-amine: Crude 2-(2-bromo-4-chloro-5-(3-methoxypropoxy)phenyl)-l-nitrosopyrrolidine was taken up in 16 mL of a 3: 1 TFA : water mixture and to this was added zinc powder (780 mg, 12 mmol) and the suspension sonicated for 30 minutes. At this point reaction is complete and was filtered rinsed with EtOAc then the filtrate was diluted in EtOAc / H20 and extracted with EtOAc (3x).
Organics were then washed with water (2x), brine, then dried over sodium sulfate before filtering and evaporating organics under reduced pressure to afford crude residue. MS (m/z) 365.1 [M+H]+.
Synthesis of et -2-((dimethylamino)methylene)-5,5-diethoxy-3-oxopentanoate
Figure imgf000073_0001
ethyl , - e oxy- -oxopen anoa e
ethyl (Z)-2- ((dimethylamino)methylene)-5,5- diethoxy-3-oxopentanoate
Ethyl 5,5-diethoxy-3-oxopentanoate (2.34 g, 10 mmol) and NN-dimethylformamide dimethylacetal (2.24 mL, 15 mmol) were combined. The mixture was stirred at RT, then concentrated under reduced pressure. The crude material was purified by silica column chromatography (0% to 20% EtO Ac/Hex) to afford ethyl (Z)-2-((dimethylamino)methylene)- 5,5-diethoxy-3-oxopentanoate (2.90 g, 86%). %). lH NMR (400 MHz, Chloroform-i ) δ 7.66 (s, 1H), 5.00 (t, J = 5.8 Hz, 1H), 4.20 (q, J = 7.1 Hz, 2H), 3.64 (dq, J = 9.3, 7.0 Hz, 2H), 3.52 (dq, J = 9.4, 7.1 Hz, 2H), 3.08 (d, J = 5.8 Hz, 2H), 1.30 (t, J = 7.1 Hz, 4H), 1.16 (t, J = 7.1 Hz, 6H). MS (m/z) 242.0 [M-EtO]+.
Synthesis of ethyl l-(2-(2-bromo-4-chloro-5-(3-methoxypropoxy)phenyl)pyrrolidin-l-yl)-4- oxo-l,4-dihydropyridine-3-carboxylate: Crude 2-(2-bromo-4-chloro-5-(3- methoxypropoxy)phenyl)pyrrolidin-l -amine was dissolved in 5 mL EtOH and to this was added ethyl (Z)-2-((dimethylamino)methylene)-5,5-diethoxy-3-oxopentanoate (839.52 mg, 2.92 mmol)). Reaction was then heated to 70° C for 1 hour at which point reaction was diluted in EtOAc / H20 and extracted with EtAc (3x). Organics were then washed with water( 2x), brine, then dried over sodium sulfate before filtering and evaporating organics under reduced pressure to afford crude residue. Crude material was purified by silica gel chromatography using EtOAc / MeOH ( 0 to 25% methanol ) to afford 720 mg (60%) of the title compound as a yellow solid. MS (m/z) 515.3 [M+H]+. XH NMR (400 MHz, Chloroform-c/) δ 8.32 (d, J = 2.8 Hz, 1H), 7.46 (s, 1H), 7.42 (dd, J = 8.0, 2.8 Hz, 1H), 7.16 (s, 1H), 6.39 (d, J = 8.0 Hz, 1H), 4.65 (t, J = 8.2 Hz, 1H), 4.32 (qd, J = 7.1 , 1.5 Hz, 2H), 4.14 (ddt, J = 32.9, 9.2, 6.2 Hz, 2H), 3.71 - 3.53 (m, 3H), 3.37 (s, 3H), 3.24 (q, J = 8.8 Hz, 1H), 2.50 (dq, J = 13.0, 7.7 Hz, 1H), 2.19 - 2.04 (m, 4H), 1.75 (dq, J = 13.0, 8.4 Hz, 1H), 1.34 (t, J = 7.1 Hz, 3H).
Synthesis of ethyl ll-chloro-12-(3-methoxypropoxy)-8-oxo-2,3,8,13b-tetrahydro-LH- pyrido[2,l-fl]pyrrolo[l,2-c]phthalazine-7-carboxylate: Ethyl l -(2-(2-bromo-4-chloro-5-(3- methoxypropoxy)phenyl)pyrrolidin-l -yl)-4-oxo- 1 ,4-dihydropyridine-3-carboxylate (215 mg, 0.42 mmol), palladium(II) acetate (9.39 mg, 0.04 mmol), Bis[(2-diphenylphosphino)phenyl] ether, DPEPhos (22.54 mg, 0.04 mmol) and potassium carbonate (144.51 mg, 1.05 mmol) were suspended in DMA (5 mL) in a sealed tube and heated to 110°C for 1 hour. At this point reaction was cooled then filtered and rinsed with 1-2 mL of THF. MS (m/z) 433.3 [M+H]+. Synthesis of ll-chloro-12-(3-methoxypropoxy)-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l- fl]pyrrolo[l,2-c]phthalazine-7-carboxylic acid (1): To the THF solution was added lmL of 2N LiOH and the reaction heated at 60°C for 2 hours. Reaction was then cooled and to the solution was added 2 drops of TFA and the material was purified by reverse phase HPLC using ACN / H20 with 0.1% TFA as the eluent on a Gemini CI 8 column to afford the title compound 1 1- chloro-12-(3-methoxypropoxy)-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2, l-a]pyrrolo[l ,2- c]phthalazine-7-carboxylic acid . MS (m/z) 405.3[M+H]+. XH NMR (400 MHz, DMSO-c 6) δ 8.57 (s, 1H), 8.31 (s, 1H), 7.50 (s, 1H), 7.23 (d, J = 1.0 Hz, 1H), 4.78 (d, J = 6.3 Hz, 1H), 4.26 (ddt, J = 29.1 , 9.9, 6.3 Hz, 2H), 3.54 - 3.45 (m, 3H), 3.24 (s, 3H), 2.78 - 2.60 (m, 2H), 2.33 - 2.21 (m, 1H), 1.99 (p, J = 6.2 Hz, 2H), 1.95 - 1.81 (m, 1H), 1.69 - 1.56 (m, 1H).
Example 2: (R) -ll-chloro-12-(3-methoxypropoxy)-8-oxo-2,3,8,13b-tetrahydro-lH- pyrido[2,l-fl]pyrrolo[l,2-c]phthalazine-7-carboxylic acid and (S -ll-chloro-12-(3- methoxypropoxy)-8-oxo-2,3,8,13b-tetrahydro- lH-pyrido [2,1-a] pyrrolo [ 1,2-c] phthalazine- 7-carboxylic acid
Figure imgf000075_0001
2
l l-chloro-12-(3-methoxypropoxy)-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2- c]phthalazine-7-carboxylic acid (1) was separated into its enantiomers by chiral SFC chromatography using OD-H 4.6X100mm columns with 30% methanol as the co-solvent. Example 2 is the slower eluting peak retention time of 5.75 min. XH NMR (400 MHz, DMSO- c¾) 5 8.57 (s, 1H), 8.31 (s, 1H), 7.50 (s, 1H), 7.23 (d, J = 1.0 Hz, 1H), 4.78 (d, J = 6.3 Hz, 1H), 4.26 (ddt, J = 29.1, 9.9, 6.3 Hz, 2H), 3.54 - 3.45 (m, 3H), 3.24 (s, 3H), 2.78 - 2.60 (m, 2H), 2.33 - 2.21 (m, 1H), 1.99 (p, J = 6.2 Hz, 2H), 1.95 - 1.81 (m, 1H), 1.69 - 1.56 (m, 1H). Example 3: (S -ll-chloro-12-(3-methoxypropoxy)-8-oxo-2,3,8,13b-tetrahydro-lH- pyrido[2,l-fl]pyrrolo[l,2-c]phthalazine-7-carboxylic acid
Figure imgf000075_0002
3
l l-chloro-12-(3-methoxypropoxy)-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2- c]phthalazine-7-carboxylic acid (1) was separated into its enantiomers by chiral SFC chromatography using OD-H 4.6X100mm columns with 30% methanol as the co-solvent. Example 3 is the faster eluting peak retention time of 4.4 min. l NMR (400 MHz, OMSO-d6) δ 8.57 (s, 1H), 8.31 (s, 1H), 7.50 (s, 1H), 7.23 (d, J= 1.0 Hz, 1H), 4.78 (d, J = 6.3 Hz, 1H), 4.26 (ddt, J= 29.1, 9.9, 6.3 Hz, 2H), 3.54 - 3.45 (m, 3H), 3.24 (s, 3H), 2.78 - 2.60 (m, 2H), 2.33 - 2.21 (m, 1H), 1.99 (p, J = 6.2 Hz, 2H), 1.95 - 1.81 (m, 1H), 1.69 - 1.56 (m, 1H).
Example 4: ll-chloro-12-(3-methoxypropoxy)-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro- lH-pyrido [2,1-a] pyrrolo [ 1,2-c] phthalazine-7-carboxylic acid
Figure imgf000076_0001
-bromo-5-chloro-2-iodo-4-(3- 5-(2-bromo-4-chloro-5-(3- methoxypropoxy)benzene methoxypropoxy)phenyl)-2,2- dimethylpyrrolidin-1 -ol
Figure imgf000076_0002
5-(2-bromo-4-chloro-5-(3- 5-(2-bromo-4-chloro-5-(3- methoxypropoxy)phenyl)-2,2- methoxypropoxy)phenyl)-2,2- dimethylpyrrolidin-1 -ol dimethylpyrrolidine
Figure imgf000076_0003
5-(2-bromo-4-chloro-5-(3- 5-(2-bromo-4-chloro-5-(3- methoxypropoxy)phenyl)-2,2- methoxypropoxy)phenyl)-2,2- dimethylpyrrolidine dimethyl-1 -nitrosopyrrolidine
Figure imgf000076_0004
5-(2-bromo-4-chloro-5-(3- 5-(2-bromo-4-chloro-5-(3- methoxypropoxy)phenyl)-2,2- methoxypropoxy)phenyl)-2,2- dimethyl-1 -nitrosopyrrolidine dimethylpyrrolidin-1 -amine
Figure imgf000077_0001
methoxypropoxy)phenyl)-2,2- 2) ACOH 60 C ethy| i -(5-(2-bromo-4-chloro-5-(3- dimethylpyrrolidin-1 -amine methoxypropoxy)phenyl)-2,2- dimethylpyrrolidin-1 -yl)-4-oxo-1 ,4- dihydropyridine-3-carboxylate
Figure imgf000077_0002
ethyl 1 -(5-(2-bromo-4-chloro-5-(3- ethyl 1 1 -chloro-12-(3-methoxypropoxy)- methoxypropoxy)phenyl)-2,2- 3,3-dimethyl-8-oxo-2,3,8, 13b-tetrahydro- dimethylpyrrolidin-1 -yl)-4-oxo-1 ,4- 1 H-pyrido[2, 1 -a]pyrrolo[1 ,2- dihydropyridine-3-carboxylate c]phthalazine-7-carboxylate
LiOH
Figure imgf000077_0003
Synthesis of 5-(2-bromo-4-chloro-5-(3-methoxypropoxy)phenyl)-2,2-dimethylpyrrolidin-l- ol : To a solution of l-bromo-5-chloro-2-iodo-4-(3-methoxypropoxy)benzene (2.0 g, 4.9 mmol) in MeTHF (20 ml) at 0 °C,was slowly added 2.9M isopropylmagnesium Bromide (3.4 ml, 9.9 mmol). The mixture was stirred for 10 minutes, then 2,2-dimethyl-3,4-dihydro-2H-pyrrole 1- oxide (1.1 g, 9.9 mmol) was added and the mixture was stirred for 10 minutes. The reaction was quenched with saturated NH4C1 and extracted 2X with EtOAc. The combined organics were dried over sodium sulfate, concentrated and purified by flash column chromatography. MS (m/z) 394.14 [M+H]+.
Synthesis of 5-(2-bromo-4-chloro-5-(3-methoxypropoxy)phenyl)-2,2-dimethylpyrrolidine:
To a solution of 5-(2-bromo-4-chloro-5-(3-methoxypropoxy)phenyl)-2,2-dimethylpyrrolidin-l- ol (0.74 g, 1.9 mmol) in TFA (11.3 ml) and water (4.5 ml) was added zinc powder (0.6 g, 9.4 mmol). The mixture was heated to 50 °C until done about 30 minutes. The solution was concentrated under vacuum. The crude mixture was quenched with saturated sodium bicarbonate until fizzing stops. The product was extracted with DCM. The organic layer was washed with water, dried under Na2SC>4, filtered, and concentrated. The product was used crude in the next reaction. MS (m/z) 378.1 [M+H]+.
Synthesis of 5-(2-bromo-4-chloro-5-(3-methoxypropoxy)phenyl)-2,2-dimethyl-l- nitrosopyrrolidine: To a solution of 5-(2-bromo-4-chloro-5-(3-methoxypropoxy)phenyl)-2,2- dimethylpyrrolidine (0.7 g, 1.9 mmol) in THF (5.0 mL) was added an aqueous solution of NaNC>2 (307.7 mg, 4.5 mmol in 2.5 mL of water) followed by acetic acid (0.3 mL, 4.6 mmol). The mixture was stirred at 50 °C until done (about 1 hour). The reaction mixture was then diluted with EtOAc, washed with brine, dried with Na2S04, filtered, and concentrated. MS (m/z) 407.6 [M+H]+.
Synthesis of 5-(2-bromo-4-chloro-5-(3-methoxypropoxy)phenyl)-2,2-dimethylpyrrolidin-l- aniine: To a solution of 5-(2-bromo-4-chloro-5-(3-methoxypropoxy)phenyl)-2,2-dimethyl-l- nitrosopyrrolidine (0.75 g, 1.9 mmol) in TFA (11.1 ml) and water (4.5 ml) was added zinc powder (0.6 g, 9.4 mmol). The mixture was heated to 50 °C until done about 30 minutes. The solution was concentrated under vacuum. The crude mixture was quenched with saturated sodium bicarbonate until fizzing stops. The product was extracted with DCM. The organic layer was washed with water, dried under Na2S04, filtered, and concentrated. The product was used crude in the next reaction. MS (m/z) 391.9 [M+H]+.
Synthesis of ethyl l-(5-(2-bromo-4-chloro-5-(3-methoxypropoxy)phenyl)-2,2- dimethylpyrrolidin-l-yl)-4-oxo-l,4-dihydropyridine-3-carboxylate: To a solution of 5-(2- bromo-4-chloro-5-(3-methoxypropoxy)phenyl)-2,2-dimethylpyrrolidin-l-amine (0.72 g, 1.8 mmol) in EtOH (4.5 ml) was added ethyl (Z)-2-((dimethylamino)methylene)-5,5-diethoxy-3- oxopentanoate (0.79 g, 2.7 mmol). The mixture was heated to 60 °C for 90 minutes after which acetic acid (4.5 ml) was added. The reaction was stirred overnight and checked for
completion. The crude mixture was diluted with saturated K2HP04 and EtOAc, the organic layer was then washed with brine and dried under Na2S04, filtered, and concentrated. The product was purified by flash column chromatography. MS (m/z) 543.3 [M+H]+.
Synthesis of ethyl ll-chloro-12-(3-methoxypropoxy)-3,3-dimethyl-8-oxo-2,3,8,13b- tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate : A solution of ethyl 1- (5-(2-bromo-4-chloro-5-(3-methoxypropoxy)phenyl)-2,2-dimethylpyrrolidin-l-yl)-4-oxo-l,4- dihydropyridine-3-carboxylate (460 mg, 0.85 mmol), PdBr2 (34 mg, 0.13 mmol), and potassium acetate (207 mg, 2.1 mmol) in NN-dimethylacetamide (5 ml) was purged with argon for 2 min. The reaction vessel was sealed and the mixture was stirred overnight at 90 °C, reaction was not complete, added more. PdBr2 (34 mg, 0.13 mmol). The mixture was cooled, diluted with EtOAc and water, extract 2X EtOAc and washed organic with brine. The organic layer was dried with Na2SC>4, filtered, and concentrated. Product was purified by flash column chromatography. MS (m/z) 461.6 [M+H]+.
Synthesis of ll-chloro-12-(3-methoxypropoxy)-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro- lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid (4): A solution of ethyl 11- chloro-12-(3-methoxypropoxy)-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l- a]pyrrolo[l,2-c]phthalazine-7-carboxylate (25 mg, 0.05 mmol) in EtOH (1 ml) and 2M LiOH (0.3 ml) was stirred at room temperature until complete. The mixture was quenched with TFA (0.5 ml) and water (0.5 ml), filtered and purified by HPLC. lH NMR (400 MHz, Chloroform-d) δ 8.56 (s, IH), 7.79 (s, IH), 7.09 (s, IH), 6.87 (s, IH), 4.79 (d, IH), 4.31 - 4.14 (m, 2H), 3.61 (q, 2H), 3.37 (s, 3H), 2.55 - 2.43 (m, IH), 2.44 - 2.34 (m, IH), 2.20 - 2.09 (m, 2H), 1.97 - 1.86 (m, IH), 1.70 - 1.57 (m, IH), 1.38 (s, 3H), 0.68 (s, 3H). MS (m/z) 433.3 [M+H]+.
Example 5: i? -ll-chloro-12-(3-methoxypropoxy)-3,3-dimethyl-8-oxo-2,3,8,13b- tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid
Figure imgf000079_0001
5
Ethyl 1 l-chloro-12-(3-methoxypropoxy)-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH- pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate was separated into its enantiomers by chiral SFC chromatography using AD-H 4.6X100mm columns with 30% methanol as the co- solvent. The faster eluting peak with a retention time of 2.1 min was taken up in in EtOH (1 ml) and 2M LiOH (0.3 ml) then stirred at room temperature until hydrolysis was complete. The mixture was acidified with TFA (0.5 ml) and water (0.5 ml), filtered and purified by HPLC. XH NMR (400 MHz, Chloroform-d) δ 8.54 (s, IH), 7.78 (s, IH), 7.06 (s, IH), 6.87 (s, IH), 4.79 (d, IH), 4.28 - 4.14 (m, 2H), 3.68 - 3.54 (m, 2H), 3.37 (s, 3H), 2.56 - 2.43 (m, IH), 2.44 - 2.34 (m, IH), 2.20 - 2.10 (m, 2H), 1.95 - 1.86 (m, IH), 1.69 - 1.56 (m, IH), 1.38 (s, 3H), 0.68 (s, 3H). MS (m/z) 433.3 [M+H]+.
Example 6: ¾ -ll-chloro-12-(3-methoxypropoxy)-3,3-dimethyl-8-oxo-2,3,8,13b- tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid
Figure imgf000080_0001
Ethyl l l-chloro-12-(3-methoxypropoxy)-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH- pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate was separated into its enantiomers by chiral SFC chromatography using AD-H 4.6X100mm columns with 30% methanol as the co- solvent. The slower eluting peak with a retention time of 3.45 min was taken up in in EtOH (1 ml) and 2M Li OH (0.3 ml) then stirred at room temperature until hydrolysis was complete. The mixture was acidified with TFA (0.5 ml) and water (0.5 ml), filtered and purified by HPLC. XH NMR (400 MHz, Chloroform-d) δ 8.54 (s, IH), 7.78 (s, IH), 7.06 (s, IH), 6.87 (s, IH), 4.79 (d, IH), 4.28 - 4.14 (m, 2H), 3.68 - 3.54 (m, 2H), 3.37 (s, 3H), 2.56 - 2.43 (m, IH), 2.44 - 2.34 (m,
IH), 2.20 - 2.10 (m, 2H), 1.95 - 1.86 (m, IH), 1.69 - 1.56 (m, IH), 1.38 (s, 3H), 0.68 (s, (m/z) 433.3 [M+H]+.
Example 7: (S^lSb^-ll-chloro-H-iS-metho ypropo yJ-S-methyl-S-o o-l^^^Sb tetrahydro-lH-pyrido [2,1-fl] pyrrolo [ 1,2-c] phthalazine-7-carboxylic acid
Figure imgf000080_0002
ethyl c/s-1 1 -chloro-12-(3- methoxypropoxy)-3-methyl-8-oxo- 2,3,8,13b-tetrahydro-1 H-pyrido[2,1 - a]pyrrolo[1 ,2-c]phthalazine-7- carboxylate
Figure imgf000080_0003
pyrido[2,1 -a]pyrrolo[1 ,2-c]phthalazine-7- ethyl trans^ 1 -chloro-12-(3- carboxylate
methoxypropoxy)-3-methyl-8-oxo- 2,3,8,13 b-tetra h yd ro- 1 H-py rid o [2 , 1 - a]pyrrolo[1 ,2-c]phthalazine-7- carboxylate Synthesis of ethyl-ll-chloro-12-(3-methoxypropoxy)-3-methyl-8-oxo-2,3,8,13b-tetrahydro- lH-pyrido [2,1-a] pyrrolo [ 1,2-c] phthalazine-7-carboxylate: Ethyl- 11 -chloro- 12-(3 - methoxypropoxy)-3-methyl-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2- c]phthalazine-7-carboxylate was prepared similarly to example 1 using fert-butyl (R,S)-2- methyl-5-oxopyrrolidine-l-carboxylate in place of 1 -(fer/-butoxycarbonyl)-2-pyrrolidinone. The cis/trans mixture was separated by reverse phase HPLC using ACN / H20 with 0.1% TFA as the eluent on a Gemini CI 8 column. The cis isomer was assigned to be the faster eluting peak and the trans the slower.
Ethyl cis-ll-chloro-12-(3-methoxypropoxy)-3-methyl-8-oxo-2,3,8,13b-tetrahydro-lH- pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate: XH NMR (400 MHz, Chloroform-<i) δ 8.61 (s, 1H), 7.91 (s, 1H), 7.76 (s, 1H), 6.86 (s, 1H), 4.77 (d, J= 6.3 Hz, 1H), 4.43 (qd, J = 7.1, 3.4 Hz, 2H), 4.23 (tdd, J = 9.2, 6.3, 3.0 Hz, 2H), 4.03 (q, J = 6.7 Hz, 1H), 3.71 - 3.53 (m, 2H), 3.38 (s, 3H), 2.61 - 2.40 (m, 2H), 2.32 (dtd, J = 11.8, 7.9, 3.5 Hz, 1H), 2.15 (p, J = 6.0 Hz, 2H), 1.49 (ddd, J = 13.7, 8.9, 5.5 Hz, 1H), 1.41 (t, J = 7.1 Hz, 3H), 0.69 (d, J= 6.6 Hz, 3H). MS (m/z) 447.3 [M+H]+.
(3i?,13bi?)-ll-chloro-12-(3-methoxypropoxy)-3-methyl-8-oxo-2,3,8,13b-tetrahydro-lH- pyrido[2,l-fl]pyrrolo[l,2-c]phthalazine-7-carboxylic acid (7): Ethyl cw-l l-chloro-12-(3- methoxypropoxy)-3-methyl-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2- c]phthalazine-7-carboxylate intermediate was separated into its single enantiomers by chiral SFC chromatography using a IA 4.6X100 mm column with 30% methanol as the co-solvent. The faster eluting peak with a retention time of 5.56 min was taken up in in EtOH (1 ml) and 2M LiOH (0.3 ml) then stirred at room temperature until hydrolysis was complete. The mixture was acidified with TFA (0.5 ml) and water (0.5 ml), filtered and purified by HPLC. XH NMR (400 MHz, Chloroform-ύ δ 8.58 (s, 1H), 7.78 (s, 1H), 7.04 (s, 1H), 6.87 (s, 1H), 4.71 (d, J = 6.1 Hz, 1H), 4.33 - 4.09 (m, 2H), 3.94 (q, J = 6.8 Hz, 1H), 3.68 - 3.54 (m, 2H), 3.37 (s, 3H), 2.49 (dd, J = 16.7, 8.0 Hz, 2H), 2.40 - 2.22 (m, 1H), 2.15 (p, J = 6.1 Hz, 2H), 1.48 - 1.35 (m, 1), 0.66 (d, J = 6.7 Hz, 3H). MS (m/z) 419.4 [M+H]+.
Figure imgf000081_0001
7 Example 8: (S^lSb^-ll-chloro-^-^-methoxypropoxyJ-S-methyl-S-oxo- tetrahydro-lH-pyrido [2,1-fl] pyrrolo [ 1,2-c] phthalazine-7-carboxylic acid
Figure imgf000082_0001
8
Ethyl cz ,-l l-chloro-12-(3-methoxypropoxy)-3-methyl-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido [2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate intermediate was separated into its single enantiomers by chiral SFC chromatography using a IA 4.6X100 mm column with 30% methanol as the co-solvent. The slower eluting peak with a retention time of 6.11 min was taken up in in EtOH (1 ml) and 2M Li OH (0.3 ml) then stirred at room temperature until hydrolysis was complete. The mixture was acidified with TFA (0.5 ml) and water (0.5 ml), filtered and purified by HPLC. XH NMR (400 MHz, Chloroform-^ δ 8.58 (s, 1H), 7.78 (s, 1H), 7.04 (s, 1H), 6.87 (s, 1H), 4.71 (d, J = 6.1 Hz, 1H), 4.33 - 4.09 (m, 2H), 3.94 (q, J = 6.8 Hz, 1H), 3.68 - 3.54 (m, 2H), 3.37 (s, 3H), 2.49 (dd, J = 16.7, 8.0 Hz, 2H), 2.40 - 2.22 (m, 1H), 2.15 (p, J = 6.1 Hz, 2H), 1.48 - 1.35 (m, 1), 0.66 (d, J = 6.7 Hz, 3H). MS (m/z) 419.4 [M+H]+. Example 9: (3i?,13bS)-ll-chloro-12-(3-methoxypropoxy)-3-methyl-8-oxo-2,3,8,13b- tetrahydro-lH-pyrido[2,l-fl]pyrrolo[l,2-c]phthalazine-7-carboxylic acid
Figure imgf000082_0002
9
Ethyl ira«s-ll-chloro-12-(3-methoxypropoxy)-3-methyl-8-oxo-2,3,8,13b-tetrahydro-lH- pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate: 'H NMR (400 MHz, Chloroform-<i) δ 8.54 (s, 1H), 7.89 (s, 1H), 7.63 (s, 1H), 6.92 - 6.89 (m, 1H), 4.81 (d, J= 6.3 Hz, 1H), 4.40 (tq, J = 7.1, 3.4 Hz, 2H), 4.23 (tdd, J= 9.2, 6.2, 3.0 Hz, 2H), 3.74 - 3.50 (m, 2H), 3.12 - 3.02 (m, 1H), 2.58 - 2.37 (m, 2H), 2.14 (p, J = 6.1 Hz, 2H), 1.99 - 1.86 (m, 1H), 1.74 - 1.55 (m, 1H), 1.39 (t, J = 7.1 Hz, 3H), 1.19 (d, J = 6.1 Hz, 3H). MS (m/z) 447.3 [M+H]+. Ethyl fra« ,-l l-chloro-12-(3-methoxypropoxy)-3-methyl-8-oxo-2,3,8,13b-tetrahydro-lH- pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate intermediate was separated into its single enantiomers by chiral SFC chromatography using a IA 4.6X100 mm column with 30% methanol as the co-solvent. The faster eluting peak with a retention time of 5.11 min was taken up in in EtOH (1 ml) and 2M LiOH (0.3 ml) then stirred at room temperature until hydrolysis was complete. ¾ NMR (400 MHz, Chloroform-i ) δ 8.57 (s, IH), 7.80 (s, IH), 7.04 (s, IH), 6.89 (s, IH), 4.74 (d, J= 6.4 Hz, IH), 4.33 - 4.13 (m, 2H), 3.61 (q, J= 5.8 Hz, 2H), 3.37 (s, 3H), 3.03 (q, J = 7.2 Hz, IH), 2.56 - 2.26 (m, 2H), 2.14 (p, J= 6.1 Hz, 2H), 1.91 (dq, J = 13.0, 9.0 Hz, IH), 1.62 (ddt, J = 13.3, 7.3, 3.3 Hz, IH), 1.18 (d, J = 6.1 Hz, 4H). MS (m/z) 419.3 [M+H]+.
Example 10: (S^lSb iJ-ll-chloro-H-iS-metho ypropo yJ-S-methyl-S-o o-l^^^Sb- tetrahydro-lH-pyrido [ -fl] pyrrolo [ 1,2-c] phthalazine-7-carboxylic acid
Figure imgf000083_0001
10 (S^lSb iJ-ll-chloro-U-iS-methoxypropoxyJ-S-methyl-S-oxo-l^^^Sb-tetrahydro-lH- pyrido[2,l-fl]pyrrolo[l,2-c]phthalazine-7-carboxylic acid: Ethyl fra«5-l l-chloro-12-(3- methoxypropoxy)-3-methyl-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2- c]phthalazine-7-carboxylate intermediate was separated into its single enantiomers by chiral SFC chromatography using a IA 4.6X100 mm column with 30% methanol as the co-solvent. The slower eluting peak with a retention time of 6.99 min was taken up in in EtOH (1 ml) and 2M LiOH (0.3 ml) then stirred at room temperature until hydrolysis was complete. XH NMR (400 MHz, Chloroform-ύ δ 8.57 (s, IH), 7.80 (s, IH), 7.04 (s, IH), 6.89 (s, IH), 4.74 (d, J= 6.4 Hz, IH), 4.33 - 4.13 (m, 2H), 3.61 (q, J= 5.8 Hz, 2H), 3.37 (s, 3H), 3.03 (q, J = 7.2 Hz, IH), 2.56 - 2.26 (m, 2H), 2.14 (p, J = 6.1 Hz, 2H), 1.91 (dq, J = 13.0, 9.0 Hz, IH), 1.62 (ddt, J = 13.3, 7.3, 3.3 Hz, IH), 1.18 (d, J = 6.1 Hz, 4H). MS (m/z) 419.3 [M+H]+.
(3.S',13bi?)-ll-chloro-12-(3-methoxypropoxy)-3-methyl-8-oxo-2,3,8,13b-tetrahydro-lH- pyrido[2,l-fl]pyrrolo[l,2-c]phthalazine-7-carboxylic acid: Ethyl fra«5-l l-chloro-12-(3- methoxypropoxy)-3-methyl-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2- c]phthalazine-7-carboxylate intermediate was separated into its single enantiomers by chiral SFC chromatography using a IA 4.6X100 mm column with 30% methanol as the co-solvent. The slower eluting peak with a retention time of 6.99 min was taken up in in EtOH (1 ml) and 2M LiOH (0.3 ml) then stirred at room temperature until hydrolysis was complete. XH NMR (400 MHz, Chloroform-ύ δ 8.57 (s, 1H), 7.80 (s, 1H), 7.04 (s, 1H), 6.89 (s, 1H), 4.74 (d, J= 6.4 Hz, 1H), 4.33 - 4.13 (m, 2H), 3.61 (q, J = 5.8 Hz, 2H), 3.37 (s, 3H), 3.03 (q, J = 7.2 Hz, 1H), 2.56 - 2.26 (m, 2H), 2.14 (p, J = 6.1 Hz, 2H), 1.91 (dq, J = 13.0, 9.0 Hz, 1H), 1.62 (ddt, J = 13.3, 7.3, 3.3 Hz, 1H), 1.18 (d, J = 6.1 Hz, 4H). MS (m/z) 419.3 [M+H]+. Example 11: 13-chloro-12-(3-methoxypropoxy)-7,7-dimethyl-2-oxo-2,7,8,9,10,10a- hexahydrodipyrido[2,l-a:l',2'-c]phthalazine-3-carboxylic acid
Figure imgf000084_0001
ethyl 1 -(6-(2-bromo-4-chloro-5-(3- ethyl 13-chloro-12-(3-methoxypropoxy)- methoxypropoxy)phenyl)-2,2- 7,7-dimethyl-2-oxo-2,7,8,9, 10, 10a- dimethylpiperidin-1 -yl)-4-oxo-1 ,4- hexahydrodipyrido
dihydropyridine-3-carboxylate [2, 1 -a: 1 ',2'-c]phthalazine-3-carboxylate
Figure imgf000084_0002
Ethyl l-(6-(2-bromo-4-chloro-5-(3-methoxypropoxy)phenyl)-2,2-dimethylpiperidin-l-yl)-4- oxo-l,4-dihydropyridine-3-carboxylate was prepared similarly to example 4 using 2,2- dimethyl-2,3,4,5-tetrahydropyridine 1 -oxide in place of 2,2-dimethyl-3,4-dihydro-2H-pyrrole 1- oxide. MS (m/z) 555.2 [M+H]+.
Synthesis of ethyl 13-chloro-12-(3-methoxypropoxy)-7,7-dimethyl-2-oxo-2,7,8,9,10,10a- hexahydrodipyrido[2,l-a:l',2'-c]phthalazine-3-carboxylate: Ethyl l-(6-(2-bromo-4-chloro-5- (3-methoxypropoxy)phenyl)-2,2-dimethylpiperidin-l-yl)-4-oxo-l,4-dihydropyridine-3- carboxylate (289 mg, 0.5 mmol) was dissolved in DMA (3.9 mL) with potassium propionate (146 mg, 1.3 mmol) under argon. Pd(OAc)2 (12 mg, 0.5 mmol), and (Oxydi-2, 1- phenylene)bis(diphenylphosphine) (28 mg, 0.05 mmol) were added and the mixture was flushed with argon. The reaction was heated to 100 °C until done. Once cool dilute with EtOAc and brine, extract with EtOAc 2X, dry the organics over sodium sulfate, concentrate, and purify by flash column chromatography. MS (m/z) 475.4 [M+H]+.
13-chloro-12-(3-methoxypropoxy)-7,7-dimethyl-2-oxo-2,7,8,9,10,10a- hexahydrodipyrido[2,l-a:l',2'-c]phthalazine-3-carboxylic acid: To a vial add ethyl 13- chloro-12-(3-methoxypropoxy)-7,7-dimethyl-2-oxo-2,7,8,9, 10, 10a-hexahydrodipyrido[2, l- a: r,2'-c]phthalazine-3-carboxylate (4 mg, 0.008 mmol), EtOH (1 ml) and 2 M LiOH (0.2ml), stir reaction until done, dilute with 0.5 ml 1 : 1 TF A: water and 1 ml DMF, filter, purify by HPLC. 'H NMR (400 MHz, Chloroform-ύ δ 8.64 (s, 1H), 7.77 (s, 1H), 7.08 (s, 1H), 6.95 - 6.87 (m, 1H), 4.62 - 4.54 (m, 1H), 4.30 - 4.16 (m, 2H), 3.70 - 3.55 (m, 2H), 3.38 (s, 3H), 2.60 - 2.50 (m, 1H), 2.26 - 2.10 (m, 3H), 1.85 - 1.73 (m, 1H), 1.72 - 1.53 (m, 3H), 1.16 (s, 3H), 0.43 (s, 3H). MS (m/z) 447.4 [M+H]+.
Synthesis of 2,2-dimethyl-2,3,4,5-tetrahydropyridine 1-oxide: To a RB was added 2,2- dimethylpiperidine (1.3 g, 11.8 mmol), water (4.3 ml) and sodium tungstate dihydrate (366.4 mg, 1.2 mmol). The mixture was cooled to 0 °C then hydrogen peroxide was slowly added (3.6 ml, 35.3 mmol, 30% aq. solution) and stirred for 2 hours allowing to warm to RT. Follow reaction by NMR looking for triplet at 7.04 ppm using CDCI3 as extraction solvent. Once complete, dilute with extract reaction mixture 2X with DCM, dry the organics over sodium sulfate, concentrate and use crude in the next reaction. XH NMR (400 MHz, Chloroform-<i) δ 7.04 (t, 1H), 2.42 - 2.33 (m, 2H 1.91 - 1.85 (m, 2H), 1.75 - 1.67 (m, 2H), 1.45 (s, 6H).
Figure imgf000085_0001
2,2-dimethylpiperidine 2,2-dimethyl-2,3,4,5- tetrahydropyridine 1 -oxide
Figure imgf000086_0001
ethyl ( )-13-chloro-12-(3- methoxypropoxy)-7,7-dimethyl-2-oxo- 2,7,8,9, 10,10a-
Figure imgf000086_0002
Ethyl (R)-13-chloro-12-(3-methoxypropoxy)-7,7-dimethyl-2-oxo-2,7,8,9,10,10a- hexahydrodipyrido[2,l-a:l',2'-c]phthalazine-3-carboxylate and ethyl (S)-13-chloro-12-(3- methoxypropoxy)-7,7-dimethyl-2-oxo-2,7,8,9,10,10a-hexahydrodipyrido[2,l-a:l',2'- c]phthalazine-3-carboxylate: Ethyl 13-chloro-12-(3-methoxypropoxy)-7,7-dimethyl-2-oxo- 2,7,8,9,10,10a-hexahydrodipyrido[2,l-a: l',2'-c]phthalazine-3-carboxylate was separated into its enantiomers by chiral SFC chromatography using AD-H 4.6X100mm columns with 30% methanol as the co-solvent. Peak 1 is the R isomer and has a retention time of 2.55 minutes and peak 2 is the S isomer and has a retention time of 3.72 minutes. Both have a MS (m/z) 475.4 [M+H]+.
Example 12: (i?)-13-chloro-12-(3-methoxypropoxy)-7,7-dimethyl-2-oxo-2,7,8,9,10,10a- hexahydrodipyrido[2,l-a:l',2'-c]phthalazine-3-carboxylic acid
Figure imgf000087_0001
(i?)-13-chloro-12-(3-methoxypropoxy)-7,7-dimethyl-2-oxo-2,7,8,9,10,10a- hexahydrodipyrido[2,l-a:l',2'-c]phthalazine-3-carboxylic acid: Ethyl (R)-13-chloro-12-(3- methoxypropoxy)-7,7-dimethyl-2-oxo-2,7,8,9,10,10a-hexahydrodipyrido[2,l-a: ,2'- c]phthalazine-3-carboxylate was taken up in in EtOH (1 ml) and 2M LiOH (0.3 ml) then stirred at room temperature until hydrolysis was complete. The mixture was acidified with TFA (0.5 ml) and water (0.5 ml), filtered and purified by HPLC. XH NMR (400 MHz, Chloroform-i ) δ 8.64 (s, 1H), 7.77 (s, 1H), 7.08 (s, 1H), 6.95 - 6.87 (m, 1H), 4.62 - 4.54 (m, 1H), 4.30 - 4.16 (m, 2H), 3.70 - 3.55 (m, 2H), 3.38 (s, 3H), 2.60 - 2.50 (m, 1H), 2.26 - 2.10 (m, 3H), 1.85 - 1.73 (m, 1H), 1.72 - 1.53 (m, 3H), 1.16 (s, 3H), 0.43 (s, 3H). MS (m/z) 447.4 [M+H]+.
Example 13: (.S)-13-chloro-12-(3-methoxypropoxy)-7,7-dimethyl-2-oxo-2,7,8,9,10,10a- hexahydrodipyrido[2,l-a:l',2'-c]phthalazine-3-carboxylic acid
Figure imgf000087_0002
hexahydrodipyrido[2,1 -a:1 ',2'-c]phthalazine- 3-carboxylate
(,S)-13-chloro-12-(3-methoxypropoxy)-7,7-dimethyl-2-oxo-2,7,8,9,10,10a- hexahydrodipyrido[2,l-a:l',2'-c]phthalazine-3-carboxylic acid: Ethyl (S)-13-chloro-12-(3- methoxypropoxy)-7,7-dimethyl-2-oxo-2,7,8,9,10,10a-hexahydrodipyrido[2,l-a: ,2'- c]phthalazine-3-carboxylate was taken up in in EtOH (1 ml) and 2M LiOH (0.3 ml) then stirred at room temperature until hydrolysis was complete. The mixture was acidified with TFA (0.5 ml) and water (0.5 ml), filtered and purified by HPLC. XH NMR (400 MHz, Chloroform-i ) δ
8.64 (s, 1H), 7.77 (s, 1H), 7.08 (s, 1H), 6.95 - 6.87 (m, 1H), 4.62 - 4.54 (m, 1H), 4.30 - 4.16 (m, 2H), 3.70 - 3.55 (m, 2H), 3.38 (s, 3H), 2.60 - 2.50 (m, 1H), 2.26 - 2.10 (m, 3H), 1.85 - 1.73 (m, 1H), 1.72 - 1.53 (m, 3H), 1.16 (s, 3H), 0.43 (s, 3H). MS (m/z) 447.4 [M+H]+.
Example 14 : (R)- 11-methoxy- 12-(3-methoxy propoxy)-3,3-dimethyl-8-oxo- tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid
Figure imgf000088_0001
5-(5-(benzyloxy)-2-bromo- 5-(5-(benzyloxy)-2-bromo-4- 4-methoxyphenyl)-2,2- methoxyphenyl)-2,2- dimethylpyrrolidin-1 -ol dimethylpyrrolidin-1 - mine
Figure imgf000088_0002
5-(5-(benzyloxy)-2-bromo-4- methoxyphenyl)-2,2- ethyl 1 -(5-(5-(benzyloxy)-2- imethylamino)methy|i bromo-4-methoxyphenyl)-2,2- dimethylpyrrolidin-1 -amine e)-5,5-diethoxy-3- dimethylpyrrolidin-1 -yl)-4-oxo-1 ,4- oxopentanoate dihydropyhdine-3-carboxylate
Figure imgf000088_0003
ethyl 1 -(5-(5-(benzyloxy)-2- bromo-4-methoxyphenyl)-2,2- ethyl 12-(benzyloxy)-1 1 -methoxy- dimethylpyrrolidin-1 -yl)-4-oxo-1 ,4- 3,3-dimethyl-8-oxo-2,3,8, 13b-tetrahydro- dihydropyhdine-3-carboxylate 1 H-pyrido[2, 1 -a]pyrrolo
[1 ,2-c]phthalazine-7-carboxylate
l-(benzyloxy)-4-bromo-5-iodo-2-methoxybenzene: 1 -(benzyloxy)-4-bromo-2- methoxybenzene (18.2 g, 62 mmol) was suspended in 162 mL methanol and 18 mL water. N- Iodosuccinimide (18. lg, 81 mmol) and trifluoroacetic acid (3.8 mL, 50 mmol) were added sequentially. The mixture was warmed to 35 °C and stirred for 7 hours in the dark. Water (54 mL) was added dropwise over 15 minutes, then the mixture was allowed to cool slowly to room temperature while stirring overnight. The crystalline product was filtered, and rinsed with a 6:4 mixture of methanol: water (2 x 20 mL). The solids were dried in vacuo at 50 °C to provide 1- (benzyloxy)-4-bromo-5-iodo-2-methoxybenzene. 1H NMR (400 MHz, Chloroform-d) δ 7.45 - 7.32 (m, 5H), 7.29 (s, 1H), 7.10 (s, 1H), 5.07 (s, 2H), 3.84 (s, 3H). MS (m/z) 419.8 [M+H]+.
5-(5-(benzyloxy)-2-bromo-4-methoxyphenyl)-2,2-dimethylpyrrolidin-l-ol: l-(benzyloxy)-4- bromo-5-iodo-2-methoxybenzene (8.8 g, 21 mmol) was suspended in 2-MeTHF (24 mL) at 5 °C under argon. iPrMgBr (2.9 M in 2-MeTHF, 7.2 mL, 21 mmol) was added dropwise over 10 minutes with stirring. After 5 minutes, 2,2-dimethyl-3,4-dihydro-2H-pyrrole 1-oxide (2.6 g, 23 mmol) was added in a single portion. The mixture was stirred at the same temperature for 45 minutes followed by the addition of aqueous saturated ammonium chloride (4 mL) and water (20 mL). The aqueous layer was removed and the organic layer was dried over sodium sulfate, filtered, and concentrated in vacuo. The crude solid was recrystallized from ethyl acetate / hexanes (1 :2) to yield 5-(5-(benzyloxy)-2-bromo-4-methoxyphenyl)-2,2-dimethylpyrrolidin-l- ol. 1H NMR (400 MHz, Chloroform-d) δ 7.46 (d, J = 7.4 Hz, 2H), 7.39 - 7.33 (m, 2H), 7.33 - 7.27 (m, 1H), 7.18 (s, 1H), 6.99 (s, 1H), 5.28 (d, J = 12.6 Hz, 1H), 5.18 (d, J = 12.7 Hz, 1H), 3.87 (s, 3H), 3.65 (s, 1H), 2.37 - 2.18 (m, 1H), 1.76 - 1.52 (m, 4H), 1.27 (s, 3H), 1.15 (s, 3H). MS (m/z) 406.4 [M+H]+.
5-(5-(benzyloxy)-2-bromo-4-methoxyphenyl)-2,2-dimethylpyrrolidin-l-amine: 5-(5- (benzyloxy)-2-bromo-4-methoxyphenyl)-2,2-dimethylpyrrolidin-l-ol (5.65 g, 13.9 mmol) was suspended in trifluoroacetic acid (6.3 mL) and water (3 mL). Zinc powder (2.6 g, 40 mmol) was added and the mixture was stirred at 40 °C for 15 minutes. LCMS analysis showed complete conversion to 5-(5-(benzyloxy)-2-bromo-4-methoxyphenyl)-2,2-dimethylpyrrolidine (MS (m/z) 392.0 [M+H]+). The crude mixture was concentrated to dryness, redissolved in DCM (20 mL) and slowly quenched with saturated aqueous sodium bicarbonate. The aqueous layer was extracted with DCM (3 x 20 mL). The combined organic layers were dried over sodium sulfate, filtered, and concentrated in vacuo. The crude 5-(5-(benzyloxy)-2-bromo-4-methoxyphenyl)- 2,2-dimethylpyrrolidine was resuspended in THF (30 mL), acetic acid (2 mL, 35 mmol), and water (2 mL). A solution of sodium nitrite (2.3 g, 33 mmol) in water (15 mL) was added dropwise over 10 minutes. The reaction was warmed to 40 °C and stirred for 35 minutes after which time LCMS analysis showed complete conversion to 5-(5-(benzyloxy)-2-bromo-4- methoxyphenyl)-2,2-dimethyl-l-nitrosopyrrolidine (MS (m/z) 421.0 [M+H]+). The reaction mixture was cooled to room temperature, diluted with ethyl acetate, rinsed with aqueous sodium bicarbonate and brine, dried over sodium sulfated, filtered, and concentrated in vacuo. The resulting crude 5-(5-(benzyloxy)-2-bromo-4-methoxyphenyl)-2,2-dimethyl-l-nitrosopyrrolidine was dissolved in trifluoroacetic acid (6.3 mL) and water (3 mL). Zinc powder (2.6 g, 40 mmol) was added. A rapid exotherm to boiling was observed, and the reaction was cooled on ice. After cooling, the reaction was warmed to 40 °C. After 2 hours, the reaction was cooled to room temperature, concentrated in vacuo and quenched with aqueous sodium bicarbonate / sodium carbonate. The crude mixture was extracted with DCM (2 x 20 mL), dried over sodium sulfate and concentrated to provide crude 5-(5-(benzyloxy)-2-bromo-4-methoxyphenyl)-2,2- dimethylpyrrolidin-1 -amine. MS (m/z) 405.4 [M+H]+.
Ethyl l-(5-(5-(benzyloxy)-2-bromo-4-methoxyphenyl)-2,2-dimethylpyrrolidin-l-yl)-4-oxo- l,4-dihydropyridine-3-carboxylate: Crude 5-(5-(benzyloxy)-2-bromo-4-methoxyphenyl)-2,2- dimethylpyrrolidin-1 -amine (5.64 g, 13.9 mmol, -75% purity), was dissolved in ethanol (5 mL) with trifluoroacetic acid (0.2 mL). The solution was concentrated to dryness. The mixture was redissolved in ethanol (22 mL) with ethyl (Z)-2-((dimethylamino)methylene)-5,5-diethoxy-3- oxopentanoate (5.6 g, 19.5 mmol). The mixture was stirred at 60 °C for 90 minutes. Acetic acid (1 mL) and water (2 mL) were added and the mixture was stirred at 50 °C overnight. The next day additional acetic acid (1 mL) was added and the reaction temperature was increased to 65 °C. After an additional 5 hours, trifluoroacetic acid (0.3 mL) was added and the reaction temperature was increased to 75 °C. After 1 hour, the reaction was cooled to room temperature, diluted with ethyl acetate and sodium bicarbonate. The organic layer was separated, dried over sodium sulfate, filtered, and concentrated. The mixture was purified by flash column chromatography (hexanes / ethyl acetate / ethanol) to provide ethyl l-(5-(5-(benzyloxy)-2- bromo-4-methoxyphenyl)-2,2-dimethylpyrrolidin-l-yl)-4-oxo-l,4-dihydropyridine-3- carboxylate. 1H NMR (400 MHz, Chloroform-d) δ 8.21 (s, 1H), 7.46 - 7.32 (m, 5H), 6.95 - 6.83 (m, 2H), 5.28 (s, 1H), 5.12 (d, J = 13.2 Hz, 1H), 4.87 (t, J = 7.8 Hz, 1H), 4.32 (qd, J = 7.1, 4.3 Hz, 2H), 3.86 (s, 3H), 2.39 - 2.25 (m, 1H), 1.89 (t, J = 7.7 Hz, 2H), 1.74 - 1.51 (m, 2H), 1.33 (t, J = 7.1 Hz, 3H), 1.19 (s, 3H), 1.14 (s, 3H). MS (m/z) 557.2 [M+H]+.
Ethyl 12-(benzyloxy)-ll-methoxy-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l- a]pyrrolo[l,2-c]phthalazine-7-carboxylate: Ethyl l-(5-(5-(benzyloxy)-2-bromo-4- methoxyphenyl)-2,2-dimethylpyrrolidin- 1 -yl)-4-oxo- 1 ,4-dihy dropy ridine-3 -carboxylate (3.67 g, 6.6 mmol) was dissolved in DMA (20 mL) with potassium propionate (1.9g, 17 mmol) under argon. Pd(OAc)2 (180 mg, 0.8 mmol), and (Oxydi-2, 1 -phenylene)bis(diphenylphosphine) (430 mg, 0.8 mmol) were added and the mixture was flushed with argon. The reaction was heated to 100 °C for 1 hour. The mixture was cooled to room temperature while water (40 mL) was added dropwise over 1 hour. The supernatant was poured off and the remaining gummy solid was redissolved in DCM, dried over sodium sulfate and concentrated in vacuo. The mixture was purified by flash column chromatography (hexanes / ethyl acetate / ethanol) to provide ethyl 12- (benzyloxy)-l l-methoxy-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2- c]phthalazine-7-carboxylate. 1H NMR (400 MHz, Chloroform-d) δ 8.30 (s, 1H), 7.45 - 7.30 (m, 6H), 7.20 (s, 1H), 6.72 (s, 1H), 5.25 (d, J = 12.4 Hz, 1H), 5.20 (d, J = 12.4 Hz, 1H), 4.69 (d, J = 6.3 Hz, 1H), 4.39 (q, J = 7.1 Hz, 2H), 3.94 (s, 3H), 2.38 - 2.26 (m, 1H), 2.21 - 2.11 (m, 1H), 1.83 - 1.71 (m, 1H), 1.50 - 1.42 (m, 1H), 1.39 (t, J = 7.1 Hz, 3H), 1.32 (s, 3H), 0.66 (s, 3H). MS (m/z) 475.4 [M+H]+.
Ethyl (i?)-12-(benzyloxy)-ll-methoxy-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH- pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate: Ethyl 12-(benzyloxy)-l 1-methoxy- 3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7- carboxylate was separated into its enantiomers by SFC using an OJ-H column with methanol as the co-solvent. Retention time of 1.1 min. XH NMR (400 MHz, Chloroform-d) δ 8.30 (s, 1H), 7.45 - 7.30 (m, 6H), 7.20 (s, 1H), 6.72 (s, 1H), 5.25 (d, J = 12.4 Hz, 1H), 5.20 (d, J = 12.4 Hz, 1H), 4.69 (d, J = 6.3 Hz, 1H), 4.39 (q, J = 7.1 Hz, 2H), 3.94 (s, 3H), 2.38 - 2.26 (m, 1H), 2.21 - 2.11 (m, 1H), 1.83 - 1.71 (m, 1H), 1.50 - 1.42 (m, 1H), 1.39 (t, J = 7.1 Hz, 3H), 1.32 (s, 3H), 0.66 (s, 3H). MS (m/z) 475.4 [M+H]+.
Ethyl (i?)-12-hydroxy-ll-methoxy-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l- a]pyrrolo[l,2-c]phthalazine-7-carboxylate:
Figure imgf000091_0001
ethyl (R)-12-(benzyloxy)-1 1 -methoxy-3,3- ethyl (R)-12-hydroxy-1 1-methoxy-3,3-dimethyl- dimethyl-8-oxo-2,3,8,13b-tetrahydro-1 H- 8-oxo-2, 3,8,13b-tetrahydro-1 H-pyrido[2,1- pyrido[2,1 ]pyrrolo[1 ,2-c]phthalazine-7- a]pyrrolo[1 ,2-c]phthalazine-7-carboxylate
carboxylate
Ethyl (i?)-12-(benzyloxy)-l l-methoxy-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l- a]pyrrolo[l,2-c]phthalazine-7-carboxylate (593 mg, 1.3 mmol) was dissolved in ethanol (10 mL) and the solution was purged with argon. Palladium on carbon (10 wt%, wet, El 01 NEAV, 160 mg) was added. The reaction was purged with argon, evacuated and refilled with hydrogen gas. The mixture was stirred vigorously under an atmosphere of hydrogen for 40 minutes after which time LCMS analysis showed complete consumption of starting material. The reaction was purged with argon, diluted with ethyl acetate (10 mL) and filtered through celite. The solution was concentrated to provide ethyl (i?)-12-hydroxy-l l-methoxy-3,3-dimethyl-8-oxo-2,3, 8,13b- tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate. MS (m/z) 385.3 [M+H]+. (i?)-ll-methoxy-12-(3-methoxypropoxy)-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH- pyrido[2,l-a]pyr
Figure imgf000092_0001
ethyl (R)-12-hydroxy-1 1 -methoxy-3,3- 1
dimethyl-8-oxo-2, 3,8, 13b-tetrahydro- 1 -/-pyrido[2, 1 -a]pyrrolo[1 ,2- c]phthalazine-7-carboxylate
Ethyl (R)-12-hydroxy-l l-methoxy-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l- a]pyrrolo[l,2-c]phthalazine-7-carboxylate (100 mg, 0.26 mmol) was combined in DMF (0.4 mL) with potassium carbonate (72 mg, 0.52 mmol) and l-bromo-3-methoxypropane (58 μί,
0.52 mmol). The reaction mixture was stirred at 65 °C for 40 minutes, followed by stirring at 70 °C for 1 hour. The mixture was cooled to room temperature. Aqueous lithium hydroxide (1 M, 0.39 mL, 0.39 mmol) and ethanol (0.5 mL) were added and the mixture was stirred at 40 °C. After 45 minutes, the mixture was diluted with trifluoroacetic acid and purified by preparative HPLC to provide (R)-l l-methoxy-12-(3-methoxypropoxy)-3,3-dimethyl-8-oxo-2,3, 8,13b- tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid as a trifluoroacetic acid salt. XH NMR (400 MHz, Acetonitrile-d3) δ 8.44 (s, IH), 7.38 (s, IH), 7.25 (s, IH), 6.95 (s, IH), 4.84 (d, J = 6.2 Hz, IH), 4.28 - 4.09 (m, 2H), 3.92 (s, 3H), 3.54 (t, J = 6.2 Hz, 2H), 3.32 (s, 3H), 2.57 - 2.35 (m, 2H), 2.05 (p, J = 6.4 Hz, 2H), 1.88 (ddd, J = 12.6, 7.9, 2.7 Hz, IH), 1.67 - 1.56 (m, IH), 1.36 (s, 3H), 0.67 (s, 3H). 19F NMR (377 MHz, Acetonitrile-d3) δ -77.32. MS (m/z) 429.3 [M+H]+.
Example 15: (.S)-ll-methoxy-12-(3-methoxypropoxy)-3,3-dimethyl-8-oxo- tetrahydro-lH-pyrido[2,l-a]p oxylic acid
Figure imgf000092_0002
15 (5)-l l -methoxy-12-(3-methoxypropoxy)-3,3-dimethyl-8-oxo-2,3,8, 13b-tetrahydro-lH- pyrido[2, l-a]pyrrolo[l ,2-c]phthalazine-7-carboxylic acid was prepared similarly to example 14 utilizing the slower eluting isomer from the resolution of racemic ethyl 12-(benzyloxy)-l l - methoxy-3,3-dimethyl-8-oxo-2,3,8, 13b-tetrahydro-lH-pyrido[2,l -a]pyrrolo[l ,2-c]phthalazine-7- carboxylate. Retention time of 1.37 min. XH NMR (400 MHz, Acetonitrile-d3) δ 8.44 (s, 1H), 7.38 (s, 1H), 7.25 (s, 1H), 6.95 (s, 1H), 4.84 (d, J = 6.2 Hz, 1H), 4.28 - 4.09 (m, 2H), 3.92 (s, 3H), 3.54 (t, J = 6.2 Hz, 2H), 3.32 (s, 3H), 2.57 - 2.35 (m, 2H), 2.05 (p, J = 6.4 Hz, 2H), 1.88 (ddd, J = 12.6, 7.9, 2.7 Hz, 1H), 1.67 - 1.56 (m, 1H), 1.36 (s, 3H), 0.67 (s, 3H). 19F NMR (377 MHz, Acetonitrile-d3) δ -77.32. MS (m/z) 429.3 [M+H]+.
Example 16: (R)-ll-methoxy-3,3-dimethyl-12-(oxetan-3-ylmethoxy)-8-oxo-2,3,8,13b- tetrahydro-lH-pyrido[2,l-a]py oxylic acid
Figure imgf000093_0001
(i?)-l l-methoxy-3,3-dimethyl-12-(oxetan-3-ylmethoxy)-8-oxo-2,3,8, 13b-tetrahydro-lH- pyrido[2, l -a]pyrrolo[l ,2-c]phthalazine-7-carboxylic acid was prepared according to the procedure for (R)-\ l -methoxy-12-(3-methoxypropoxy)-3,3-dimethyl-8-oxo-2,3, 8, 13b- tetrahydro-lH-pyrido[2, l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid using 3- (bromomethyl)oxetane in place of l -bromo-3-methoxypropane. XH NMR (400 MHz,
Acetonitrile-d3) δ 8.44 (d, J = 1.9 Hz, 1H), 7.39 (s, 1H), 7.23 (d, J = 1.9 Hz, 1H), 6.99 (s, 1H), 4.96 - 4.70 (m, 3H), 4.49 (t, J = 6.2 Hz, 2H), 4.36 (dt, J = 29.9, 9.1 Hz, 2H), 3.92 (d, J = 1.9 Hz, 2H), 3.52 - 3.41 (m, 1H), 2.60 - 2.37 (m, 2H), 1.63 (q, J = 10.5 Hz, 1H), 1.37 (s, 3H), 1.29 (s, 2H), 0.67 (s, 3H). MS (m/z) 427.2 [M+H]+.
Example 17: 13-chloro-12-(3-methoxypropoxy)-8,8-dimethyl-2-oxo-2,7,8,9,10,10a- hexahydrodipyrido[2,l-a:l',2'-c]phthalazine-3-carboxylic acid
Figure imgf000093_0002
13-Chloro-12-(3-methoxypropoxy)-8,8-dimethyl-2-oxo-2,7,8,9, 10,10a-hexahydrodipyrido[2, 1 - a: l',2'-c]phthalazine-3-carboxylic acid prepared similarly to example 11 using 3,3- dimethylpiperidine in place of 2,2-dimethylpiperidine. XH NMR (400 MHz, Chloroform-cf) δ 8.64 (s, 1H), 7.82 (s, 1H), 7.06 (s, 1H), 6.92 (s, 1H), 4.57 (s, 1H), 4.31 - 4.15 (m, 2H), 3.71 - 3.56 (m, 2H), 3.38 (s, 3H), 3.02 (d, 1H), 2.61 - 2.46 (m, 2H), 2.44 - 2.35 (m, 2H), 2.22 - 2.09 (m, 2H), 1.36 (d, 1H), 1.32 - 1.15 (m, 1H), 1.24 (s, 3H), 0.80 (s, 3H). (m/z) 447.4 [M+H]+.
Example 18: ll-(difluoromethoxy)-12-(3-methoxypropoxy)-3,3-dimethyl-8-oxo-2,3,8,13b- tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid
Figure imgf000094_0001
2-(benzyloxy)- 2-(benzyloxy)-4-bromo-1 -(3-
Figure imgf000094_0002
2-(benzyloxy)-4-bromo-1-(3- 1 -(benzyloxy)-5-bromo-4-iodo-2- methoxypropoxy)benzene (3-methoxypropoxy)benzene
Figure imgf000094_0003
1 -(benzyloxy)-5-bromo-4-iodo-2- 5-(4-(benzyloxy)-2-bromo-5-(3- (3-methoxypropoxy)benzene methoxypropoxy)phenyl)-2,2- dimeth lpyrrolidin-1 -ol
Figure imgf000094_0004
methoxypropoxy)phenyl)-2,2- 5-(4-(benzyloxy)-2-bromo-5-(3- dimethylpyrrolidin-1 -ol methoxypropoxy)phenyl)-2,2- dimethylpyrrolidine
Figure imgf000095_0001
3- 5-(4-(benzyloxy)-2-bromo-5-(3- methoxypropoxy)phenyl)-2,2- methoxypropoxy)phenyl)-2,2- dimet ylpyrrolidine dimethyl-1 -nitrosopyrrolidine
Figure imgf000095_0002
5-(4-(benzyloxy)-2-bromo-5-(3- 5-(4-(benzyloxy)-2-bromo-5-(3- methoxypropoxy)phenyl)-2,2- methoxypropoxy)phenyl)-2,2- dimethyl-1 -nitrosopyrrolidine dimethylpyrrolidin-1 -amine
5-(4-(benzyloxy)-2-bromo-5-(3- methoxypropoxy)phenyl)-2,2- dimethylpyrrolidin-1 -amine -5-(3- ,4-
Figure imgf000095_0003
ethyl 1 -(5-(4-(benzyloxy)-2-bromo-5-(3- ethyl 1 1 -(benzyloxy)-12-(3-methoxypropoxy)- methoxypropoxy)phenyl)-2,2- 3,3-dimethyl-8-oxo-2,3,8, 13b-tetrahydro-1 H- dimethylpyrrolidin-1 -yl)-4-oxo-1 ,4- pyrido[2,1 -a]pyrrolo[1 ,2-c]phthalazine-7- dihydropyridine-3-carboxylate carboxylate
Synthesis of 2-(benzyloxy)-4-bromo-l-(3-methoxypropoxy)benzene: To a stirring solution of 2-(benzyloxy)-4-bromophenol (34.85 g, 0.12 mol) in DMF (35 ml) was added cesium carbonate (44.77 g, 0.14 mol) followed by l-bromo-3-methoxypropane (16.67 ml, 0.14 mol). The reaction was heated at 60°C for lh. The mixture was cooled, diluted with water (400 ml) and extracted with EtOAc (2x300 ml). The organic layers were combined, washed with 5% LiCl (aq, 500 ml), followed by water (500 ml). The organic layer was dried with Na2SC>4, filtered, and
concentrated. Product was purified by silica chromatography using EtOAc in hexane (0- 20%). 23. lg 'H NMR (400 MHz, Chloroform-^ δ 7.48 - 7.28 (m, 5H), 7.07 - 6.93 (m, 2H), 6.79 (d, J = 8.3 Hz, 1H), 5.09 (s, 2H), 4.08 (t, J = 6.3 Hz, 2H), 3.55 (t, J = 6.2 Hz, 2H), 3.33 (s, 3H), 2.07 (t, J = 6.3 Hz, 2H). Synthesis of l-(benzyloxy)-5-bromo-4-iodo-2-(3-methoxypropoxy)benzene: To a solution of 2-(benzyloxy)-4-bromo-l-(3-methoxypropoxy)benzene (23.1 g, 65.77 mmol) in
methanol/water (9: 1) (230 ml) was added N-iodosuccinimide (17.02 g, 75.63 mmol) followed by trifluoroacetic acid (1.26 ml, 16.44 mmol). After heating at 35°C for 15h, the mixture was heated to reflux for lh. Additional N-iodosuccinimide (1.7 g, 7.56 mmol) was added and the mixture was refiuxed for 2.5h. The reaction was cooled to ambient temperature and water (90 ml) was added. The solids were filtered, washed with water, and the resulting solids were taken up into ethyl acetate (150 ml). The organic solution was washed with 5% NaHS03 (100 ml) followed by water (100 ml) and brine (100 ml). The organic layer was dried with Na2SC>4, filtered, and concentrated. The product was precipitated from 8: 1 heptane :z-PrO Ac (100 ml) by vigorously stirring for 30 minutes. The solids were filtered, washed with hexane, and dried under vacuum. 27.5 g. lH NMR (400 MHz, Chloroform-i ) δ 7.44 - 7.31 (m, 5H), 7.30 (s, 1H), 7.13 (s, 1H), 5.07 (s, 2H), 4.06 (t, J = 6.3 Hz, 2H), 3.54 (t, J = 6.1 Hz, 2H), 3.34 (s, 3H), 2.06 (p, J = 6.2 Hz, 2H). 5-(4-(benzyloxy)-2-bromo-5-(3-methoxypropoxy)phenyl)-2,2-dimethylpyrroli din- l-ol: To a solution of l-(benzyloxy)-5-bromo-4-iodo-2-(3-methoxypropoxy)benzene (12.65 g, 26.51 mmol) in 2-MeTHF (36 ml) was added isopropylmagnesium chloride (1.3M in 2-MeTHF) (22.4 ml) over 5 minutes maintaining an internal temperature below 0°C. The reaction was stirred for an additional 5 minutes after the addition was complete. To the cooled solution was added dropwise 2,2-dimethyl-3,4-dihydro-2H-pyrrole 1-oxide (3.6 g, 31.81 mmol) in 2-MeTHF (10 ml) maintaining an internal temperature below 5°C. The mixture was stirred for 20 minutes, 1M NH4C1 (75 ml) was added, and the layers were separated. The organic layer was washed with 1.0M NaCl (75 ml). The organic layer was dried with Na2SC>4, filtered, and
concentrated. The product was purified by silica chromatography using EtOAc in hexane (5- 25%). 10. lg lH NMR (400 MHz, Chloroform-^ δ 7.46 - 7.28 (m, 5H), 7.09 (s, 1H), 6.22 (s, 1H), 5.40 (dd, J = 8.7, 4.0 Hz, 1H), 5.05 (s, 2H), 3.96 (t, J = 6.2 Hz, 2H), 3.58 - 3.41 (m, 2H), 3.30 (s, 3H), 2.57 - 2.39 (m, 1H), 2.08 - 1.91 (m, 4H), 1.86 (s, 4H), 1.69 (s, 3H). MS (m/z) 464.6 [M+H]+.
Synthesis of 5-(4-(benzyloxy)-2-bromo-5-(3-methoxypropoxy)phenyl)-2,2- dimethylpyrrolidine: 5-(4-(benzyloxy)-2-bromo-5-(3-methoxypropoxy)phenyl)-2,2- dimethylpyrrolidine was prepared analogously to 5-(2-bromo-4-chloro-5-(3- methoxypropoxy)phenyl)-2,2-dimethylpyrrolidine in Example 4. MS (m/z) 448.8 [M+H]+. Synthesis of 5-(4-(benzyloxy)-2-bromo-5-(3-methoxypropoxy)phenyl)-2,2-dimethyl-l- nitrosopyrrolidine: 5-(4-(benzyloxy)-2-bromo-5-(3-methoxypropoxy)phenyl)-2,2-dimethyl-l- nitrosopyrrolidine was prepared analogously to 5-(2-bromo-4-chloro-5-(3- methoxypropoxy)phenyl)-2,2-dimethyl-l-nitrosopyrrolidine in Example 4. XH NMR (400 MHz, Chloroform-c 57.46 - 7.28 (m, 5H), 7.09 (s, 1H), 6.22 (s, 1H), 5.40 (dd, J = 8.7, 4.0 Hz, 1H), 5.05 (s, 2H), 3.96 (t, J = 6.2 Hz, 2H), 3.58 - 3.41 (m, 2H), 3.30 (s, 3H), 2.57 - 2.39 (m, 1H), 2.08 - 1.91 (m, 4H), 1.86 (s, 4H), 1.69 (s, 3H). MS (m/z) 477.7 [M+H]+.
Synthesis of 5-(4-(benzyloxy)-2-bromo-5-(3-methoxypropoxy)phenyl)-2,2-dimethyl pyrrolidin-l-amine: 5-(4-(benzyloxy)-2-bromo-5-(3-methoxypropoxy)phenyl)-2,2-dimethyl pyrrolidin-l-amine was prepared analogously to 5-(2-bromo-4-chloro-5-(3- methoxypropoxy)phenyl)-2,2-dimethylpyrrolidin-l -amine in example 4. MS (m/z) 463.7
[M+H]+.
Synthesis of ethyl l-(5-(4-(benzyloxy)-2-bromo-5-(3-methoxypropoxy)phenyl)-2,2- dimethylpyrrolidin-l-yl)-4-oxo-l,4-dihydropyridine-3-carboxylate: Ethyl 1 -(5-(4- (benzyloxy)-2-bromo-5-(3-methoxypropoxy)phenyl)-2,2-dimethylpyrrolidin-l-yl)-4-oxo-l,4- dihydropyridine-3-carboxylate was prepared analogously to ethyl l-(5-(2-bromo-4-chloro-5-(3- methoxypropoxy)phenyl)-2,2-dimethylpyrrolidin-l-yl)-4-oxo-l,4-dihydropyridine-3- carboxylate in example 4. XH NMR (400 MHz, Chloroform-c ) δ 8.24 (s, 1H), 7.44 - 7.27 (m, 6H), 7.04 (s, 1H), 6.96 (s, 1H), 6.32 (d, J = 7.8 Hz, 1H), 5.11 - 5.00 (s, 2H), 4.93 (t, J = 7.9 Hz, 1H), 4.37 - 4.27 (m, 2H), 4.17 - 4.09 (m, 1H), 4.07 - 4.00 (m, 1H), 3.59 - 3.49 (m, 2H), 3.33 (s, 3H), 2.46 - 2.26 (m, 1H), 2.08 - 1.99 (m, 3H), 1.99 - 1.87 (m, 1H), 1.78 - 1.65 (m, 1H), 1.40 - 1.32 (m, 6H), 1.20 (s, 3H). MS (m/z) 614.0 [M+H]+.
Synthesis of ethyl ll-(benzyloxy)-12-(3-methoxypropoxy)-3,3-dimethyl-8-oxo-2,3,8,13b- tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate: Argon was bubbled through a mixture of ethyl l-(5-(4-(benzyloxy)-2-bromo-5-(3-methoxypropoxy)phenyl)-2,2- dimethylpyrrolidin-l-yl)-4-oxo-l,4-dihydropyridine-3-carboxylate (6.5 g, 10.59 mmol), Pd(OAc)2 (0.24 g, 1.06 mmol), DPEphos (0.57 g, 1.06 mmol), and potassium carbonate (3.66 g, 26.51 mmol) in N,N-dimethylacetamide (40 ml). The mixture was heated at 110°C for
3h. After cooling to ambient temperature, the mixture was filtered through celite. The filtrate was diluted with water (200 ml) and product extracted with ethyl acetate (200 ml). The extractive mixture was filtered. The organic layer was washed with 5% LiCl (aq, 2 x 200 ml). The organic layer was dried with Na2SC>4, filtered, and concentrated. Product was purified by silica chromatography using EtOH in dichloromethane. The partially purified product was precipitated from 3: 1 MTBE:hexane (30 ml), filtered, and dried under vacuum. The filtrate was concentrated and additional product was isolated from 3: 1 MTBE/EtOAc. 3.58g XH NMR (400 MHz, Chloroform-ύ δ 8.27 (s, 1H), 7.48 - 7.41 (m, 2H), 7.41 - 7.34 (m, 2H), 7.34 - 7.28 (m, 1H), 7.23 (s, 1H), 6.81 (s, 1H), 6.78 (s, 1H), 5.13 (s, 2H), 4.72 (d, J = 5.9 Hz, 1H), 4.43 - 4.31 (m, 2H), 4.16 (qt, J = 9.3, 6.3 Hz, 2H), 3.64 - 3.51 (m, 2H), 3.34 (s, 3H), 2.45 - 2.27 (m, 2H), 2.1 1 (p, J = 6.2 Hz, 2H), 1.82 (ddd, J = 12.5, 7.6, 2.8 Hz, 1H), 1.60 (ddd, J = 12.5, 10.8, 7.8 Hz, 1H), 1.38 (t, J = 7.1 Hz, 3H), 1.32 (s, 3H), 0.68 (s, 3H). MS (m/z) 533.6 [M+H]+.
Synthesis of ethyl ll-hydroxy-12-(3-methoxypropoxy)-3,3-dimethyl-8-oxo-2,3,8,13b- tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate:
Figure imgf000098_0001
ethyl 1 1 -(benzyloxy)-12-(3-methoxypropoxy)-3,3- ethyl 1 1 -hydroxy-12-(3-methoxypropoxy)-3,3- dimethyl-8-oxo-2,3,8, 13b-tetrahydro-1 H-pyrido[2, 1 - dimethyl-8-oxo-2,3,8, 13b-tetrahydro-1 H- a]pyrrolo[1 ,2-c]phthalazine-7-carboxylate pyrido[2,1 -a]pyrrolo[1 ,2-c]phthalazine-7- carboxylate
A solution of ethyl l l-(benzyloxy)-12-(3-methoxypropoxy)-3,3-dimethyl-8-oxo-2,3, 8,13b- tetrahydro-lH-pyrido[2, l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate (400mg g, 0.75 mmol) in EtOH (3 ml) and dichloromethane (3 ml) was added to 10% palladium on carbon (40 mg, 0.04 mmol). The reaction was stirred under a hydrogen balloon for 1.5h. The reaction vessel was purged with nitrogen and solids filtered through celite. The filtrate was concentrated under vacuum. The product was taken to next step without further purification. 330 mg. XH NMR
(400 MHz, Chloroform-ύ δ 8.29 (s, 1H), 7.41 (s, 1H), 6.94 (s, 1H), 6.78 - 6.74 (m, 1H), 4.72 (d, J = 6.0 Hz, 1H), 4.38 (qd, J = 7.1 , 1.7 Hz, 2H), 4.27 - 4.10 (m, 2H), 3.60 (m, 2H), 3.38 (s, 3H), 2.46 - 2.25 (m, 1H), 2.10 (p, J = 6.0 Hz, 2H), 1.82 (m, 1H), 1.67 - 1.54 (m, 1H), 1.39 (t, J = 7.1 Hz, 3H), 1.32 (s, 3H), 0.69 (s, 3H). MS (m/z) 443.4 [M+H]+. ll-(difluoromethoxy)-12-(3-methoxypropoxy)-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro- lH-pyrido [2,1-a] pyrrolo [ 1,2-c] phthalazine-7-carboxylic acid ethyl
di
py
Figure imgf000099_0001
18
To a vigorously stirring solution of ethyl l l-hydroxy-12-(3-methoxypropoxy)-3,3-dimethyl-8- oxo-2,3, 8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate (85 mg, 0.19 mmol) in acetonitrile (0.4 ml) and 8M NaOH (0.2 ml) was added dropwise difluoroiodomethane (10% in THF) (751.87 mg, 0.42 mmol). After stirring for 30 minutes, the mixture was concentrated and the resulting mixture was diluted with ethanol (0.5ml) and heated at 45°C for 45 minutes. The mixture was concentrated and acidified with 1.0M HC1 (1.5 ml). The product was purified by prep HPLC using ACN in water with 0.1% TFA. 35 mg. l NMR (400 MHz, Chloroform-ύ δ 8.54 (s, 1H), 7.57 (s, 1H), 7.04 (s, 1H), 6.92 - 6.14 (m, 2H), 4.80 (d, J = 6.2 Hz, 1H), 4.20 (qt, J = 9.2, 6.3 Hz, 2H), 3.67 - 3.47 (m, 2H), 3.36 (s, 3H), 2.50 (tdd, J = 10.9, 7.9, 6.4 Hz, 1H), 2.44 - 2.31 (m, 1H), 2.12 (p, J = 6.1 Hz, 2H), 1.96 - 1.86 (m, 1H), 1.70 - 1.57 (m, 1H), 1.38 (s, 3H), 0.69 (s, 3H). MS (m/z) 465.4 [M+H]+.
Example 19: (i?)-ll-(difluoromethoxy)-12-(3-methoxypropoxy)-3,3-dimethyl-8-oxo- 2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid
Figure imgf000099_0002
19 l l-(difluoromethoxy)-12-(3-methoxypropoxy)-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH- pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid (18) was separated into its enantiomers by chiral SFC chromatography using AD-H 4.6X100mm columns with 30% methanol as the co- solvent. Example 18 is the faster eluting peak with a retention time of 1.63 min. XH NMR (400 MHz, Chloroform-d) δ 8.55 (s, 1H), 7.58 (s, 1H), 7.05 (s, 1H), 6.91 (s, 1H), 6.60 (t, J = 74.0 Hz, 1H), 4.80 (d, J = 6.3 Hz, 1H), 4.36 - 4.02 (m, 2H), 3.71 - 3.42 (m, 2H), 3.37 (s, 3H), 2.60 - 2.45 (m, 1H), 2.45 - 2.30 (m, 1H), 2.13 (p, J = 6.1 Hz, 2H), 1.92 (ddd, J = 12.8, 7.9, 2.6 Hz, 1H), 1.64 (ddd, J = 12.7, 10.9, 7.7 Hz, 1H), 1.39 (s, 3H), 0.69 (s, 3H). MS (m/z) 465.6 [M+H]+.
Example 20: (.S)-ll-(difluoromethoxy)-12-(3-methoxypropoxy)-3,3-dimethyl-8-oxo- 2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid
Figure imgf000100_0001
20 l l-(difluoromethoxy)-12-(3-methoxypropoxy)-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH- pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid (18) was separated into its enantiomers by chiral SFC chromatography using AD-H 4.6X100mm columns with 30% methanol as the co- solvent. Example 20 is the slower eluting peak with a retention time of 2.06 min. XH NMR (400 MHz, Chloroform-d) δ 8.55 (s, 1H), 7.58 (s, 1H), 7.05 (s, 1H), 6.91 (s, 1H), 6.60 (t, J = 74.0 Hz, 1H), 4.80 (d, J = 6.3 Hz, 1H), 4.36 - 4.02 (m, 2H), 3.71 - 3.42 (m, 2H), 3.37 (s, 3H), 2.60 - 2.45 (m, 1H), 2.45 - 2.30 (m, 1H), 2.13 (p, J = 6.1 Hz, 2H), 1.92 (ddd, J = 12.8, 7.9, 2.6 Hz, 1H), 1.64 (ddd, J = 12.7, 10.9, 7.7 Hz, 1H), 1.39 (s, 3H), 0.69 (s, 3H). MS (m/z) 465.6 [M+H]+.
Example 21: (i?)-ll-ethoxy-12-(3-methoxypropoxy)-3,3-dimethyl-8-oxo-2,3,8,13b- tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic
Figure imgf000101_0001
ethyl ( )-1 1 -(benzyloxy)-12-(3-methoxypropoxy)- ethyl (R)-1 1 -hydroxy-12-(3- 3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro- methoxypropoxy)-3,3-dimethyl-8-oxo- 1 H-pyrido[2,1 -a]pyrrolo[1 ,2-c]phthalazine-7-carboxylate 2,3,8, 13b-tetrahydro-1 H-pyrido[2,1 - a]pyrrolo[1 ,2-c]phthalazine-7-carboxylate
CH3CH2I,
Cs2C03
Figure imgf000101_0002
ethyl (R)-1 1 -ethoxy-12-(3-methoxypropoxy)- 21 3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro-1 H- pyrido[2, 1 -a]pyrrolo[1 ,2-c]phthalazine-7- carboxylate
Synthesis of ethyl (i?)-ll-(benzyloxy)-12-(3-methoxypropoxy)-3,3-dimethyl-8-oxo- 2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate and ethyl (.S)-ll-(benzyloxy)-12-(3-methoxypropoxy)-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH- pyrido[2,l-a] pyrrolo[l,2-c]phthalazine-7-carboxylate: Racemic ethyl l l-(benzyloxy)-12-(3- methoxypropoxy)-3,3-dimethyl-8-oxo-2,3,8, 13b-tetrahydro-lH-pyrido[2,l -a]pyrrolo[l,2- c]phthalazine-7-carboxylate (3.2 g) was purified by chiral SFC chromatography using AD-H 4.6X100mm columns with 30% ethanol as the co-solvent. To give the faster eluting peak as ethyl (5)-l l -(benzyloxy)-12-(3-methoxypropoxy)-3,3-dimethyl-8-oxo-2,3,8, 13b-tetrahydro-lH- pyrido[2, l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate (1.43 g), retention time 1.63 min. XH
NMR (400 MHz, Chloroform-c δ 8.27 (s, 1H), 7.48 - 7.41 (m, 2H), 7.41 - 7.34 (m, 2H), 7.34 - 7.28 (m, 1H), 7.23 (s, 1H), 6.81 (s, 1H), 6.78 (s, 1H), 5.13 (s, 2H), 4.72 (d, J = 5.9 Hz, 1H), 4.43 - 4.31 (m, 2H), 4.16 (qt, J = 9.3, 6.3 Hz, 2H), 3.64 - 3.51 (m, 2H), 3.34 (s, 3H), 2.45 - 2.27 (m, 2H), 2.11 (p, J = 6.2 Hz, 2H), 1.82 (ddd, J = 12.5, 7.6, 2.8 Hz, 1H), 1.60 (ddd, J = 12.5, 10.8, 7.8 Hz, 1H), 1.38 (t, J = 7.1 Hz, 3H), 1.32 (s, 3H), 0.68 (s, 3H). MS (m/z) 533.6 [M+H]+.
And ethyl (R)-\ l -(benzyloxy)-12-(3-methoxypropoxy)-3,3-dimethyl-8-oxo-2,3, 8, 13b- tetrahydro-lH-pyrido[2, l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate (1.47 g) as the slower eluting peak , retention time 2.06 min. XH NMR (400 MHz, Chloroform-c/) δ 8.27 (s, 1H), 7.48 - 7.41 (m, 2H), 7.41 - 7.34 (m, 2H), 7.34 - 7.28 (m, 1H), 7.23 (s, 1H), 6.81 (s, 1H), 6.78 (s, 1H), 5.13 (s, 2H), 4.72 (d, J = 5.9 Hz, 1H), 4.43 - 4.31 (m, 2H), 4.16 (qt, J = 9.3, 6.3 Hz, 2H), 3.64 - 3.51 (m, 2H), 3.34 (s, 3H), 2.45 - 2.27 (m, 2H), 2. 11 (p, J = 6.2 Hz, 2H), 1.82 (ddd, J = 12.5, 7.6, 2.8 Hz, IH), 1.60 (ddd, J = 12.5, 10.8, 7.8 Hz, IH), 1.38 (t, J = 7.1 Hz, 3H), 1.32 (s, 3H), 0.68 (s, 3H). MS (m/z) 533.6 [M+H]+.
Synthesis of ethyl (.S)-ll-hydroxy-12-(3-methoxypropoxy)-3,3-dimethyl-8-oxo-2,3,8,13b- tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate: Ethyl (S)-\ 1- hydroxy-12-(3-methoxypropoxy)-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l- a]pyrrolo[l,2-c]phthalazine-7-carboxylate was prepared analogously to ethyl 11 -hydroxy- 12-(3 - methoxypropoxy)-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2- c]phthalazine-7-carboxylate in Example 18. XH NMR (400 MHz, Chloroform-d) δ 8.29 (s, IH), 7.42 (s, IH), 6.96 (s, IH), 6.76 (d, J = 1.0 Hz, IH), 4.72 (d, J = 5.9 Hz, IH), 4.43 - 4.31 (m, 2H), 4.27 - 4.11 (m, 2H), 3.60 (td, J = 6.0, 1.5 Hz, 2H), 3.38 (s, 3H), 2.41 - 2.26 (m, IH), 2.10 (p, J = 6.0 Hz, 2H), 1.82 (ddd, J = 12.6, 7.8, 2.8 Hz, IH), 1.65 - 1.56 (m, IH), 1.39 (t, J = 7.1 Hz, 3H), 1.32 (s, 3H), 0.68 (s, 3H). MS (m/z) 443.3 [M+H]+. The absolute stereochemistry was assigned unambiguously by X-ray crystallography.
Synthesis of ethyl (i?)-ll-hydroxy-12-(3-methoxypropoxy)-3,3-dimethyl-8-oxo-2,3,8,13b- tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate: Ethyl (i?)-l l- hydroxy-12-(3-methoxypropoxy)-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l- a]pyrrolo[l,2-c]phthalazine-7-carboxylate was prepared analogously to ethyl 11 -hydroxy- 12-(3 - methoxypropoxy)-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2- c]phthalazine-7-carboxylate in Example 18. XH NMR (400 MHz, Chloroform-d) δ 8.29 (s, IH), 7.42 (s, IH), 6.96 (s, IH), 6.76 (d, J = 1.0 Hz, IH), 4.72 (d, J = 5.9 Hz, IH), 4.43 - 4.31 (m, 2H), 4.27 - 4.11 (m, 2H), 3.60 (td, J = 6.0, 1.5 Hz, 2H), 3.38 (s, 3H), 2.41 - 2.26 (m, IH), 2.10 (p, J = 6.0 Hz, 2H), 1.82 (ddd, J = 12.6, 7.8, 2.8 Hz, IH), 1.65 - 1.56 (m, IH), 1.39 (t, J = 7.1 Hz, 3H), 1.32 (s, 3H), 0.68 (s, 3H). MS (m/z) 443.3 [M+H]+.
Synthesis of (i?)-ll-ethoxy-12-(3-methoxypropoxy)-3,3-dimethyl-8-oxo-2,3,8,13b- tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid : To a solution of ethyl (i?)-l l-hydroxy-12-(3-methoxypropoxy)-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH- pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate (30 mg, 0.07 mmol) in DMF (0.2 ml) was added Cs2C03 (32.95 mg, 0.1 mmol) followed by diethyl sulfate (9.58 μΐ, 0.07 mmol). The reaction was heated at 70°C for 2h. The reaction was cooled to ambient temperature and 2M LiOH(aq) (0.15 ml) was added. The reaction was stirred for lh, acidified with 2M HCl (300uL), and the product was purified by prep HPLC using acetonitrile in water with 0.1% TFA. XH NMR (400 MHz, Chloroform-d) δ 8.54 (s, IH), 7.18 (s, IH), 7.12 (s, IH), 6.80 (s, IH), 4.77 (d, J = 5.8 Hz, 1H), 4.24 - 4.07 (m, 4H), 3.65 - 3.51 (m, 2H), 3.36 (s, 3H), 2.52 - 2.34 (m, 2H), 2.12 (p, J = 6.3 Hz, 2H), 1.92 - 1.82 (m, 1H), 1.67 - 1.54 (m, 1H), 1.47 (t, J = 7.0 Hz, 3H), 1.36 (s, 3H), 0.66 (s, 3H). MS (m/z) 443.3 [M+H]+.
Example 22: (i?)-ll-isopropoxy-12-(3-methoxypropoxy)-3,3-dimethyl-8-oxo-2,3,8,13b- tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid
Figure imgf000103_0001
22
(i?)-l l-isopropoxy-12-(3-methoxypropoxy)-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH- pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid was prepared analogously to Example 21 using 2-iodopropane in place of diethyl sulfate. XH NMR (400 MHz, Chloroform-d) δ 8.54 (s, 1H), 7.24 (s, 1H), 7.12 (s, 1H), 6.79 (s, 1H), 4.76 (d, J = 5.8 Hz, 1H), 4.53 (hept, J = 6.1 Hz, 1H), 4.22 - 4.08 (m, 2H), 3.64 - 3.51 (m, 2H), 3.35 (s, 3H), 2.51 - 2.33 (m, 2H), 2.12 (q, J = 6.2 Hz, 2H), 1.93 - 1.82 (m, 1H), 1.68 - 1.55 (m, 1H), 1.41 - 1.33 (m, 9H), 0.66 (s, 3H). MS (m/z) 457.4 [M+H]+.
Example 23: (i?)-ll,12-bis(3-methoxypropoxy)-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro- lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid
Figure imgf000103_0002
23
(i?)-l l,12-bis(3-methoxypropoxy)-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l- a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid was prepared analogously to Example 21 using 1- bromo-3-methoxypropane in place of diethyl sulfate. 23 mg. XH NMR (400 MHz, Chloroform- d) δ 8.53 (s, 1H), 7.22 (s, 1H), 7.08 (s, 1H), 6.78 (s, 1H), 4.76 (d, J = 5.8 Hz, 1H), 4.23 - 4.08 (m, 4H), 3.64 - 3.50 (m, 4H), 3.37 (s, 3H), 3.35 (s, 3H), 2.49 - 2.31 (m, 2H), 2.16 - 2.05 (m, 4H), 1.92 - 1.81 (m, 1H), 1.66 - 1.54 (m, 1H), 1.35 (s, 3H), 0.66 (s, 3H). MS (m/z) 487.4 [M+H]+. Example 24: (.S)-ll,12-bis(3-methoxypropoxy)-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro- lH-pyrido [2,1-a] pyrrolo [ 1,2-c] phthalazine-7-carboxylic acid
Figure imgf000104_0001
24
(^-l l,12-bis(3-methoxypropoxy)-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l- a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid was prepared analogously to Example 23 using ethyl (5)-l l-(benzyloxy)-12-(3-methoxypropoxy)-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH- pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate in place of ethyl (i?)-l l-(benzyloxy)-12- (3-methoxypropoxy)-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2- c]phthalazine-7-carboxylate. 'H NMR (400 MHz, Chloroform-d) δ 8.53 (s, 1H), 7.22 (s, 1H), 7.08 (s, 1H), 6.78 (s, 1H), 4.76 (d, J = 5.8 Hz, 1H), 4.23 - 4.08 (m, 4H), 3.64 - 3.50 (m, 4H), 3.37 (s, 3H), 3.35 (s, 3H), 2.49 - 2.31 (m, 2H), 2.16 - 2.05 (m, 4H), 1.92 - 1.81 (m, 1H), 1.66 - 1.54 (m, 1H), 1.35 (s, 3H), 0.66 (s, 3H). MS (m/z) 487.4 [M+H]+.
Example 25: (i?)-ll-(tert-butoxy)-12-(3-methoxypropoxy)-3,3-dimethyl-8-oxo-2,3,8,13b- tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid
Figure imgf000104_0002
ethyl (R)-1 1 -hydroxy-12-(3- ethyl (R)-1 1 -(fert-butoxy)-12-(3- methoxypropoxy)-3,3-dimethyl-8-oxo- methoxypropoxy)-3,3-dimethyl-8-oxo-
2,3,8, 13b-tetrahydro-1 H-pyrido[2, 1 - 2,3,8, 13b-tetrahydro-1 H-pyrido[2, 1 - a]pyrrolo[1 ,2-c]phthalazine-7-carboxylate a]pyrrolo[1 ,2-c]phthalazine-7-carboxylate
LiOH
Figure imgf000104_0003
25 To a solution of ethyl (i?)-l l -hydroxy-12-(3-methoxypropoxy)-3,3-dimethyl-8-oxo-2,3, 8, 13b- tetrahydro-lH-pyrido[2, l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate (60 mg, 0.07 mmol) in toluene (5 ml) was added dropwise l ,l -di-tert-butoxy-N,N-dimethylmethanamine (406.38 μΐ, 1.69 mmol) over lh at 80°C. The mixture was heated for 45 minutes, concentrated under vacuum, and the resulting mixture was diluted with ethanol (0.5 ml) and treated with 2M
LiOH(aq) (0.15 ml). After stirring for lh, the mixture was acidified with 2M HC1 (0.2 ml). The product was purified by prep HPLC using acetonitrile in water with 0.1% TFA. 23 mg. IH NMR (400 MHz, Chloroform-d) δ 8.53 (s, IH), 7.38 (s, IH), 7.07 (s, IH), 6.81 (s, IH), 4.77 (d, J = 5.9 Hz, IH), 4.19 - 4.04 (m, 2H), 3.65 - 3.52 (m, 2H), 3.35 (s, 3H), 2.54 - 2.34 (m, 2H), 2.11 (p, J = 6.2 Hz, 2H), 1.93 - 1.83 (m, IH), 1.67 - 1.55 (m, IH), 1.36 (s, 9H), 1.35 (s, 3H), 0.64 (s, 3H). MS (m/z) 471.3 [M+H]+.
Example 26: (.S)-ll-(tert-butoxy)-12-(3-methoxypropoxy)-3,3-dimethyl-8-oxo-2,3,8,13b- tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid
Figure imgf000105_0001
ethyl (S)-1 1 -hydroxy-12-(3- ethyl (S)-1 1 -(terf-butoxy)-12-(3- methoxypropoxy)-3,3-dimethyl-8-oxo- methoxypropoxy)-3,3-dimethyl-8-oxo- 2,3,8, 13b-tetrahydro-1 H-pyrido[2, 1 - 2,3,8, 13b-tetrahydro-1 H-pyrido[2, 1 - a]pyrrolo[1 ,2-c]phthalazine-7-carboxylate a]pyrrolo[1 ,2-c]phthalazine-7-carboxylate
LiOH
Figure imgf000105_0002
26
To a solution of ethyl (5 -l l -hydroxy-12-(3-methoxypropoxy)-3,3-dimethyl-8-oxo-2,3, 8, 13b- tetrahydro-lH-pyrido[2, l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate (60 mg, 0.07 mmol) in toluene (5 ml) was added dropwise l ,l -di-tert-butoxy-N,N-dimethylmethanamine (406.38 μΐ, 1.69 mmol) over lh at 80°C. The mixture was heated for 45 minutes, concentrated under vacuum, and the resulting mixture was diluted with ethanol (0.5 ml) and treated with 2M LiOH(aq) (0.15 ml). After stirring for lh, the mixture was acidified with 2M HC1 (0.2 ml). The product was purified by prep HPLC using acetonitrile in water with 0.1% TFA. XH NMR (400 MHz, Chloroform-d) δ 8.53 (s, 1H), 7.38 (s, 1H), 7.07 (s, 1H), 6.81 (s, 1H), 4.77 (d, J = 5.9 Hz, 1H), 4.19 - 4.04 (m, 2H), 3.65 - 3.52 (m, 2H), 3.35 (s, 3H), 2.54 - 2.34 (m, 2H), 2.11 (p, J = 6.2 Hz, 2H), 1.93 - 1.83 (m, 1H), 1.67 - 1.55 (m, 1H), 1.36 (s, 9H), 1.35 (s, 3H), 0.64 (s, 3H). MS (m/z) 471.3 [M+H]+.
Example 27 : (R)- 1 l-(2,2-difluoroethoxy)- 12-(3-methoxypropoxy)-3,3-dimethyl-8-oxo- 2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid
Figure imgf000106_0001
27 A mixture of ethyl (<S)-1 l-hydroxy-12-(3-methoxypropoxy)-3,3-dimethyl-8-oxo-2,3, 8,13b- tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate (30 mg, 0.07 mmol), Cs2C03 (88.4 mg, 0.27 mmol), and l,l-difluoro-2-iodoethane (52.05 mg, 0.27 mmol) in was stirred at 50 °C for 2h. To the reaction was added ethanol (0.5 ml) followed by 2M Li OH (aq) (0.1 ml). The mixture was stirred for 30 min at 50 °C. The mixture was acidified with trifluoroacetic acid (10 uL) and the product was purified by prep HPLC using ACN in water with 0.1% TFA (35%-65%). lH NMR (400 MHz, Chloroform-d) δ 8.56 (s, 1H), 7.29 (s, 1H), 7.18 (s, 1H), 6.84 (s, 1H), 6.13 (tt, J = 54.9, 4.0 Hz, 1H), 4.79 (d, J = 6.1 Hz, 1H), 4.34 - 4.09 (m, 4H), 3.65 - 3.50 (m, 2H), 3.37 (s, 3H), 2.55 - 2.31 (m, 2H), 2.13 (p, J = 6.2 Hz, 2H), 1.95 - 1.85 (m, 1H), 1.69 - 1.56 (m, 1H), 1.38 (s, 3H), 0.67 (s, 3H). MS (m/z) 479.4 [M+H]+.
Example 28: (i?)-ll-cyclopropyl-12-(3-methoxypropoxy)-3,3-dimethyl-8-oxo-2,3,8,13b- tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid oxo- ne-7-
Figure imgf000107_0001
28 Synt hesis of ethyl (i?)-12-(3-methoxypropoxy)-3,3-dimethyl-8-oxo-ll-(((trifluoromethyl) - sulfonyl)oxy)-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7- carboxylate: Ethyl (R)-l l-hydroxy-12-(3-methoxypropoxy)-3,3-dimethyl-8-oxo-2,3, 8,13b- tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate (200 mg, 0.452 mmol) and N-phenyl-bis(trifluoromethanesulfonimide) (242 mg, 0.678 mmol) were suspended in DMF (2.25 mL) and DIPEA (0.40 mL, 2.26 mmol) was added. After stirring o/n at RT, the reaction mixture was diluted with EtOAc and washed with H20 and brine. The organic layer was dried over MgSC>4, filtered and concentrated under reduced pressure. The crude residue was purified by silica column chromatography (0% to 40% MeOH/EtOAc) to afford ethyl (R)-12-(3- methoxypropoxy)-3,3-dimethyl-8-oxo-l l-(((trifluoromethyl)sulfonyl)oxy)-2,3,8,13b-tetrahydro- lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate (255 mg, 98%). MS (m/z) 575.5
[M+H]+.
Synthesis of ethyl (i?)-ll-cyclopropyl-12-(3-methoxypropoxy)-3,3-dimethyl-8-oxo- 2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate: Ethyl (R)- 12-(3-methoxypropoxy)-3,3-dimethyl-8-oxo-l l-(((trifluoromethyl)sulfonyl)oxy)-2,3, 8,13b- tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate (255 mg, 0.444 mmol), potassium cyclopropyltrifluoroborate (99 mg, 0.67 mmol), RuPhos (83 mg, 0.18 mmol) and Pd(OAc)2 were suspended in PhMe (4.4 mL) and K3P04 (2M in H20, 1.1 mL, 2.2 mmol) was added. The mixture was degassed by pulling vacuum and back filling with Ar 5x. After heating to reflux for 1.5 h, the reaction mixture was cooled to RT, diluted with EtOAc and washed with H20 and brine. The organic layer was dried over MgSC>4, filtered and concentrated under reduced pressure. The crude residue was purified by silica column chromatography (0% to 40% MeOH/EtOAc) to afford ethyl (R)-l l-cyclopropyl-12-(3-methoxypropoxy)-3,3-dimethyl-8-oxo- 2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate (204 mg, 99%). MS (m/z) 467.5 [M+H]+.
(i?)-ll-cyclopropyl-12-(3-methoxypropoxy)-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH- pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid
Ethyl (i?)-l l-cyclopropyl-12-(3-methoxypropoxy)-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH- pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate (204 mg, 0.437 mmol) was suspended in EtOH (4.4 mL) and treated with Li OH (2M in H20, 0.44 mL, 0.88 mmol) was added. The reaction was stirred at 60 °C for 2 h, then cooled to RT. TFA (0.1 mL) and DMF (3 mL) were added and the mixture was concentrated to a volume of 3.5 mL under reduced pressure. The crude solution was then purified by HPLC to afford the title compound. XH NMR (400 MHz, Chloroform-c δ 8.62 (s, 1H), 7.30 (s, 1H), 7.28 (s, 1H), 6.75 (s, 1H), 4.82 (d, 1H), 4.19 (ddt, 2H), 3.71 - 3.53 (m, 2H), 3.38 (d, 3H), 2.61 - 2.35 (m, 2H), 2.15 (h, 3H), 1.64 (td, 1H), 1.39 (d, 3H), 1.02 (dq, 2H), 0.79 - 0.68 (m, 2H), 0.65 (s, 3H). MS (m/z) 439.3 [M+H]+.
Example 29: (i?)-ll-chloro-12-(3-methoxypropoxy)-2,2-dimethyl-8-oxo-2r
tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid
Figure imgf000108_0001
Synthesis of ethyl ll-chloro-12-(3-methoxypropoxy)-2,2-dimethyl-8-oxo-2,3,8,13b- tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate: Ethyl 1 l-chloro-12- (3-methoxypropoxy)-2,2-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2- c]phthalazine-7-carboxylate was prepared ethyl l l-chloro-12-(3-methoxypropoxy)-8-oxo- 2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate in example 1 using tert-butyl 4,4-dimethyl-2-oxopyrrolidine-l-carboxylate in place of \-(tert- butoxycarbonyl)-2-pyrrolidinone. XH NMR (400 MHz, Chloroform-d) δ 8.31 (s, 1H), 7.73 (s, 1H), 6.87-6.77 (m, 2H), 4.69 (d, J = 7.1 Hz, 1H), 4.35 (dd, J = 7.1, 2.2 Hz, 2H), 4.23-4.08 (m, 2H), 3.58 (d, J = 2.8Hz, 2H), 3.34 (s, 3H), 3.01 (d, J = 8.3Hz, 1H), 2.74 (d, J = 8.3 Hz, 1H), 2.36-2.19 (m, 2H), 2.1 (t, J = 6.1 Hz, 2H), 1.36 ( t, J = 7.1 Hz, 3H), 1.26 (s, 3H), 0.89 (s, 3H). MS (m/z) 461.34 [M+H]+.
(i?)-ll-chloro-12-(3-methoxypropoxy)-2,2-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH- pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid : Ethyl l l-chloro-12-(3- methoxypropoxy)-2,2-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2- c]phthalazine-7-carboxylate was separated into its enantiomers by chiral SFC chromatography using IA 5uM-4.6X150mm columns with 30% isopropanol as the co-solvent. The faster eluting peak with a retention time of 3.77 min was taken up in EtOH (1 ml) and 2M LiOH (0.3 ml) then stirred at room temperature until hydrolysis was complete. The mixture was acidified with TFA (0.5 ml) and water (0.5 ml), filtered and purified by HPLC. lH NMR (400 MHz, Chloroform-d) δ 8.66 (s, 1H), 7.81 (s, 1H), 7.04 (s, 1H), 6.86 (s, 1H), 4.76 (d, J = 7.3 Hz, 1H), 4.22 (dt, J = 6.4, 3.2 Hz, 2H), 3.61 (td, J = 6.1, 3.4 Hz, 2H), 3.37 (s, 3H), 3.08 (d, J = 8.3 Hz, 1H), 2.81 (d, J = 8.2 Hz, 1H), 2.36 (d, J = 7.5 Hz, 1H), 2.32 - 2.23 (m, 1H), 2.19 - 2.11 (m, 2H), 1.29 (s, 3H), 0.95 (s, 3H). MS (m/z) 433.357 [M+H]+.
Example 30: (.S)-ll-chloro-12-(3-methoxypropoxy)-2,2-dimethyl-8-oxo-2,3,8,13b- tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid
Figure imgf000109_0001
Ethyl l l-chloro-12-(3-methoxypropoxy)-2,2-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH- pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate was separated into its enantiomers by chiral SFC chromatography using IA 5uM-4.6X150mm columns with 30% isopropanol as the co-solvent. The slower eluting peak with a retention time of 4.99 min was taken up in in EtOH (1 ml) and 2M LiOH (0.3 ml) then stirred at room temperature until hydrolysis was complete. The mixture was acidified with TFA (0.5 ml) and water (0.5 ml), filtered and purified by HPLC. 'H NMR (400 MHz, Chloroform-d) δ 8.66 (s, 1H), 7.81 (s, 1H), 7.04 (s, 1H), 6.86 (s, 1H), 4.76 (d, J = 7.3 Hz, 1H), 4.22 (dt, J = 6.4, 3.2 Hz, 2H), 3.61 (td, J = 6.1, 3.4 Hz, 2H), 3.37 (s, 3H), 3.08 (d, J = 8.3 Hz, 1H), 2.81 (d, J = 8.2 Hz, 1H), 2.36 (d, J = 7.5 Hz, 1H), 2.32 - 2.23 (m, 1H), 2.19 - 2.11 (m, 2H), 1.29 (s, 3H), 0.95 (s, 3H). MS (m/z) 433.357 [M+H]+.
Example 31: ira«s-10-Chloro-ll-(3-methoxypropoxy)-3,3-dimethyl-7-oxo-l,2,3,3a,7,12b- hexahydrocyclopenta[c]pyrido[2,l-a]isoquinoline-6-carboxylic acid (racemate) and Example 32: cis-10-chloro-ll-(3-methoxypropoxy)-3,3-dimethyl-7-oxo-l,2,3,3a,7,12b- hexahydrocyclopenta[c]pyrido[2,l-a]isoquinoline-6-carboxylic acid (racemate)
Figure imgf000110_0001
1 -bromo-5-chloro-2-iodo-4- 5-(2-bromo-4-chloro-5-(3- (3-methoxypropoxy)benzene methoxypropoxy)phenyl)-2,2- dimethylcyclopentan-1 -one
Figure imgf000111_0001
5-(2-bromo-4-ch loro-5-(3- methoxypropoxy)phenyl)-2,2- (£)-5-(2-bromo-4-chloro-5-(3- dimethylcyclopentan-1 -one methoxypropoxy)phenyl)-2,2- dimethylcyclopentan-1-one
Figure imgf000111_0002
cis isomer trans isomer
(cis)-5-(2-bromo-4-ch loro-5-(3- (trans)-5-(2-bromo-4-chloro-5- methoxypropoxy)phenyl)-2,2- (3-methoxypropoxy)phenyl)- dimethylcyclopentan-1 -amine 2,2-dimethylcyclopentan-1 - amine
Figure imgf000111_0003
ethyl 1-((trans)-5-(2-bromo-4-chloro-5- ethyl 1-((cis)-5-(2-bromo-4-chloro-5- (3-methoxypropoxy)phenyl)-2,2- (3-methoxypropoxy)phenyl)-2,2- dimethylcyclopentyl)-4-oxo-1 ,4- dimethylcyclopentyl)-4-oxo-1 ,4- d ihyd ropyrid in e-3-ca rboxylate d ihyd ropyrid in e-3-ca rboxylate
Figure imgf000112_0001
ethyl 1 -((trans)-5-(2-bromo-4-chloro-5- ethyl 1 -((cis)-5-(2-bromo-4-chloro-5- (3-methoxypropoxy)phenyl)-2,2- (3-methoxypropoxy)phenyl)-2,2- dimethylcyclopentyl)-4-oxo-1 ,4- dimethylcyclopentyl)-4-oxo-1 ,4- dihydropyridine-3-carboxylate dihydropyridine-3-carboxylate
Pd(OAc)2 Pd(OAc)2
DPEPhos DPEPhos
K C03 K2C03
Figure imgf000112_0002
ethyl (trans)-10-chloro-1 1 -(3- ethyl (cis)-10-chloro-1 1 -(3- methoxypropoxy)-3,3-dimethyl-7-oxo methoxypropoxy)-3,3-dimethyl-7-oxo- 1 , 2, 3, 3a, 7, 12b- 1 , 2, 3, 3a, 7, 12b- hexahydrocyclopenta[c]pyrido[2, 1 - hexahydrocyclopenta[c]pyrido[2, 1 - a]isoquinoline-6-carboxylate a]isoquinoline-6-carboxylate
Synthesis of 5-(2-bromo-4-chloro-5-(3-methoxypropoxy)phenyl)-2,2-dimethylcyclopentan- 1-one : Argon was bubbled through a mixture of l-bromo-5-chloro-2-iodo-4-(3- methoxypropoxy)benzene (5.0 g, 12.33 mmol), Cs2C03 (8.84 g, 27.13 mmol), Pd2(DBA)3 (0.28 g, 0.31 mmol), xantphos (0.43 g, 0.74 mmol), and 2,2-dimethylcyclopentan-l-one (1.38 g, 12.33 mmol) in dioxane (15 ml). The reaction was heated under inert atmosphere for 20h. The mixture was cooled, diluted with ethyl acetate (150 ml) and washed with water (150 ml) followed by 0.5M NaCl (150 ml). The organic layer was dried with Na2SC>4, filtered, and concentrated. Product was purified by silica chromatography using ethyl acetate in hexane. 2.5 g. XH NMR (400 MHz, Chloroform-d) δ 7.54 (s, 1H), 6.53 (s, 1H), 4.03 (td, J = 6.2, 2.6 Hz,
2H), 3.88 - 3.79 (m, 1H), 3.62 - 3.49 (m, 2H), 3.34 (s, 3H), 2.54 - 2.41 (m, 1H), 2.05 (p, J = 6.1 Hz, 2H), 1.99 - 1.78 (m, 3H), 1.19 (s, 3H), 1.13 (s, 3H).
Synthesis of 5-(2-bromo-4-chloro-5-(3-methoxypropoxy)phenyl)-2,2-dimethylcyclopentan- 1-one oxime: To a solution of 5-(2-bromo-4-chloro-5-(3-methoxypropoxy)phenyl)-2,2- dimethylcyclopentan-l-one in EtOH (4 ml) was added hydroxylamine hydrochloride (0.54 g, 7.7 mmol) and sodium acetate (0.63 g, 7.7 mmol). The mixture was heated at 80°C for 30 minutes. The reaction vessel was sealed and the mixture was heated in a microwave reactor at 120°C for 30 minutes. The reaction was incomplete. Additional hydroxylamine hydrochloride (2 eq.) and sodium acetate (2 eq.) was added and the mixture was heated at 120°C for 30 minutes. After cooling the reaction vessel remained under pressure and the evolved gas was carefully released. The mixture was diluted with EtOAc (15 mL) and washed with water (2 x 15 mL). The organic layer was dried with Na2SC>4, filtered, and concentrated. Product was purified by silica chromatography using EtOAc in hexane. 550 mg. XH NMR (400 MHz, Chloroform-d) δ 7.53 (s, 1H), 6.56 (s, 1H), 4.35 (dd, J = 8.6, 6.4 Hz, 1H), 4.09 - 3.95 (m, 2H), 3.63 - 3.49 (m, 2H), 3.34 (s, 3H), 2.52 - 2.37 (m, 1H), 2.04 (p, J = 6.1 Hz, 2H), 1.77 - 1.55 (m, 3H), 1.31 (s, 3H), 1.26 (s, 3H). MS (m/z) 406.1 [M+H]+.
cis-5-(2-Bromo-4-chloro-5-(3-methoxypropoxy)phenyl)-2,2-dimethylcyclopentan-l-amine and ira«s-5-(2-bromo-4-chloro-5-(3-methoxypropoxy)phenyl)-2,2-dimethylcyclopentan-l- amine: To a solution of 5-(2-bromo-4-chloro-5-(3-methoxypropoxy)phenyl)-2,2- dimethylcyclopentan-l-one oxime (500 mg, 1.24 mmol) and ammonium acetate (405.36 mg, 4.94 mmol) in methanol (8 mL), portions of sodium cyanoborohydride (310.53 mg, 4.94 mmol) was added at 0°C. To the cooled solution was added dropwise titanium trichloride (12% in aq. HC1) (12%, 3175.58 mg, 2.47 mmol) maintaining an internal temperature below 10°C. The mixture was warmed to ambient temperature and sonicated for 30 mins. To the reaction was added ammonium acetate (405.36 mg, 4.94 mmol), sodium cyanoborohydride (310.53 mg, 4.94 mmol) and titanium trichloride (12% in aq. HC1) (12%, 1587.79 mg, 1.24 mmol). The mixture was sonicated for 1.5h. The reaction mixture was partially concentrated, diluted with EtOAc (100 mL), washed with 0.2M HC1 (2x100 mL), followed by 1M NaOH (100 mL), and brine. The organic layer was dried with Na2S04, filtered, and concentrated. Product was purified by silica chromatography using ethanol in dichloromethane to give a partially purified product as a 3:2 mixture of diastereomers. 340 mg. MS (m/z) 392.4 [M+H]+.
cis-Ethyl l-(5-(2-bromo-4-chloro-5-(3-methoxypropoxy)phenyl)-2,2-dimethylcyclopentyl)- 4-oxo-l,4-dihydropyridine-3-carboxylate: cis-ethyl l-(5-(2-bromo-4-chloro-5-(3- methoxypropoxy)phenyl)-2,2-dimethylcyclopentyl)-4-oxo-l,4-dihydropyridine-3-carboxylate was prepared analogously to ethyl l l-(benzyloxy)-12-(3-methoxypropoxy)-3,3-dimethyl-8-oxo- 2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate in Example 18. The products were purified by silica chromatography using ethanol in dichloromethane followed by purification by prep HPLC using acetonitrile in water with 0.1% TFA.
cis-Ethyl l-(5-(2-bromo-4-chloro-5-(3-methoxypropoxy)phenyl)-2,2-dimethylcyclopentyl)- 4-oxo-l,4-dihydropyridine-3-carboxylate: l NMR (400 MHz, Chloroform-d) δ 8.10 (d, J = 2.4 Hz, 1H), 7.45 (s, 1H), 7.36 (d, J = 7.7 Hz, 1H), 6.93 (d, J = 7.5 Hz, 1H), 6.82 (s, 1H), 4.62 (d, J = 7.8 Hz, 1H), 4.38 - 4.29 (m, 2H), 4.25 - 4.17 (m, 1H), 4.11 - 4.03 (m, 1H), 4.02 - 3.92 (m, 1H), 3.60 - 3.50 (m, 2H), 3.35 (s, 3H), 2.53 - 2.39 (m, 1H), 2.39 - 2.27 (m, 1H), 2.10 - 1.91 (m, 4H), 1.39 (s, 3H), 1.35 (t, J = 7.1 Hz, 3H), 0.94 (s, 3H). MS (m/z) 542.2 [M+H]+.
trans-ethyl l-(5-(2-bromo-4-chloro-5-(3-methoxypropoxy)phenyl)-2,2- dimethylcyclopentyl)-4-oxo-l,4-dihydropyridine-3-carboxylate: XH NMR (400 MHz, Chloroform-d) δ 8.21 (d, J = 2.5 Hz, 1H), 7.51 (s, 1H), 7.34 (d, J = 7.9 Hz, 1H), 6.82 (s, 1H), 6.50 (d, J = 7.7 Hz, 1H), 4.40 - 4.29 (m, 2H), 4.16 - 4.01 (m, 4H), 3.62 - 3.53 (m, 2H), 3.38 (s, 3H), 2.47 - 2.35 (m, 1H), 2.11 - 2.02 (m, 2H), 1.92 - 1.84 (m, 2H), 1.77 - 1.64 (m, 1H), 1.36 (t, J = 7.1 Hz, 3H), 1.23 (s, 3H), 0.98 (s, 3H). MS (m/z) 542.2 [M+H]+.
cis- 10-Chloro-ll-(3-methoxypropoxy)-3,3-dimethyl-7-oxo-l,2,3,3a,7,12b- hexahydrocyclopenta[c]pyrido[2,l-a]isoquinoline-6-carboxylic acid :
Figure imgf000114_0001
cw-lO-Chloro-l l-iS-methoxypropoxy^^-dimethyl^-oxo-l^^^a^,^^
hexahydrocyclopenta[c]pyrido[2,l-a]isoquinoline-6-carboxylic acid was prepared analogously to 1 l-chloro-12-(3-methoxypropoxy)-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l- a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid (Example 11) using cis-ethyl l-(5-(2-bromo-4- chloro-5-(3-methoxypropoxy)phenyl)-2,2-dimethylcyclopentyl)-4-oxo-l,4-dihydropyridine-3- carboxylate. lH NMR (400 MHz, Chloroform-d) δ 8.40 (s, 1H), 7.79 (s, 1H), 7.12 (s, 1H), 6.91 (d, J = 1.1 Hz, 1H), 4.28 - 4.12 (m, 3H), 3.80 (t, J = 7.6 Hz, 1H), 3.68 - 3.56 (m, 2H), 3.37 (s, 3H), 2.44 - 2.22 (m, 2H), 2.14 (p, J = 6.2 Hz, 2H), 1.68 (ddd, J = 13.3, 8.1, 5.3 Hz, 1H), 1.51 (dt, J = 13.1, 8.0 Hz, 1H), 1.26 (s, 3H), 0.51 (s, 3H). MS (m/z) 432.3 [M+H]+.
ira«s-10-Chloro-ll-(3-methoxypropoxy)-3,3-dimethyl-7-oxo-l,2,3,3a,7,12b- hexahydrocyclopenta[c]pyrido[2,l-a]isoquinoline-6-carboxylic acid
Figure imgf000114_0002
fra« ,-10-Chloro-l l-(3-methoxypropoxy)-3,3-dimethyl-7-oxo-l,2,3,3a,7,12b- hexahydrocyclopenta[c]pyrido[2,l-a]isoquinoline-6-carboxylic acid was prepared analogously to l l-chloro-12-(3-methoxypropoxy)-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l- a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid (Example 11) using trans-ethyl l-(5-(2-bromo-4- chloro-5-(3-methoxypropoxy)phenyl)-2,2-dimethylcyclopentyl)-4-oxo-l,4-dihydropyridine-3- carboxylate. XH NMR (400 MHz, Chloroform-d) δ 8.78 (d, J = 0.7 Hz, 1H), 7.72 (s, 1H), 7.07 (s, 1H), 6.79 (d, J = 1.1 Hz, 1H), 4.28 - 4.08 (m, 2H), 3.62 - 3.54 (m, 3H), 3.49 - 3.38 (m, 1H), 3.37 (s, 3H), 2.39 - 2.23 (m, 1H), 2.14 (p, J = 6.1 Hz, 2H), 2.08 - 1.83 (m, 3H), 1.58 (s, 3H), 1.33 (s, 3H). MS (m/z) 432.3 [M+H]+.
Example 33: (3aS^2bi?)-10-Chloro-ll-(3-methoxypropoxy)-3^-dimethyl-7-oxo- l,2,3,3a,7,12b-hexahydrocyclopenta[c]pyrido[2,l-a]isoquinoline-6-carboxylic acid
Figure imgf000115_0001
33
cw-lO-Chloro-l l-iS-methoxypropoxy^^-dimethyl^-oxo-l^^^a^,^^
hexahydrocyclopenta[c]pyrido[2,l-a]isoquinoline-6-carboxylic acid (31) was separated into its enantiomers by chiral SFC chromatography using OD-H 4.6X100mm columns with 30% isopropanol as the co-solvent. Compound 33 is the slower eluting peak retention time of 4.47 min. 'H NMR (400 MHz, Chloroform-d) δ 8.40 (s, 1H), 7.79 (s, 1H), 7.12 (s, 1H), 6.91 (d, J = 1.1 Hz, 1H), 4.28 - 4.12 (m, 3H), 3.80 (t, J = 7.6 Hz, 1H), 3.68 - 3.56 (m, 2H), 3.37 (s, 3H), 2.44 - 2.22 (m, 2H), 2.14 (p, J = 6.2 Hz, 2H), 1.68 (ddd, J = 13.3, 8.1, 5.3 Hz, 1H), 1.51 (dt, J = 13.1, 8.0 Hz, 1H), 1.26 (s, 3H), 0.51 (s, 3H). MS (m/z) 432.3 [M+H]+.
Example 34: (3a ?,12bS)-10-Chloro-ll-(3-methoxypropoxy)-3,3-dimethyl-7-oxo- l,2,3,3a,7,12b-hexahydrocyclopenta[c]pyrido[2,l-a]isoquinoline-6-carboxylic acid
Figure imgf000115_0002
34
cw-lO-Chloro-l l-iS-methoxypropoxy^^-dimethyl^-oxo-l^^^a^,^^
hexahydrocyclopenta[c]pyrido[2,l-a]isoquinoline-6-carboxylic acid (31) was separated into its enantiomers by chiral SFC chromatography using OD-H 4.6X100mm columns with 30% isopropanol as the co-solvent. Compound 34 is the faster eluting peak retention time of 3.52 min. ¾ NMR (400 MHz, Chloroform-d) δ 8.40 (s, 1H), 7.79 (s, 1H), 7.12 (s, 1H), 6.91 (d, J = 1.1 Hz, 1H), 4.28 - 4.12 (m, 3H), 3.80 (t, J = 7.6 Hz, 1H), 3.68 - 3.56 (m, 2H), 3.37 (s, 3H), 2.44 - 2.22 (m, 2H), 2.14 (p, J = 6.2 Hz, 2H), 1.68 (ddd, J = 13.3, 8.1, 5.3 Hz, 1H), 1.51 (dt, J = 13.1, 8.0 Hz, 1H), 1.26 (s, 3H), 0.51 (s, 3H). MS (m/z) 432.3 [M+H]+.
Example 35: ((3aS,12bS)-10-Chloro-ll-(3-methoxypropoxy)-3,3-dimethyl-7-oxo- l,2,3,3a,7,12b-hexahydrocyclopenta[c]pyrido[2,l-a]isoquinoline-6-carboxylic acid
Figure imgf000116_0001
35
trans-10-chloro-l l-(3-methoxypropoxy)-3,3-dimethyl-7-oxo-l,2,3,3a,7,12b- hexahydrocyclopenta[c]pyrido[2,l-a]isoquinoline-6-carboxylic acid (32) was separated into its enantiomers by chiral SFC chromatography using AD-H 4.6X100mm columns with 30% isopropanol as the co-solvent. Compound 35 is the slower eluting peak retention time of 4.72 min. ¾ NMR (400 MHz, Chloroform-d) δ 8.78 (d, J = 0.7 Hz, 1H), 7.72 (s, 1H), 7.07 (s, 1H), 6.79 (d, J = 1.1 Hz, 1H), 4.28 - 4.08 (m, 2H), 3.62 - 3.54 (m, 3H), 3.49 - 3.38 (m, 1H), 3.37 (s, 3H), 2.39 - 2.23 (m, 1H), 2.14 (p, J = 6.1 Hz, 2H), 2.08 - 1.83 (m, 3H), 1.58 (s, 3H), 1.33 (s, 3H). MS (m/z) 432.3 [M+H]+.
Example 36: ((3aR,12bi?)-10-chloro-ll-(3-methoxypropoxy)-3,3-dimethyl-7-oxo- l,2,3,3a,7,12b-hexahydrocyclopenta[c]pyrido[2,l-a]isoquinoline-6-carboxylic acid
Figure imgf000116_0002
36
trans-10-chloro-l l-(3-methoxypropoxy)-3,3-dimethyl-7-oxo-l,2,3,3a,7,12b- hexahydrocyclopenta[c]pyrido[2,l-a]isoquinoline-6-carboxylic acid (32) was separated into its enantiomers by chiral SFC chromatography using AD-H 4.6X100mm columns with 30% isopropanol as the co-solvent. Compound 36 is the faster eluting peak retention time of 4.06 min. ¾ NMR (400 MHz, Chloroform-d) δ 8.78 (d, J = 0.7 Hz, 1H), 7.72 (s, 1H), 7.07 (s, 1H), 6.79 (d, J = 1.1 Hz, 1H), 4.28 - 4.08 (m, 2H), 3.62 - 3.54 (m, 3H), 3.49 - 3.38 (m, 1H), 3.37 (s, 3H), 2.39 - 2.23 (m, 1H), 2.14 (p, J = 6.1 Hz, 2H), 2.08 - 1.83 (m, 3H), 1.58 (s, 3H), 1.33 (s, 3H). MS (m/z) 432.3 [M+H]+.
Example 37: ((i?)-ll-methoxy-3,3-dimethyl-8-oxo-12-((3-oxocyclobutyl)methoxy)- 2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid
Figure imgf000117_0001
ethyl (R)-12-hydroxy-1 1 -methoxy- ethyl (f?)-1 1 -methoxy-3,3-dimethyl-8-oxo- 3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro-1 H- 12-((3-oxocyclobutyl)methoxy)-2,3,8,13b- pyrido[2, 1 -a]pyrrolo[1 ,2-c]phthalazine-7- tetrahydro-1 H-pyrido[2, 1 -a]pyrrolo[1 ,2- carboxylate c]phthalazine-7-carboxylate
LiOH
Figure imgf000117_0002
37
To a solution of ethyl (i?)-12-hydroxy-l l-methoxy-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro- lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate (15 mg, 0.04 mmol) in THF (2 ml) was added triphenylphosphine (20 mg, 0.08 mmol), (5,8-dioxaspiro[3.4]octan-2-yl)methanol (5.6 mg, 0.04 mmol) followed by the dropwise addition of DIAD (12 μΐ, 0.6 mmol) over 10 min at 0°C. The mixture was stirred for 16 h at rt, concentrated under vacuum, and the resulting mixture was diluted with ethanol (0.5 ml) and treated with 2M LiOH (aq) (0.15 ml). After stirring for 2h, the mixture was acidified with TFA. The product was purified by prep HPLC using acetonitrile in water with 0.1% TFA. XH NMR (400 MHz, Chloroform-d) δ 8.59 (s, 1H), 7.32 (s, 1H), 7.23 (s, 1H), 6.79 (s, 1H), 4.80 (d, J = 6.1 Hz, 1H), 4.22 (d, J = 6.1 Hz, 2H), 3.94 (s, 3H), 3.38 - 3.18 (m, 2H), 3.19 - 2.81 (m, 2H), 2.67 - 2.19 (m, 2H), 1.91 (ddd, J = 12.6, 7.8, 2.5 Hz, IH), 1.63 (td, J = 11.7, 7.5 Hz, IH), 1.39 (s, 3H), 1.26 (t, J = 5.4 Hz, IH), 0.69 (s, 3H). MS (m/z) 439.5 [M+H]+.
Example 38: 13-chloro-12-(3-methoxypropoxy)-10,10-dimethyl-2-oxo-2,7 ,8,9,10,10a- hexahydrodipyrido[2,l-a:l',2'- d
Figure imgf000118_0001
13-Chloro-12-(3-methoxypropoxy)-10,10-dimethyl-2-oxo-2,7,8,9,10,10a- hexahydrodipyrido[2,l-a: ,2'-c]phthalazine-3-carboxylic acid prepared similarly to example 11 using 3,3-dimethylpiperidine in place of 2,2-dimethylpiperidine. XH NMR (400 MHz,
Chloroform-ύ δ 8.88 (s, IH), 7.84 (s, IH), 7.76 - 7.42 (m, IH), 7.35 (s, IH), 4.22 (t, 2H), 4.07 (s, IH), 3.73 - 3.63 (m, 2H), 3.46 - 3.33 (m, 3H), 2.24 - 2.15 (m, 2H), 1.79 (d, IH), 1.68 - 1.52 (m, 4H), 1.52 - 1.37 (m, 3H), 1.33 - 1.18 (m, 3H), 0.96 - 0.75 (m, IH). MS (m/z) 447.2
[M+H]+.
Example 39: (R)-12-chloro-13-(3-methoxypropoxy)-4,4-dimethyl-9-oxo-3,4,9,14b- tetrahydro-lH- [ 1,4] oxazino [3,4-a] pyrido [ 1,2-c] phthalazine-8-carboxylic acid
Figure imgf000118_0002
(R)-12-chloro-13-(3-methoxypropoxy)-4,4-dimethyl-9-oxo-3,4,9,14b-tetrahydro-lH- [l,4]oxazino[3,4-a]pyrido[l,2-c]phthalazine-8-carboxylic acid was prepared similarly to example 13 using 2,2-dimethyltetrahydro-2H-pyran in place of 2,2-dimethylpiperidine was separated into its enantiomers by chiral SFC chromatography using OD-H 4.6X100mm column with 30% methanol as the co-solvent. The faster eluting peak with a retention time of 4.7 min was taken up in in EtOH (1 mL) and 2M Li OH (0.3 mL) then stirred at room temperature until hydrolysis was complete. The mixture was acidified with TFA (0.5 mL) and water (0.5 mL), filtered and purified by HPLC. XH NMR (400 MHz, Chloroform-d) δ 8.63 (s, IH), 7.79 (s, IH), 7.14 (s, IH), 7.03 (s, IH), 4.75 (d, IH), 4.39 (s, IH), 4.32 - 4.18 (m, 2H), 4.10 (dd, IH), 3.65 - 3.57 (m, 3H), 3.57 - 3.46 (m, 1H), 3.38 (s, 3H), 2.16 (p, 2H), 1.11 (s, 3H), 0.54 (s, 3H).. MS (m/z) 449.2 [M+H]+.
Example 40 : (i?)-13-bromo- 11-methoxy- 12-(3-methoxypropoxy)-3,3-dimethyl-8-oxo- 2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid
Figure imgf000119_0001
ethyl (R)-12-hydroxy-1 1 -methoxy- ethyl (R)-13-bromo-12-hydroxy-1 1 -methoxy- 3,3-dimethyl-8-oxo-2,3,8, 13b-tetrahydro- 3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro- 1 H-pyrido[2, 1 -a]pyrrolo[1 ,2-c] 1 H-pyrido[2 , 1 - a]pyrrolo[1 ,2- c] phthalazine-7-carboxylate phthalazine-7-carboxylate
Synthesis of Ethyl (R)-13-bromo-12-hydroxy-ll-methoxy-3,3-dimethyl-8-oxo-2,3,8,13b- tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate: Ethyl (R)-12- hydroxy-l l-methoxy-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2- c]phthalazine-7-carboxylate (48 mg, 0.12 mmol) was dissolved in a mixture of 0.4 mL acetic acid and 0.4 mL THF. Potassium acetate (61 mg, 0.62 mmol) was added and the reaction was cooled to 5 °C. N-bromosuccinimide (22 mg, 0.12 mmol) was added in a single portion. After 3 minutes, LCMS analysis showed complete conversion. The crude mixture was diluted with 1M TFA and purified by preparative HPLC to provide ethyl (R)-13-bromo-12-hydroxy-l 1-methoxy- 3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7- carboxylate as a TFA salt after lyophilization. 1H NMR (400 MHz, DMSO-d6) δ 8.10 (s, 1H), 7.46 (s, 1H), 6.92 (s, 1H), 4.85 (dd, J = 8.5, 4.5 Hz, 1H), 4.29 - 4.10 (m, 2H), 3.92 (s, 3H), 2.77 (dtd, J = 12.5, 8.5, 3.5 Hz, 1H), 2.23 (dtd, J = 13.7, 9.0, 4.7 Hz, 1H), 1.71 (dt, J = 11.8, 9.0 Hz, 1H), 1.58 (ddd, J = 12.1, 8.5, 3.6 Hz, 1H), 1.28 - 1.19 (m, 3H), 1.21 (s, 3H), 1.20 (s, 3H), 0.70 (s +H]+.
et
Figure imgf000119_0002
tetrahydro-1 H-pyrido[2, 1 - a]pyrrolo[1 ,2-c]phthalazine-7- carboxylate (i?)-13-bromo-ll-methoxy-12-(3-methoxypropoxy)-3,3-dimethyl-8-oxo-2,3,8,13b- tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid: Ethyl (i?)-13- bromo-12-hydroxy-l l-methoxy-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l- a]pyrrolo[l,2-c]phthalazine-7-carboxylate TFA salt (25 mg, 0.04 mmol) was combined in DMF (0.3 mL) with potassium carbonate (25 mg, 0.18 mmol) and l-bromo-3-methoxypropane (16 μί, 0.15 mmol). The reaction mixture was stirred at 70 °C for 30 minutes after which time LCMS analysis showed complete conversion of the starting material. The reaction was cooled to room temperature. Aqueous lithium hydroxide (1 M, 0.07 mL, 0.07 mmol) was added and the mixture was stirred at for 25 minutes after which time LCMS analysis showed complete ester hydrolysis. The mixture was diluted with TFA and purified by preparative HPLC to provide (R)- 13-bromo-l l-methoxy-12-(3-methoxypropoxy)-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH- pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid as a TFA salt. XH NMR (400 MHz, Acetonitrile-d3) δ 8.42 (s, 1H), 7.48 (s, 1H), 7.20 (s, 1H), 4.99 (dd, J = 8.6, 4.7 Hz, 1H), 4.22 (dt, J = 9.3, 6.4 Hz, 1H), 4.08 (dt, J = 9.4, 6.4 Hz, 1H), 3.97 (s, 3H), 3.58 (t, J = 6.3 Hz, 2H), 3.32 (s, 3H), 2.99 - 2.86 (m, 1H), 2.40 (ddd, J = 13.8, 9.1, 4.7 Hz, 1H), 2.02 (p, J = 6.3 Hz, 2H), 1.90 - 1.77 (m, 1H), 1.68 (ddd, J = 12.3, 8.6, 3.6 Hz, 1H), 1.30 (s, 3H), 0.76 (s, 3H). 19F NMR (376 MHz, Acetonitrile-d3) δ -77.29 . MS (m/z) 507.3 [M+H]+.
Example 41: (i?)-ll-methoxy-3,3-dimethyl-8-oxo-12-(pyrimidin-2-yloxy)-2,3,8,13b- tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid
Figure imgf000120_0001
Ethyl (i?)-12-hydroxy-l l-methoxy-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l- a]pyrrolo[l,2-c]phthalazine-7-carboxylate (17 mg, 44 μιτιοΐ) was combined with 2- chloropyrimidine (15 mg, 133 μπιοΐ) and potassium carbonate (24 mg, 0.18 mmol) in NMP (0.25 mL). The mixture was stirred at 70°C for 18 hours, and then cooled to room temperature. Aqueous 1M lithium hydroxide (88 μί) and ethanol (0.2 mL) were added and the mixture was stirred at 40 °C for 20 minutes. The mixture was cooled to room temperature, diluted with TFA, and purified by preparative HPLC to provide (i?)-l l-methoxy-3,3-dimethyl-8-oxo-12- (pyrimidin-2-yloxy)-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7- carboxylic acid as a TFA salt. 1H NMR (400 MHz, Acetonitrile-d3) δ 8.56 (d, J = 4.8 Hz, 2H), 8.48 (s, 1H), 7.57 (s, 1H), 7.37 (s, 1H), 7.32 (d, J = 1.0 Hz, 1H), 7.18 (t, J = 4.8 Hz, 1H), 4.89 (t, J = 3.8 Hz, 1H), 2.48 - 2.39 (m, 2H), 1.93 - 1.85 (m, 1H), 1.65 (dt, J = 12.7, 9.5 Hz, 1H), 1.38 (s, 3H), 0.71 (s, 3H). 19F NMR (376 MHz, Acetonitrile-d3) δ -77.31 . MS (m/z) 436.3 [M+H]+.
Example 42: (i?)-ll-Methoxy-3,3-dimethyl-12-((l-methyl-lH-imidazol-5-yl)ethynyl)-8-oxo- 2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid
Figure imgf000121_0001
ethyl (R)-12-hydroxy-1 1 -methoxy-3,3-dimethyl-8- ethyl (R)-1 1 -methoxy-3,3-dimethyl-8- oxo-2,3,8, 13b-tetrahydro-1 H-pyrido[2, 1 - oxo-12-(((trifluoromethyl)sulfonyl)oxy)- a]pyrrolo[1 ,2-c]phthalazine-7-carboxylate 2,3,8, 13b-tetrahydro-1 H-pyrido[2, 1 - a]pyrrolo[1 ,2-c]phthalazine-7- carboxylate PPh2)2Cl2
Figure imgf000121_0002
Synthesis of Ethyl (R)-ll-methoxy-3,3-dimethyl-8-oxo-12-(((trifluoromethyl)sulfonyl)oxy)- 2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate: Ethyl (R)- 12-hydroxy-l l-methoxy-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2- c]phthalazine-7-carboxylate (100 mg, 0.26 mmol) was combined with N-Phenyl- bis(trifluoromethanesulfonimide) (167 mg, 0.47 mmol) in DCM (2 mL) at room temperature. N,N-diisopropylethylamine (0.44 mL, 2.6 mmol) was added and the reaction was stirred at room temperature. After 20 minutes, LCMS analysis showed complete conversion. Aqueous NaHC03 was added, the DCM layer was removed, dried over Na2SC>4, filtered, and concentrated in vacuo. The mixture was purified by flash column chromatography (ethyl acetate / hexanes/ ethanol) to provide ethyl (R)-l l-methoxy-3,3-dimethyl-8-oxo-12-(((trifluoromethyl)sulfonyl)oxy)- 2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate. XH NMR (400 MHz, Chloroform-d) δ 8.31 (s, 1H), 7.35 (s, 1H), 7.16 (d, J = 1.0 Hz, 1H), 6.98 (s, 1H), 4.76 (d, J = 6.3 Hz, 1H), 4.38 (q, J = 7.1 Hz, 2H), 3.97 (s, 3H), 2.45 (dddd, J = 13.1 , 10.7, 8.2, 6.5 Hz, 1H), 2.28 (ddt, J = 13.3, 7.0, 2.2 Hz, 1H), 1.88 (ddd, J = 12.7, 8.1 , 2.6 Hz, 1H), 1.69 (s, 1H), 1.60 (ddd, J = 12.7, 10.8, 7.7 Hz, 1H), 1.39 (t, J = 7.1 Hz, 3H), 1.35 (s, 3H), 0.68 (s, 3H). MS (m/z) 517.2 [M+H]+.
(i?)-ll-Methoxy-3^-dimethyl-12-((l-methyl-lH-imidazol-5-yl)ethynyl)-8-oxo-2,3,8,13b- tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid: Ethyl (R)-\ \ - methoxy-3,3-dimethyl-8-oxo-12-(((trifluoromethyl)sulfonyl)oxy)-2,3,8,13b-tetrahydro-lH- pyrido[2, l-a]pyrrolo[l ,2-c]phthalazine-7-carboxylate (10 mg, 19 μηιοΐ) was combined with Copper(I) iodide (0.81 mg, 4 μηιοΐ) and Pd(tBu2PPh)2Cl2 (2.06 mg, 3 μηιοΐ) in a vial equipped with a magnetic stir bar. 5-ethynyl-l -methyl-lH-imidazole (10 mg, 0.1 mmol) was added along with 1 mL MeCN/Et3N (3: 1). The mixture was placed under argon and stirred at 60 °C. After 100 minutes, LCMS analysis showed complete conversion, the reaction was cooled to room temperature and quenched with 50 mg thiol-linked silica. The mixture was filtered, rinsing forward with MeCN/EtOH, and concentrated to dryness. The crude mixture was dissolved in ethanol (0.5 mL), aqueous 1M lithium hydroxide (0.1 ml), and the resulting mixture was stirred at 40°C for 30 minutes after which time LCMS analysis showed complete conversion. The mixture was diluted with TFA and purified by preparative HPLC to provide (R)-l 1-methoxy- 3,3-dimethyl-12-((l -methyl-lH-imidazol-5-yl)ethynyl)-8-oxo-2,3,8, 13b-tetrahydro-lH- pyrido[2, l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid as a TFA salt. 1H NMR (400 MHz, Acetonitrile-d3) δ 8.49 (s, 1H), 8.32 (s, 1H), 7.61 (d, J = 1.0 Hz, 1H), 7.59 (d, J = 1.3 Hz, 1H), 7.52 (s, 1H), 7.41 (s, 1H), 4.86 (d, J = 5.9 Hz, 1H), 4.04 (s, 3H), 3.88 (s, 3H), 2.54 - 2.41 (m, 2H), 1.92 - 1.84 (m, 1H), 1.70 - 1.58 (m, 1H), 1.38 (s, 3H), 0.67 (s, 3H). 19F NMR (376 MHz, Acetonitrile-d3) δ -76.90. MS (m/z) 445.2 [M+H]+.
Example 43: (i?)-ll-Methoxy-12-(3-methoxy-3-methylbut-l-yn-l-yl)-3,3-dimethyl-8-oxo- 2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid
Figure imgf000122_0001
(i?)-l l-Methoxy-12-(3-methoxy-3-methylbut-l-yn-l-yl)-3,3-dimethyl-8-oxo-2,3,8,13b- tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid was prepared analogously to (R)-l l-methoxy-3,3-dimethyl-12-((l-methyl-lH-imidazol-5-yl)ethynyl)-8-oxo- 2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid in example 43 using 3-methoxy-3-methylbut-l-yne in place of 5-ethynyl-l-methyl-lH-imidazole. 'll NMR (400 MHz, Acetonitrile-d3) δ 8.47 (s, 1H), 7.46 (s, 1H), 7.44 (s, 1H), 7.36 (s, 1H), 4.83 (d, J = 6.0 Hz, 1H), 3.98 (s, 3H), 3.41 (s, 3H), 2.54 - 2.38 (m, 2H), 1.93 - 1.86 (m, 1H), 1.67 - 1.57 (m, 1H), 1.53 (s, 6H), 1.36 (s, 3H), 0.66 (s, 3H). 19F NMR (376 MHz, Acetonitrile-d3) δ -76.67. MS (m/z) 437.3 [M+H]+.
Example 44: (i?)-12-(l-(Difluoromethyl)-lH-pyrazol-4-yl)-ll-methoxy-3,3-dimethyl-8-oxo- 2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid
Figure imgf000123_0001
l-(difluoromethyl)-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-pyrazole (24 mg, 0.097 mmol) was combined with potassium carbonate (19 mg, 0.14 mmol) in 0.4 mL dioxane and 0.4 mL water. The mixture was stirred under argon at 75 °C for 90 minutes. The reaction was then cooled to room temperature. Ethyl (R)-l l-methoxy-3,3-dimethyl-8-oxo-12- (((trifluoromethyl)sulfonyl)oxy)-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2- c]phthalazine-7-carboxylate (10 mg, 19 μηιοΐ), Chloro(2-dicyclohexylphosphino-2',6'-di-i- propoxy-l, -biphenyl)(2-amino-l, -biphenyl-2-yl)palladium(II) (0.3 mg, 0.4 μηιοΐ), and Pd(tBu2PPh)2Cl2 (1.4 mg, 0.2 μηιοΐ) were added. The mixture was placed under argon and heated at 80 °C for 35 minutes after which time LCMS analysis showed complete conversion. The reaction was cooled to room temperature and 1M aqueous lithium hydroxide (0.06 ml) was added. The reaction was stirred at 40 °C for 50 minutes after which time LCMS analysis showed complete conversion. The reaction was cooled to room temperature, diluted with TFA and purified by preparative HPLC to provide(R)-12-(l-(difluoromethyl)-lH-pyrazol-4-yl)-l l- methoxy-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7- carboxylic acid as a TFA salt. XH NMR (400 MHz, Acetonitrile-d3) δ 8.57 (s, 1H), 8.48 (s, 1H), 8.28 (s, 1H), 7.69 (d, J = 1.0 Hz, 1H), 7.52 (s, 1H), 7.43 (t, J = 59.9 Hz, 1H), 7.39 (s, 1H), 4.89 (d, J = 6.3 Hz, 1H), 4.06 (s, 3H), 2.69 - 2.59 (m, 1H), 2.46 (dddd, J = 13.1, 10.8, 8.1, 6.4 Hz, 1H), 1.91 (ddd, J = 12.7, 8.2, 2.5 Hz, 1H), 1.64 (ddd, J = 12.6, 10.9, 7.8 Hz, 1H), 1.38 (s, 3H), 0.67 (s, 3H). 19F NMR (376 MHz, Acetonitrile-d3) δ -77.32, -96.11 (d, J = 60.0 Hz). MS (m/z) 457.3 [M+H]+.
Example 45: 10-Chloro-ll-(3-methoxypropoxy)-2,2-dimethyl-7-oxo- tetrahydroazeto[2,l-a]pyrido[l,2-c]phthalazine-6-carboxylic acid
-
Figure imgf000124_0001
methoxypropoxy)phenyl)-2,2-
2,2-dimethyl- dimethylazetidin- 1 -ol
2,3-dihydroazete 1 -oxide
2,2-di
Figure imgf000124_0002
4-(2-bromo-4-chloro-5-(3-methoxypropoxy)phenyl)-2,2-dimethylazetidin-l-ol: 2,2- dimethylazetidine (563 mg, 6.61 mmol) was combined with sodium tungstate dihydrate (619 mg, 1.98 mmol) in water (5 mL). The mixture was cooled to 0 °C and hydrogen peroxide (30 wt% in water, 1.5 mL, 15 mmol) was added dropwise over 10 minutes. The mixture was stirred while maintaining the temperature below 5 °C for 3 hours. The mixture was then extracted with CH2CI2 (5 x 5 mL), the combined organic layers were dried over Na2SC>4, filtered and concentrated in vacuo (100 mbar, bath set to 10 °C) to provide 2,2-dimethyl-2,3-dihydroazete 1- oxide: XH NMR (400 MHz, Chloroform-d) δ 6.61 (t, J = 1.2 Hz, 1H), 2.43 (d, J = 1.2 Hz, 2H), 1.48 (s, 6H); 13C NMR (101 MHz, Chloroform-d) δ 132.91 , 80.37 , 35.68 , 22.47.
Concurrently and in a separate round bottom flask, l-bromo-5-chloro-2-iodo-4-(3- methoxypropoxy)benzene (3.30 g, 8.13 mmol) was dissolved in MeTHF (20 mL) at 0°C under argon and a solution of isopropylmagnesium chloride lithium chloride (1.3 M in THF, 6.25 ml, 8.13 mmol) was added dropwise. The solution of Grignard reagent was stirred at 0 °C for 10 minutes, followed by addition of a solution of the 2,2-dimethyl-2,3-dihydroazete 1 -oxide prepared above in 2-MeTHF (2 mL). After an additional 10 minutes at 0 °C, the reaction was quenched with a mixture of aqueous NH4C1 and aqueous NaHCC . The mixture was diluted with EtOAc, the organics were removed, dried over sodium sulfate, filtered, concentrated, and purified by flash column chromatography (15% - 35% EtOAc in hexanes) to provide 4-(2- bromo-4-chloro-5-(3-methoxypropoxy)phenyl)-2,2-dimethylazetidin-l-ol. XH NMR (400 MHz, Chloroform-d) δ 7.46 (s, 1H), 7.38 (s, 1H), 4.62 (t, J = 9.1 Hz, 1H), 4.25 - 4.11 (m, 2H), 3.59 (td, J = 6.1, 1.0 Hz, 2H), 3.37 (s, 3H), 2.46 - 2.33 (m, 1H), 2.08 (p, J = 6.1 Hz, 2H), 1.42 (s, 3H), 1.28 (s, 3H). MS (m/z) 378.3 [M+H]+.
10-chloro-ll-(3-methoxypropoxy)-2,2-dimethyl-7-oxo-l,2,7,12b-tetrahydroazeto[2,l- a]pyrido[l,2-c]phthalazine-6-carboxylic acid: Prepared from 4-(2-bromo-4-chloro-5-(3- methoxypropoxy)phenyl)-2,2-dimethylazetidin-l-ol analogously to the conversion of 5-(2- bromo-4-chloro-5-(3-methoxypropoxy)phenyl)-2,2-dimethylpyrrolidin-l-ol to 1 l-chloro-12-(3- methoxypropoxy)-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2- c]phthalazine-7-carboxylic acid. ¾ NMR (400 MHz, Acetonitrile-d3) δ 8.21 (s, 1H), 8.06 (s, 1H), 7.25 (s, 1H), 6.97 (d, J = 1.0 Hz, 1H), 5.30 (dd, J = 8.0, 2.9 Hz, 1H), 4.30 - 4.14 (m, 2H), 3.56 (t, J = 6.3 Hz, 2H), 3.32 (s, 3H), 2.85 (dd, J = 11.2, 8.0 Hz, 1H), 2.23 (dd, J = 11.2, 2.9 Hz, 1H), 2.07 (p, J = 6.4 Hz, 2H), 1.48 (s, 3H), 1.04 (s, 3H). 19F NMR (376 MHz, Acetonitrile-d3) δ -77.32 . MS (m/z) 419.1 [M+H]+. Example 46: (R)-10-chloro-ll-(3-methoxypropoxy)-2,2-dimethyl-7-oxo-l,2,7,12b- tetrahydroazeto[2,l-a]pyrido[l,2-c]phthalazine-6-carboxylic acid and (S)-10-chloro-ll-(3- methoxypropoxy)-2,2-dimethyl-7-oxo-l,2,7,12b-tetrahydroazeto[2,l-a]pyrido[l,2- c]
Figure imgf000125_0001
1 0-chloro- 1 1 -(3-methoxypropoxy)-2,2- dimethyl-7-oxo- 1 ,2,7, 12b- tetrahydroazeto[2, 1 -a]pyrido[ 1 ,2- c]phthalazine-6-carboxylic acid
Racemic 10-chloro-l l-(3-methoxypropoxy)-2,2-dimethyl-7-oxo-l,2,7,12b-tetrahydroazeto[2,l- a]pyrido[l,2-c]phthalazine-6-carboxylic acid was purified by SFC on an OD-H column with isopropanol as the co-solvent. Example 47: (R)-ll-chloro-12-(3-methoxypropoxy)-l,l-dimethyl-8-oxo-2,3,8,13b- tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid
Figure imgf000126_0001
Synthesis of ethyl ll-chloro-12-(3-methoxypropoxy)-l,l-dimethyl-8-oxo-2,3,8,13b- tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate: Ethyl 1 l-chloro-12- (3-methoxypropoxy)-l ,1 -dimethyl-8-oxo-2,3,8, 13b-tetrahydro-lH-pyrido[2, 1 -a]pyrrolo[l ,2- c]phthalazine-7-carboxylate was prepared similarly to example 1 using tert-butyl 3, 3-dimethyl- 2-oxopyrrolidine-l-carboxylate in place of l-( ert-butoxycarbonyl)-2-pyrrolidinone. XH NMR (400 MHz, Chloroform-d) δ 8.34 (s, 1H), 7.79 (s, 1H), 7.03 (d, J = 1.0 Hz, 1H), 6.84 (s, 1H), 4.41 - 4.33 (m, 2H), 4.20 (s, 1H), 4.16 (t, J = 6.1 Hz, 2H), 3.59 (td, J = 6.1, 2.7 Hz, 2H), 3.47 (d, J = 5.4 Hz, 1H), 3.35 (s, 3H), 3.20 (dd, J = 5.9, 1.2 Hz, 1H), 2.15 - 2.08 (m, 2H), 1.86 - 1.77 (m, 1H), 1.68 - 1.59 (m, 1H), 1.49 (s, 3H), 1.41 - 1.33 (m, 6H). MS (m/z) 461.42 [M+H]+.
(R)-ll-chloro-12-(3-methoxypropoxy)-l,l-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH- pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid: ethyl l l-chloro-12-(3- methoxypropoxy)-l,l-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2- c]phthalazine-7-carboxylate was separated into its enantiomers by chiral SFC chromatography using IA 5uM-4.6X150mm columns with 30% isopropanol as the co-solvent. The slower eluting peak was taken up in in EtOH (1 mL) and 2M LiOH (0.3 ml) then stirred at room temperature until hydrolysis was complete. The mixture was acidified with TFA (0.5 mL) and water (0.5 mL), filtered and purified by HPLC. XH NMR (400 MHz, Chloroform-d) δ 8.64 (s, 1H), 7.83 (s, 1H), 7.07 (s, 1H), 7.03 (s, 1H), 4.24 - 4.17 (m, 3H), 3.61 (td, J = 6.0, 2.0 Hz, 2H), 3.54 - 3.45 (m, 1H), 3.40 (d, J = 5.4 Hz, 1H), 3.36 (s, 3H), 2.18 - 2.10 (m, 2H), 1.97 - 1.90 (m, 1H), 1.82 - 1.77 (m, 1H), 1.52 (s, 3H), 1.31 (s, 3H). MS (m/z) 433.41 [M+H]+. Example 48 : (S)- 1 l-chloro-12-(3-methoxypropoxy)- l,l-dimethyl-8-oxo-2,3,8,13b- tetrahydro-lH-pyrido[2,l- oxylic acid
Figure imgf000127_0001
Ethyl l l-chloro-12-(3-methoxypropoxy)-l,l-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH- pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate was separated into its enantiomers by chiral SFC chromatography using IA 5uM-4.6X150mm columns with 30% isopropanol as the co-solvent. The faster eluting peak was taken up in in EtOH (1 ml) and 2M LiOH (0.3 ml) then stirred at room temperature until hydrolysis was complete. The mixture was acidified with TFA (0.5 mL) and water (0.5 mL), filtered and purified by HPLC. XH NMR (400 MHz, Chloroform- d) δ 8.63 (s, 1H), 7.82 (s, 1H), 7.07 (s, 1H), 7.02 (s, 1H), 4.23 - 4.17 (m, 3H), 3.61 (td, J = 6.0, 2.0 Hz, 2H), 3.49 (d, J = 6.2 Hz, 1H), 3.44 - 3.38 (m, 1H), 3.36 (s, 3H), 2.17 - 2.11 (m, 2H), 1.93 (d, J = 4.8 Hz, 1H), 1.79 (d, J = 6.3 Hz, 1H), 1.52 (s, 3H), 1.31 (s, 3H). MS (m/z) 433.314 [M+H]+. Example 49: (i?)-ll-chloro-3,3-dimethyl-12-((3-methyloxetan-3-yl)methoxy)-8-oxo- 2,3,8,13b-tetrahy d:
Figure imgf000127_0002
methyl (R)-1 1 -chloro-12-hydroxy-3,3- 49
dimethyl-8-oxo-2,3,8, 13b-tetrahydro-1 H- pyrido[2, 1 -a]pyrrolo[1 ,2-c]phthalazine-7- carboxylate
Methyl (i?)-l l-chloro-12-hydroxy-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l- a]pyrrolo[l,2-c]phthalazine-7-carboxylate (10 mg, 0.027 mmol) was combined in DMF (0.5 mL) with cesium carbonate (7 mg, 0.05 mmol) and 3-(chloromethyl)-3-methyloxetane (10 mg, 0.08 mmol). The reaction mixture was stirred at 70 °C for 1 hour. The mixture was cooled to room temperature. Aqueous lithium hydroxide (1 M, 0.20 mL, 0.20 mmol) and ethanol (0.5 mL) were added and the mixture was overnight at rt. The mixture was then diluted with
trifluoroacetic acid and purified by preparative HPLC to provide (i?)-l l-chloro-3,3-dimethyl-12- ((3-methyloxetan-3-yl)methoxy)-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2- c]phthalazine-7-carboxylic acid. MS (m/z) 445.3 [M+H]+.
Example 50: (R)-12-((3,3-difluorocyclobutyl)methoxy)-ll-methoxy-3,3-dimethyl-8-oxo- 2,3,8,13b-tetr lic acid:
Figure imgf000128_0001
Ethyl (R)-12-hydroxy-l l-methoxy-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l- a]pyrrolo[l,2-c]phthalazine-7-carboxylate (59 mg, 150 μηιοΐ) was combined with 3- (bromomethyl)-l,l-difluorocyclobutane (85 mg, 460 μmol) and Potassium Carbonate (85 mg, 0.61 mmol) in DMF (0.4 mL). The mixture was stirred at 70 °C for 55 minutes, and then cooled to room temperature. Aqueous 1M lithium hydroxide (334 μί) was added and the mixture was stirred at 35 °C for 30 minutes. The mixture was cooled to room temperature, diluted with TFA, and purified by preparative HPLC to provide (R)-12-((3,3-difluorocyclobutyl)methoxy)-l l- methoxy-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7- carboxylic acid as a TFA salt. l NMR (400 MHz, Acetonitrile-d3) δ 8.45 (s, IH), 7.39 (s, IH), 7.26 (s, IH), 6.95 (d, J = 0.9 Hz, IH), 4.84 (d, J = 6.2 Hz, IH), 4.16 (qt, J = 12.8, 6.5 Hz, 2H), 3.92 (s, 3H), 2.85 - 2.33 (m, 7H), 1.89 (ddd, J = 12.6, 7.8, 2.7 Hz, IH), 1.62 (ddd, J = 12.4, 10.8, 7.8 Hz, IH), 1.36 (s, 3H), 0.66 (s, 3H). 19F NMR (376 MHz, Acetonitrile-d3) δ -77.33 , -84.17 - -85.00 (m), -93.89 - -94.83 (m). MS (m/z) 461.3 [M+H]+.
Example 51: (S)-12-chloro-13-(3-methoxypropoxy)-4,4-dimethyl-9-oxo-3,4,9,14b- tetrahydro-lH- [ 1,4] oxazino [3,4-a] pyrido [ 1,2-c] phthalazine-8-carboxylic acid
Figure imgf000128_0002
(S)-12-Chloro-13-(3-methoxypropoxy)-4,4-dimethyl-9-oxo-3,4,9,14b-tetrahydro-lH- [l,4]oxazino[3,4-a]pyrido[l,2-c]phthalazine-8-carboxylic acid was prepared similarly to example 12 using 2,2-dimethyltetrahydro-2H-pyran in place of 2,2-dimethylpiperidine was separated into its enantiomers by chiral SFC chromatography using OD-H 4.6X100 mm column with 30% methanol as the co-solvent. The slower eluting peak with a retention time of 5.3 min was taken up in in EtOH (1 ml) and 2M LiOH (0.3 ml) then stirred at room temperature until hydrolysis was complete. The mixture was acidified with TFA (0.5 mL) and water (0.5 mL), filtered and purified by HPLC. XH NMR (400 MHz, Chloroform-d) δ 8.63 (s, 1H), 7.79 (s, 1H), 7.14 (s, 1H), 7.03 (s, 1H), 4.75 (d, 1H), 4.39 (s, 1H), 4.32 - 4.18 (m, 2H), 4.10 (dd, 1H), 3.65 - 3.57 (m, 3H), 3.57 - 3.46 (m, 1H), 3.38 (s, 3H), 2.16 (p, 2H), 1.11 (s, 3H), 0.54 (s, 3H).. MS (m/z) 449.2 [M+H]+. Example 52: (R)-13-methoxy-12-(3-methoxypropoxy)-7,7-dimethyl-2-oxo-2,7,8,9,10,10a- hexahydrodipyrido[2,l-a:l',2'-c]phthalazine-3-carboxylic acid and Example 53: (S)-13- methoxy-12-(3-methoxypropoxy)-7,7-dimethyl-2-oxo-2,7,8 ,9,10,10a- hexahydrodipyrido[2,l-a:l',2'-c]phthalazine-3-carboxylic acid
Figure imgf000129_0001
ethyl 13-methoxy-12-(3- 13-methoxy-12-(3- methoxypropoxy)-7,7-dimethyl-2-oxo- methoxypropoxy)-7,7-dimethyl-2- 2,7,8,9,10,10a- oxo-2, 7, 8, 9, 10, 10a- hexahydrodipyrido[2,1-a: 1 ',2'- hexahydrodipyrido[2,1-a: 1 ',2'- c]phthalazine-3-carboxylate c]phthalazine-3-carboxylic acid
Syn thesis of 13-chloro-12-(3-methoxypropoxy)-7,7-dimethyl-2-oxo-2,7,8,9,10,10a- hexahydrodipyrido[2,l-a:l',2'-c]phthalazine-3-carboxylic acid: Ethyl 13-methoxy-12-(3- methoxypropoxy)-7,7-dimethyl-2-oxo-2,7,8,9,10,10a-hexahydrodipyrido[2,l-a: l',2'- c]phthalazine-3-carboxylate was prepared similarly to ethyl 13-chloro-12-(3-methoxypropoxy)- 7,7-dimethyl-2-oxo-2,7, 8,9,10,10a-hexahydrodipyrido[2,l-a: l',2'-c]phthalazine-3-carboxylate in example 11 using l-bromo-2-iodo-5-methoxy-4-(3-methoxypropoxy)benzene in place of 1- bromo-5-chloro-2-iodo-4-(3-methoxypropoxy)benzene. Instead of purifying the ester, it was hydrolyzed by adding 0.2 mL 2 M LiOH into the unworked up mixture, which was then filtered over celite, rinsing with DCM, concentrated, diluted with DMF and purified by HPLC. MS (m/z) 443.2 [M+H]+.
(R)-13-methoxy-12-(3-methoxypropoxy)-7,7-dimethyl-2-oxo-2,7 ,8,9,10,10a- hexahydrodipyrido[2,l-a:l',2'-c]phthalazine-3-carboxylic acid
Figure imgf000130_0001
13-Methoxy- 12-(3-methoxypropoxy)-7,7-dimethyl-2-oxo-2,7,8,9, 10, 10a- hexahydrodipyrido[2,l-a: l',2'-c]phthalazine-3-carboxylic acid was separated into its
enantiomers by chiral SFC chromatography using OD-H 4.6X100mm columns with 30% methanol as the co-solvent. (R)-13-methoxy-12-(3-methoxypropoxy)-7,7-dimethyl-2-oxo- 2,7,8,9,10,10a-hexahydrodipyrido[2,l-a: ,2'-c]phthalazine-3-carboxylic acid is the faster eluting peak with a retention time of 0.9 min. XH NMR (400 MHz, Chloroform-d) δ 8.62 (s, 1H), 7.02 (s, 1H), 6.86 (s, 1H), 4.62 - 4.52 (m, 1H), 4.21 (t, 2H), 3.94 (s, 3H), 3.66 - 3.51 (m, 2H), 3.37 (s, 3H), 2.60 - 2.48 (m, 1H), 2.22 - 2.08 (m, 2H), 1.86 - 1.74 (m, 2H), 1.72 - 1.44 (m, 4H), 1.16 (s, 3H), 0.41 (s, 3H). MS (m/z) 443.2 [M+H]+.
Example 53: (S)-13-methoxy-12-(3-methoxypropoxy)-7,7-dimethyl-2-oxo-2,7,8,9,10,10a- hexahydrodipyrido[2,l-a:l',2'-c]phthalazine-3-carboxylic acid
Figure imgf000130_0002
13-Methoxy- 12-(3-methoxypropoxy)-7,7-dimethyl-2-oxo-2,7,8,9, 10, 10a- hexahydrodipyrido[2,l-a: ,2'-c]phthalazine-3-carboxylic acid was separated into its
enantiomers by chiral SFC chromatography using OD-H 4.6X100mm columns with 30% methanol as the co-solvent. (S)-13-methoxy-12-(3-methoxypropoxy)-7,7-dimethyl-2-oxo- 2,7,8, 9,10,10a-hexahydrodipyrido[2,l-a: ,2'-c]phthalazine-3-carboxylic acid is the slower eluting peak with a retention time of 1.32 min. XH NMR (400 MHz, Chloroform-d) δ 8.62 (s, 1H), 7.02 (s, 1H), 6.86 (s, 1H), 4.62 - 4.52 (m, 1H), 4.21 (t, 2H), 3.94 (s, 3H), 3.66 - 3.51 (m, 2H), 3.37 (s, 3H), 2.60 - 2.48 (m, 1H), 2.22 - 2.08 (m, 2H), 1.86 - 1.74 (m, 2H), 1.72 - 1.44 (m, 4H), 1.16 (s, 3H), 0.41 (s, 3H). MS (m/z) 443.2 [M+H]+. Example 54: (R)-ll-chloro-12-((3,3-difluorocyclobutyl)methoxy)-3,3-dimethyl-8-oxo- 2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid
Figure imgf000131_0001
(R)- 11 -Chloro- 12-((3 ,3 -difluorocy clobu^
lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid was prepared similarly to example 55 using (3,3-difluorocyclobutyl)methanol in place of 3-(trifluoromethoxy)propan-l-ol. XH NMR (400 MHz, Chloroform-d) δ 8.59 (s, IH), 7.82 (s, IH), 7.18 (s, IH), 6.82 (s, IH), 4.81 (d, IH), 4.18 - 4.08 (m, 2H), 2.89 - 2.69 (m, 2H), 2.68 - 2.47 (m, 2H), 2.42 - 2.34 (m, 4H), 1.99 - 1.87 (m, IH), 1.71 - 1.58 (m, IH), 1.39 (s, 3H), 0.69 (s, 3H).MS (m/z) 465.2 [M+H]+.
Example 55: (R)-ll-chloro-3,3-dimethyl-8-oxo-12-(3-(trifluoromethoxy)propoxy)- 2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid
- 4-
Figure imgf000132_0001
chlorophenyl)-2,2- dimethylpyrrolidin-1 -ol
Figure imgf000132_0002
5-(5-(benzyloxy)-2-bromo-4- 5-(5-(benzyloxy)-2-bromo-4- chlorophenyl)-2,2- chlorophenyl)-2,2- dimethylpyrrolidin-1 -ol dimethylpyrrolidine
5-(
Figure imgf000132_0003
5-(benzyloxy)-2-bromo-4- chlorophenyl)-2,2- 5-(5-(benzyloxy)-2-bromo-4- dimethylpyrrolidine chlorophenyl)-2,2-dimethyl-1 - nitrosopyrrolidine
Figure imgf000132_0004
5-(5-(benzyloxy)-2-bromo-4-
5-(5-(benzyloxy)-2-bromo-4- chlorophenyl)-2,2-dimethyl-1 - chlorophenyl)-2,2- nitrosopyrrolidine
dimethylpyrrolidin-1 -amine
Figure imgf000133_0001
5-(5-(benzyloxy)-2-bromo-4- ethyl (Z)-2- eth , 1 -(5-(5-(benzyloxy)-2- chlorophenyl)-2,2- ((dimethylamino)methylen bromo-4-c lorophenyl)-2,2- dimethylpyrrohdm-1 -amine e)-5,5-diethoxy-3- dimethylpyrrolidin-1 -yl)-4-oxo-1 ,4- oxopentanoate dihydropyridine-3-carboxylate
Figure imgf000133_0002
ethyl 1 -(5-(5-(benzyloxy)-2- ethyl 12-(benzyloxy)-11 -chloro- bromo-4-chlorophenyl)-2,2- 3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro- dimethylpyrrolidin-1 -yl)-4-oxo-1 ,4- 1 H- py rid o [2 , 1 - a] py rro I o
dihydropyridine-3-carboxylate [1 ,2-c]phthalazine-7-carboxylate
Figure imgf000133_0003
ethyl 12-(benzyloxy)-11 -chloro- methyl (R)-12-(benzyloxy)- 3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro- 11 -chloro-3,3-dimethyl-8-oxo-2, 3,8,13b-tetrahydro- 1 H- py rid o [2 , 1 - a] py rro lo
1 H- py rid o [2 , 1 - a] py rro lo
[1 ,2-c]phthalazine-7-carboxylate
[1 ,2-c]phthalazine-7-carboxylate
Synthesis of l-(benzyloxy)-4-bromo-2-chloro-5-iodobenzene: To an RB add 4-bromo-2- chloro-5-iodophenol (10 g, 30 mmol), potassium carbonate (20.7 g, 150 mmol), and DMF (124 ml). Allow the mixture to stir for 10 minutes, then add benzyl bromide (4.2 ml, 36 mmol) and continue stirring ovemight. Dilute the mixture with EtOAc, 5% LiCl solution, and brine. Wash the organic layer with 5% LiCl 2 times, dry organic layer over sodium sulfate, filter, and concentrate. The product was used crude in the next reaction. MS (m/z) 338.3 [M+H]+.
Synthesis of 5-(5-(benzyloxy)-2-bromo-4-chlorophenyl)-2,2-dimethylpyrrolidin-l-ol: To a RB add l-(benzyloxy)-4-bromo-2-chloro-5-iodobenzene (12.7 g, 30 mmol) and MeTHF (100 ml), cool the reaction to 0 C, then slowly add 1.3 M Isopropylmagnesium chloride lithium chloride complex solution (25.4 ml, 33 mmol) and stir for 10 minutes, then add 2,2-dimethyl- 3,4-dihydro-2H-pyrrole 1-oxide (4.9 g, 44 mmol) and stir for 10 minutes. Reaction was checked by LC/MS and was done. Quench reaction with saturated NH4C1 and extract 2X with EtOAc, dry the organics over sodium sulfate, concentrate and purify by flash column chromatography. MS (m/z) 410.9 [M+H]+. Synthesis of 5-(5-(benzyloxy)-2-bromo-4-chlorophenyl)-2,2-dimethylpyrrolidine: To a solution 5-(5-(benzyloxy)-2-bromo-4-chlorophenyl)-2,2-dimethylpyrrolidin-l-ol (7 g, 17 mmol) in TFA (102 ml) and water (41 ml) was added zinc powder (2.3 g, 35 mmol). The mixture was heated to 50 C until done about 30 minutes. The solution was concentrated under vacuum. The crude mixture was quenched with saturated sodium bicarbonate until fizzing stops. The product was extracted with DCM. The organic layer was washed with water, dried under Na2SC>4, filtered, and concentrated. The product was used crude in the next reaction. MS (m/z) 394.8 [M+H]+.
Synthesis of 5-(5-(benzyloxy)-2-bromo-4-chlorophenyl)-2,2-dimethyl-l-nitrosopyrrolidine: To a solution of 5-(5-(benzyloxy)-2-bromo-4-chlorophenyl)-2,2-dimethylpyrrolidine (6.7 g, 17 mmol) in THF (45 mL) was added an aqueous solution of NaN02 (2.8 g, 41 mmol in 22.6 mL of water) followed by acetic acid (2.4 mL, 43 mmol). The mixture was stirred at 50 C until done (about 1 hour). The reaction mixture was then diluted with EtOAc, washed with brine, dried with Na2S04, filtered, and concentrated. MS (m/z) 424.1 [M+H]+.
Synthesis of 5-(5-(benzyloxy)-2-bromo-4-chlorophenyl)-2,2-dimethylpyrrolidin-l-amine: To a solution of 5-(5-(benzyloxy)-2-bromo-4-chlorophenyl)-2,2-dimethyl-l-nitrosopyrrolidine (6.8 g, 16 mmol) in TFA (97 ml) and water (39 ml) was added zinc powder (2.6 g, 40 mmol). The mixture was heated to 50 C until done about 30 minutes. The solution was concentrated under vacuum. The crude mixture was quenched with saturated sodium bicarbonate until fizzing stops. The product was extracted with DCM. The organic layer was washed with water, dried under Na2SC>4, filtered, and concentrated. The product was used crude in the next reaction. MS (m/z) 410.0 [M+H]+.
Synthesis of ethyl l-(5-(5-(benzyloxy)-2-bromo-4-chlorophenyl)-2,2-dimethylpyrrolidin-l- yl)-4-oxo-l,4-dihydropyridine-3-carboxylate: To a solution of 5-(5-(benzyloxy)-2-bromo-4- chlorophenyl)-2,2-dimethylpyrrolidin-l-amine (6.6 g, 16 mmol) in EtOH (40 ml) was added ethyl (Z)-2-((dimethylamino)methylene)-5,5-diethoxy-3-oxopentanoate (6.9 g, 24 mmol). The mixture was heated to 60 C for 90 minutes after which water (2.5 ml) was added. The reaction was stirred overnight and checked for completion. The reaction was not complete so added TFA (0.3 ml). The crude mixture was diluted with brine and EtOAc, the aqueous layer was extracted 2X EtOAc. The organic layer was dried over Na2SC>4, filtered, and concentrated. The product was purified by flash column chromatography. MS (m/z) 559.8 [M+H]+.
Synthesis of ethyl 12-(benzyloxy)-ll-chloro-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH- pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate: Ethyl l-(5-(5-(benzyloxy)-2-bromo-4- chlorophenyl)-2,2-dimethylpyrrolidin-l-yl)-4-oxo-l,4-dihydropyridine-3-carboxylate (5.4 g, 10 mmol) was dissolved in DMA (80 niL) with potassium carbonate (3.3g, 23 mmol) under argon. Pd(OAc)2 (215 mg, 1 mmol), and (Oxydi-2,l-phenylene)bis(diphenylphosphine) (516 mg, 1 mmol) were added and the mixture was flushed with argon. The reaction was heated to 100 °C for 4 hours. Once cool dilute with EtOAc and brine, extract with EtOAc 2X, dry the organics over sodium sulfate, concentrate, and purify by flash column chromatography. MS (m/z) 479.8 [M+H]+.
Methyl (R)-12-(benzyloxy)-ll-chloro-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH- pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate: Ethyl 12-(benzyloxy)-l l-chloro-3,3- dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate was separated into its enantiomers by chiral SFC using an IA column with 30% methanol as the co-solvent. The R isomer has a Retention time of 3.81 min. Under the chiral separation conditions and concentration most of the ethyl ester was exchanged to the methyl ester. ΧΗ NMR (400 MHz, Chloroform-i ) δ 8.30 (s, 1H), 7.76 (s, 1H), 7.47 - 7.37 (m, 4H), 7.37 - 7.30 (m, 1H), 6.90 (s, 1H), 6.81 (s, 1H), 5.23 (s, 2H), 4.70 (d, 1H), 3.91 (s, 3H), 2.46 - 2.30 (m, 1H), 2.24 - 2.12 (m, 1H), 1.85 - 1.76 (m, 1H), 1.52 - 1.41 (m, 1H), 1.32 (s, 3H), 0.66 (s, 3H). MS (m/z) 465.4 [M+H]+.
Synthesis of methyl (R)-ll-chloro-12-hydroxy-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro- lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate:
Figure imgf000135_0001
methyl (R)-12-(benzyloxy)-1 1 -chloro- methyl (R)-1 1 -chloro-12-hydroxy-3,3- 3,3-dimethyl-8-oxo-2,3,8, 13b-tetrahydro- dimethyl-8-oxo-2, 3,8, 13b-tetrahydro- 1 H-pyrido[2, 1 -a]pyrrolo[1 ,2-c]phthalazine-7- 1 /-/-pyrido[2, 1 -a]pyrrolo[1 ,2- carboxylate c]phthalazine-7-carboxylate
Methyl (R)-12-(benzyloxy)-l l-chloro-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l- a]pyrrolo[l,2-c]phthalazine-7-carboxylate (795 mg, 1.7 mmol) was dissolved in ethanol (500 mL) and the solution was purged with argon. Palladium on carbon (10 wt%, wet, E101 NE/W, 109 mg) was added. The reaction was purged with argon, evacuated and refilled with hydrogen gas. The mixture was stirred vigorously under an atmosphere of hydrogen for 2 hours after which time LCMS analysis showed complete consumption of starting material. The reaction was purged with argon, diluted with ethyl acetate and filtered through celite. The solution was concentrated to methyl (R)-l l-chloro-12-hydroxy-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH- pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate. MS (m z) 375.2 [M+H]+. Synthesis of (R)-ll-chloro-3,3-dimethyl-8-oxo-12-(3-(trifluoromethoxy)propoxy)-2,3,8,13b- tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid
met
dim
Figure imgf000136_0001
c]phthalazine-7-carboxylate
To a vial add to methyl (R)-l l-chloro-12-hydroxy-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH- pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate (10 mg, 0.03 mmol), 3- (trifluoromethoxy)propan-l-ol (7.7 mg, 0.05 mmol), THF (1 ml), Diisopropyl Azodicarboxylate (11 μΐ, 0.06 mmol), and Triphenylphosphine, polymer-supported (79%, 18 mg, 0.05 mmol), stir overnight, then add 0.2 ml 2 M LiOH to hydrolyze ester, dilute with 1 ml DMF, filter off solids and purify by HPLC. XH NMR (400 MHz, Chloroform-d) δ 8.56 (s, 1H), 7.80 (s, 1H), 7.10 (s, 1H), 6.85 (s, 1H), 4.80 (d, 1H), 4.32 - 4.16 (m, 4H), 2.58 - 2.45 (m, 1H), 2.45 - 2.33 (m, 1H), 2.33 - 2.22 (m, 2H), 1.98 - 1.87 (m, 1H), 1.69 - 1.56 (m, 1H), 1.39 (s, 3H), 0.69 (s, 3H). MS (m/z) 487.2 [M+H]+.
Example 56: (R)-ll'-chloro-12'-(3-methoxypropoxy)-8'-oxo-l',2',8',13b'- tetrahydrospiro[cyclopropane-l,3'-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine]-7'-carboxylic acid
Figure imgf000136_0002
Synthesis of ethyl ll'-chloro-12'-(3-methoxypropoxy)-8'-oxo-l',2',8',13b'- tetrahydrospiro[cyclopropane-l,3'-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine]-7'-carboxylate: ethyl H'-chloro-12'-(3-methoxypropoxy)-8'-oxo-r,2',8',13b'-tetrahydrospiro[cyclopropane-l,3'- pyrido[2,l-a]pyrrolo[l,2-c]phthalazine]-7'-carboxylate was prepared similarly to example 1 using tert-butyl 4-oxo-5-azaspiro[2.4]heptane-5-carboxylate in place of \- tert- butoxycarbonyl)-2-pyrrolidinone. XH NMR (400 MHz, Chloroform-d) δ 8.10 (s, 1H), 7.73 (s, 1H), 6.88 (s, 1H), 6.80 (s, 1H), 4.75 (d, J = 5.7 Hz, 1H), 4.33 (dd, J = 7.1, 2.4 Hz, 2H), 4.25 - 4.13 (m, 2H), 3.60 (q, J = 6.1 Hz, 2H), 3.35 (s, 3H), 2.56 - 2.41 (m, 2H), 2.12 (t, J = 6.1 Hz, 3H), 1.73 (d, J = 12.7 Hz, 1H), 1.35 (t, J = 7.1 Hz, 3H), 0.59 (dt, J = 10.7, 6.9 Hz, 2H), 0.23 (d, J = 10.9 Hz, 1H), 0.10 (d, J = 10.3 Hz, 1H). MS (m/z) 459.323 [M+H]+.
(R)-ll-chloro-12-(3-methoxypropoxy)-l,l-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH- pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid: ethyl l l-chloro-12-(3- methoxypropoxy)-l,l-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2- c]phthalazine-7-carboxylate was separated into its enantiomers by chiral SFC chromatography using IA 5uM-4.6X150mm columns with 30% isopropanol as the co-solvent. The slower eluting peak was taken up in in EtOH (1 ml) and 2M LiOH (0.3 ml) then stirred at room temperature until hydrolysis was complete. The mixture was acidified with TFA (0.5 ml) and water (0.5 ml), filtered and purified by HPLC. 1H NMR (400 MHz, Chloroform-d) δ 8.39 (s, 1H), 7.79 (s, 1H), 7.01 (s, 1H), 6.92 (s, 1H), 4.81 (d, J = 5.9 Hz, 1H), 4.27 - 4.19 (m, 2H), 3.62 (d, J = 6.6 Hz, 2H), 3.37 (s, 3H), 2.64 - 2.49 (m, 2H), 2.15 (t, J = 6.0 Hz, 3H), 1.76 (d, J = 11.2 Hz, 1H), 0.65 (dd, J = 17.2, 9.4 Hz, 2H), 0.13 (td, J = 11.4, 11.0, 6.8 Hz, 2H). MS (m/z) 431.226 [M+H]+.
Example 57: (S)-ll'-chloro-12'-(3-methoxypropoxy)-8'-oxo-l',2',8',13b'- tetrahydrospiro[cyclopropane-l,3'-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine]-7'-carboxylic acid
Figure imgf000137_0001
Ethyl l l-chloro-12-(3-methoxypropoxy)-l,l-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH- pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate was separated into its enantiomers by chiral SFC chromatography using IA 5uM-4.6X150mm columns with 30% isopropanol as the co-solvent. The faster eluting peak was taken up in in EtOH (1 ml) and 2M LiOH (0.3 ml) then stirred at room temperature until hydrolysis was complete. The mixture was acidified with TFA (0.5 ml) and water (0.5 ml), filtered and purified by HPLC. 1H NMR (400 MHz, Chloroform-d) 5 8.39 (s, 1H), 7.79 (s, 1H), 7.01 (s, 1H), 6.92 (s, 1H), 4.81 (d, J = 5.9 Hz, 1H), 4.28 - 4.18 (m, 2H), 3.62 (d, J = 6.5 Hz, 2H), 3.37 (s, 3H), 2.54 (dd, J = 20.8, 7.9 Hz, 2H), 2.15 (t, J = 6.1 Hz, 3H), 1.83 - 1.73 (m, 1H), 0.65 (dd, J = 17.2, 9.4 Hz, 2H), 0.13 (td, J = 11.1, 7.0 Hz, 2H). MS (m/z) 431.204 [M+H]+. Example 58: (R)-ll-methoxy-3,3-dimethyl-8-oxo-12-(3-(trifluoromethoxy)propoxy)- 2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid
Figure imgf000138_0001
Ethyl (R)-12-hydroxy-l l-methoxy-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l- a]pyrrolo[l,2-c]phthalazine-7-carboxylate (26 mg, 68 μηιοΐ) was combined with 3- (trifluoromethoxy)propan-l-ol (18 mg, 130 μηιοΐ) and polymer-bound triphenylphosphine (100- 200 mesh, 3 mmol/g 45 mg) in tetrahydrofuran (0.8 mL). Diisopropyl azodicarboxylate (28 μΐ, 0.14 mmol) was added and the mixture was stirred at room temperature for 4 hours. After this time additional reagents were added: 3-(trifluoromethoxy)propan-l-ol (10 mg, 72 μηιοΐ), polymer-bound triphenylphosphine (100-200 mesh, 3 mmol/g 10 mg), and diisopropyl azodicarboxylate (10 μΐ, 51 μηιοΐ). The mixture was stirred at room temperature for 1 hour. 1M LiOH (200 μΐ) was added and the mixture was stirred at 45 °C for 10 minutes. The mixture was cooled to room temperature, diluted with TFA, and purified by preparative HPLC to provide (R)-l l-methoxy-3,3-dimethyl-8-oxo-12-(3-(trifluoromethoxy)propoxy)-2,3,8,13b-tetrahydro- lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid as a TFA salt. 1H NMR (400 MHz, Acetonitrile-d3) δ 8.43 (s, 1H), 7.39 (s, 1H), 7.24 (s, 1H), 6.96 (s, 1H), 4.84 (d, J = 6.2 Hz, 1H), 4.29 - 4.14 (m, 4H), 3.92 (s, 3H), 2.56 - 2.39 (m, 2H), 2.24 - 2.17 (m, 2H), 1.88 (ddd, J = 12.5, 7.9, 2.7 Hz, 1H), 1.61 (td, J = 12.2, 11.7, 7.8 Hz, 1H), 1.36 (s, 3H), 0.67 (s, 3H). 19F NMR (376 MHz, Acetonitrile-d3) δ -61.66 , -77.20 . MS (m/z) 483.2 [M+H]+.
Example 59: ll'-chloro-12'-(3-methoxypropoxy)-8'-oxo-l',2',8',13b'- tetrahydrospiro[cyclopropane-l,3'-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine]-7'-carboxylic acid
Figure imgf000139_0001
ll'-chloro-12'-(3-methoxypropoxy)-8'-oxo-l',2',8',13b'-tetrahydrospiro[cyclopropane-l,3'- pyrido[2,l-a]pyrrolo[l,2-c]phthalazine]-7'-carboxylic acid: Ethyl l l-chloro-12-(3- methoxypropoxy)-l,l-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2- c]phthalazine-7-carboxylate (2.8mg) was taken up in EtOH (1 ml), and 2M Li OH (0.3 ml) was added then stirred at room temperature until hydrolysis was complete. The mixture was acidified with IN HC1 to pH = 2 and water (5 ml) was added, filtered to collect product. After washed with water and dried to provide 2.5mg product. 1H NMR (400 MHz, Chloroform-d) δ 8.38 (s, 1H), 7.79 (s, 1H), 7.01 (s, 1H), 6.92 (s, 1H), 4.81 (d, J = 5.9 Hz, 1H), 4.27 - 4.20 (m, 2H), 3.61 (dt, J = 6.8, 5.7 Hz, 2H), 3.37 (s, 3H), 2.54 (dd, J = 20.5, 7.8 Hz, 2H), 2.15 (t, J = 6.0 Hz, 2H), 1.80 - 1.71 (m, 2H), 0.65 (ddd, J = 11.0, 8.7, 7.1 Hz, 2H), 0.13 (dd, J = 18.4, 11.0 Hz, 2H). MS (m/z) 431.2 [M+H]+.
Example 60: (R)-ll-methoxy-3,3-dimethyl-8-oxo-12-(3-(2,2,2-trifluoroethoxy)propoxy)- 2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid:
Figure imgf000139_0002
Ethyl (R)-12-hydroxy-l l-methoxy-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l- a]pyrrolo[l,2-c]phthalazine-7-carboxylate (34 mg, 88 μιτιοΐ) was combined with l-bromo-3- (2,2,2-trifluoroethoxy)propane (49 mg, 221 μιτιοΐ) and Potassium Carbonate (25 mg, 0.18 mmol) in DMF (0.4 mL). The mixture was stirred at 70 °C for 2.5 hours, and then cooled to room temperature. Aqueous 1M Lithium Hydroxide (334 μΐ) was added and the mixture was stirred at 30 °C for 30 minutes followed by stirring at 40 °C for 15 minutes. The mixture was cooled to room temperature, diluted with TFA, and purified by preparative HPLC to provide (R)-l 1- methoxy-3,3-dimethyl-8-oxo-12-(3-(2,2,2-trifluoroethoxy)propoxy)-2,3,8,13b-tetrahydro-lH- pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid as a TFA salt. 1H NMR (400 MHz, Acetonitrile-d3) δ 8.43 (s, 1H), 7.39 (s, 1H), 7.23 (s, 1H), 6.95 (s, 1H), 4.84 (d, J = 6.1 Hz, 1H), 4.29 - 4.10 (m, 2H), 3.96 (q, J = 9.2 Hz, 2H), 3.92 (s, 3H), 3.81 (t, J = 6.2 Hz, 2H), 2.55 - 2.37 (m, 2H), 2.10 (p, J = 6.2 Hz, 2H), 1.88 (ddd, J = 12.6, 7.8, 2.8 Hz, IH), 1.61 (td, J = 11.9, 11.5, 7.8 Hz, IH), 1.36 (s, 3H), 0.67 (s, 3H). 19F NMR (376 MHz, Acetonitrile-d3) δ -75.58 (t, J = 9.1 Hz), -77.29. MS (m/z) 497.2 [M+H]+.
Example 61: (R)-ll-methoxy-3,3-dimethyl-8-oxo-12-(3-phenoxypropoxy)-2,3,8,13b- tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid
Figure imgf000140_0001
61
Prepared analogously to (R)-l l-methoxy-3,3-dimethyl-8-oxo-12-(3-(2,2,2- trifluoroethoxy)propoxy)-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7- carboxylic acid in Example 60 using (3-bromopropoxy)benzene in place of l-bromo-3 -(2,2,2- trifluoroethoxy)propane. ¾ NMR (400 MHz, Acetonitrile-d3) δ 8.44 (s, IH), 7.38 (s, IH), 7.35 - 7.27 (m, 2H), 7.25 (s, IH), 6.99 - 6.88 (m, 4H), 4.81 (d, J = 6.2 Hz, IH), 4.41 - 4.24 (m, 2H), 4.18 (t, J = 6.1 Hz, 2H), 3.91 (s, 3H), 2.57 - 2.32 (m, 2H), 2.27 (p, J = 6.2 Hz, 2H), 1.87 (ddd, J = 12.6, 7.9, 2.7 Hz, IH), 1.60 (td, J = 12.1, 11.6, 7.8 Hz, IH), 1.35 (s, 3H), 0.66 (s, 3H). 19F NMR (376 MHz, Acetonitrile-d3) δ -77.33. MS (m/z) 491.2 [M+H]+.
Example 62: (R)-12-(3-ethoxypropoxy)-ll-methoxy-3,3-dimethyl-8-oxo-2,
tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid
Figure imgf000140_0002
Prepared analogously to (R)-l l-methoxy-3,3-dimethyl-8-oxo-12-(3-(2,2,2- trifluoroethoxy)propoxy)-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7- carboxylic acid in Example 60 using l-bromo-3 -ethoxypropane in place of l-bromo-3-(2,2,2- trifluoroethoxy)propane. ¾ NMR (400 MHz, Acetonitrile-d3) δ 8.43 (s, IH), 7.38 (s, IH), 7.23 (s, IH), 6.95 (s, IH), 4.84 (d, J = 6.2 Hz, IH), 4.26 - 4.10 (m, 2H), 3.92 (s, 3H), 3.58 (t, J = 6.2 Hz, 2H), 3.49 (q, J = 7.0 Hz, 2H), 2.58 - 2.36 (m, 2H), 2.04 (p, J = 6.3 Hz, 2H), 1.92 - 1.83 (m, 1H), 1.62 (td, J = 12.3, 11.7, 7.8 Hz, 1H), 1.36 (s, 3H), 1.16 (t, J = 7.0 Hz, 3H), 0.67 (s, 3H). 19F NMR (376 MHz, Acetonitrile-d3) δ -77.33. MS (m/z) 443.2 [M+H]+. Example 63: (i?)-ll-Ethyl-12-(3-methoxypropoxy)-3,3-dimethyl-8-oxo-2,3,8,13b- tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid
Figure imgf000141_0001
car oxy a e
Synthesis of (R)-ll-ethyl-12-(3-methoxypropoxy)-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro- lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid: Ethyl (R)-12-(3- methoxypropoxy)-3,3-dimethyl-8-oxo-l l-(((trifluoromethyl)sulfonyl)oxy)-2,3,8,13b-tetrahydro- lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate (175 mg, 0.305 mmol) and [Ι,Γ- Bis(diphenylphosphino)ferrocene]palladium(II) dichloride (22 mg, 0.030 mmol) were suspended in DME and treated with diethyl zinc (1.1 M in PhMe, 1.4 mL, 1.5 mmol). The resulting solution was stirred at 85 °C o/n. Upon completion, the reaction mixture was cooled to RT and diluted with DCM. The organic suspension was washed with 10% HC1. The aqueous layer was then back extracted with DCM. The combined organics were dried over MgSC>4, filtered and concentrated under reduced pressure. The crude residue was purified by HPLC to provide the title compound. 'H NMR (400 MHz, Chloroform-i ) δ 8.57 (s, 1H), 7.56 (s, 1H), 7.25 (s, 1H), 6.75 (s, 1H), 4.81 (d, J = 5.8 Hz, 1H), 4.29 - 4.00 (m, 2H), 3.59 (q, J = 5.6 Hz, 2H), 3.37 (s, 3H), 2.68 (p, J = 7.2 Hz, 2H), 2.44 (p, J = 10.5, 9.5 Hz, 2H), 2.11 (t, J = 6.1 Hz, 2H), 1.89 (ddd, J = 12.6, 7.5, 2.7 Hz, 1H), 1.64 (ddd, J = 12.7, 10.9, 7.8 Hz, 1H), 1.41 (s, 3H), 1.24 (t, J = 7.5 Hz, 3H), 0.66 (s, 3H). MS (m/z) 427.3 [M+H]+.
Example 64: (R)-ll-methoxy-12-(3-methoxy-3-methylbutoxy)-3,3-dimethyl-8-oxo- 2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid
Figure imgf000142_0001
Prepared analogously to (R)-l l-methoxy-3,3-dimethyl-8-oxo-12-(3-(2,2,2- trifluoroethoxy)propoxy)-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7- carboxylic acid in Example 60 using l-bromo-3-methoxy-3-methylbutane in place of 1-bromo- 3-(2,2,2-trifluoroethoxy)propane. 'H NMR (400 MHz, Acetonitrile-d3) δ 8.43 (s, 1H), 7.37 (s, 1H), 7.23 (s, 1H), 6.97 (s, 1H), 4.84 (d, J = 6.3 Hz, 1H), 4.29 - 4.12 (m, 2H), 3.91 (s, 3H), 3.20 (s, 3H), 2.59 - 2.37 (m, 2H), 2.02 (t, J = 7.3 Hz, 2H), 1.89 (ddd, J = 12.6, 7.9, 2.7 Hz, 1H), 1.63 (td, J = 11.4, 7.8 Hz, 1H), 1.36 (s, 3H), 1.24 (d, J = 1.2 Hz, 6H), 0.67 (s, 3H). 19F NMR (376 MHz, Acetonitrile-d3) δ -77.31. MS (m/z) 457.3 [M+H]+.
Example 65: (R)-12-(3-(tert-butoxy)propoxy)-ll-methoxy-3,3-dimethyl-8-oxo-2,3,8,13b- tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid
Figure imgf000142_0002
Prepared analogously to (R)-l l-methoxy-3,3-dimethyl-8-oxo-12-(3-(2,2,2- trifluoroethoxy)propoxy)-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7- carboxylic acid in Example 60 using l-bromo-3-(tert-butoxy)propane in place of l-bromo-3- (2,2,2-trifluoroethoxy)propane. ¾ NMR (400 MHz, Acetonitrile-d3) δ 8.44 (s, 1H), 7.38 (s, 1H), 7.25 (s, 1H), 6.96 (s, 1H), 4.84 (d, J = 6.2 Hz, 1H), 4.28 - 4.10 (m, 2H), 3.92 (s, 3H), 3.53 (t, J = 6.1 Hz, 2H), 2.58 - 2.36 (m, 2H), 2.01 - 1.97 (m, 2H), 1.89 (ddd, J = 12.6, 7.8, 2.7 Hz, 1H), 1.62 (td, J = 12.3, 11.7, 7.8 Hz, 1H), 1.36 (s, 3H), 1.17 (s, 9H), 0.67 (s, 3H). 19F NMR (376 MHz, Acetonitrile-d3) δ -77.34. MS (m/z) 471.3 [M+H]+. Example 66: (R)-ll-cyclopropyl-3,3-dimethyl-12-(oxetan-3-ylmethoxy)-8-oxo-2,3,8,13b- tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid
Figure imgf000143_0001
methyl (R)-12-(benzyloxy)-1 1 - methyl (R)-12-(benzyloxy)-1 1 - chloro-3,3-dimethyl-8-oxo- cyclopropyl-3,3-dimethyl-8-oxo- 2,3,8, 13b-tetrahydro-1 H- 2,3,8, 13b-tetrahydro-1 H- pyrido[2, 1 -a]pyrrolo[1 ,2- pyrido[2, 1 -a]pyrrolo[1 ,2- c]phthalazine-7-carboxylate c]phthalazine-7-carboxylate
Figure imgf000143_0002
methyl (R)-1 1 -cyclopropyl-12- hydroxy-3,3-dimethyl-8-oxo- 2,3,8, 13b-tetrahydro-1 H- pyrido[2, 1 -a]pyrrolo[1 ,2- c]phthalazine-7-carboxylate
Synthesis of methyl (R)-12-(benzyloxy)-ll-cyclopropyl-3,3-dimethyl-8-oxo-2,3,8,13b- tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate: To a solution of methyl (R)-12-(benzyloxy)-l l-chloro-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l- a]pyrrolo[l,2-c]phthalazine-7-carboxylate (542 mg, 1.17 mmol) in toluene/water (4ml/0.5ml), was added cyclopropylboronic acid (500.7 mg, 5.83 mmol), tricyclohexylphosphonium tetrafluoroborate (244 mg) , palladium (II) acetate (37 mg) and potassium phosphate tribasic (
742 mg). The reaction mixture was degassed and filled with argon. After heating for 30 min at
135°C, the mixture was cooled to rt, diluted with EtOAc, and washed with brine. The organic layer was dried over MgSC>4, filtered and concentrated under reduced pressure. The crude residue was purified by silica column chromatography (0% to 20% MeOH/EtOAc) to provide
385mg of methyl (R)-12-(benzyloxy)-l l-cyclopropyl-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro- lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate. MS (m/z) 471.466 [M+H]+.
Synthesis of (R)-12-(3-methoxypropoxy)-3,3-dimethyl-ll-(oxetan-3-yl)-8-oxo-2,3,8,13b- tetrahydro-lH-pyrido[2,l-a] pyrrolo [1,2-c] phthalazine-7-carboxylic acid: (R)- 12-(3- methoxypropoxy)-3,3-dimethyl-l l-(oxetan-3-yl)-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l- a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid was prepared similarly to Example 55 by first debenzylation and then misunobu reaction using oxetan-3-yl-methanol. XH NMR (400 MHz, Chloroform-d) δ 8.53 (s, 1H), 7.05 (s, 1H), 6.74 (s, 1H), 4.93 (t, J = 7.0 Hz, 2H), 4.79 (d, J = 6.1 Hz, 1H), 4.65 (d, J = 6.1 Hz, 2H), 4.33 (d, J = 7.4 Hz, 1H), 4.27 (d, J = 7.0 Hz, 1H), 3.58 - 3.47 (m, 1H), 2.54 - 2.37 (m, 2H), 2.20 - 2.10 (m, 1H), 1.94 - 1.85 (m, 1H), 1.67 - 1.56 (m, 3H), 1.37 (s, 3H), 1.01 (d, J = 8.5 Hz, 2H), 0.66 (s, 3H). MS (m/z) 437.3 [M+H]+.
Example 67: (R)-13-fluoro-ll-methoxy-12-(3-methoxypropoxy)-3,3-dimethyl-8-oxo- 2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid
Figure imgf000144_0001
Synthesis of methyl (R)-13-fluoro-12-hydroxy-ll-methoxy-3,3-dimethyl-8-oxo-2,3,8,13b- tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate: Methyl (R)-12- hydroxy-l l-methoxy-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2- c]phthalazine-7-carboxylate (30 mg, 81 μηιοΐ), N-fluorobenzenesulfonimide (38 mg, 0.12 mmol), and sodium bicarbonate (30 mg) were combined in 1,2-DCE (1 mL) and heated at 80 °C for 2 hours. The mixture was cooled to room temperature, filtered, and concentrated to dryness. The residue was redissolved in ACN/water and purified by preparative HPLC to provide methyl (R)-13-fluoro-12-hydroxy-l l-methoxy-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l- a]pyrrolo[l,2-c]phthalazine-7-carboxylate. ¾ NMR (400 MHz, Acetonitrile-d3) δ 8.30 (d, J = 1.0 Hz, 1H), 7.70 (s, 1H), 6.97 (d, J = 1.0 Hz, 1H), 4.73 (d, J = 5.8 Hz, 1H), 3.93 (s, 3H), 3.83 (s, 3H), 2.45 - 2.28 (m, 2H), 1.87 - 1.76 (m, 1H), 1.57 (td, J = 11.7, 7.9 Hz, 1H), 1.33 (s, 3H), 0.66 (s, 3H). MS (m/z) 389.2 [M+H]+.
(R)-13-fluoro-ll-methoxy-12-(3-methoxypropoxy)-3,3-dimethyl-8-oxo-2,3,8,13b- tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid. Prepared analogously to (R)-l l-methoxy-3,3-dimethyl-8-oxo-12-(3-(2,2,2-trifluoroethoxy)propoxy)-
2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid in Example 60 using l-bromo-3-methoxypropane in place of l-bromo-3-(2,2,2-trifluoroethoxy)propane and methyl (R)-13-fluoro-12-hydroxy-l l-methoxy-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH- pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate in place of ethyl (R)-12-hydroxy-l l- methoxy-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7- carboxylate. ¾ NMR (400 MHz, Acetonitrile-d3) δ 8.46 (d, J = 1.0 Hz, 1H), 7.71 (s, 1H), 7.04 (s, 1H), 4.81 (d, J = 6.1 Hz, 1H), 4.31 - 4.10 (m, 2H), 3.89 (s, 3H), 3.54 (td, J = 6.2, 0.9 Hz, 2H), 3.32 (s, 3H), 2.57 - 2.35 (m, 2H), 2.06 (p, J = 6.3 Hz, 2H), 1.93 - 1.82 (m, 1H), 1.66 - 1.52 (m, 1H), 1.36 (s, 3H), 0.65 (s, 3H). 19F NMR (376 MHz, Acetonitrile-d3) δ -77.08 , -146.50. MS (m/z) 447.3 [M+H]+.
Example 68: (R)-12-(imidazo[l,2-b]pyridazin-3-ylethynyl)-ll-methoxy-3,3-dimethyl-8-oxo- 2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid
Figure imgf000145_0001
Prepared analogously to (R)-l l-methoxy-3,3-dimethyl-12-((l-methyl-lH-imidazol-5- yl)ethynyl)-8-oxo-2,3,8,13btetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid in example 42 using 3-ethynylimidazo[l,2-b]pyridazine in place of 5-ethynyl-l-methyl-lH- imidazole. 'H NMR (400 MHz, Acetonitrile-d3) δ 8.69 - 8.59 (m, 1H), 8.49 (s, 1H), 8.17 (dd, J = 9.3, 1.6 Hz, 1H), 8.12 (s, 1H), 7.63 (d, J = 1.0 Hz, 1H), 7.52 (s, 1H), 7.43 - 7.35 (m, 2H), 4.88 (d, J = 6.1 Hz, 1H), 4.05 (s, 3H), 2.59 - 2.38 (m, 1H), 1.94 - 1.87 (m, 2H), 1.67 (td, J = 12.4,
11.7, 8.3 Hz, 1H), 1.38 (s, 3H), 0.69 (s, 3H). 19F NMR (376 MHz, Acetonitrile-d3) δ -77.27. MS (m/z) 482.1 [M+H]+.
Example 69: (R)-12-(3-methoxypropoxy)-3,3-dimethyl-ll-(methylsulfonyl)-8-oxo- 2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid
Figure imgf000146_0001
4-(benzyloxy)-l-bromo-2-iodobenzene: 4-bromo-3-iodophenol (16.35 g, 54.7 mmol), benzyl bromide (8.45 ml, 71.1 mmol), and potassium carbonate, anhydrous (10.58 g, 76.58 mmol) were combined in DMF (100 ml) and stirred overnight at 50 °C. The following day the reaction was warmed to 80 °C for 4 hours. The reaction was cooled to room temperature, diluted with water (100 mL) and extracted with EtOAc/Et20 (100 mL). The combined organic layers were rinsed with aqueous sodium bicarbonate (50 mL), then brine (50 mL), dried over sodium sulfate, filtered, concentrated, and purified by flash column chromatography to provide 4-(benzyloxy)-l- bromo-2-iodobenzene. Ti NMR (400 MHz, Chloroform-d) δ 7.49 (d, J = 3.0 Hz, 1H), 7.47 (d, J = 8.8 Hz, 1H), 7.42 - 7.30 (m, 5H), 6.83 (dd, J = 8.9, 2.9 Hz, 1H), 5.01 (s, 2H). MS (m/z) 390.9 [M+H]+.
Ethyl 12-(benzyloxy)-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l- a]pyrrolo[l,2-c]phthalazine-7-carboxylate: Ethyl 12-(benzyloxy)-3,3-dimethyl-8-oxo- 2,3,8, 13b-tetrahydro-lH-pyrido[2, l -a]pyrrolo[l ,2-c]phthalazine-7-carboxylate was prepared similarly to ethyl l l -(benzyloxy)-12-(3-methoxypropoxy)-3,3-dimethyl-8-oxo-
2,3,8, 13btetrahydro-lH-pyrido[2, l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate in example 18. XH NMR (400 MHz, Acetonitrile-d3) δ 8.20 (s, 1H), 7.82 (d, J = 8.7 Hz, 1H), 7.54 - 7.46 (m, 2H), 7.46 - 7.32 (m, 3H), 7.10 - 6.98 (m, 2H), 6.77 (s, 1H), 5.20 (dd, J = 1 1.6, 2.0 Hz, 2H), 4.79 (d, J = 5.9 Hz, 1H), 4.32 - 4.18 (m, 2H), 2.48 - 2.32 (m, 2H), 1.83 (ddd, J = 12.6, 7.6, 3.3 Hz, 1H), 1.56 (ddd, J = 12.6, 10.3, 8.2 Hz, 1H), 1.36 - 1.28 (m, 6H), 0.66 (s, 3H). MS (m/z) 445.5
[M+H]+.
Ethyl 12-hydroxy-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2- c]phthalazine-7-carboxylate: Ethyl 12-(benzyloxy)-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro- lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate (3.5 g, 7.9 mmol) and palladium on carbon (10wt%, wet) E101 NEAV (5%, 838 mg) were combined in EtOH (50 mL) under argon. The system was placed under vacuum and backfilled with hydrogen gas. The mixture was stirred vigorously for 30 minutes after which time LCMS analysis showed complete conversion. The mixture was diluted with EtOAc (50 mL) and filtered through celite. The supernatant was discarded. The wet cake, containing the desired product was rinsed with 3 x 100 mL hot
DCM/EtOH. The resulting supernatant was concentrated in vacuo to provide ethyl 12-hydroxy- 3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7- carboxylate. ¾ NMR (400 MHz, Chloroform-d) δ 8.35 (s, 1H), 7.53 (d, J = 8.8 Hz, 1H), 7.02 (dd, J = 8.6, 2.3 Hz, 1H), 6.93 (d, J = 2.7 Hz, 2H), 4.70 (d, J = 5.9 Hz, 1H), 4.37 (qd, J = 7.2, 1.8 Hz, 2H), 2.47 - 2.28 (m, 2H), 1.88 - 1.73 (m, 1H), 1.62 (td, J = 11.3, 7.9 Hz, 1H), 1.37 (t, J = 7.1 Hz, 3H), 1.33 (s, 3H), 0.66 (s, 3H). MS (m/z) 355.2 [M+H]+.
Ethyl ll-iodo-12-(3-methoxypropoxy)-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH- pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate: Ethyl 12-hydroxy-3,3-dimethyl-8-oxo- 2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate (2.44 g, 6.89 mmol) was suspended in EtOH (70 mL). 1M NaOH (7.57 ml) was added and the mixture was cooled to 0 °C. N-iodosuccinimide (1.63 g, 7.23 mmol) in ethanol (20 mL) was added dropwise over 5 minutes. After 20 minutes, the reaction was quenched with aq Na2S203 (10 mL). The mixture was stirred overnight, allowing to slowly warm to room temperature. The reaction was diluted with ethyl acetate ( 50 mL) and sat aq NH4C1 (10 mL). The layers were separated, the organics were rinsed with brine (20 mL), and the combined aqueous layers were back extracted with ethyl acetate (50 mL). The combined organics were dried over magnesium sulfate, filtered, and concentrated in vacuo. The resulting crude solids were combined with l-bromo-3- methoxypropane (1.7g, 11 mmol) and potassium carbonate (1.9 g, 14 mmol) in DMF (11 mL). The mixture was stirred at 65 °C for 130 minutes. The mixture was cooled to rt, diluted with isopropyl acetate (50 mL) and water (30 mL). The layers were separated and the organic layer was rinsed with aq NaHCC (20 mL), then brine (20 mL), then dried over sodium sulfate, filtered, and concentrated in vacuo. The reaction was purified by flash column chromatography to provide ethyl l l-iodo-12-(3-methoxypropoxy)-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH- pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate. ¾ NMR (400 MHz, Chloroform-d) δ 8.28 (s, 1H), 8.15 (s, 1H), 6.94 (s, 1H), 6.68 (s, 1H), 4.71 (d, J = 6.3 Hz, 1H), 4.38 (q, J = 7.1 Hz, 2H), 4.22 - 4.07 (m, 2H), 3.75 - 3.57 (m, 2H), 3.38 (s, 3H), 2.51 - 2.27 (m, 2H), 2.13 (p, J = 6.1 Hz, 2H), 1.85 (dd, J = 12.1, 8.7 Hz, 1H), 1.70 - 1.55 (m, 1H), 1.39 (t, J = 7.2 Hz, 3H), 1.34 (s, 3H), 0.70 (s, 3H). MS (m/z) 553.4 [M+H]+.
Ethyl (R)-ll-iodo-12-(3-methoxypropoxy)-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH- pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate: Ethyl 1 l-iodo-12-(3- methoxypropoxy)-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2- c]phthalazine-7-carboxylate was separated into its enantiomers by chiral SFC chromatography using OD-H 4.6X100mm columns with 30% isopropanol as the co-solvent. The (i?)-enantiomer is the slower eluting peak with a retention time of 3.52 min. MS (m/z) 553.3 [M+H]+.
Synthesis of (R)-12-(3-methoxypropoxy)-3,3-dimethyl-ll-(methylsulfonyl)-8-oxo-2,3,8,13b- tetrahydro-l -pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid
Figure imgf000148_0001
Ethyl (R)-l l-iodo-12-(3-methoxypropoxy)-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH- pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate (39 mg, 71 umol) was combined with 1,4- diazabicyclo[2.2.2]octane bis(sulfur dioxide) adduct (10 mg, 42 umol), palladium (II) acetate (0.95 mg, 4.24 μηιοΐ), and butyldi-l-adamantylphosphine (2.33 mg, 6.5 μηιοΐ) in isopropanol (0.5 mL) and triethylamine (30 μί, 212 μηιοΐ) under argon. The mixture was warmed to 80 °C and stirred for 2.5 hours. The mixture was cooled to 40 °C and iodomethane (13 μΐ, 0.21 mmol) was added. After 30 minutes, 1M LiOH (0.2 mL) was added and the mixture was stirred at 40 °C. After an additional 10 minutes, the mixture was diluted with aq TFA (1M) and purified by preparative HPLC to provide (R)-12-(3-methoxypropoxy)-3,3-dimethyl-l l-(methylsulfonyl)-8- oxo-2,3, 8, 13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid as a TFA salt. l NMR (400 MHz, Acetonitrile-d3) δ 8.45 (s, 1H), 8.37 (s, 1H), 7.21 (s, 2H), 4.92 (d, J = 6.3 Hz, 1H), 4.47 - 4.29 (m, 2H), 3.60 (t, J = 6.0 Hz, 2H), 3.32 (s, 3H), 3.24 (s, 3H), 2.59 - 2.49 (m, 1H), 2.12 (p, J = 6.1 Hz, 2H), 1.94 - 1.86 (m, 1H), 1.69 - 1.59 (m, 1H), 1.37 (s, 3H), 0.67 (s, 3H). 19F NMR (376 MHz, Acetonitrile-d3) δ -77.11. MS (m/z) 377.3 [M+H]+. Example 70: (R)-12-(3-hydroxy-3-methylbut-l-yn-l-yl)-ll-(methoxymethyl)-3,3-dimethyl- 8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid
Figure imgf000149_0001
An 80:20 mixture of ethyl (R)-l l-chloro-3,3-dimethyl-8-oxo-12-
(((trifluoromethyl)sulfonyl)oxy)-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2- c]phthalazine-7-carboxylate and methyl (R)-l l-chloro-3,3-dimethyl-8-oxo-12- (((trifluoromethyl)sulfonyl)oxy)-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2- c]phthalazine-7-carboxylate (129 mg, -0.25 mmol) was combined with Pd(tBu2PPh)2Cl2 (14 mg, 0.020 mmol), Cul (7.0 mg, 0.037 mmol), and 2-methylbut-3-yn-2-ol (72 μΐ, 0.74 mmol) in acetonitrile/triethylamine (3: 1, 1 mL) under argon. The mixture was stirred at 60 °C for 30 minutes after which time LCMS analysis showed complete conversion. The crude mixture was concentrated to dryness, redissolved in DMF/MeCN, diluted with aq TFA (1M) and purified by preparative HPLC to provide ethyl (R)-l l-chloro-12-(3-hydroxy-3-methylbut-l-yn-l-yl)-3,3- dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate: MS (m/z) 455.3 [M+H]+; and methyl (R)-l l-chloro-12-(3-hydroxy-3-methylbut-l-yn-l-yl)-3,3- dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate: MS (m/z) 441.4 [M+H]+. Ethyl (R)-l l-chloro-12-(3-hydroxy-3-methylbut-l-yn-l-yl)-3,3- dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate (53 mg, 0.093 mmol) was combined with trifluoro(methoxymethyl)-borane, potassium salt (40 mg, 0.26 mmol), Ruphos Pd G2 (5.1 mg, 0.007 mmol), and potassium carbonate (52 mg, 0.37 mmol) in dioxane:water (5: 1, ImL) under argon in a sealed vial. The mixture was stirred at 110 °C for 2.5 hours, after which time it was cooled to 50 °C and 1M lithium hydroxide (0.19 ml) was added. The mixture was stirred for 90 minutes, then cooled to room temperature, diluted with TFA and acetonitrile, and purified by preparative HPLC to provide (R)-12-(3-hydroxy-3- methylbut- 1 -yn-1 -yl)- 11 -(methoxymethyl)-3,3-dimethyl-8-oxo-2,3,8, 13b-tetrahydro- 1H- pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid as a TFA salt. XH NMR (400 MHz, Acetonitrile-d3) δ 8.47 (s, 1H), 8.01 (s, 1H), 7.50 (d, J = 1.1 Hz, 1H), 7.29 (s, 1H), 4.88 (d, J = 5.9 Hz, 1H), 4.62 (t, J = 0.8 Hz, 2H), 3.47 (s, 3H), 2.60 - 2.43 (m, 2H), 1.94 - 1.86 (m, 1H), 1.67 - 1.60 (m, 1H), 1.58 (s, 6H), 1.37 (s, 3H), 0.63 (s, 3H). iyF NMR (376 MHz, Acetonitrile- d3) δ -77.28 . MS (m/z) 437.2 [M+H]+.
Example 71: (R)-ll-cyclopropyl-12-(3-hydroxy-3-methylbut-l-yn-l-yl)-3,3-dimethyl-8-oxo- 2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid
Figure imgf000150_0001
A mixture of ethyl (R)-l l-chloro-12-(3-hydroxy-3-methylbut-l-yn-l-yl)-3,3-dimethyl-8-oxo- 2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate (28 mg, 0.062 mmol) and methyl (R)-l l-chloro-12-(3-hydroxy-3-methylbut-l-yn-l-yl)-3,3-dimethyl-8-oxo- 2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate (25 mg, 0.057 mmol) was combined with cyclopropylboronic acid MIDA ester (51 mg, 0.26 mmol), Ruphos Pd G2 (5.1 mg, 0.007 mmol), and potassium carbonate (52 mg, 0.37 mmol) in dioxane:water (5: 1, lmL) under argon in a sealed vial. The mixture was stirred at 110 °C for 1 hour. The mixture was cooled to 50 °C and 1M lithium hydroxide (0.09 ml) was added. After 2 hours, the mixture was cooled to room temperature, diluted with TFA and acetonitrile, and purified by preparative HPLC to provide (R)-l l-cyclopropyl-12-(3-hydroxy-3-methylbut-l-yn-l-yl)-3,3- dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid as a TFA salt. lH NMR (400 MHz, Acetonitrile-d3) δ 8.45 (s, 1H), 7.45 (d, J = 1.0 Hz, 1H), 7.38 (s, 1H), 7.33 (s, 1H), 4.84 (d, J = 6.0 Hz, 1H), 2.53 - 2.34 (m, 3H), 1.89 (ddd, J = 12.7, 7.7, 3.1 Hz, 1H), 1.67 - 1.59 (m, 1H), 1.59 (s, 6H), 1.36 (s, 3H), 1.17 - 1.04 (m, 2H), 0.95 - 0.84 (m, 2H), 0.61 (s, 3H). 19F NMR (376 MHz, Acetonitrile-d3) δ -77.32. MS (m/z) 433.2 [M+H]+.
Example 72: (R)-ll-cyclopropyl-12-(3-methoxy-3-methylbut-l-yn-l-yl)-3,3-dimethyl-8- oxo-2,3,8,13b-tetrahydro-lH-py thalazine-7-carboxylic acid
Figure imgf000150_0002
Prepared similarly to (R)-l l-cyclopropyl-12-(3-hydroxy-3-methylbut-l-yn-l-yl)-3,3-dimethyl- 8-oxo-2,3, 8, 13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid in example 71, using 3-methoxy-3-methylbut-l-yne in place of 2-methylbut-3-yn-2-ol. 'H NMR (400 MHz, Methanol-c 4) δ 8.60 (s, 1H), 7.54 - 7.48 (m, 2H), 7.41 (s, 1H), 4.87 (d, J = 6.2 Hz, 1H), 3.44 (s, 3H), 2.57 - 2.43 (m, 2H), 1.93 (ddd, J= 12.8, 7.8, 2.6 Hz, 1H), 1.64 (td, J= 12.1, 11.6, 7.9 Hz, 1H), 1.57 (s, 6H), 1.39 (s, 3H), 1.14 - 1.06 (m, 2H), 0.89 (dt, J = 5.6, 3.5 Hz, 2H), 0.63 (s, 3H). MS (m/z) 447.3 [M+H]+
Example 73: (R)-ll-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-oxo- 2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid
Figure imgf000151_0001
Synthesis of ethyl 12-(benzyloxy)-ll-(methoxymethyl)-3,3-dimethyl-8-oxo-2,3,8,13b- tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate: Ethyl 12-(benzyloxy)- l l-chloro-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine- 7-carboxylate (737 mg, 1.54 mmol) was combined with trifluoro(methoxymethyl)-borane, potassium salt (701 mg, 4.62 mmol), Pd RuPhos G3 (154 mg, 0.185 mmol), RuPhos (129 mg, 0.28 mmol), and cesium carbonate (2.51 g, 7.69 mmol) in toluene:water (3: 1, 10 mL) under argon in a sealed vial. The mixture was heated at 110 °C for 90 minutes with vigorous stirring, then cooled to room temperature, the aqueous layer was removed, and the organics were concentrated in vacuo and purified by flash column chromatography (hexanes / ethyl acetate / ethanol / triethylamine) to provide ethyl 12-(benzyloxy)-l l-(methoxymethyl)-3,3-dimethyl-8- oxo-2,3, 8, 13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate. 'H NMR (400 MHz, Chloroform-d) δ 8.27 (s, 1H), 7.84 (s, 1H), 7.45 - 7.30 (m, 5H), 7.00 (s, 1H), 6.75 (s, 1H), 5.24 - 5.08 (m, 2H), 4.77 - 4.68 (m, 1H), 4.60 - 4.47 (m, 2H), 4.38 (q, J = 7.1 Hz, 2H), 3.51 (s, OH), 3.50 - 3.44 (m, 3H), 2.47 - 2.32 (m, 1H), 2.25 (t, J = 10.3 Hz, 1H), 1.79 (dd, J = 11.7, 8.9 Hz, 1H), 1.54 - 1.45 (m, 1H), 1.39 (t, J = 7.1 Hz, 3H), 1.32 (s, 3H), 0.67 (s, 3H). MS (m/z) 489.5 [M+H]+.
Synthesis of ethyl (R)-12-(benzyloxy)-ll-(methoxymethyl)-3,3-dimethyl-8-oxo-2,3,8,13b- tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate: Ethyl 12-(benzyloxy)- l l-(methoxymethyl)-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2- c]phthalazine-7-carboxylate was separated into its enantiomers by chiral SFC chromatography using AD-H 4.6X100mm columns with 30% isopropanol as the co-solvent. The (i?)-enantiomer is the faster eluting peak with a retention time of 5.18 min. MS (m/z) 489.5 [M+H]+.
Synthesis of ethyl (R)-12-hydroxy-ll-(methoxymethyl)-3,3-dimethyl-8-oxo-2,3,8,13b- tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate: Ethyl (R)-12-
(benzyloxy)-l l-(methoxymethyl)-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l- a]pyrrolo[l,2-c]phthalazine-7-carboxylate (288 mg, 589 μηιοΐ) was combined with palladium on carbon (10wt%, wet) E101 NEAV (5%, 63 mg) in ethanol (10 mL) under argon. The system was placed under vacuum and backfilled with hydrogen gas. The mixture was stirred vigorously for 55 minutes. The mixture was diluted with DCM (50 mL) and filtered through celite. The supernatant was concentrated to provide ethyl (R)-12-hydroxy-l l-(methoxymethyl)-3,3- dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate. MS (m/z) 399.3 [M+H]+.
Synthesis of (R)-ll-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-oxo- 2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid: Ethyl (R)-12-hydroxy-l l-(methoxymethyl)-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l- a]pyrrolo[l,2-c]phthalazine-7-carboxylate (82 mg, 210 μιτιοΐ) was combined with potassium carbonate (71 mg, 0.52 mmol) and l-bromo-3-methoxypropane (63 mg, 0.41 mmol) in DMF (0.8 mL) and stirred at 85 °C for 30 minutes, after which time LCMS analysis showed complete conversion. The mixture was cooled to room temperature and filtered, rinsing forward with acetonitrile (3 x 0.3 mL). 1M lithium hydroxide (0.4 mL) was added and the mixture was stirred at room temperature overnight. The reaction was diluted with 1M TFA purified by preparative HPLC to provide (R)-l l-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-oxo- 2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid as a TFA salt. lH NMR (400 MHz, Acetonitrile-c¾) δ 8.45 (s, 1H), 7.90 (s, 1H), 7.21 (s, 1H), 6.98 (s, 1H), 4.87 (d, J= 6.3 Hz, 1H), 4.56 - 4.42 (m, 2H), 4.20 (ddt, J= 27.5, 9.6, 6.2 Hz, 2H), 3.56 (t, J= 6.2 Hz, 2H), 3.43 (s, 3H), 3.32 (s, 3H), 2.63 - 2.39 (m, 2H), 2.05 (p, J = 6.2 Hz, 2H), 1.90 (ddd, J = 12.7, 8.0, 2.9 Hz, 1H), 1.62 (ddd, J = 12.7, 10.6, 7.9 Hz, 1H), 1.36 (s, 3H), 0.64 (s, 3H). 19F NMR (376 MHz, Acetonitrile-c¾) δ -77.30. MS (m/z) 443.5 [M+H]+. Example 74: (R)-12-((3-cyanobicyclo[l.l.l]pentan-l-yl)methoxy)-ll-(methoxymethyl)-3,3- dimethyl-8-oxo-2,3,8,13b-tetrahydro- lH-pyrido [2,1-a] pyrrolo [ 1,2-c] phthalazine-7- carboxylic aci
Figure imgf000153_0001
Prepared similarly to (R)-l l-methoxy-3,3-dimethyl-8-oxo-12-(3-(trifluoromethoxy)propoxy)- 2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid in example 58, except using ethyl (R)-12-hydroxy-l l-(methoxymethyl)-3,3-dimethyl-8-oxo-2,3, 8,13b- tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate in place of ethyl (R)-12- hydroxy-l l-methoxy-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lHpyrido[2,l-a]pyrrolo[l,2- c]phthalazine-7-carboxylate and 3-(hydroxymethyl)bicyclo[l . l . l]pentane-l-carbonitrile in place of 3-(trifluoromethoxy)propan-l-ol. 'H NMR (400 MHz, Acetonitrile-d3) δ 8.45 (s, 1H), 7.91 (s, 1H), 7.22 (s, 1H), 6.90 (s, 1H), 4.86 (d, J = 6.2 Hz, 1H), 4.60 - 4.41 (m, 2H), 4.21 (d, J = 11.1 Hz, 1H), 4.11 (d, J = 11.1 Hz, 1H), 3.43 (s, 3H), 2.57 - 2.39 (m, 1H), 2.33 (s, 6H), 1.90 (ddd, J = 12.7, 7.8, 3.0 Hz, 1H), 1.68 - 1.52 (m, 1H), 1.36 (s, 3H), 0.63 (s, 3H). 19F NMR (376 MHz, Acetonitrile-d3) δ -77.33. MS (m/z) 476.2 [M+H]+.
Example 75: (R)-12-(benzyloxy)-3,3-dimethyl-8-oxo-ll-(trifluoromethoxy)-2,3,8,13b- tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid:
Figure imgf000154_0001
Synthesis of 2-(benzyloxy)-4-bromo-l-(trifluoromethoxy)benzene: To an RB add 5-bromo-2- (trifluoromethoxy)phenol (20 g, 77.8 mmol), potassium carbonate (12.91 g, 93.4 mmol), and DMF (80 ml). Allow the mixture to stir for 10 minutes, then add benzyl bromide (9.7 ml, 81.7 mmol) and continue stirring overnight. Dilute the mixture with EtOAc, 5% LiCl solution, and brine. Wash the organic layer with 5% LiCl two times, dry organic layer over sodium sulfate, filter, and concentrate. The residue was purified by silica gel chromatography to afford the title compound. lH NMR (400 MHz, DMSO-d6) δ 7.54 (d, J = 2.2 Hz, 1H), 7.45 - 7.36 (m, 4H), 7.35 - 7.26 (m, 2H), 7.20 (dd, J = 8.6, 2.2 Hz, 1H), 5.23 (s, 2H).
Synthesis of 2-(benzyloxy)-4-iodo-l-(trifluoromethoxy)benzene: A RB was charged with Cul (646 mg, 3.39mmol), 2-(benzyloxy)-4-bromo-l-(trifluoromethoxy)benzene (11.78, 33.94 mmol) and Nal (10.17 g, 67.87 mmol), briefly evacuated and backfilled with argon. trans-N,N'- dimethyl-l,2-cyclohexanediamine (1.07 mL, 3.39 mmol), and 1,4-dioxane (30 mL) were added under argon. The reaction mixture was stirred at 110 °C for 22-24 h. The resulting suspension was allowed to reach room temperature, diluted with 30% aq ammonia (5 mL), poured into water (20 mL), and extracted with ethyl acetate. The combined organic phases were dried over MgSC>4, concentrated, and the residue was purified by flash chromatography on silica gel to provide the desired product. l NMR (400 MHz, DMSO-d6) δ 7.64 (d, J = 2.0 Hz, 1H), 7.48 - 7.25 (m, 6H), 7.13 (dq, J = 8.4, 1.2 Hz, 1H), 5.21 (s, 2H).
Synthesis of l-(benzyloxy)-4-bromo-5-iodo-2-(trifluoromethoxy)benzene: 2-(Benzyloxy)-4- iodo-l-(trifluoromethoxy)benzene (27.90 g, 70.79 mmol) was dissolved in 300 mL of methylene chloride, to it was added DBDMH ( 12.14 g, 42.47 mmol) and TMSOTf (7.7 mL, 42 mmol). The reaction mixture was allowed to stir at ambient temperature overnight. The reaction mixture was diluted with methylene chloride; wash with saturated NaHC03 and brine. The organic phase was dried over MgSC>4, concentrated, and the residue was purified by flash chromatography on silica gel to provide the desired product. XH NMR (400 MHz, DMSO-d6) δ 7.84 (s, 1H), 7.74 (q, J = 1.1 Hz, 1H), 7.45 - 7.29 (m, 5H), 5.22 (s, 2H).
Synthesis of (R)- 12-(benzyloxy)-3,3-dimethyl-8-oxo- 1 l-(trifluoromethoxy)-2,3,8,13b- tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid: The title compound was prepared according to the method presented for the synthesis of Example 55 utilizing l-(benzyloxy)-4-bromo-5-iodo-2-(trifluoromethoxy)benzene: MS (m/z): 501.19
[M+H]+. lH NMR (400 MHz, Chloroform-d) δ 8.60 (s, 1H), 7.69 (d, J = 1.4 Hz, 1H), 7.51 - 7.33 (m, 4H), 7.26 (d, J = 6.9 Hz, 2H), 6.93 (s, 1H), 5.43 - 5.16 (m, 2H), 4.78 (d, J = 6.4 Hz, 1H), 2.47 (d, J = 4.3 Hz, 1H), 2.36 - 2.13 (m, 1H), 1.88 (ddd, J = 12.6, 8.1, 2.5 Hz, 1H), 1.50 (td, J = 11.7, 7.5 Hz, 1H), 1.38 (s, 3H), 0.64 (s, 3H).
Example 76: (R)-ll-chloro-12-(l-(difluoromethyl)-lH-pyrazol-4-yl)-3,3-dimethyl-8-oxo- -tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid
Figure imgf000155_0001
Ethyl (R)-l l-chloro-3,3-dimethyl-8-oxo-12-(((trifluoromethyl)sulfonyl)oxy)-2,3,8,13b- tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate (30 mg, 0.058 mmol), 1- (difluoromethyl)-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-pyrazole (28 mg, 0.11 mmol), [l,l'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (2.4 mg, 0.003 mmol), and potassium carbonate (24 mg, 0.17 mmol) were charged in a microwave tube and placed under argon. 1,4-dioxane (1.2 mL) and water (0.2 mL) were added, and the reaction mixture was heated to 120 °C in a microwave reactor (Biotage® Initiator+) for 10 minutes. The reaction mixture was cooled to ambient temperature and to it was added 0.1 ml 2 N LiOH, and the reaction was stirred until complete. The reaction mixture was partitioned between EtOAc and
0.1 N HCl. the aqueous layer was removed. The organic layer was concentrated under vacuum, and the resulting residue was purified by RP-HPLC to provide the title compound. MS (m/z) 461.12 [M+H]+). ¾ NMR (400 MHz, Chloroform-d) δ 8.67 (s, 1H), 8.32 (s, 1H), 8.04 (s, 1H), 7.94 (s, 1H), 7.47 (d, J = 1.1 Hz, 1H), 7.41 (s, 1H), 7.45 - 7.09 (m, 1H), 4.87 (d, J = 6.2 Hz, 1H), 2.67 - 2.35 (m, 2H), 2.06 - 1.90 (m, 1H), 1.68 (td, J = 11.6, 7.7 Hz, 1H), 1.42 (s, 3H), 0.71 (s, 3H).
Example 77: (R)-12-(3-methoxypropoxy)-3,3-dimethyl-ll-(oxetan-3-yl)-8-oxo-2,3,8,13b- tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid
Figure imgf000156_0001
(R)-12-(3-methoxypropoxy)-3,3-dimethyl-l l-(oxetan-3-yl)-8-oxo-2,3,8,13b-tetrahydro-lH- pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid was prepared similarly to example 28 using ethyl (R)-l l-iodo-12-(3-methoxypropoxy)-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH- pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate and trifluoro(oxetan-3-yl)-14-borane, potassium salt in place of ethyl (R)-12-(3-methoxypropoxy)-3,3-dimethyl-8-oxo-l l- (((trifluoromethyl)sulfonyl)oxy)-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2- c]phthalazine-7-carboxylate and cyclopropyltrifluoro-14-borane, potassium salt. 'H NMR (400 MHz, Chloroform-d) δ 9.83 (s, 1H), 8.55 (s, 1H), 7.57 (s, 1H), 7.15 (s, 1H), 6.76 (s, 1H), 4.24 - 4.08 (m, 2H), 3.57 (dd, J = 5.4, 1.3 Hz, 2H), 3.37 (s, 3H), 2.99 (d, J = 6.2 Hz, 2H), 2.80 (dd, J = 7.1, 1.3 Hz, 2H), 2.54 - 2.34 (m, 3H), 2.19 - 2.02 (m, 3H), 1.89 (ddd, J = 12.4, 7.8, 2.6 Hz, 1H), 1.71 - 1.55 (m, 1H), 1.37 (s, 3H), 0.66 (s, 3H). MS (m/z) 455.583 [M+H]+.
Example 78: (R)-ll-methoxy-12-((2-methoxyethoxy)methyl)-3,3-dimethyl-8-oxo-2,3,8,13b- tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid
Figure imgf000156_0002
(R)-l l-methoxy-12-((2-methoxyethoxy)methyl)-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH- pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid was prepared similarly to example 44 using trill uoro((2-methoxyethoxy)methyl)-14-borane, potassium salt in place of 1-
(difluoromethyl)-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-pyrazole. XH NMR (400 MHz, Chloroform-d) δ 8.58 (s, 1H), 7.49 (s, 1H), 7.19 (s, 1H), 7.14 (s, 1H), 4.80 (d, J = 6.0 Hz, 1H), 4.65 (s, 2H), 3.90 (s, 3H), 3.75 - 3.71 (m, 2H), 3.65 - 3.61 (m, 2H), 3.43 (s, 3H), 2.54 - 2.37 (m, 2H), 1.89 - 1.83 (m, 1H), 1.65 - 1.55 (m, 1H), 1.37 (s, 3H), 0.65 (s, 3H). MS (m/z) 429.639 [M+H]+.
Example 79: (R)-12-(3-methoxypropoxy)-3,3-dimethyl-8-oxo-ll-(trifluoromethoxy)- 2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid
Figure imgf000157_0001
5-bromo-2-(trifluoromethoxy)phenol 4-bromo-2-(3-methoxypropoxy)-1-
(tnfluoromethoxy)benzene
Figure imgf000157_0002
4-iodo-2-(3-methoxypropoxy)-1 - 1 -bromo-2-iodo-4-(3-methoxypropoxy)-5-
(trifluoromethoxy)benzene (trifluoromethoxy)benzene
Synthesis of 4-Bromo-2-(3-methoxypropoxy)-l-(trifluoromethoxy): 4-Bromo-2-(3- methoxypropoxy)-l-(trifluoromethoxy)benzene was prepared similarly to l-bromo-5-chloro-2- iodo-4-(3-methoxypropoxy)benzene using 5-bromo-2-(trifluoromethoxy)phenol in place of of
4-bromo-2-chloro-5-iodophenol.
Synthesis of 4-iodo-2-(3-methoxypropoxy)-l-(trifluoromethoxy)benzene: 4-Bromo-2-(3- methoxypropoxy)-l-(trifluoromethoxy)benzene (6.01 g, 18.3 mmol), Nal (5.47 g, 36.5 mmol), Cul (348 mg, 1.83 mmol) and NN'-dimethylethylenediamine (0.39 mL, 3.7 mmol) were combined in 18 mL dioxane. The reaction mixture was degassed by pulling vacuum and backfilling the reaction vessel with Ar 5x. After degassing, the stirred mixture was heated to 110 °C overnight. Upon completion, the mixture was cooled to RT, diluted with EtOAc, filtered over celite and concentrated under reduced pressure. The resulting residue was dissolved in EtOAc and washed successively with 5% ammonia, water and brine. The organics were dried over MgSC>4, filtered and concentrated to provide the title compound (6.59 g, 96%), which was carried on without further purification.
Synthesis of l-bromo-2-iodo-4-(3-methoxypropoxy)-5-(trifluoromethoxy)benzene: 4-Iodo- 2-(3-methoxypropoxy)-l-(trifluoromethoxy)benzene (6.07 g, 16.1 mmol) was suspended in 32 mL MeOH and treated with DBDMH (11.07 g, 38.73 mmol). After stirring 3 days at RT, the reaction mixture was diluted with EtO Ac, washed with saturated aqueous NaHCC and brine, dried over MgSC>4, filtered and concentrated under reduced pressure. The crude residue wash purified by silica column chromatography (0% to 10% EtO Ac/hex) to afford the title compound (6.37 g, 87%).
Synthesis of ethyl 12-(3-methoxypropoxy)-3,3-dimethyl-8-oxo-ll-(trifluoromethoxy)- 2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate: Ethyl 12- (3-methoxypropoxy)-3,3-dimethyl-8-oxo-l l-(trifluoromethoxy)-2,3,8,13b-tetrahydro-lH- pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate was prepared similarly to ethyl 11-chloro- 12-(3-methoxypropoxy)-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2- c]phthalazine-7-carboxylate, using l-bromo-2-iodo-4-(3-methoxypropoxy)-5- (trifluoromethoxy)benzene in place of l-bromo-5-chloro-2-iodo-4-(3-methoxypropoxy)benzene.
Figure imgf000158_0001
ethyl 12-(3-methoxypropoxy)-3,3-dimethyl-8- (R)-ethyl 12-(3-methoxypropoxy)-3,3- oxo-1 1 -(trifluoromethoxy)-2,3,8, 13b- dimethyl-8-oxo-1 1 -(trifluoromethoxy)- tetrahydro-1 -/-pyrido[2, 1 -a]pyrrolo[1 ,2- 2,3,8, 13b-tetrahydro-1 H-pyrido[2, 1 - c]phthalazine-7-carboxylate a]pyrrolo[1 ,2-c]phthalazine-7-carboxylate
Figure imgf000158_0002
Purification of (R)-ethyl 12-(3-methoxypropoxy)-3,3-dimethyl-8-oxo-ll- (trifluoromethoxy)-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7- carboxylate: Ethyl 12-(3-methoxypropoxy)-3,3-dimethyl-8-oxo-l l-(trifluoromethoxy)- 2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate was separated into its constituent enantiomers by reverse phase chiral HPLC using a Chirlapak AD-H column (SFC with 20% IP A). The i?-enantiomer was assigned as the faster-eluting peak.
Synthesis of (R)-12-(3-methoxypropoxy)-3,3-dimethyl-8-oxo-ll-(trifluoromethoxy)-
2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid: (R)-12- (3-Methoxypropoxy)-3,3-dimethyl-8-oxo-l l-(trifluoromethoxy)-2,3,8,13b-tetrahydro-lH- pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid was prepared similarly to Example 4, using (R)-ethyl 12-(3-methoxypropoxy)-3,3-dimethyl-8-oxo-l l -(trifluoromethoxy)-2,3,8, 13b- tetrahydro-lH-pyrido[2, l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate in place of ethyl 11 -chloro- 12-(3-methoxypropoxy)-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2, l -a]pyrrolo[l,2- c]phthalazine-7-carboxylate. XH NMR (400 MHz, Chloroform-c ) δ 8.59 (s, 1H), 7.65 (d, J = 1.3 Hz, 1H), 7.14 (s, 1H), 6.96 (s, 1H), 4.87 (d, J = 6.2 Hz, 1H), 4.34 - 4.10 (m, 2H), 3.70 - 3.47 (m, 2H), 3.36 (s, 3H), 2.53 (dq, J = 13.9, 7.9, 6.7 Hz, 1H), 2.12 (p, J= 6.0 Hz, 2H), 1.94 (ddd, J = 12.8, 8.0, 2.5 Hz, 1H), 1.65 (ddd, J = 12.6, 10.7, 7.6 Hz, 1H), 1.39 (s, 3H), 0.69 (s, 3H). MS (m/z) 483.5 [M+H]+.
Example 80: (R)-ll-chloro-3,3-bis(methoxymethyl)-12-(3-methoxypropoxy)-8-oxo- 2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid
Figure imgf000160_0001
2-bromo-4-chloro-5-(3- -(2-bromo-4-chloro-5-(3- methoxypropoxy) methoxypropoxy)phenyl) benzaldehyde prop-2-en-1 -ol
D
Figure imgf000160_0002
1 -(2-bromo-4-chloro-5-(3- methoxypropoxy)phenyl)prop-2- en-1 -one
Figure imgf000160_0003
diethyl 2-(3-(2-bromo-4-chloro-5-(3- methoxypropoxy)phenyl)-3-oxopropyl)- 2-((ie t-butoxycarbonyl)amino)malonate
Figure imgf000160_0004
diethyl (S)-2-(3-(2-bromo-4-chloro-5-(3- methoxypropoxy)phenyl)-3- hydroxypropyl)-2-(( tert- butoxycarbonyl)amino)malonate o-
Figure imgf000161_0001
ferf-butyl (R)-5-(2-bromo-4-chloro-5- (R)-(5-(2-bromo-4-chloro- (3-methoxypropoxy)phenyl)-2,2- 5-(3- bis(hydroxymethyl)pyrrolidine-1 - methoxypropoxy)phenyl)p carboxylate yrrolidine-2,2- diyl)dimethanol
Figure imgf000161_0002
(R)-(5-(2-bromo-4-chloro-5-(3- methoxypropoxy)phenyl)-1 - (R)-(1 -amino-5-(2-bromo-4- nitrosopyrrolidine-2,2- chloro-5-(3- diyl)dimethanol methoxypropoxy)phenyl)pyrrolidi
ne-2,2-diyl)dimethanol
Figure imgf000162_0001
ethyl (R)-1 -(5-(2-bromo-4-chloro-5-(3- methoxypropoxy)phenyl)-2,2- bis(hydroxymethyl)pyrrolidin-1 -yl)-4-oxo-1 ,4- dihydropyridine-3-carboxylate
Figure imgf000162_0002
Synthesis of l-(2-bromo-4-chloro-5-(3-methoxypropoxy)phenyl)prop-2-en-l-ol: To a solution of 2-bromo-4-chloro-5-(3-methoxypropoxy)benzaldehyde (1 g, 3.25 mmol) in 2- methyltetrahydrofuran (12 ml) was added dropwise over 20 minutes at -20°C vinylmagnesium bromide (1M in tetrahydrofuran) (3.3 ml). The mixture was warmed to room temperature and stirred for 1 hour. The reaction was quenched with sat NH4C1 (aq, 20 ml) and extracted with ethyl acetate (8 ml). The organic layer was washed with brine (20 ml). The organic layer was dried with anhydrous sodium sulfate, filtered, and concentrated. The crude product was taken to next step without further purification (1.09 g). XH NMR (400 MHz, Chloroform-d) δ 7.51 (s, 1H), 7.14 (s, 1H), 5.97 (ddd, J = 17.1, 10.4, 5.4 Hz, 1H), 5.52 (d, J = 5.5 Hz, 1H), 5.39 (dt, J = 17.1, 1.4 Hz, 1H), 5.23 (dt, J = 10.4, 1.3 Hz, 1H), 4.21 - 4.04 (m, 3H), 3.58 (t, J = 6.1 Hz, 3H), 3.35 (s, 3H), 2.09 (q, J = 6.1 Hz, 3H).
Synthesis of l-(2-bromo-4-chloro-5-(3-methoxypropoxy)phenyl)prop-2-en-l-one: To a solution of l-(2-bromo-4-chloro-5-(3-methoxypropoxy)phenyl)prop-2-en-l-ol (1.09 g, 3.25 mmol) in dichloromethane (20 ml) was added portionwise at 0°C Dess-Martin periodinane (1.65 g, 3.9 mmol). The mixture was warmed to room temperature and stirred for 1 hour. The reaction mixture was washed with water (20 ml), followed by 1M NaHCC (aq, 20 ml), and water (20 ml). The organic layer was dried with anhydrous sodium sulfate, filtered, and concentrated. Product was purified by silica chromatography using ethyl acetate in
hexane (350mg). lH NMR (400 MHz, Chloroform-d) δ 7.59 (s, 1H), 6.92 (s, 1H), 6.74 (dd, J = 17.5, 10.5 Hz, 1H), 6.16 (dd, J = 17.5, 1.0 Hz, 1H), 6.08 (dd, J = 10.5, 1.0 Hz, 1H), 4.11 (t, J = 6.2 Hz, 2H), 3.57 (t, J = 6.0 Hz, 2H), 3.34 (s, 3H), 2.22 - 1.89 (m, 2H).
Synthesis of Diethyl 2-(3-(2-bromo-4-chloro-5-(3-methoxypropoxy)phenyl)-3-oxopropyl)-2- ((tert-butoxycarbonyl)amino)malonate: To a solution of l-(2-bromo-4-chloro-5-(3- methoxypropoxy)phenyl)prop-2-en-l-one (3.8 g, 11.39 mmol) in ethanol (10 ml) was added diethyl 2-((tert-butoxycarbonyl)amino)malonate (2.9 ml, 11.39 mmol) followed by sodium ethoxide (0.08 g, 1.14 mmol). After stirring at room temperature for 1 hour, the mixture was concentrated, diluted with ethyl acetate (50 ml) and washed with water. The organic layer was dried with anhydrous sodium sulfate, filtered, and concentrated. Product was purified by silica chromatography using ethyl acetate in hexanes (5.4g). XH NMR (400 MHz, Chloroform-d) δ 7.55 (s, 1H), 6.94 (s, 1H), 5.92 (s, 1H), 4.35 - 4.16 (m, 4H), 4.12 (t, J = 6.1 Hz, 2H), 3.57 (t, J = 6.1 Hz, 2H), 3.35 (s, 3H), 3.04 - 2.82 (m, 2H), 2.76 - 2.65 (m, 2H), 2.08 (p, J = 6.1 Hz, 2H), 1.42 (s, 9H), 1.26 (t, J = 7.1 Hz, 6H).
Synthesis of diethyl (S)-2-(3-(2-bromo-4-chloro-5-(3-methoxypropoxy)phenyl)-3- hydroxypropyl)-2-((tert-butoxycarbonyl)amino)malonate: To a solution of borane dimethylsulfide complex in tetrahydrofuran (2M) (4.4 ml) and (R)-(+)-2-Methyl-CBS- oxazaborolidine (0.16 g, 0.58 mmol) in tetrahydrofuran (20 ml) was added dropwise at 0°C diethyl 2-(3-(2-bromo-4-chloro-5-(3-methoxypropoxy)phenyl)-3-oxopropyl)-2-((tert- butoxycarbonyl)amino)malonate (5.4 g, 8.87 mmol) in tetrahydrofuran (10 ml) over 1.5h. After the addition was complete, mixture was stirred for 1 hour. The reaction was quenched with ethanol (40 ml) and the mixture was stirred for 30 minutes. The resulting solution was concentrated under vacuum and the product was purified by silica chromatography using ethyl acetate in hexanes (4.8g). Enantiomeric ratio was determined to be 85: 15 from NMR analysis of the Mosher amide of l-(tert-butyl) 2,2-diethyl (R)-5-(2-bromo-4-chloro-5-(3- methoxypropoxy)phenyl)pyrrolidine-l,2,2-tricarboxylate in a subsequent step. XH NMR (400 MHz, Chloroform-d) δ 7.47 (s, 1H), 7.15 (s, 1H), 5.90 (s, 1H), 4.95 (dd, J = 8.4, 3.5 Hz, 1H), 4.22 (q, J = 8.0, 6.1 Hz, 5H), 4.12 (t, J = 6.2 Hz, 2H), 3.58 (t, J = 6.1 Hz, 2H), 3.35 (s, 3H), 2.61
- 2.35 (m, 2H), 2.08 (p, J = 6.2 Hz, 2H), 1.70 - 1.52 (m, 3H), 1.41 (s, 9H), 1.24 (t, J = 7.1 Hz, 6H).
Synthesis diethyl (S)-2-(3-(2-bromo-4-chloro-5-(3-methoxypropoxy)phenyl)-3- ((methylsulfonyl)oxy)propyl)-2-((tert-butoxycarbonyl)amino)malonate: To a solution of diethyl (S)-2-(3-(2-bromo-4-chloro-5-(3-methoxypropoxy)phenyl)-3-hydroxypropyl)-2-((tert- butoxycarbonyl)amino)malonate (4 g, 6.6 mmol) and triethylamine (1.19 ml, 8.57 mmol) in dichloromethane (24 ml) was added dropwise methanesulfonyl chloride (0.56 ml, 7.25 mmol) at 0°C. The mixture was warmed to room temperature and stirred for 30 minutes. The resulting solution was washed with 0.1M HC1 (aq, 40 ml). The organic layer was washed with dichloromethane (20 ml). The aqueous layers were back extracted with dichloromethane (20 ml). The organic layers were combined, dried with anhydrous sodium sulfate, filtered, and concentrated. Product was purified by silica chromatography using ethyl acetate in hexanes (3.6g). lH NMR (400 MHz, Chloroform-d) δ 7.52 (s, 1H), 7.02 (s, 1H), 5.89 (s, 1H), 5.79 (t, J = 6.3 Hz, 1H), 4.32 - 4.15 (m, 2H), 4.11 (t, J = 6.2 Hz, 2H), 3.58 (t, J = 6.1 Hz, 2H), 3.35 (s, 3H), 2.92 (s, 3H), 2.54 - 2.29 (m, 2H), 2.08 (p, J = 6.1 Hz, 2H), 1.89 - 1.69 (m, 3H), 1.40 (s, 9H), 1.26
- 1.21 (m, 6H).
Synthesis of l-(tert-butyl) 2,2-diethyl (R)-5-(2-bromo-4-chloro-5-(3- methoxypropoxy)phenyl)pyrrolidine-l,2,2-tricarboxylate: To a solution of diethyl (S)-2-(3- (2-bromo-4-chloro-5-(3-methoxypropoxy)phenyl)-3-((methylsulfonyl)oxy)propyl)-2-((tert- butoxycarbonyl)amino)malonate (3.6 g, 5.26 mmol) in dimethylformamide (12 ml) was added portionwise sodium hydride (0.15 g, 6.31 mmol). The reaction was stirred at 20°C for 2h and allowed to sit for 18 hours at 4°C. To the reaction was added acetic acid (0.32 g, 5.26 mmol) and the mixture was concentrated under vacuum. The product was extracted with ethyl acetate (50 ml) and washed twice with 5% LiCl (aq, 50 ml). The organic layer was dried with anhydrous sodium sulfate, filtered, and concentrated. The crude product was taken to next step without further purification (3. lg). MS (m/z) 616.0 [M+H]+. Synthesis of tert-butyl (R)-5-(2-bromo-4-chloro-5-(3-methoxypropoxy)phenyl)-2,2- bis(hydroxymethyl)pyrrolidine-l-carboxylate: To a solution of 1 -(tert-butyl) 2,2-di ethyl (R)- 5-(2-bromo-4-chloro-5-(3-methoxypropoxy)phenyl)pyrrolidine-l,2,2-tricarboxylate (2.9 g, 4.89 mmol) in diethyl ether (30 ml) was added 2M lithium borohydride in tetrahydrofuran (13.5 ml). The reaction was stirred at 20°C for 4h. To the reaction was added water (10 ml) and the mixture was stirred for 10 minutes. The product was extracted with ethyl acetate (50 ml) and washed twice with brine (50 ml). The organic layer was dried with anhydrous sodium sulfate, filtered, and concentrated. The crude product was taken to next step without further
purification (3.1g). MS (m/z) 509.7 [M+H]+. Synthesis of (R)-(5-(2-bromo-4-chloro-5-(3-methoxypropoxy)phenyl)pyrrolidine-2,2- diyl)dimethanol: A solution of tert-butyl (R)-5-(2-bromo-4-chloro-5-(3- methoxypropoxy)phenyl)-2,2-bis(hydroxymethyl)pyrrolidine-l-carboxylate (2.49 g, 4.89 mmol) in dichloromethane (20 ml) and trifluoroacetic acid (20 ml) was stirred for 1 hour. The mixture was concentrated, diluted with isopropyl acetate (50 ml) and concentrated. The crude product was dissolved in isopropyl acetate (40 ml) and basified with 1.0M NaOH (40 ml). The organic layer was dried with anhydrous sodium sulfate, filtered, and concentrated. The crude product was taken to next step without further purification (1.9g). MS (m/z) 410.2 [M+H]+.
Synthesis of ethyl (R)-ll-hydroxy-12-(3-methoxypropoxy)-3,3-dimethyl-8-oxo-2,3,8,13b- tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate: Ethyl (R)-l 1- hydroxy-12-(3-methoxypropoxy)-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l- a]pyrrolo[l,2-c]phthalazine-7-carboxylate was prepared analogously to Example 1 using (R)-(5- (2-bromo-4-chloro-5-(3-methoxypropoxy)phenyl)pyrrolidine-2,2-diyl)dimethanol in place of 2- (2-bromo-4-chloro-5-(3-methoxypropoxy)phenyl)pyrrolidine (1.2 g). XH NMR (400 MHz, Chloroform-d) δ 7.51 (s, 1H), 6.89 (s, 1H), 5.40 (dd, J = 8.9, 6.0 Hz, 1H), 4.36 (d, J = 11.5 Hz, 1H), 4.16 - 3.99 (m, 5H), 3.52 (td, J = 5.8, 1.7 Hz, 2H), 3.35 (s, 3H), 2.69 - 2.58 (m, 1H), 2.26 - 2.17 (m, 1H), 2.08 - 1.93 (m, 3H), 1.90 - 1.78 (m, 1H). MS (m/z) 438.9 [M+H]+.
Synthesis of ethyl (R)-l-(5-(2-bromo-4-chloro-5-(3-methoxypropoxy)phenyl)-2,2- bis(hydroxymethyl)pyrrolidin-l-yl)-4-oxo-l,4-dihydropyridine-3-carboxylate: A solution of ethyl (R)-l l-hydroxy-12-(3-methoxypropoxy)-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH- pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate (1.17 g, 2.77 mmol) and ethyl (Z)-2- ((dimethylamino)methylene)-5,5-diethoxy-3-oxopentanoate (0.87 g, 3.04 mmol) in ethanol (5 ml) was heated at 60°C for 1 hour. A solution of citric acid (0.8 g, 4.15 mmol) in water (2.0 ml) and added and the reaction was stirred for 1 hour at 60°C. The mixture was concentrated, and the product was extracted with ethyl acetate (50 ml) and washed with water (50 ml), followed by 1M K2HPO4 (aq, 50 ml), and water (50 ml). The organic layer was dried with anhydrous sodium sulfate, filtered, and concentrated. Product was purified by silica chromatography using ethanol in dichloromethane (1.05g). XH NMR (400 MHz, Chloroform-d) δ 8.42 (s, 1H), 7.92 (s, 1H), 7.44 (s, 1H), 7.19 (s, 1H), 6.27 (s, 1H), 5.24 (t, J = 7.8 Hz, 1H), 4.29 (q, J = 7.1 Hz, 2H), 4.16 (s, OH), 4.14 - 4.04 (m, 1H), 3.75 - 3.65 (m, 4H), 3.59 (q, J = 5.9 Hz, 2H), 3.38 (s, 3H), 2.43 (s, 1H), 2.26 - 2.13 (m, 1H), 2.12 - 1.95 (m, 3H), 1.75 - 1.63 (m, 1H), 1.33 (t, J = 7.1 Hz, 3H). MS (m/z) 575.30 [M+H]+. Synthesis of (R)- (5-(2-bromo-4-chloro-5-(3-methoxypropoxy)phenyl)-l-(3-
(ethoxycarbonyl)-4-oxopyridin-l(4H)-yl)pyrrolidine-2,2-diyl)bis(methylene) diacetate: A solution of ethyl (R)-l-(5-(2-bromo-4-chloro-5-(3-methoxypropoxy)phenyl)-2,2- bis(hydroxymethyl)pyrrolidin-l-yl)-4-oxo-l,4-dihydropyridine-3-carboxylate (1.05 g, 1.83 mmol) and 4-dimethylaminopyridine (11.2 mg, 0.09 mmol) in acetic anhydride (10 ml) was heated at 60°C for 1 hour. The mixture was concentrated, diluted with ethyl acetate (40 ml) and washed with water (2 x 40 ml). The aqueous layers were combined, back-extracted with ethyl acetate (40 ml), and organic layer was washed with water (40 ml). The organic layers were combined, dried with anhydrous sodium sulfate, filtered, and concentrated. Product was purified by silica chromatography using ethanol in dichloromethane (l . lg). MS (m/z) 659.3 [M+H]+.
Synthesis of (R)- (ll-chloro-7-(ethoxycarbonyl)-12-(3-methoxypropoxy)-8-oxo-2,3,8,13b- tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-3,3-diyl)bis(methylene) diacetate:
(l l-chloro-7-(ethoxycarbonyl)-12-(3-methoxypropoxy)-8-oxo-2,3,8,13b-tetrahydro-lH- pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-3,3-diyl)bis(methylene) diacetate was prepared analogously to Example 1 using (5-(2-bromo-4-chloro-5-(3-methoxypropoxy)phenyl)-l-(3- (ethoxycarbonyl)-4-oxopyridin-l(4H)-yl)pyrrolidine-2,2-diyl)bis(methylene) diacetate in place of ethyl l-(2-(2-bromo-4-chloro-5-(3-methoxypropoxy)phenyl)pyrrolidin-l-yl)-4-oxo-l,4- dihydropyridine-3-carboxylate (215 mg, 0.42 mmol). The crude product was taken to next step without further purification (1.1 g). MS (m/z) 577.5 [M+H]+. Synthesis ethyl (R)-ll-chloro-3,3-bis(hydroxymethyl)-12-(3-methoxypropoxy)-8-oxo- 2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate: To a solution of (R)- (l l-chloro-7-(ethoxycarbonyl)-12-(3-methoxypropoxy)-8-oxo-2,3, 8,13b- tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-3,3-diyl)bis(methylene) diacetate (964.72 mg, 1.67 mmol) in ethanol (5 ml) was added sodium ethoxide (50.16 mg, 0.84 mmol). After stirring for 20 minutes, acetic acid (60 ul) was added and the mixture was concentrated under vacuum. Product was purified by silica chromatography using ethanol in
dichloromethane (430mg). XH NMR (400 MHz, DMSO-d6) δ 8.44 (s, 1H), 8.06 (s, 1H), 7.16 (s, 1H), 6.83 (s, 1H), 4.94 (t, J = 5.5 Hz, 1H), 4.76 (d, J = 5.8 Hz, 1H), 4.41 (t, J = 4.7 Hz, 1H), 4.29 - 4.10 (m, 3H), 3.54 - 3.41 (m, 4H), 3.24 (s, 3H), 2.94 (qd, J = 11.2, 4.7 Hz, 2H), 2.62 - 2.52 (m, 1H), 2.23 - 2.09 (m, 1H), 1.97 (p, J = 6.3 Hz, 2H), 1.69 (dd, J = 12.9, 7.2 Hz, 1H), 1.32 - 1.19 (m, 4H). MS (m/z) 493.4 [M+H]+.
Figure imgf000167_0001
ethyl (R)-1 1 -chloro-3,3-bis(hydroxymethyl)-12- 80
(3-methoxypropoxy)-8-oxo-2,3,8, 13b- tetrahydro-1 H-pyrido[2, 1 -a]pyrrolo[1 ,2- c]phthalazine-7-carboxylate
Synthesis of (R)-ll-chloro-3,3-bis(methoxymethyl)-12-(3-methoxypropoxy)-8-oxo- 2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid:
To a solution of ethyl (R)-l l-chloro-3,3-bis(hydroxymethyl)-12-(3-methoxypropoxy)- 8-oxo-2,3, 8, 13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate (10 mg, 20.29 μιτιοΐ) in dimethylformamide (200 μΐ) was added sodium hydride (2.3 mg, 101.4 μιτιοΐ). After stirring for 1 min, iodomethane (6.31 μΐ, 101.43 μιτιοΐ) was added the reaction was stirred for 1 hour. Additional sodium hydride (2.33 mg, 101.43 μιτιοΐ) was added. After stirring for 20 minutes, the mixture was diluted with ethanol (0.5 ml) and 2M Li OH (aq, 300ul). After stirring at room temperature for 30 minutes, the mixture was acidified with concentrated HC1 (-50 ul) and concentrated under vacuum. The product was purified by preparative HPLC using acetonitrile in water with 0.1 % trifluoroacetic acid (4.2mg). XH NMR (400 MHz, Chloroform- d) δ 8.76 (s, 1H), 7.80 (s, 1H), 7.12 (s, 1H), 6.85 (d, J = 1.0 Hz, 1H), 4.81 (t, J = 3.4 Hz, 1H), 4.29 - 4.09 (m, 2H), 3.70 - 3.57 (m, 2H), 3.47 - 3.40 (m, 4H), 3.38 (s, 3H), 2.99 (d, J = 10.5 Hz, 1H), 2.88 (d, J = 10.6 Hz, 1H), 2.85 (s, 3H), 2.48 - 2.38 (m, 2H), 2.15 (p, J = 6.1 Hz, 2H), 1.97 - 1.89 (m, 1H), 1.53 - 1.40 (m, 1H). MS (m/z) 493.4 [M+H]+. Example 81: (R)-ll-chloro-12-(3-methoxypropoxy)-2',2'-dimethyl-8-oxo-l,2,8,13b- tetrahydrospiro [pyrido [2,1-a] pyrrolo [ 1,2-c] phthalazine-3,5'- [ 1,3] dioxane]-7-carboxylic acid
Figure imgf000168_0001
ethyl (R)-1 1 -chloro-3,3-bis(hydroxymethyl)-12-
(3-methoxypropoxy)-8-oxo-2,3,8,13b- 81
tetrahydro-1 H-pyrido[2, 1 -a]pyrrolo[1 ,2- c]phthalazine-7-carboxylate To a solution of ethyl (R)-l l -chloro-3,3-bis(hydroxymethyl)-12-(3-methoxypropoxy)-8-oxo- 2,3,8, 13b-tetrahydro-lH-pyrido[2, l -a]pyrrolo[l ,2-c]phthalazine-7-carboxylate (10 mg, 20.3 μηιοΐ) in acetone (0.4 ml) was added />-toluenesulfonic acid monohydrate (1.0 mg, 5.1 μηιοΐ) followed by 3A activated molecular sieves. The reaction was stirred 18 hours at 60°C. The mixture was filtered through celite and concentrated. The resulting crude mixture was diluted with ethanol (0.5 ml) and 2M LiOH (aq, 0.1 ml). After stirring at room temperature for 1 hour, the mixture was acidified with concentrated HC1 and the product was purified by preparative HPLC using acetonitrile in water with 0.1% trifluoroacetic acid (6.4mg). During purification -15% of the starting diol was formed as a bi-product. XH NMR (400 MHz, Chloroform-d) δ 9.05 (s, 1H), 7.85 (s, 1H), 7.23 (s, 1H), 6.88 (s, 1H), 4.83 (d, J = 5.3 Hz, 1H), 4.30 - 4.15 (m, 2H), 4.09 (dd, J = 12.1, 2.2 Hz, 1H), 3.86 (d, J = 12.0 Hz, 1H), 3.71 - 3.57 (m, 2H), 3.49 (d, J = 13.2 Hz, 1H), 3.39 (s, 4H), 3.21 (dd, J = 13.1 , 2.2 Hz, 1H), 2.57 - 2.34 (m, 2H), 2.20 - 2.12 (m, 2H), 1.85 - 1.72 (m, 1H), 1.46 - 1.33 (m, 1H), 1.30 (s, 3H), 1.14 (s, 3H). MS (m/z) 505.4
[M+H]+.
Example 82: (R)-ll'-chloro-12'-(3-methoxypropoxy)-8'-oxo-l',2',8',13b'- tetrahydrospiro[oxetane-3,3'-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine]-7'-carboxylic acid
eth
me
Figure imgf000169_0001
carboxylate
To a stirred solution of ethyl (R)-l l-chloro-3,3-bis(hydroxymethyl)-12-(3-methoxypropoxy)-8- oxo-2,3, 8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate (10 mg, 0.02 mmol) in tetrahydrofuran (0.3 ml) was added sodium hydride (60% dispersion in mineral oil) (4.1 mg, 0.1 mmol). After stirring at room temperature for 5 minutes, the reaction was heated to 60°C and a solution of p-toluenesulfonic anhydride (7.9 mg, 0.02 mmol) in tetrahydrofuran (0.3 ml) was added dropwise. After stirring for 30 minutes, the mixture was partially concentrated and diluted with ethanol (0.5 ml) and 2M Li OH (aq, 0.1 ml). After stirring at room temperature for 1 hour, the mixture was acidified with concentrated HC1 and the product was purified by preparative HPLC using acetonitrile in water with 0.1% trifluoroacetic acid (3. lmg). XH NMR (400 MHz, Chloroform-d) δ 8.72 (s, 1H), 7.81 (s, 1H), 7.14 (s, 1H), 6.86 (s, 1H), 4.87 (d, J = 7.4 Hz, 1H), 4.74 (t, J = 3.6 Hz, 1H), 4.59 (d, J = 7.4 Hz, 1H), 4.30 - 4.14 (m, 2H), 4.13 (d, J = 7.4 Hz, 1H), 3.80 (d, J = 7.4 Hz, 1H), 3.69 - 3.52 (m, 2H), 3.38 (s, 3H), 2.54 (dt, J = 12.3, 5.6 Hz, 1H), 2.49 - 2.37 (m, 2H), 2.24 (dt, J = 13.1, 9.1 Hz, 1H), 2.15 (p, J = 6.0 Hz, 2H). MS (m/z) 447.4 [M+H]+.
Example 83: (R)-ll-methoxy-3,3-dimethyl-12-(3-methyl-3-(methylsulfonyl)but-l-yn-l-yl)- 8-oxo-2,3,8,13b-tetrahydro- lH-py -a] pyrrolo [ 1,2-c] phthalazine-7-carboxylic acid
Figure imgf000169_0002
Pd(tBu2PPh)2Cl2 (10.31mg, 0.015mmol) and Cul (4.056mg, 0.021mmol) were added into a round bottom flask (5ml) containing ethyl (R)-l l-methoxy-3,3-dimethyl-8-oxo-12- (((trifluoromethyl)sulfonyl)oxy)-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2- c]phthalazine-7-carboxylate (50mg, 0.097mmol) and 3-methyl-3-(methylsulfonyl)but-l-yne (70mg, 0.484mmol) in MeCN (0.6ml) and Et3N (0.3ml), after degassing the reaction mixture, it was stirred at 60 °C for lh. Sample of reaction mixture was taken for LC-MS and it showed the reaction was complete. The reaction mixture was cooled to rt, and quenched with thiol-linked silica, after stirring or 5 min, solid was filtered and was rinsed forward with 1 : 1 EtOH:MeCN. Filtrate was concentrate to dryness. The crude material was dissolved in EtOH (0.5ml) and LiOH (0.5ml, IN) was added. The mixture was stirred for 30min and then TFA was added to quench reaction. The solvent was stripped off, and the crude material was purified by HPLC. XH NMR (400 MHz, Chloroform-d) δ 8.62 (s, IH), 7.48 - 7.34 (m, 2H), 7.26 (s, 2H), 7.24 (s, IH), 4.77 (d, J = 5.5 Hz, IH), 3.96 (s, 3H), 3.15 (s, 3H), 2.52 - 2.28 (m, 2H), 1.92 (ddd, J = 12.6, 7.4, 3.1 Hz, IH), 1.77 (s, 6H), 1.74 - 1.55 (m, IH), 1.39 (s, 3H), 0.66 (s, 3H). MS (m/z) 485.11 (M+H+).
Example 84: (R)-12-(3-(cyclopropylsulfonyl)-3-methylbut-l-yn-l-yl)-ll-methoxy-3,3- dimethyl-8-oxo-2,3,8,13b-tetrahydro- lH-pyrido [2,1-a] pyrrolo [ 1,2-c] phthalazine-7- carboxylic acid
Figure imgf000170_0001
Prepared similarly to (R)-l l-methoxy-3,3-dimethyl-12-(3-methyl-3-(methylsulfonyl)but-l-yn-l- yl)-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid in Example 83 using ((2-methylbut-3-yn-2-yl)sulfonyl)cyclopropane in place of 3-methyl-3- (methylsulfonyl)but-l-yne. ¾ NMR (400 MHz, Chloroform-d) δ 8.63 (s, IH), 7.53 (s, IH), 7.44 - 7.34 (m, IH), 7.26 (s, 3H), 4.78 (d, J = 5.3 Hz, IH), 3.95 (s, 3H), 3.00 - 2.64 (m, IH), 2.61 -
2.35 (m, 2H), 1.92 (ddd, J = 12.5, 7.3, 3.3 Hz, IH), 1.79 (s, 6H), 1.75 - 1.58 (m, 3H), 1.47 - 1.30 (m, 5H), 1.14 (ddd, J = 7.6, 4.6, 2.6 Hz, 2H), 0.66 (s, 3H). MS (m/z) 511.5 (M+H+). Example 85: (R)-ll'-chloro-12'-(3-methoxy-3-methylbut-l-yn-l-yl)-8'-oxo-l',2',8',13b'- tetrahydrospiro[cyclopropane-l,3'-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine]-7'-carboxylic acid
Figure imgf000171_0001
ethyl 12'-(benzyloxy)-1 1 '- methyl (R)-12'-(benzyloxy)- chloro-8'-oxo-1 ',2',8', 13b'- 1 1 '-chloro-8'-oxo-1 ',2',8', 13b'- tetrahydrospiro[cyclopropan tetrahydrospiro[cyclopropane- e-1 ,3'-pyrido[2, 1 - 1 ,3'-pyrido[2, 1 -a]pyrrolo[1 ,2- a]pyrrolo[1 ,2-c]phthalazine]- c]phthalazine]-7'-carboxylate
7'-carboxylate
Figure imgf000171_0002
methyl (R)-1 1 '-chloro-8'-oxo-12'- (((trifluoromethyl)sulfonyl)oxy)- V, 2', 8', 13b'- tetrahydrospiro[cyclopropane-1 ,3'- pyrido[2, 1 -a]pyrrolo[1 ,2- c]phthalazine]-7'-carboxylate
Synthesis of methyl (R)-12'-(benzyloxy)-ll'-chloro-8'-oxo-l',2',8',13b'- tetrahydrospiro[cyclopropane-l,3'-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine]-7'-carboxylate:
Ethyl 12'-(benzyloxy)-H'-chloro-8'-oxo- ,2',8',13b'-tetrahydrospiro[cyclopropane-l,3'- pyrido[2,l-a]pyrrolo[l,2-c]phthalazine]-7'-carboxylate was prepared similarly to ethyl 11- chloro-12-(3-methoxypropoxy)-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2- c]phthalazine-7-carboxylate in Example 1, but using tert-butyl 5-oxo-4-azaspiro[2.4]heptane-4- carboxylate in place of tert-butyl 2-oxopyrrolidine-l-carboxylate and l-(benzyloxy)-4-bromo-2- chloro-5-iodobenzene in place of l-bromo-5-chloro-2-iodo-4-(3-methoxypropoxy)benzene. Ethyl 12'-(benzyloxy)-i -chloro-8'-oxo- ,2',8',13b'-tetrahydrospiro[cyclopropane-l,3'- pyrido[2,l-a]pyrrolo[l,2-c]phthalazine]-7'-carboxylate was separated into its enantiomers by chiral SFC chromatography using AD-H 5X250mm columns with 40% methanol as the co- solvent. The (R)-enantiomer was found to be the faster eluting enantiomer. During separation and concentration of the solvent the ethyl ester was converted to the methyl ester. XH NMR (400 MHz, Chloroform-d) δ 8.14 (s, 1H), 7.76 (s, 1H), 7.48 - 7.37 (m, 4H), 7.37 - 7.31 (m, 1H), 6.87 (s, 1H), 6.85 (s, 1H), 5.25 (d, J = 2.1 Hz, 2H), 4.72 (d, J = 5.9 Hz, 1H), 3.88 (s, 3H), 2.46 (s, 1H), 2.32 (d, J = 9.3 Hz, 1H), 2.01 (dd, J = 12.4, 9.6 Hz, 1H), 1.63 - 1.51 (m, 1H), 0.89 - 0.82 (m, 1H), 0.59 (dd, J = 8.8, 5.4 Hz, 1H), 0.20 (d, J = 10.7 Hz, 1H), 0.07 (d, J = 10.2 Hz, 1H). MS (m/z) 463.7 [M+H]+.
Synthesis of methyl (R)-ll'-chloro-8'-oxo-12'-(((trifluoromethyl)sulfonyl)oxy)-l',2',8',13b'- tetrahydrospiro[cyclopropane-l,3'-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine]-7'-carboxylate: Prepared from methyl (R)-12'-(benzyloxy)-l l'-chloro-8'-oxo-l',2',8',13b'- tetrahydrospiro[cyclopropane-l,3'-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine]-7'-carboxylate in a manner similar to the preparation of (R)-l l-methoxy-3,3-dimethyl-8-oxo-12-
(((trifluoromethyl)sulfonyl)oxy)-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2- c]phthalazine-7-carboxylate in Example 42. MS (m/z) 505.6 [M+H]+.
Synthesis of (R)-ll'-chloro-12'-(3-methoxy-3-methylbut-l-yn-l-yl)-8'-oxo-l',2',8',13b'- tetrahydrospiro[cyclopropane-l,3'-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine]-7'-carboxylic acid:
Figure imgf000172_0001
Prepared similarly to (R)-l l-methoxy-3,3-dimethyl-12-(3-methyl-3-(methylsulfonyl)but-l-yn-l- yl)-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid in Example 83 using 3-methoxy-3-methylbut-l-yne to replace 3-methyl-3-(methylsulfonyl)but-l- yne and methyl (R)-ir-chloro-8'-oxo-12'-(((trifluoromethyl)sulfonyl)oxy)-r,2',8',13b'- tetrahydrospiro[cyclopropane-l,3'-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine]-7'-carboxylate to replace ethyl (R)-l l-methoxy-3,3-dimethyl-8-oxo-12-(((trifluoromethyl)sulfonyl)oxy)- 2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate. XH NMR (400 MHz, Chloroform-d) δ 8.44 (s, 1H), 7.84 (s, 1H), 7.51 (d, J = 1.1 Hz, 1H), 7.26 (s, 2H), 7.16 (s, 1H), 5.04 - 4.59 (m, 1H), 3.47 (s, 3H), 3.36 (s, 2H), 2.57 (td, J = 9.3, 8.8, 5.2 Hz, 2H), 2.15 (ddd, J = 12.2, 8.5, 3.3 Hz, 1H), 1.77 (dt, J = 12.9, 9.5 Hz, 1H), 1.59 (s, 6H), 1.46 (s, 4H), 0.66 (ddd, J = 21.8, 10.9, 6.9 Hz, 2H), 0.11 (ddd, J = 23.8, 10.9, 6.8 Hz, 2H). MS (m/z) 439.78(M+H+). Example 86: (R)-ll'-chloro-12'-(l-(oxetan-3-yl)-lH-pyrazol-4-yl)-8'-oxo-l',2',8',13b'- tetrahydrospiro[cyclopropane-l,3'-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine]-7'-carboxylic acid
Figure imgf000173_0001
Methyl (R)-l r-chloro-8'-oxo-12'-(((trifluoromethyl)sulfonyl)oxy)-r,2',8',13b'- tetrahydrospiro[cyclopropane-l,3'-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine]-7'-carboxylate (17 mg, 0.034 mmol) was combined with l-(3-Oxetanyl)-lH-pyrazole-4-boronic acid pinacol ester (25 mg, 0.10 mmol), Dichloro l,l-bis(diphenylphosphino)ferrocene palladium(II)
dichloromethane (1.4 mg, 1.6 μιτιοΐ), and potassium carbonate (14 mg, 0.10 mmol) in dioxane (1.7 mL) and water (0.3 mL) in a microwave vial. The mixture was heated under microwave irradiation at 120 °C for 10 minutes, then cooled to room temperature and 2N LiOH (0.1 mL) was added. After LCMS analysis indicated complete conversion, the mixture was diluted with TFA and water and extracted with ethyl acetate x 2. The combined organic layers were concentrated, redissolved in DMF and purified by HPLC to provide (R)-l l'-chloro-12'-(l- (oxetan-3-yl)-lH-pyrazol-4-yl)-8'-oxo- ,2',8',13b'-tetrahydrospiro[cyclopropane-l,3'- pyrido[2,l-a]pyrrolo[l,2-c]phthalazine]-7'-carboxylic acid. 'H NMR (400 MHZ, Chloroform-d) δ 8.47 (s, 1H), 8.18 (s, 1H), 7.99 (s, 1H), 7.90 (s, 1H), 7.52 (s, 1H), 7.23 (s, 1H), 5.55 (t, J = 6.8 Hz, 1H), 5.32 - 5.00 (m, 4H), 4.87 (d, J = 5.4 Hz, 1H), 2.59 (d, J = 10.0 Hz, 2H), 2.16 (s, 1H), 1.78 (d, J = 10.8 Hz, 1H), 0.76 - 0.52 (m, 2H), 0.28 - -0.13 (m, 2H). MS (m/z) 465.60 (M+H+).
Example 87: (R)-ll'-(methoxymethyl)-12'-(3-methoxypropoxy)-8'-oxo-l',2',8',13b'- tetrahydrospiro[cyclopropane-l,3'-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine]-7'-carboxylic acid
Figure imgf000174_0001
Synthesis of Isopropyl (R)-12'-(benzyloxy)-ll'-(methoxymethyl)-8'-oxo-l',2',8',13b'- tetrahydrospiro[cyclopropane-l,3'-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine]-7'-carboxylate:
Methyl (R)-12'-(benzyloxy)-H'-chloro-8'-oxo- ,2',8',13b'-tetrahydrospiro[cyclopropane-l,3'- pyrido[2,l-a]pyrrolo[l,2-c]phthalazine]-7'-carboxylate (234 mg, 0.51 mmol) was dissolved in isopropanol (10 mL) with 2 drops of acetic acid. The mixture was stirred at reflux for 2.5 hours, then cooled to room temperature to provide isopropyl (R)-12'-(benzyloxy)-H'-chloro-8'-oxo- ,2',8',13b'-tetrahydrospiro[cyclopropane-l,3'-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine]-7'- carboxylate. MS (m/z) 491.3 [M+H]+. The crude ester was combined with
trifluoro(methoxymethyl)-borane, potassium salt (230 mg, 1.52 mmol), Pd RuPhos G4 (52 mg, 0.061 mmol), RuPhos (42 mg, 0.091 mmol), and cesium carbonate (823 mg, 2.53 mmol) in toluene:water (3: 1, 5 mL) under argon in a sealed vial. The mixture was heated at 110 °C for 45 minutes with vigorous stirring, then cooled to room temperature, the aqueous layer was removed, and the organics were concentrated in vacuo and purified by flash column
chromatography (hexanes / ethyl acetate / ethanol / triethylamine) to provide isopropyl (R)-12'- (benzyloxy)-i -(methoxymethyl)-8'-oxo- ,2',8',13b'-tetrahydrospiro[cyclopropane-l,3'- pyrido[2,l-a]pyrrolo[l,2-c]phthalazine]-7'-carboxylate. MS (m/z) 501.4 [M+H]+.
Synthesis of (R)-ll'-(methoxymethyl)-12'-(3-methoxypropoxy)-8'-oxo-l',2',8',13b'- tetrahydrospiro[cyclopropane-l,3'-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine]-7'-carboxylic acid: isopropyl (R)-12'-(benzyloxy)-ir-(methoxymethyl)-8'-oxo-r,2',8',13b'- tetrahydrospiro[cyclopropane-l,3'-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine]-7'-carboxylate (180 mg, 360 μιτιοΐ)) was combined with Palladium on carbon (10wt%, wet) E101 NEAV (5%, 38 mg) in ethanol (5 mL) under argon. The system was placed under vacuum and backfilled with hydrogen gas. The mixture was stirred vigorously for 45 minutes after which time LCMS analysis showed complete conversion. The mixture was diluted with DCM (50 mL) and filtered through celite. The supernatant was concentrated to provide crude isopropyl (R)-12'-hydroxy- H'-(methoxymethyl)-8'-oxo- ,2',8',13b'-tetrahydrospiro[cyclopropane-l,3'-pyrido[2,l- a]pyrrolo[l,2-c]phthalazine]-7'-carboxylate. The crude solids were combined with potassium carbonate (149 mg, 1.08 mmol) and l-bromo-3-methoxypropane (166 mg, 1.08 mmol) in DMF (2 mL) and stirred at 80 °C for 75 minutes after which time LCMS analysis showed complete conversion. 1M lithium hydroxide (0.3 mL) was added and the mixture was stirred at 60 °C for 30 minutes. The mixture was cooled to rt, the aqueous layer was removed and the organic layer was diluted with 1M TFA and MeCN and purified by preparative HPLC to provide (R)-l Γ- (methoxymethyl)-12'-(3-methoxypropoxy)-8'-oxo- ,2',8',13b'-tetrahydrospiro[cyclopropane- l,3'-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine]-7'-carboxylic acid as a TFA salt. XH NMR (400 MHz, Acetonitrile-d3) δ 8.28 (s, 1H), 7.92 (s, 1H), 7.14 (s, 1H), 7.05 (s, 1H), 4.92 (d, J = 6.0 Hz, 1H), 4.51 (ddt, J = 4.5, 0.7 Hz, 2H), 4.33 - 4.11 (m, 2H), 3.57 (td, J = 6.2, 0.7 Hz, 2H), 3.45 (s, 3H), 3.33 (s, 3H), 2.73 - 2.61 (m, 1H), 2.56 - 2.43 (m, 1H), 2.14 - 2.02 (m, 3H), 1.77 (dt, J = 12.9, 9.6 Hz, 1H), 0.67 (dt, J = 10.3, 6.5 Hz, 1H), 0.57 (dt, J = 11.0, 6.8 Hz, 1H), 0.19 - 0.06 (m, 2H). 19F NMR (376 MHz, Acetonitrile-d3) δ -77.29 . MS (m/z) 441.3 [M+H]+.
Example 88: (R)-12-(3-(((l-(Difluoromethyl)cyclopropyl)carbamoyl)oxy)propoxy)-ll- (methoxymethyl)-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2- c]phthalazine-7-carboxylic acid
Figure imgf000175_0001
(difluoromethyl)cyclopro 3-bromopropyl (1- pane-1-carboxylic acid (difluoromethyl)cyclo ethyl ( )-12-hydroxy- propyl)carbamate 1 1 -(methoxymethyl)-3,3-dimethyl- 8 -2,3,8,13b-tetrahydro- 1 H-pyrido[2, 1 -a]pyrrolo
[1 ,2-c]phthalazine-7-carboxylate
Figure imgf000175_0002
88
(R)-12-(3-(((1-(difluoromethyl)cyclopropyl)carbamoyl)oxy)propoxy)- 1 1-(methoxymethyl)-3,3-dimethyl-8-oxo-2, 3,8,13b-tetrahydro-1 H- pyrido[2,1-a]pyrrolo[1 ,2-c]phthalazine-7-carboxylic acid
Synthesis of 3-bromopropyl (l-(difluoromethyl)cyclopropyl)carbamate: 1-
(Difluoromethyl)cyclopropane-l-carboxylic acid (2.00 g, 14.7 mmol) was suspended in PhMe (8 mL). DIPEA (3.33 mL, 19.1 mmol) and DPPA (3.33 mL, 15.4 mmol) were added and the reaction mixture was stirred at reflux for 1.5 h. After cooling to RT, 3-bromopropan-l-ol (0.53 mL, 5.9 mmol) and DCM (8 mL) were added. The reaction mixture was stirred o/n at RT. Upon completion, the reaction mixture was concentrated under reduced pressure. The crude residue was purified by silica column chromatography (0% to 30% EtO Ac/hex) to provide 3- bromopropyl (l-(difluoromethyl)cyclopropyl)carbamate (1.60 g, 87%).
Synthesis of (R)-12-(3-(((l-(difluoromethyl)cyclopropyl)carbamoyl)oxy)propoxy)-ll- (methoxymethyl)-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2- c]phthalazine-7-carboxylic acid: The title compound was prepared similarly to (R)-l l- (methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH- pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid (Example 73), substituting 3- bromopropyl (l-(difluoromethyl)cyclopropyl)carbamate for l-bromo-3-methoxypropane. XH NMR (400 MHz, Chloroform-c δ 8.57 (s, IH), 7.85 (s, IH), 7.29 (s, IH), 6.78 (s, IH), 5.84 (t, J = 57.7 Hz, IH), 5.57 (s, IH), 4.83 (d, J = 5.9 Hz, IH), 4.49 (s, 2H), 4.28 (t, J= 5.9 Hz, 2H), 4.14 (dd, J = 11.1, 5.0 Hz, 2H), 3.49 (s, 3H), 2.27 - 2.07 (m, 2H), 1.90 (ddd, J = 12.8, 7.5, 2.6 Hz, IH), 1.62 (td, J = 11.6, 7.7 Hz, IH), 1.37 (s, 3H), 1.11 (q, J = 5.6 Hz, 2H), 0.95 (p, J = 2.7 Hz, 2H), 0.64 (s, 3H). MS (m/z) 562.6 [M+H]+.
Example 89 : (R)-3,3-dimethyl- 12-(3-methyl-3-(methylsulfonyl)but-l-yn- l-yl)-8-oxo- 11- (trifluoromethoxy)-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7- carboxylic acid
Figure imgf000177_0001
ethyl (R)-12-(benzyloxy)-3,3-dimethyl-8-oxo- ethyl (R)-12-hydroxy-3,3- 1 1 -(trifluoromethoxy)-2, 3,8, 13b-tetrahydro-1 H- dimethyl-8-oxo-1 1 - pyrido[2, 1 -a]pyrrolo[1 ,2-c]phthalazine-7- (trifluoromethoxy)-2,3,8, 13b- carboxylate tetrahydro-1 /-/-pyrido[2, 1 - a]pyrrolo[1 ,2-c]phthalazine-7- carboxylate
ethyl (fi)- 12-(((t
tetra
Figure imgf000177_0002
hydro-1 H-pyrido[2,1-a]pyrrolo[1 ,2- c]phthalazine-7-carboxylate
Synthesis of ethyl (R)-12-hydroxy-3,3-dimethyl-8-oxo-ll-(trifluoromethoxy)-2,3,8,13b- tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate (JZ-B): The title compound was prepared similarly to ethyl (R)-12-hydroxy-l l-methoxy-3,3-dimethyl-8-oxo- 2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate in example 14 using ethyl (R)-12-(benzyloxy)-3,3-dimethyl-8-oxo-l l-(trifluoromethoxy)-2,3,8,13b-tetrahydro- lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate in place of ethyl (R)-12-(benzyloxy)- l l-methoxy-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2- c]phthalazine-7-carboxylate: MS (m/z) 439.15 [M+H]+.
Synthesis of ethyl (R)-3,3-dimethyl-8-oxo-ll-(trifluoromethoxy)-12- (((trifluoromethyl)sulfonyl)oxy)-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2- c] phthalazine-7-carboxylate:
The title compound was prepared similarly to ethyl (R)-l l-methoxy-3,3-dimethyl-8-oxo-12- (((trifluoromethyl)sulfonyl)oxy)-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2- c]phthalazine-7-carboxylate in example 42 using ethyl (R)-12-hydroxy-3,3-dimethyl-8-oxo-l l- (trifluoromethoxy)-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7- carboxylate in place of ethyl (R)-12-hydroxy-l l-methoxy-3,3-dimethyl-8-oxo-2,3, 8,13b- tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate: MS (m/z) 571.15 [M+H]+. Synthesis of (R)-3,3-dimethyl-12-(3-methyl-3-(methylsulfonyl)but-l-yn-l-yl)-8-oxo-ll- (trifluoromethoxy)-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7- carboxylic acid (89):
The title compound was prepared similarly to (R)-l l-methoxy-3,3-dimethyl-12-(3-methyl-3- (methylsulfonyl)but-l-yn-l-yl)-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2- c]phthalazine-7-carboxylic acid in example 83 using ethyl (R)-3,3-dimethyl-8-oxo-l 1- (trifluoromethoxy)-12-(((trifluoromethyl)sulfonyl)oxy)-2,3,8,13b-tetrahydro-lH-pyrido[2,l- a]pyrrolo[l,2-c]phthalazine-7-carboxylate in place of ethyl (R)-l l-methoxy-3,3-dimethyl-8-oxo- 12-(((trifluoromethyl)sulfonyl)oxy)-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2- c]phthalazine-7-carboxylate: XH NMR (400 MHz, Chloroform-d) δ 8.66 (s, 1H), 7.72 (d, J = 1.5 Hz, 1H), 7.55 (d, J = 1.0 Hz, 1H), 7.44 (s, 1H), 4.83 (d, J = 6.2 Hz, 1H), 3.09 (s, 3H), 2.70 - 2.34 (m, 2H), 1.98 (ddd, J = 12.8, 8.0, 2.7 Hz, 1H), 1.78 (s, 6H), 1.67 (ddd, J = 13.0, 10.9, 7.8 Hz, 1H), 1.41 (s, 3H), 0.67 (s, 3H). MS (m/z): 539.11 [M+H]+. Example 90: (R)-12-(3-methoxy-3-methylbut-l-yn-l-yl)-3,3-dimethyl-8-oxo-ll-
(trifluoromethoxy)-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7- carboxylic acid
Figure imgf000178_0001
The title compound was prepared similarly to (R)-l l-Methoxy-12-(3-methoxy-3-methylbut-l- yn-l-yl)-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7- carboxylic acid in example 43 using ethyl (R)-3,3-dimethyl-8-oxo-l l-(trifluoromethoxy)-12- (((trifluoromethyl)sulfonyl)oxy)-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2- c]phthalazine-7-carboxylate in place of ethyl (R)-l l-methoxy-3,3-dimethyl-8-oxo-12- (((trifluoromethyl)sulfonyl)oxy)-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2- c]phthalazine-7-carboxylate: MS (m/z): 491.49 [M+H]+. 'H NMR (400 MHz, Chloroform-d) δ 8.60 (s, 1H), 7.66 (d, J = 1.4 Hz, 1H), 7.49 (d, J = 1.1 Hz, 1H), 7.21 (s, 1H), 4.81 (d, J = 6.2 Hz, 1H), 3.44 (s, 3H), 2.62 - 2.32 (m, 2H), 1.95 (ddd, J = 12.8, 8.0, 2.8 Hz, 1H), 1.66 (ddd, J = 12.7, 10.7, 7.8 Hz, 1H), 1.57 (s, 6H), 1.40 (s, 3H), 0.68 (s, 3H). Example 91: (R)-3,3-dimethyl-8-oxo-12-(2-(3-oxo-[l,2,4]triazolo[4,3-a]pyridin-2(3H)- yl)ethoxy)-ll-(trifluoromethoxy)-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2- c]phthalazine-7-carboxylic acid:
Figure imgf000179_0001
The title compound was prepared similarly to (R)-12-(3-(((l-
(Difluoromethyl)cyclopropyl)carbamoyl)oxy)propoxy)-l l-(methoxymethyl)-3,3-dimethyl-8- oxo-2,3, 8, 13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid in example 88 using (R)-ethyl 12-hydroxy-3,3-dimethyl-8-oxo-l l-(trifluoromethoxy)-2,3, 8,13b- tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate and 2-(2-bromoethyl)- [l,2,4]triazolo[4,3-a]pyridin-3(2H)-one in place of (R)-ethyl 12-hydroxy-l 1 -(methoxymethyl)- 3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7- carboxylate and 3-bromopropyl (l-(difluoromethyl)cyclopropyl)carbamate: MS (m/z): 572.20 [M+H]+. XH NMR (400 MHz, Chloroform-d) δ 8.58 (s, 1H), 7.79 (dt, J = 7.1, 1.3 Hz, 1H), 7.62 (d, J = 1.3 Hz, 1H), 7.22 - 7.03 (m, 3H), 6.98 (s, 1H), 6.56 (ddd, J = 7.2, 6.1, 1.3 Hz, 1H), 4.78 (d, J = 6.3 Hz, 1H), 4.64 - 4.39 (m, 4H), 2.65 - 2.34 (m, 2H), 1.92 (ddd, J = 11.0, 8.0, 2.7 Hz, 1H), 1.62 (td, J = 11.5, 7.6 Hz, 1H), 1.38 (s, 3H), 0.67 (d, J = 8.1 Hz, 3H).
Example 92: (R)-12-((3-cyanobicyclo[l.l.l]pentan-l-yl)methoxy)-3,3-dimethyl-8-oxo-ll- (trifluoromethoxy)-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7- carboxylic acid:
Figure imgf000179_0002
The title compound was prepared similarly to (R)-12-((3-cyanobicyclo[l.1. l]pentan-l- yl)methoxy)-l l-(methoxymethyl)-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l- a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid in example 74 using ethyl (R)- 12-hydroxy-3,3- dimethyl-8-oxo-l 1 -(trifluoromethoxy)-2,3,8, 13b-tetrahydro-lH-pyrido[2, 1 -a]pyrrolo[l ,2- c]phthalazine-7-carboxylate in place of (R)-ethyl 12-hydroxy-l l-(methoxymethyl)-3,3- dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate: MS (m/z): 516.28 [M+H]+). XH NMR (400 MHz, Chloroform-d) δ 8.61 (s, 1H), 7.69 (d, J = 1.3 Hz, 1H), 7.29 (s, 1H), 6.83 (s, 1H), 4.82 (d, J = 6.4 Hz, 1H), 4.19 - 4.02 (m, 2H), 2.54 (dd, J = 11.3, 6.3 Hz, 1H), 2.36 (s, 7H), 1.95 (ddd, J = 11.2, 8.0, 2.6 Hz, 1H), 1.69 - 1.55 (m, 1H), 1.40 (d, J = 2.0 Hz, 3H), 0.68 (s, 3H). Example 93: (R)-3,3-dimethyl-12-(l-(oxetan-3-yl)-lH-pyrazol-4-yl)-8-oxo-ll-
(trifluoromethoxy)-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7- carboxylic acid:
Figure imgf000180_0001
The title compound was prepared similarly to (R)-l l-chloro-12-(l-(difluoromethyl)-lH-pyrazol- 4-yl)-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7- carboxylic acid in example 76 using (R)-ethyl 3,3-dimethyl-8-oxo-l l-(trifluoromethoxy)-12- (((trifluoromethyl)sulfonyl)oxy)-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2- c]phthalazine-7-carboxylate and 1 -(oxetan-3-yl)-4-(4,4,5,5-tetramethyl-l ,3,2-dioxaborolan-2- yl)-lH-pyrazole in place of ethyl (R)-l l-chloro-3,3-dimethyl-8-oxo-12- (((trifluoromethyl)sulfonyl)oxy)-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2- c]phthalazine-7-carboxylate and l-(difluoromethyl)-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan- 2-yl)-lH-pyrazole: MS (m/z): 517.16 [M+H]+. 'H NMR (400 MHz, Chloroform-d) δ 8.63 (s, 1H), 8.07 (d, J = 0.8 Hz, 1H), 8.02 (s, 1H), 7.74 (d, J = 1.5 Hz, 1H), 7.58 (d, J = 1.1 Hz, 1H), 7.32 (s, 1H), 5.62 - 5.48 (m, 1H), 5.23 - 5.03 (m, 4H), 4.88 (t, J = 6.6 Hz, 1H), 2.55 (dd, J = 16.5, 9.3 Hz, 2H), 1.97 (ddd, J = 11.3, 7.9, 2.9 Hz, 1H), 1.69 (td, J = 11.2, 7.7 Hz, 1H), 1.42 (s, 3H), 0.71 (s, 3H). Example 94: (R)-ll-(methoxymethyl)-3,3-dimethyl-12-(3-(oxetan-3-yloxy)propoxy)-8-oxo- 2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid
Figure imgf000181_0001
Prepared analogously to (R)-12-((3-cyanobicyclo[l . l. l]pentan-l-yl)methoxy)-l l- (methoxymethyl)-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2- c]phthalazine-7-carboxylic acid in example 74 using 3-(oxetan-3-yloxy)propan-l-ol in place of 3-(hydroxymethyl)bicyclo[l . l . l]pentane-l-carbonitrile. This compound was free based prior to lyophilization. 'H NMR (400 MHz, Acetonitrile-d3) δ 8.40 (s, 1H), 7.87 (s, 1H), 7.13 (s, 1H), 6.97 (s, 1H), 4.86 (d, J = 6.3 Hz, 1H), 4.72 (td, J = 6.2, 0.9 Hz, 2H), 4.60 - 4.52 (m, 1H), 4.51 - 4.41 (m, 4H), 4.22 (ddt, J = 27.9, 9.7, 6.1 Hz, 2H), 3.56 (t, J = 6.2 Hz, 2H), 3.41 (s, 3H), 2.62 - 2.36 (m, 2H), 2.05 (p, J = 6.2 Hz, 2H), 1.89 (ddd, J = 12.7, 8.0, 2.9 Hz, 1H), 1.61 (ddd, J = 12.7, 10.6, 7.9 Hz, 1H), 1.35 (s, 3H), 0.63 (s, 3H). MS (m/z) 485.6 [M+H]+.
Example 95: (R)-ll-(methoxymethyl)-3,3-dimethyl-8-oxo-12-(2-(3-oxo-[l,2,4]triazolo[4,3- a] pyridin-2(3H)-yl)ethoxy)-2,3,8,13b-tetrahydro- lH-pyrido [2,1-a] pyrrolo [ 1,2- c]phthalazine-7-carboxylic ac
Figure imgf000181_0002
Prepared analogously to (R)-l l-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-oxo- 2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid in example 73 using 2-(2-bromoethyl)-[l,2,4]triazolo[4,3-a]pyridin-3(2H)-one in place of l-bromo-3- methoxypropane. ¾ NMR (400 MHz, Acetonitrile-d3) δ 8.44 (s, 1H), 7.85 (s, 1H), 7.70 (dt, J = 7.1, 1.2 Hz, 1H), 7.18 (s, 1H), 7.15 (ddd, J = 9.5, 6.2, 1.3 Hz, 1H), 7.09 (dt, J = 9.5, 1.2 Hz, 1H), 6.97 (s, 1H), 6.54 (ddd, J = 7.2, 6.2, 1.2 Hz, 1H), 4.83 (d, J = 6.4 Hz, 1H), 4.61 - 4.44 (m, 2H), 4.44 . 4.26 (m, 4H), 3.30 (s, 3H), 2.60 - 2.38 (m, 2H), 1.88 (ddd, J = 12.7, 8.0, 2.9 Hz, 1H), 1.59 (ddd, J = 12.7, 10.5, 7.9 Hz, 1H), 1.35 (s, 3H), 0.60 (s, 3H). 19F NMR (376 MHz, Acetonitrile- d3) δ -77.34. MS (m/z) 532.5 [M+H]+. Example 96: (R)-ll-cyclopropyl-3,3-dimethyl-8-oxo-12-(2-(3-oxo-[l,2,4]triazolo[4,3- a] pyridin-2(3H)-yl)ethoxy)-2,3,8,13b-tetrahydro- lH-pyrido [2,1-a] pyrrolo [ 1,2- c]phthalazine-7-carboxylic acid
Figure imgf000182_0001
ethyl (R)-1 1 -chloro-12-hydroxy-3,3- ethyl (R)-1 1 -chloro-3,3-dimethyl-8-oxo-12-(2- dimethyl-8-oxo-2, 3,8, 13b-tetrahydro- (3-oxo-[1 ,2,4]triazolo[4,3-a]pyridin-2(3 -/)- 1 /-/-pyrido[2, 1 -a]pyrrolo[1 ,2- y I ) eth oxy)-2 , 3 , 8 , 13 b-tetrahyd ro- 1 H- c]phthalazine-7-carboxylate pyrido[2, 1 -a]pyrrolo[1 ,2-c]phthalazine-7- carboxylate
Figure imgf000182_0002
(R)-1 1 -cyclopropyl-3,3-dimethyl-8-oxo-
12-(2-(3-oxo-[1 ,2,4]triazolo[4,3- a]pyridin-2(3H)-yl)ethoxy)-2,3,8, 13b- tetrahydro-1 H-pyrido[2, 1 -a]pyrrolo[1 ,2- c]phthalazine-7-carboxylic acid
Ethyl (R)-ll-chloro-3,3-dimethyl-8-oxo-12-(2-(3-oxo-[l,2,4]triazolo[4,3-a]pyridin-2(3H)- yl)ethoxy)-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate:
Prepared analogously to (R)-l l-(methoxymethyl)-3,3-dimethyl-8-oxo-12-(2-(3-oxo- [l,2,4]triazolo[4,3-a]pyridin-2(3H)-yl)ethoxy)-2,3,8,13b-tetrahydro-lH-pyrido[2,l- a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid in example 95 using ethyl (R)-l l-chloro-12- hydroxy-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7- carboxylate in place of ethyl (R)-12-hydroxy-l l-(methoxymethyl)-3,3-dimethyl-8-oxo- 2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate. MS (m/z) 550.3 [M+H]+.
(R)-l l-cyclopropyl-3,3-dimethyl-8-oxo- 12-(2-(3-oxo- [ 1,2,4] triazolo [4,3-a] pyridin-2(3H)- yl)ethoxy)-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid: Prepared analogously to (R)-l l-cyclopropyl-12-(3-hydroxy-3-methylbut-l-yn-l-yl)-3,3- dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid in example 71 using ethyl (R)-l l-chloro-3,3-dimethyl-8-oxo-12-(2-(3-oxo- [l,2,4]triazolo[4,3-a]pyridin-2(3H)-yl)ethoxy)-2,3,8,13b-tetrahydro-lH-pyrido[2,l- a]pyrrolo[l,2-c]phthalazine-7-carboxylate in place of ethyl (R)-l l-chloro-12-(3-hydroxy-3- methylbut-l-yn-l-yl)-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2- c]phthalazine-7-carboxylate. XH NMR (400 MHz, Acetonitrile-d3) δ 8.41 (s, IH), 7.70 (dt, J = 7.1, 1.2 Hz, IH), 7.29 (s, IH), 7.18 (s, IH), 7.17 - 7.12 (m, IH), 7.09 (dt, J = 9.5, 1.2 Hz, IH), 6.92 (s, IH), 6.55 (ddd, J = 7.2, 6.2, 1.1 Hz, IH), 4.80 (d, J = 6.3 Hz, IH), 4.53 (qt, J = 10.4, 5.2 Hz, 2H), 4.38 (t, J = 5.2 Hz, 2H), 2.47 - 2.33 (m, 2H), 2.11 - 2.02 (m, IH), 1.86 (ddd, J = 12.7, 8.0, 2.7 Hz, IH), 1.58 (td, J = 11.4, 7.8 Hz, IH), 1.34 (s, 3H), 0.91 - 0.79 (m, 2H), 0.70 - 0.64 (m, 2H), 0.60 (s, 3H). 19F NMR (376 MHz, Acetonitrile-d3) δ -77.33. MS (m/z) 528.4 [M+H]+.
Example 97: (R)-12-(3-methoxy-3-methylbut-l-yn-l-yl)-ll-(methoxymethyl)-3,3-dimethyl- 8-oxo-2,3,8,13b-tetrahydro- lH- hthalazine-7-carboxylic acid
Figure imgf000183_0001
Prepared analogously to (R)-12-(3-hydroxy-3-methylbut-l-yn-l-yl)-l l-(methoxymethyl)-3,3- dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid in example 70 using 3-methoxy-3-methylbut-l-yne in place of 2-methylbut-3-yn-2-ol. XH NMR (400 MHz, Acetonitrile-d3) δ 8.47 (s, IH), 8.01 (s, IH), 7.54 (s, IH), 7.30 (s, IH), 4.88 (d, J = 6.1 Hz, IH), 4.68 - 4.57 (m, 2H), 3.46 (s, 3H), 3.42 (s, 3H), 2.57 - 2.43 (m, 2H), 1.94 - 1.87 (m, IH), 1.68 - 1.58 (m, IH), 1.56 (s, 6H), 1.37 (s, 3H), 0.63 (s, 3H). 19F NMR (376 MHz, Acetonitrile-d3) δ -77.33. MS (m/z) 451.5 [M+H]+.
Example 98: (R)-ll-chloro-3,3-dimethyl-12-(3-(oxetan-3-yloxy)propoxy)-8-oxo-2,3,8,13b- tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid
Figure imgf000183_0002
Prepared analogously to (R)-l l-(methoxymethyl)-3,3-dimethyl-12-(3-(oxetan-3- yloxy)propoxy)-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7- carboxylic acid using ethyl (R)-l l-chloro-12-hydroxy-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro- lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate in place of ethyl (R)-12-hydroxy-l l- (methoxymethyl)-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2- c]phthalazine-7-carboxylate. ¾ NMR (400 MHz, Acetonitrile-d3) δ 8.43 (s, IH), 8.03 (s, IH), 7.18 (s, IH), 7.09 (s, IH), 4.86 (d, J = 6.4 Hz, IH), 4.72 (t, J = 6.4 Hz, 2H), 4.57 (p, J = 5.4 Hz, IH), 4.51 - 4.42 (m, 2H), 4.30 (ddt, J = 27.2, 9.7, 6.2 Hz, 2H), 3.58 (t, J = 6.1 Hz, 2H), 2.63 - 2.39 (m, 2H), 2.08 (p, J = 6.3 Hz, 2H), 1.93 - 1.84 (m, IH), 1.65 (td, J = 12.6, 11.8, 7.9 Hz, IH), 1.36 (s, 3H), 0.67 (s, 3H). MS (m/z) 475.2 [M+H]+.
Example 99: (R)-12-((3-cyanobicyclo[l.l.l]pentan-l-yl)methoxy)-ll-cyclopropyl-3,3- dimethyl-8-oxo-2,3,8,13b-tetrahydro- lH-pyrido [2,1-a] pyrrolo [ 1,2-c] phthalazine-7-
Figure imgf000184_0001
Ethyl (R)-l l-chloro-12-((3-cyanobicyclo[l. l . l]pentan-l-yl)methoxy)-3,3-dimethyl-8-oxo-
2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate was prepared analogously to (R)-12-((3-cyanobicyclo[l . l. l]pentan-l-yl)methoxy)-l l-(methoxymethyl)-3,3- dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid in example 74 , using ethyl (R)-l l-chloro-12-hydroxy-3,3-dimethyl-8-oxo-2,3, 8,13b- tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate in place of ethyl (R)-12- hydroxy-l l-(methoxymethyl)-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l- a]pyrrolo[l,2-c]phthalazine-7-carboxylate and omitting the lithium hydroxide hydrolysis step.
(R)-12-((3-cyanobicyclo[l.1. l]pentan-l-yl)methoxy)-l l-cyclopropyl-3,3-dimethyl-8-oxo-
2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid was prepared from ethyl (R)-l l-chloro-12-((3-cyanobicyclo[l . l. l]pentan-l-yl)methoxy)-3,3-dimethyl-8-oxo-
2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate analogously to the preparation of (R)-l l-cyclopropyl-12-(3-hydroxy-3-methylbut-l-yn-l-yl)-3,3-dimethyl-8- oxo-2,3, 8, 13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid in example 71. 'H NMR (400 MHz, Acetonitrile-d3) δ 8.43 (s, IH), 7.38 (s, IH), 7.24 (s, IH), 6.84 (d, J = 0.9 Hz, 1H), 4.82 (d, J = 6.2 Hz, 1H), 4.21 (d, J = 11.0 Hz, 1H), 4.11 (d, J = 11.0 Hz, 1H), 2.57 - 2.37 (m, 2H), 2.35 (s, 6H), 2.18 (tt, J = 8.6, 5.4 Hz, 1H), 1.88 (ddd, J = 12.6, 7.8, 2.8 Hz, 1H), 1.59 (ddd, J = 12.5, 10.7, 7.9 Hz, 1H), 1.35 (s, 3H), 1.05 - 0.91 (m, 2H), 0.88 - 0.74 (m, 2H), 0.61 (s, 3H). 19F NMR (376 MHz, Acetonitrile-d3) δ -77.32. MS (m/z) 472.5 [M+H]+.
Example 100: (R)- 12-((3-cyanobicyclo [ 1.1.1] pentan-l-yl)methoxy)- 1 l-ethyl-3,3-dimethyl-8- oxo-2,3,8,13b-tetrahydro-l -pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid
Figure imgf000185_0001
Ethyl (R)-l l-chloro-12-((3-cyanobicyclo[l. l.l]pentan-l-yl)methoxy)-3,3-dimethyl-8-oxo- 2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate (62 mg, 126 μηιοΐ) was combined with Pd RuPhos G4 (8.5 mg, 10 μιτιοΐ) and RuPhos (5.8 mg, 13 μιτιοΐ) in N-methylpyrrolidine (1 mL) under argon. Diethylzinc (0.57 mL, 1.1 M solution in toluene) was added and the mixture was stirred at 80 °C for 5 minutes after which time LCMS analysis showed complete conversion to the desired product. The mixture was cooled to room
temperature, concentrated to remove toluene, diluted with aqueous TFA, and purified by purified by HPLC to provide the title compound. XH NMR (400 MHz, Acetonitrile-d3) δ 8.44 (s, 1H), 7.76 (s, 1H), 7.23 (s, 1H), 6.84 (s, 1H), 4.84 (d, J = 6.2 Hz, 1H), 4.19 (d, J = 11.0 Hz, 1H), 4.08 (d, J = 11.0 Hz, 1H), 2.70 (qd, J = 7.2, 5.0 Hz, 2H), 2.55 - 2.37 (m, 2H), 2.34 (s, 6H), 1.89 (ddd, J = 12.6, 7.8, 2.8 Hz, 1H), 1.67 - 1.49 (m, 1H), 1.36 (s, 3H), 1.23 (t, J = 7.5 Hz, 3H), 0.64 (s, 3H). 19F NMR (376 MHz, Acetonitrile-d3) δ -77.33. MS (m/z) 460.6 [M+H]+.
Example 101: (S)-12-cyclopropyl-13-(3-methoxypropoxy)-4,4-dimethyl-9-oxo- tetrahydro-lH- [ 1,4] oxazino [3,4-a] pyrido [ 1,2-c] phthalazine-8-carboxylic acid
Figure imgf000185_0002
Prepared analogously to (R)-l l-cyclopropyl-12-(3-hydroxy-3-methylbut-l-yn-l-yl)-3,3- dimethyl-8-oxo-2,3,8J3b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid in example 71, using ethyl (S)-12-chloro-13-(3-methoxypropoxy)-4,4-dimethyl-9-oxo- 3,4,9, 14b-tetrahydro-lH-[l,4]oxazino[3,4-a]pyrido[l,2-c]phthalazine-8-carboxylate (example 51) in place of ethyl (R)-l l-chloro-12-(3-hydroxy-3-methylbut-l-yn-l-yl)-3,3-dimethyl-8-oxo- 2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate. XH NMR (400 MHz, Acetonitrile-d3) δ 8.52 (s, 1H), 7.35 (s, 1H), 7.23 (s, 1H), 7.03 (s, 1H), 4.85 (dt, J = 12.7, 1.3 Hz, 1H), 4.50 (d, J = 2.9 Hz, 1H), 4.26 - 4.14 (m, 2H), 4.02 (dd, J = 12.8, 3.2 Hz, 1H), 3.65 - 3.46 (m, 4H), 3.33 (s, 3H), 2.22 (tt, J = 8.5, 5.3 Hz, 1H), 2.09 (p, J = 6.2 Hz, 2H), 1.06 (s, 3H), 1.02 - 0.93 (m, 2H), 0.90 - 0.73 (m, 2H), 0.45 (s, 3H). 19F NMR (376 MHz, Acetonitrile-d3) δ - 77.31. MS (m/z) 455.5 [M+H]+.
Example 102: (S)-12-(methoxymethyl)-13-(3-methoxypropoxy)-4,4-dimethyl-9-oxo- 3,4,9,14b-tetrahydro-lH-[l,4]oxazino[3,4-a]pyrido[l,2-c]phthalazine-8-carboxylic acid
Figure imgf000186_0001
Prepared analogously to (R)-l l-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-oxo- 2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid in example 73, using ethyl (S)-13-hydroxy-12-(methoxymethyl)-4,4-dimethyl-9-oxo-3,4,9,14b-tetrahydro- lH-[l,4]oxazino[3,4-a]pyrido[l,2-c]phthalazine-8-carboxylate (example 51) in place of ethyl (R)-12-hydroxy-l l-(methoxymethyl)-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l- a]pyrrolo[l,2-c]phthalazine-7-carboxylate. l NMR (Chloroform-c δ: 8.60 (s, 1H), 7.84 (s, 1H), 7.20 (s, 1H), 6.93 (s, 1H), 4.76 (d, 1H), 4.56 - 4.48 (m, 2H), 4.45 - 4.37 (m, 1H), 4.28 - 4.20 (m, 1H), 4.20 - 4.13 (m, 1H), 4.12 - 3.97 (m, 1H), 3.66 - 3.53 (m, 4H), 3.51 (s, 3H), 3.37 (s, 3H), 2.16 - 2.06 (m, 2H), 1.09 (s, 3H), 0.51 (s, 3H). MS (m/z) 459.2 [M+H]+. A procedure for the preparation of 3,3-dimethyl-3,6-dihydro-2H-l,4-oxazine 4-oxide used in the preparation of ethyl (S)-13-hydroxy-12-(methoxymethyl)-4,4-dimethyl-9-oxo-3,4,9,14b-tetrahydro-lH- [l,4]oxazino[3,4-a]pyrido[l,2-c]phthalazine-8-carboxylate is given below.
Figure imgf000186_0002
Synthesis of 3,3-dimethyl-3,6-dihydro-2H-l,4-oxazine 4-oxide : To a solution of 3,3- dimethylmorpholine (10 g, 89 mmol) in MeOH (100 ml),was slowly added sodium tungstate dihydrate (2.8 g, 8.9 mmol, dissolved in 5 ml water). The mixture was cooled to 0 °C stirred for 10 minutes, then 30% Hydrogen peroxide (23 ml, 224 mmol) was added and the mixture was stirred for 1 hour then warmed to RT and stirred another hour. The reaction was quenched with Na2SC>3 dissolved in water. The resulting mixture was decanted into a round bottom, rinsing with MeOH and concentrated to remove most of the solvent. Sodium chloride was added to the mixture which was then extracted 3X with chloroform. The combined organics were dried over sodium sulfate, concentrated and purified by flash column chromatography. XH NMR
(Chloroform-c δ: 6.94 (t, 1H), 4.33 (d, 2H), 3.65 (s, 2H), 1.37 (s, 7H). MS (m/z) 130.1
[M+H]+.
Example 103: (R)-ll-(difluoromethoxy)-12-(3-methoxy-3-methylbut-l-yn-l-yl)-3,3- dimethyl-8-oxo-2,3,8,13b-tetrahydro- lH-pyrido [2,1-a] pyrrolo [ 1,2-c] phthalazine-7- carboxylic acid
Figure imgf000187_0001
Prepared similarly to (R)-l l-methoxy-3,3-dimethyl-12-(3-methyl-3-(methylsulfonyl)but-l-yn-l- yl)-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid (example 84) using ethyl (R)-l l-(difluoromethoxy)-3,3-dimethyl-8-oxo-12- (((trifluoromethyl)sulfonyl)oxy)-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2- c]phthalazine-7-carboxylate to replace ethyl (R)-l l-methoxy-3,3-dimethyl-8-oxo-12- (((trifluoromethyl)sulfonyl)oxy)-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2- c]phthalazine-7-carboxylate. 'H NMR (400 MHz, Chloroform-d) δ 8.60 (s, 1H), 7.59 (s, 1H), 7.47 (d, J = 1.1 Hz, 1H), 7.25 (d, J = 0.9 Hz, 2H), 6.64 (t, J = 72.8 Hz, 1H), 4.80 (d, J = 6.0 Hz, 1H), 3.40 (d, J = 32.0 Hz, 6H), 2.65 - 2.36 (m, 2H), 1.93 (d, J = 2.8 Hz, OH), 1.66 (ddd, J = 12.5, 10.7, 7.7 Hz, 1H), 1.57 (s, 6H), 1.46 (s, 6H), 1.39 (s, 3H), 0.67 (s, 3H). MS=473.6 (M+H+)
Example 104: (R)- 12-((3-cyanobicyclo [ 1.1.1] pentan-l-yl)methoxy)- 1 l-(difluoromethoxy)- 3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7- carboxylic acid
Figure imgf000188_0001
Prepared similarly to(R)-12-((3-cyanobicyclo[l .1. l]pentan-l-yl)methoxy)-3,3-dimethyl-8-oxo- l l-(trifluoromethoxy)-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7- carboxylic acid (example 92) using ethyl (R)- 12-hydroxy-3,3-dimethyl-8-oxo-l l- (difluoromethoxy)-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7- carboxylate in place of ethyl (R)- 12-hydroxy-3,3-dimethyl-8-oxo-l l-(trifluoromethoxy)- 2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate. XH NMR (400 MHz, Chloroform-d) δ 8.60 (s, 1H), 7.62 (s, 1H), 6.80 (s, 1H), 6.57(s, 1H), 4.81 (d, J = 6.0 Hz, 1H), 4.10 (m, 2H), 3.70 (s, 1H), 2.53 (m, 1H), 2.36(s, 6H), 2.15 (s, 1H) 1.94 (m, 1H), 1.62 (m, 1H), 1.39 (s, 3H), 1.26 (m, 1H), 0.67 (s, 3H). MS=498.7 (M+H+)
Example 105: (R)-ll-(difluoromethoxy)-12-((3-(methoxymethyl)bicyclo[l.l.l]pentan-l- yl)methoxy)-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2- c]phthalazine-7-carboxylic acid
Figure imgf000188_0002
Methyl 3-(methoxymethyl)bicyclo[l.l.l]pentane-l-carboxylate: At 0 °C , to methyl 3- (hydroxymethyl)bicyclo[l. l. l]pentane-l-carboxylate (0.6 g, 0.32 mmol) was added NaH (60%,
0.2 g, 4.99 mmol) , then the mixture was stirred at 0 °C for 30min, then lodomethane (0.71 ml, 7.68 mmol) was added, the mixture was stirred at rt for 2h, TLC(20%EA/Hex) showed SM was still left. NaH (60%, 0.31 g, 7.68 mmol) was added at 0 °C , after 30min, lodomethane (0.71 ml, 7.68 mmol) was added again. Then the mixture was stirred at rt for overnight. TLC showed reaction was complete. Et20/H20 was added and two phases separated. Organic phase was dried with MgS04 and solvent was removed in vacuo. Crude material was used for next step.
(3-(methoxymethyl)bicyclo[l.l.l]pentan-l-yl)methanol: At 0 °C, to methyl 3- (methoxymethyl)bicyclo[l . l. l]pentane-l-carboxylate (0.33 g, 0 mol) (crude) in THF (5ml) was added 1M lithium aluminum hydride (2.13 ml) in THF dropwise, then stirred at rt overnight. TLC showed complete conversion. Then the reaction was diluted with ΈΧ2Ο and washed with
H2O. The organic phase was dried with MgSC>4 and solvent was removed under vacuo. The crude material was used directly to next step.
(R)-ll-(difluoromethoxy)-12-((3-(methoxymethyl)bicyclo[l.l.l]pentan-l-yl)methoxy)-3,3- dimethyl-8-oxo-2,3,8,13b-tetrahydro- lH-pyrido [2,1-a] pyrrolo [ 1,2-c] phthalazine-7- carboxylic acid: To dry ethyl l l-(difluoromethoxy)-12-hydroxy-3,3-dimethyl-8-oxo-2,3, 8,13b- tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate (50 mg, 0.12 mmol) was added THF (2ml) and (Tributylphosphoranylidene)acetonitrile (86.11 mg, 0.36 mmol) . The mixture was heated to 80 °C with vented needle. 30min later reaction was cooled to rt, the (3- (methoxymethyl)bicyclo[l . l. l]pentan-l-yl)methanol (42.28 mg, 0.3 mmol) was added . it was heated at 90C for lh. then TLC showed complete conversion, the reaction mixture was cooled to room temp. 1M LiOH (0.59 ml) was added to crude reaction. After 2h, hydrolysis was complete. Solvent was stripped off, and the residue was purified by HPLC. XH NMR (400 MHz, Chloroform-d) δ 8.59 (s, 1H), 7.59 (s, 1H), 7.21 (s, 1H), 6.87 - 6.83 (m, 1H), 6.62 (t, J = 74.1 Hz, 1H), 4.80 (d, J = 6.3 Hz, 1H), 4.13 (q, J = 10.4 Hz, 2H), 3.44 (s, 2H), 3.38 (d, J = 4.1 Hz, 4H), 2.51 (dddd, J = 13.9, 10.7, 8.1, 6.7 Hz, 1H), 2.43 - 2.31 (m, 1H), 1.93 (ddd, J = 12.7, 7.9, 2.5 Hz, 1H), 1.82 (s, 6H), 1.73 (s, 1H), 1.63 (ddd, J = 12.6, 10.9, 7.6 Hz, 1H), 1.39 (s, 3H), 0.68 (s, 3H). MS=517.8 (M+H+) Example 106: (R)-12-((6-aminopyridin-3-yl)ethynyl)-ll-(difluoromethoxy)-3,3-dimethyl-8- oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid
Figure imgf000190_0001
Figure imgf000190_0002
Ethyl (R)-ll-methoxy-3,3-dimethyl-8-oxo-12-((trimethylsilyl)ethynyl)-2,3,8,13b- tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate: Copper(i) iodide (0.01 g, 0 mol) and Pd(tBu2PPh)2C12 (0.02 g, 0 mol) were charged in a vial containing ethyl (R)-l l- methoxy-3,3-dimethyl-8-oxo-12-(((trifluoromethyl)sulfonyl)oxy)-2,3,8,13b-tetrahydro-lH- pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate (0.1 g, 0 mol) and ethynyltrimethylsilane (0.1 g, 0 mol), then MeCN/Et3N(3: l) (12ml) was added. After degassing, the mixture was stirred at 60 °C for 2h. LCMS showed complete conversion. The mixture was cooled to rt, and quenched with thiol-linked silica, stirred for 5 min, after filtration to remove silica gel, the solvent was removed under vacuo. The residue was purified by SGC from l-100%Hex/EA to provide the title compound.
Ethyl (R)-ll-(difluoromethoxy)-12-ethynyl-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH- pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate: A solution of ethyl (R)-l l- (difluoromethoxy)-3,3-dimethyl-8-oxo-12-((trimethylsilyl)ethynyl)-2,3,8,13b-tetrahydro-lH- pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate (100 mg, 199.75 μιτιοΐ) and Potassium
Carbonate (82.82 mg, 0.6 mmol) in EtOH (8ml) was stirred at rt for lh. LCMS shows desired reaction complete. The solid was filtered off, and solvent was stripped off. the crude was used directly without further purification.
Ethyl (R)-12-((6-aminopyridin-3-yl)ethynyl)-ll-(difluoromethoxy)-3,3-dimethyl-8-oxo- 2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate: Pd(tBu2PPh)2Cl2 (9.94mg, 0.014mmol) and Cul (2.67mg, 0.0014mmol) were added into a round bottom flask containing ethyl (R)-l l -(difluoromethoxy)-12-ethynyl-3,3-dimethyl-8-oxo- 2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate (60mg,
0.14mmol) and 5-bromopyridin-2-amine (24.2mg, 0.14mmol) in DMF (1ml) and Et3N (0.2ml), after degassing the reaction mixture, it was stirred at 60 °C for lh. The reaction mixture was cooled to rt, and extracted with ethyl acetate (50ml), washed with brine and dried with Mg2S04. After removed solvent, the residue was taken up in DCM and purified by column to provide 12.7mg of ethyl (R)-12-((6-aminopyridin-3-yl)ethynyl)-l l-(difluoromethoxy)-3,3-dimethyl-8- oxo-2,3, 8, 13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate. MS (m/z) 521.622 (M+H+).
(R)-12-((6-aminopyridin-3-yl)ethynyl)-ll-(difluoromethoxy)-3,3-dimethyl-8-oxo-2,3,8,13b- tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid: Into the solution of ethyl (R)-12-((6-aminopyridin-3-yl)ethynyl)-l l-(difluoromethoxy)-3,3-dimethyl-8-oxo- 2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate (12.5mg, 0.024mmol) in MeOH (2ml), was added LiOH (2.5N, 0.2ml) at rt., after 30 minutes, the reaction was quenched with addition of TFA (0.2ml). The solvent was stripped off, and the crude material was purified by HPLC. To provide 12mg of (R)-12-((6-aminopyridin-3-yl)ethynyl)-l l- (difluoromethoxy)-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2- c]phthalazine-7-carboxylic acid as TFA salt. ¾ NMR (400 MHz, Methanol-d4) δ 8.63 (s, IH), 8.13 (s, IH), 7.89 (s, IH), 7.76 (s, IH), 7.42 (s, IH), 7.12 (s, IH), 6.90 (s, IH), 2.56 (s, 3H), 1.96 (s, IH), 1.68 (s, IH), 1.41 (s, 3H), 0.69 (s, 3H). MS (m/z) 493.516 (M+H+).
Example 107: (R)-12'-((3-cyanobicyclo[l.l.l]pentan-l-yl)methoxy)-ll'-(methoxymethyl)- 8'-oxo-l',2',8',13b'-tetrahydrospiro[cyclopropane-l,3'-pyrido[2,l-a]pyrrolo[l,2- c]phthalazine]-7'-carboxylic acid
Figure imgf000192_0001
Figure imgf000192_0002
Figure imgf000192_0003
(R)-12'-((3-cyanobicyclo[l. l. l]pentan-l-yl)methoxy)-ir-(methoxymethyl)-8'-oxo-r,2',8',13b'- tetrahydrospiro[cyclopropane-l,3'-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine]-7'-carboxylic acid was prepared similarly to compound 74 following the same reaction sequences in example 73 and example 75. XH NMR (400 MHz, Chloroform-d) δ 8.42 (s, IH), 7.89 (s, IH), 7.25 (s, IH), 6.71 (s, IH), 4.83 (d, J = 6.0 Hz, IH), 4.50 (d, J = 3.0 Hz, 2H), 4.11 - 4.03 (m, 2H), 3.54 (s, 3H), 2.61 - 2.54 (m, 2H), 2.36 (s, 6H), 2.14 - 2.08 (m, 2H), 1.75 - 1.68 (m, IH), 0.63 (dd, J = 17.5, 8.1 Hz, 2H), 0.09 (dd, J = 11.8, 4.8 Hz, 2H).. MS (m/z) 474.491 [M+H]+. Example 108: (R)-ll-(difluoromethoxy)-12-((2-methoxyethoxy)methyl)-3,3-dimethyl-8- oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid
Figure imgf000193_0001
Figure imgf000193_0002
Ethyl (R)-l l -(difluoromethoxy)-3,3-dimethyl-8-oxo-12-(((trifluoromethyl)sulfonyl)oxy)- 2,3,8, 13b-tetrahydro-lH-pyrido[2, l -a]pyrrolo[l ,2-c]phthalazine-7-carboxylate (135 mg, 0.244 mmol) was combined with trifluoro((2-methoxyethoxy)methyl)-14-borane, potassium salt (71.9 mg, 0.367 mmol), Tris(dibenzylideneacetone)dipalladium(0)(11.2mg, 0.012mmol), 2- dicyclohexylphosphino-2',6'-diisopropoxybiphenyl (13.1mg, 0.029mmol) and sodium carbonate (38.9mg, 0.39mmol) , in dioxane/water(20/l) (2ml) under argon in a sealed vial. The mixture was heated at 1 10 °C for 2h with vigorous stirring, then cooled to room temperature, extracted with ethyl acetate and the organics were concentrated in vacuo and purified by flash column chromatography to provide24 mg of ethyl (R)-l l -(difluoromethoxy)-12-((2- methoxyethoxy)methyl)-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2, l -a]pyrrolo[l,2- c]phthalazine-7-carboxylate. MS (m/z) 493.74 [M+H]+. Into the solution of ethyl (R)-l l- (difluoromethoxy)-12-((2-methoxyethoxy)methyl)-3,3-dimethyl-8-oxo-2,3,8, 13b-tetrahydro-lH- pyrido[2, l-a]pyrrolo[l ,2-c]phthalazine-7-carboxylate (24mg, 0.049mmol) in MeOH (2ml) was added LiOH (2.5N, 0.2ml) at rt., after 30min., the reaction was quenched with addition of TFA (0.2ml). The solvent was stripped off, and the crude material was purified by HPLC. To provide l Omg of (R)-l l -(difluoromethoxy)-12-((2-methoxyethoxy)methyl)-3,3-dimethyl-8-oxo- 2,3,8, 13b-tetrahydro-lH-pyrido[2, l -a]pyrrolo[l ,2-c]phthalazine-7-carboxylic acid. XH NMR (400 MHz, Chloroform-d) δ 8.61 (s, 1H), 7.61 (s, 1H), 7.53 (s, 1H), 7.27 (s, 1H), 6.71 (d, J = 72.8 Hz, 1H), 4.83 (s, 1H), 4.68 (s, 2H), 3.74 (d, J = 5.1 Hz, 2H), 3.64 (d, J = 4.8 Hz, 2H), 3.42 (s, 3H), 2.50 (d, J = 5.3 Hz, 2H), 1.94 - 1.87 (m, 1H), 1.68 - 1.58 (m, 1H), 1.39 (s, 3H), 0.66 (s, 3H). 19F NMR (376 MHz, Chloroform-d) δ -76.31 , -81.75 (d, J = 71.7 Hz). MS (m/z) 465.7 [M+H]+. Example 109: (R)-ll-(methoxymethyl)-12-((l-(methoxymethyl)cyclopropyl)methoxy)-3,3- dimethyl-8-oxo-2,3,8,13b-tetrahydro- lH-pyrido [2,1-a] pyrrolo [ 1,2-c] phthalazine-7- carboxylic acid
Figure imgf000194_0001
Prepared analogously to (R)-12-((3-cyanobicyclo[l . l. l]pentan-l-yl)methoxy)-l l-
(methoxymethyl)-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2- c]phthalazine-7-carboxylic acid in example 74 using (l-(methoxymethyl)cyclopropyl) methanol in place of 3-(hydroxymethyl)bicyclo[l . l. l]pentane-l-carbonitrile. 'H NMR (400 MHz, Chloroform-d) δ 8.53 (s, 1H), 7.84 (s, 1H), 7.15 (s, 1H), 6.74 (s, 1H), 4.97 (q, J = 6.1 Hz, 2H), 4.79 (d, J = 6.2 Hz, 1H), 4.52 (d, J = 1.4 Hz, 1H), 4.05 - 3.91 (m, 2H), 3.51 (s, 2H), 3.44 - 3.32 (m, 4H), 3.29 (s, 2H), 3.24 (s, 1H), 2.54 - 2.30 (m, 2H), 1.87 (ddd, J = 10.8, 7.7, 2.6 Hz, 1H), 1.67 - 1.59 (m, 1H), 1.37 (s, 3H), 1.25 (dd, J = 8.5, 6.3 Hz, 6H), 1.12 (d, J = 6.8 Hz, 1H), 0.72 - 0.61 (m, 5H), 0.50 (s, 2H). MS (m/z) 469.4 [M+H]+. Example 110: (R)-ll'-(methoxymethyl)-12'-(3-methoxypropoxy)-8'-oxo-l',2',8',13b'- tetrahydrospiro[cyclobutane-l,3'-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine]-7'-carboxylic acid
Figure imgf000194_0002
5-azaspiro[3.4] octane was converted to 5-azaspiro[3.4]oct-5-ene 5-oxide in a method analogous to the preparation of 2,2-dimethyl-2,3,4,5-tetrahydropyridine 1 -oxide (example 11). The 5- azaspiro[3.4]oct-5-ene 5-oxide was converted to ethyl (R)-12'-(benzyloxy)-H'-chloro-8'-oxo- ,2',8',13b'-tetrahydrospiro[cyclobutane-l,3'-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine]-7'- carboxylate using a sequence analogous to that used for the preparation of methyl (R)-12- (benzyloxy)-l l-chloro-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2- c]phthalazine-7-carboxylate. The ethyl (R)-12'-(benzyloxy)-l l'-chloro-8'-oxo-l',2',8',13b'- tetrahydrospiro[cyclobutane-l,3'-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine]-7'-carboxylate was converted to R)-l -(methoxymethyl)-12'-(3-methoxypropoxy)-8'-oxo- ,2',8',13b'- tetrahydrospiro[cyclobutane-l,3'-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine]-7'-carboxylic acid using a sequence analogous to that used for the preparation of (R)-l 1 -(methoxy methyl)- 12-(3 - methoxypropoxy)-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2- c]phthalazine-7-carboxylic acid in example 73. XH NMR (400 MHz, Acetonitrile-d3) δ 8.46 (s, 1H), 7.89 (s, 1H), 7.19 (s, 1H), 6.97 (s, 1H), 4.80 (d, J = 6.7 Hz, 1H), 4.57 - 4.41 (m, 2H), 4.20 (ddt, J = 29.9, 9.5, 6.2 Hz, 2H), 3.56 (td, J = 6.2, 1.1 Hz, 2H), 3.42 (s, 3H), 3.32 (s, 3H), 2.60 - 2.51 (m, 1H), 2.48 - 2.35 (m, 1H), 2.25 - 2.00 (m, 6H), 1.59 - 1.37 (m, 3H), 0.96 - 0.85 (m, 1H). 19F NMR (376 MHz, Acetonitrile-d3) δ -77.3. MS (m/z) 455.4 [M+H]+.
Example 111: Synthesis of (R)-12-(3-hydroxypropoxy)-ll-(methoxymethyl)-3,3-dimethyl- 8-oxo-2,3,8,13b-tetrahydro- lH-pyrido [2,1-a] pyrrolo [ 1,2-c] phthalazine-7-carboxylic acid
Figure imgf000195_0001
Prepared analogously to (R)-l l-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-oxo- 2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid in example 73 using 3-bromopropan-l-ol in place of l-bromo-3-methoxypropane. XH NMR (400 MHz, Acetonitrile-d3) δ 8.43 (s, 1H), 7.90 (s, 1H), 7.18 (s, 1H), 7.04 - 6.97 (m, 1H), 4.88 (d, J = 6.4 Hz, 1H), 4.56 - 4.43 (m, 2H), 4.24 (ddt, J = 28.3, 9.6, 6.1 Hz, 2H), 3.73 (t, J = 6.1 Hz, 2H), 3.42 (s, 3H), 2.66 - 2.39 (m, 2H), 2.00 (p, J = 6.1 Hz, 2H), 1.90 (ddd, J = 12.7, 8.0, 2.9 Hz, 1H), 1.62 (ddd, J = 12.7, 10.6, 7.8 Hz, 1H), 1.36 (s, 3H), 0.65 (s, 3H). 19F NMR (376 MHz, Acetonitrile- d3) δ -77.3. MS (m/z) 429.5 [M+H]+.
Example 112: Synthesis of (R)-ll-(difluoromethoxy)-3,3-dimethyl-12-(3-methyl-3- (methylsulfonyl)but-l-yn-l-yl)-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2- c]phthalazine-7-carboxylic acid
Figure imgf000196_0001
The compound of this example was prepared analogous to (R)-l l -Methoxy-12-(3-methoxy-3- methylbut-l -yn-l -yl)-3,3-dimethyl-8-oxo-2,3,8, 13b-tetrahydro-lH-pyrido[2, l-a]pyrrolo[l,2- c]phthalazine-7-carboxylic acid in example 43 using ethyl (R)-l l-(difluoromethoxy)-3,3- dimethyl-8-oxo-12-(((trifluoromethyl)sulfonyl)oxy)-2,3,8, 13b-tetrahydro-lH-pyrido[2, l - a]pyrrolo[l ,2-c]phthalazine-7-carboxylate in place of ethyl (R)-l l -methoxy-3,3-dimethyl-8-oxo- 12-(((trifluoromethyl)sulfonyl)oxy)-2,3,8, 13b-tetrahydro-lH-pyrido[2, l-a]pyrrolo[l,2- c]phthalazine-7-carboxylate, and 3-methyl-3-(methylsulfonyl)but-l-yne in place of 3-methoxy- 3-methylbut-l -yne. MS (m/z): 521.53 [M+H]+. 'H NMR (400 MHz, Chloroform-d) δ 8.63 (s, 1H), 7.60 (s, 1H), 7.50 (d, J = 1.1 Hz, 1H), 7.40 (s, 1H), 7.25 (s, 1H), 6.68 (t, J = 72.5 Hz, 1H), 4.81 (d, J = 6.1 Hz, 1H), 3.1 1 (s, 3H), 2.70 - 2.36 (m, 2H), 2.10 - 1.54 (m, 9H), 1.40 (s, 3H), 0.67 (s, 3H).
Example 113: Synthesis of (R)-ll-(hydroxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl- -oxo-2,3,8,13b-tetrahyd ro- lH-pyrido [2,1-a] pyrrolo [ 1,2-c] phthalazine-7-carboxylic acid
Figure imgf000196_0002
(R)-1 1 -(methoxymethyl)-12-(3- (R)-1 1 -(hydroxymethyl)-12-(3- methoxypropoxy)-3,3-dimethyl-8-oxo- methoxypropoxy)-3,3-dimethyl-8-oxo- 2,3,8, 13b-tetrahydro-1 H-pyrido[2, 1 - 2,3,8, 13b-tetrahydro-1 H-pyrido[2, 1 - a]pyrrolo[1 ,2-c]phthalazine-7- a]pyrrolo[1 ,2-c]phthalazine-7- carboxylic acid carboxylic acid
To a solution of (R)-l l-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-oxo- 2,3,8, 13b-tetrahydro-lH-pyrido[2, l -a]pyrrolo[l ,2-c]phthalazine-7-carboxylic acid (example 73, 0.012 g, 0.027 mmol) in 0.40 mL 1 : 1 DMF:H20 was added 0.2 mL concentrated sulfuric acid (0.368 mg; 0.003 mmol). The solution was heated to 90°C for 2 hours. After 2 hours, the reaction was diluted with dichloromethane and water. Saturated NaHCC solution (aq.) was added until the aqueous layer pH was <3. The layers were separated and the dichloromethane layer was concentrated under reduced pressure. The crude residue was purified by preparative HPLC to afford (R)-l l-(hydroxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-oxo- 2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid (113) as trifluoroacetic acid salt (0.003 g; 0.00553 mmol; 20.4%). ¾ NMR (400 MHz, Acetonitrile-d3) δ 8.43 (s, 1H), 7.92 (s, 1H), 7.17 (s, 1H), 6.96 (s, 1H), 4.87 (d, J = 6.5 Hz, 1H), 4.64 (s, 2H), 4.21 (ddt, J = 27.6, 9.6, 6.1 Hz, 2H), 3.67 - 3.48 (m, 8H), 3.32 (s, 3H), 2.60 - 2.38 (m, 1H), 2.06 (p, J = 6.1 Hz, 2H), 1.90 (ddd, J = 12.6, 8.0, 2.8 Hz, 1H), 1.62 (ddd, J = 12.7, 10.6, 7.9 Hz, 1H), 1.33 (d, J = 29.8 Hz, 4H), 0.66 (s, 3H). 19F NMR (376 MHz, Acetonitrile-d3) δ -76.30. MS (m/z) 429.5 [M+H]+.
Example 114: (S)-12'-(methoxymethyl)-13'-(3-methoxypropoxy)-9'-oxo-9',14b'-dihydro- l'H,3'H-spiro[cyclobutane-l,4'-[l,4]oxazino[3,4-a]pyrido[l,2-c]phthalazine]-8'-carboxylic
Figure imgf000197_0001
yl)benzene
Figure imgf000197_0002
6-(2-bromo-4-(methoxymethyl)-5-(3- methoxypropoxy)phenyl)-5-nitroso-8- oxa-5-azaspiro[3.5]nonane
Figure imgf000198_0001
ethyl 12'-(methoxymethyl)-13'-(3- (S)-12'-(methoxymethyl)-13'-(3- methoxypropoxy)-9'-oxo-9', 14b'- methoxypropoxy)-9'-oxo-9',14b'-dihydro- dihydro-1 ' - ,3'/-/-spiro[cyclobutane-1 ,4' 17-/,3'/-/-spiro[cyclobutane-1 ,4'-
[1 ,4]oxazino[3,4-a]pyrido[1 ,2- [1 ,4]oxazino[3,4-a]pyrido[1 ,2- c]phthalazine]-8'-carboxylate c]phthalazine]-8'-carboxylic acid
Synthesis of 6-(5-(benzyloxy)-2-bromo-4-(methoxymethyl)phenyl)-8-oxa-5- azaspiro[3.5]nonan-5-ol:
8-oxa-5-azaspiro[3.5]non-5-ene 5-oxide was prepared analogously to 3,3-dimethyl-3,6-dihydro- 2H-l,4-oxazine 4-oxide (example 102) and reacted with the Grignard reagent formed from 1- (benzyloxy)-4-bromo-5-iodo-2-(methoxymethyl)benzene similarly to the procedure in example 55 to produce 6-(5-(benzyloxy)-2-bromo-4-(methoxymethyl)phenyl)-8-oxa-5- azaspiro[3.5]nonan-5-ol. MS (m/z) 439.0 [M+H]+.
Synthesis of 4-bromo-2-(methoxymethyl)-5-(8-oxa-5-azaspiro[3.5]nonan-6-yl)phenol: 4-bromo-2-(methoxymethyl)-5-(8-oxa-5-azaspiro[3.5]nonan-6-yl)phenol was prepared similarly to example 55 using 6-(5-(benzyloxy)-2-bromo-4-(methoxymethyl)phenyl)-8-oxa-5- azaspiro[3.5]nonan-5-ol in place of 5-(5-(benzyloxy)-2-bromo-4-chlorophenyl)-2,2- dimethylpyrrolidin-l-ol. MS (m/z) 342.4 [M+H]+.
Synthesis of 4-bromo-2-(methoxymethyl)-5-(5-nitroso-8-oxa-5-azaspiro[3.5]nonan-6- yl)phenol:
4-bromo-2-(methoxymethyl)-5-(5-nitroso-8-oxa-5-azaspiro[3.5]nonan-6-yl)phenol was prepared similarly to example 55 using 4-bromo-2-(methoxymethyl)-5-(8-oxa-5-azaspiro[3.5]nonan-6- yl)phenol in place of 5-(5-(benzyloxy)-2-bromo-4-chlorophenyl)-2,2-dimethylpyrrolidine. MS (m/z) 371.3 [M+H]+.
Synthesis of (S)-12'-(methoxymethyl)-13'-(3-methoxypropoxy)-9'-oxo-9',14b'-dihydro- l'H,3'H-spiro[cyclobutane-l,4'-[l,4]oxazino[3,4-a]pyrido[l,2-c]phthalazine]-8'-carboxylic acid (114): 6-(2-bromo-4-(methoxymethyl)-5-(3-methoxypropoxy)phenyl)-5-nitroso-8-oxa-5- azaspiro[3.5]nonane was prepared similarly to example 1 using 4-bromo-2-(methoxymethyl)-5- (5-nitroso-8-oxa-5-azaspiro[3.5]nonan-6-yl)phenol in place of 4-bromo-2-chloro-5-iodophenol. MS (m/z) 411.6 [M-NOJ+. This material was carried forward using a sequence analogous to that in example 55. Ethyl 12'-(methoxymethyl)-13'-(3-methoxypropoxy)-9'-oxo-9',14b'-dihydro- H,3'H-spiro[cyclobutane-l,4'-[l,4]oxazino[3,4-a]pyrido[l,2-c]phthalazine]-8'-carboxylate (MS (m/z) 499.5 [M+H]+) was separated into its enantiomers by chiral SFC using a CHIRALPAK IA column with 30% methanol as the co-solvent. Under the chiral separation conditions and concentration most of the ethyl ester was exchanged to the methyl ester. The desired S isomer eluted first and was hydrolyzed using aqueous lithium hydroxide and purified by preparative HPLC to provide (S)-12'-(methoxymethyl)-13'-(3-methoxypropoxy)-9'-oxo-9',14b'-dihydro- H,3'H-spiro[cyclobutane-l,4'-[l,4]oxazino[3,4-a]pyrido[l,2-c]phthalazine]-8'-carboxylic acid as a TFA salt. lH NMR (400 MHz, Chloroform-d) δ 8.55 (s, IH), 7.84 (s, IH), 7.28 (s, IH), 6.91 (s, IH), 4.71 (d, IH), 4.57 - 4.47 (m, 2H), 4.35 (s, IH), 4.29 - 4.09 (m, 3H), 4.09 - 3.95 (m, IH), 3.68 - 3.61 (m, IH), 3.58 (t, 2H), 3.51 (s, 3H), 3.37 (s, 3H), 2.14 - 2.04 (m, 2H), 2.04 - 1.91 (m, IH), 1.68 - 1.57 (m, IH), 1.51 - 1.31 (m, 3H), 1.31 - 1.15 (m, IH). MS (m/z) 471.3 [M+H]+.
Example 115: Synthesis of (R)-12-((S)-3-(tert-butoxycarbonyl)pyrrolidin-l-yl)-3,3- dimethyl-8-oxo-ll-(trifluoromethoxy)-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2- c]phthalazine-7-carboxylic acid (115):
Figure imgf000199_0001
carboxylic acid
A reaction mixture of ethyl (R)-3,3-dimethyl-8-oxo-l l-(trifluoromethoxy)-12- (((trifluoromethyl)sulfonyl)oxy)-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2- c]phthalazine-7-carboxylate (50 mg, 0.088 mmol), tert-butyl (S)-pyrrolidine-3-carboxylate hydrochloride (36 mg, 0.18 mmol), cesium carbonate (57 mg, 0.17 mmol) and RuPhos Pd G4 (7 mg, 0.0088 mmol) in 1 mL of toluene was degassed and purged with nitrogen. The resulting mixture was heated to 130 °C for overnight. After cooling to room temperature, added 0.1 mL of 2N LiOH and 1 mL of ethanol, stirred at room temperature until hydrolysis was complete. The reaction was quenched with TFA and then partitioned between water and ethyl acetate. The organic layer was separated, washed with brine, dried over Na2SC>4 and concentrated to dryness. The residue was purified by RP-HPLC to afford the title compound. MS (m/z): 564.50 [M+H] 'H NMR (400 MHz, Chloroform-d) δ 8.55 (s, IH), 7.54 (d, J = 1.5 Hz, IH), 7.11 (s, IH), 6.51 (s, IH), 4.73 (d, J = 6.3 Hz, IH), 3.89 - 3.50 (m, 4H), 3.11 (p, J = 7.2 Hz, IH), 2.57 - 2.31 (m, 2H), 2.33 - 2.07 (m, 2H), 1.90 (ddd, J = 11.2, 8.1, 2.7 Hz, 1H), 1.76 - 1.60 (m, 1H), 1.47 (s, 9H), 1.38 (s, 3H), 0.69 (s, 3H).
Example 116: Synthesis of (R)-12-(2-carboxyethoxy)-ll-(methoxymethyl)-3,3-dimethyl-8- oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid (11
Figure imgf000200_0001
methyl (R)-12-hydroxy-1 1 -
(R)-12-(2-carboxyethoxy)-1 l -(methoxymethyl)- (methoxymethyl)-3,3-dimethyl-8-oxo- 3 dimethyl-8 >xo-2,3A 13b etrahydro-1 - - 2,3,8, 13b-tetrahydro-1 H-pyrido[2, 1- pyrido[2, 1-a]pyrrolo[1 ,2-c]phthalazine-7- a]pyrrolo[1 ,2-c]phthalazine-7-carboxylate
carboxylic acid
To a solution of methyl (R)-12-hydroxy-l l-(methoxymethyl)-3,3-dimethyl-8-oxo-2,3, 8,13b- tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate (50 mg, 0.13 mmol) in 0.7 mL dry DMF at 0 °C was added sodium hydride (60 %, 16 mg, 0.39 mmol). The reaction mixture was stirred at 0 °C for 30 min under nitrogen. A solution of 3-Bromopropionic acid (30 mg , 0.2 mmol) in 0.3 mL of DMF was added and the mixture was stirred at room temperature for 30 min, then heated it at 70 °C for 3h. The reaction was cooled to 0 °C, and sodium hydride (16 mg, 0.39 mmol) was added. The resulting mixture was heated at 70 °C overnight. The reaction was quenched by saturated NH4C1 and partitioned between EtOAc and 1 N HC1. The organic layer was dried over Na2S04, filtered, and concentrated under reduced pressure. The product was dissolved in 1 mL of methanol and added 0.1 mL of 1 N LiOH, stirred at room temperature for 20 min. It was purified by RP-HPLC to afford the title compound. MS (m/z): 443.23 [M+H]+. 1H NMR (400 MHz, Chloroform-d) δ 8.49 (s, 1H), 7.79 (s, 1H), 7.10 (s, 1H), 6.76 (s, 1H), 4.76 (d, J = 6.3 Hz, 1H), 4.42 (s, 2H), 4.36 - 4.10 (m, 2H), 3.42 (s, 3H), 2.80 (t, J = 6.3 Hz, 2H), 2.40 (dd, J = 17.0, 9.8 Hz, 2H), 1.84 (t, J = 9.7 Hz, 1H), 1.65 - 1.48 (m, 1H), 1.32 (s, 3H), 0.60 (s, 3H). Example 117: Synthesis of (R)-ll-(methoxymethyl)-12-((R)-3-(methoxymethyl)pyrrolidin- l-yl)-3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine- 7-carboxylic acid (117):
HCl
e
Figure imgf000201_0001
thyl (R)-1 1 -(methoxymethyl)-3,3- dimethyl-8-oxo-12- (R)-1 1 -(methoxymethyl)-l 2-((R)-3- (((trifluoromethyl)sulfonyl)oxy)-2,3,8, 13b- (methoxymethyl)pyrrolidin-l -yl)- tetrahydro-1 H-pyrido[2, 1 -a]pyrrolo[1 ,2- 3,3-dimethyl-8-oxo-2,3,8, 13b-tetrahydro-1 H- c]phthalazine-7-carboxylate pyrido[2, 1 -a]pyrrolo[1 ,2-c]phthalazine-7- carboxylic acid
Compound 117 was prepared similarly to (R)-12-((S)-3-(tert-butoxycarbonyl)pyrrolidin-l-yl)- 3,3-dimethyl-8-oxo-l l-(trifluoromethoxy)-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2- c]phthalazine-7-carboxylic acid (115) using ethyl (R)-l l-(methoxymethyl)-3,3-dimethyl-8-oxo- 12-(((trifluoromethyl)sulfonyl)oxy)-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2- c]phthalazine-7-carboxylate and (R)-3-(methoxymethyl)pyrrolidine hydrochloride: MS (m/z): 468.43 [M+H]+. 'H NMR (400 MHz, Chloroform-d) δ 8.53 (s, 1H), 7.66 (s, 1H), 7.16 (s, 1H), 6.49 (s, 1H), 4.73 (d, J = 5.9 Hz, 1H), 4.61 - 4.40 (m, 2H), 3.70 - 3.50 (m, 3H), 3.48 - 3.32 (m, 9H), 2.63 (p, J = 6.9 Hz, 1H), 2.43 (dd, J = 18.0, 7.2 Hz, 2H), 2.12 (dq, J = 12.3, 6.7 Hz, 1H), 1.98 - 1.75 (m, 2H), 1.71 - 1.57 (m, 1H), 1.37 (s, 3H), 0.68 (s, 3H). Example 118: Synthesis of (R)-ll-(methoxymethyl)-12-(3-methoxypropoxy-l,l,2,2,3,3-d6)- 3,3-dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7- carboxylic acid (118):
Figure imgf000202_0001
methyl (R)-12-hydroxy-1 1 - methyl (R)-12-(3-hydroxypropoxy- (methoxymethyl)-3,3-dimethyl- 1 , 1 ,2,2,3,3-d6)-1 l -(methoxymethyl)- 8-oxo-2,3,8, 13b-tetrahydro- 1 H-pyrido[2, 1 -a]pyrrolo 3,3-dimethyl-8-oxo-2,3,8, 13b- [1 ,2-c]phthalazine-7-carboxylate tetrahydro-1 H-pyrido[2, 1 - a]pyrrolo[1 ,2-c]phthalazine-7- carboxylate
Figure imgf000202_0002
methyl (R)-1 1 -(methoxymethyl)-12- (3-methoxypropoxy-1 , 1 , 2,2,3, 3- 6)- 3,3-dimethyl-8-oxo-2,3,8, 13b- tetrahydro-1 H-pyrido[2, 1 - a]pyrrolo[1 ,2-c]phthalazine-7- carboxylate
Figure imgf000202_0003
(R)-1 1 -(methoxymethyl)-12-(3- methoxypropoxy-1 , 1 , 2,2,3, 3-d6)- 3,3-dimethyl-8-oxo-2,3,8,13b- tetrahydro-1 /-/-pyrido[2, 1 - a]pyrrolo[1 ,2-c]phthalazine-7- carboxylic acid
Synthesis of methyl (R)-12-(3-hydroxypropoxy-l,l,2,2,3,3-d6)-ll-(methoxymethyl)-3,3- dimethyl-8-oxo-2,3,8,13b-tetrahydro- lH-pyrido [2,1-a] pyrrolo [ 1,2-c] phthalazine-7- carboxylate
To a mixture of methyl (R)-12-hydroxy-l l-(methoxymethyl)-3,3-dimethyl-8-oxo-2,3, 8,13b- tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate (300 mg, 0.78 mmol), propane-d6-l,3-diol (256 mg, 3 mmol), and Triphenylphosphine (614 mg, 2.3 mmol) in THF (6 ml) was added diisopropyl azodicarboxylate (0.38 mL, 2 mmol). The reaction was allowed to stir at room temperature for 30 minutes. The product was purified by silica gel chromatography to afford the title compound. MS (m/z) 449.30 [M+H]+.
Synthesis of methyl (R)-ll-(methoxymethyl)-12-(3-methoxypropoxy-l,l,2,2,3,3-d6)-3,3- dimethyl-8-oxo-2,3,8,13b-tetrahydro- lH-pyrido [2,1-a] pyrrolo [ 1,2-c] phthalazine-7- carboxylate
To a solution of methyl (R)-12-(3-hy droxypropoxy-1, 1,2,2,3, 3-d6)-l l-(methoxymethyl)-3, 3- dimethyl-8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate (300 mg, 0.7 mmol) in 5 mL dry DMF at 0 °C was added sodium hydride (60 %, 107 mg, 2.7 mmol). The mixture was stirred at 0 °C for 30 min under N2. A solution of iodomethane (0.13 mL , 2 mmol) in 1 mL of DMF was added and the mixture was stirred at room temperature for 40 min. The reaction was quenched by saturated NH4C1 and partitioned between EtOAc and 1 N HC1. The organic layer was dried over Na2SC>4, filtered, and concentrated under reduced pressure to afford the title compound. MS (m/z): 463.32 [M+H]+.
Synthesis of (R)-ll-(methoxymethyl)-12-(3-methoxypropoxy-l,l,2,2,3,3-d6)-3,3-dimethyl- 8-oxo-2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylic acid (118):
Methyl (R)-l l-(methoxymethyl)-12-(3-methoxypropoxy-l,l,2,2,3,3-d6)-3,3-dimethyl-8-oxo- 2,3,8,13b-tetrahydro-lH-pyrido[2,l-a]pyrrolo[l,2-c]phthalazine-7-carboxylate (1.74 g, 3.76 mmol) was dissolved in 36 mL of THF/MeOH/water (3:2: 1), to it was added lithium hydroxide monohydrate (316 mg, 7.5 mmol). The reaction mixture was stirred at room temperature for overnight. The resulting product was partitioned between IN HC1 and EtOAc. The organic was separated and concentrated to dryness. The residue was purified on RP-HPLC to afford the title compound. ¾ NMR (400 MHz, Chloroform-d) δ 8.56 (s, 1H), 7.85 (s, 1H), 7.26 (d, J = 0.9 Hz, 1H), 6.77 (d, J = 1.0 Hz, 1H), 4.81 (d, J = 6.2 Hz, 1H), 4.65 - 4.28 (m, 2H), 3.51 (s, 3H), 3.37 (s, 3H), 2.72 - 2.33 (m, 2H), 1.89 (ddd, J = 12.6, 7.8, 2.6 Hz, 1H), 1.62 (td, J = 11.7, 7.7 Hz, 1H), 1.38 (s, 3H), 0.66 (s, 3H). MS (m/z): 449.36 [M+H]+.
Biological Example 1:
NTCP-HepG2 Antiviral Assay for Secreted HBsAg
HepG2 cells stably expressing sodium-taurocholate cotransporting polypeptide (NTCP-HepG2) were grown in Dulbecco's Modified Eagle Medium (DMEM) without sodium pyruvate (Thermo Fisher Scientific, Waltham, MA) supplemented with 10% fetal bovine serum, 2 mM L- glutamine, 1% penicillin/streptomycin, and 0.25 mg/mL G-418. NTCP-HepG2 cells were infected with 4000 genome equivalent per cell of genotype D (AD38-derived) HBV in DMEM without sodium pyruvate (Thermo Fisher Scientific, Waltham, MA) supplemented with 2% fetal bovine serum, 2 mM L-glutamine, 1% penicillin/streptomycin, 2.5% DMSO, and 4% PEG 8000 (Promega, Madison, WI). After 24-hour incubation, cells were washed three times with
OptiMEM (Thermo Fisher Scientific, Waltham, MA) and fed with fresh DMEM without sodium pyruvate (Thermo Fisher Scientific, Waltham, MA) supplemented with 2% fetal bovine serum, 2 mM L-glutamine, 1% penicillin/streptomycin, and 2.5% DMSO. At 4 days after infection, infected NTCP-HepG2 cells were seeded on 384-well plates pre-coated with collagen at a density of 20000 cells per well containing serially diluted compounds of the present disclosure or DMSO (0.5%) in a final volume of 80 μΐ of DMEM without sodium pyruvate (Thermo Fisher Scientific, Waltham, MA) supplemented with 2% fetal bovine serum, 2 mM L-glutamine, 1% penicillin/streptomycin, and 1% DMSO. After an incubation time of 5 days, cell culture supernatant was collected and measured for HBsAg. Secreted HBsAg in the supernatant were measured using a multiplex chemiluminescent MSD assay (Meso Scale Discovery, Rockville, MD) using capture and detection antibody pairs specific for HBsAg. The EC50 values were calculated from the fit of the dose-response curves to a four-parameter equation. All EC 50 values represent geometric mean values of a minimum of four determinations. EC50 values for certain compounds of the present disclosure are reported in Table 1 below.
Biological Example 2: MT-4 Cytotoxicity Assay
The MT-4 cell line (HTLV-1 transformed, human T lymphoblastoid cells) was obtained from the NIH AIDS Reagent program (Bethesda, MD). MT-4 cells were maintained in RPMI-1640 media (Thermo Fisher Scientific, Waltham, MA) supplemented with 10% fetal bovine serum, 100 Units/mL penicillin, and 100 μg/mL streptomycin. For the MT-4 cytotoxicity assay, 0.4 of serially diluted solutions of certain compounds disclosed herein were added to 40 μΐ. of cell maintenance media in 384-well black, solid bottom plate using a Biomek FX workstation (Beckman Coulter, Brea, CA). Two thousand cells in 35 μΐ. were added to each well using a Biotek uFlow Workstation (Biotek, Winooski, VT). Each assay plate contained 10 μΜ puromycin (final concentration) and 0.5% DMSO in RPMI-1640 media as positive and negative controls, respectively. Assay plates were incubated for five days at 37 °C in an incubator set at 5% CO2 and 90% humidity. After five days, 22 uL of Cell Titer Glo reagent (Promega, Madison, WI) was added to the assay plates with a Biotek uFlow Workstation. Plates were subsequently placed on an Envision Plate Reader (Perkin Elmer, Waltham, MA) for five minutes before the luminescence signal was read. CC50 values were defined as the compound
concentration that caused a 50% decrease in luminescence signal, and were calculated by non- linear regression using Pipeline Pilot software by applying a four parameter fit equation
(Accelrys, San Diego, CA) and are reported in the following Table 1.
TABLE 1
Figure imgf000205_0001
Figure imgf000206_0001
acid
Figure imgf000207_0001
Figure imgf000208_0001
Figure imgf000209_0001
Figure imgf000210_0001
acid
Figure imgf000211_0001
Figure imgf000212_0001
Figure imgf000213_0001
Figure imgf000214_0001
Figure imgf000215_0001
carboxylic acid
Figure imgf000216_0001
carboxylic acid
Figure imgf000217_0001
acid
Figure imgf000218_0001
Figure imgf000219_0001
Figure imgf000220_0001
acid
Figure imgf000221_0001
carboxylic acid
Figure imgf000222_0001
acid
Figure imgf000223_0001
Biological Example 3: In Vitro Metabolic Stability
Pooled hepatic microsomes were diluted in 0.1 mM potassium phosphate buffer to 1.0 mg/mL final protein concentration. Alamethicin was added to the microsomal fraction to permeabilize the membrane to allow access of the UDP-glucronic acid (UDPGA) co-substrate to the active site of the UDP glucuronosyl transferase (UGT) enzymes. The final concentration was 25 μg/mL (ratio 25 μg alamethicin/mg microsomal protein) and the microsomes were then placed on ice for 15 min prior to the start of the reaction. Test compound was added to a final concentration of 1 μΜ. Positive control compounds known to be metabolized by oxidative and UGT enzymes were used. The metabolic reaction was warmed to 37 °C and initiated by the addition of a cofactor mix that consisted of 1.55 mM NADP, 3.3 mM glucose-6-phosphate,
0.4 U/mL glucose-6-phosphate dehydrogenase, 5 mM UDP-glucuronic acid and 3.3 mM MgC , all dissolved in 0.1 M potassium phosphate buffer, pH 7.4. At 2, 12, 25, 45, and 65 min, 25 aliquots of the reaction mixture were transferred to plates containing 225 μΐ of quenching solution (acetonitrile containing 300 nM labetalol IS and 0.1% formic acid). After quenching, the plates are centrifuged at 3000 x g for 30 minutes to precipitate proteins, and \0 μΐ. aliquots of the supernatant are analyzed by HPLC coupled to a high-resolution mass spectrometer.
For hepatocyte stability incubations, cells were obtained from BioreclamationlVT (Baltimore, MD), thawed according to the manufacturer's directions, and resuspended to a final concentration of 1 x 106 cells/mL in Krebs-Henseleit buffer prewarmed to 37 °C. The total cell count and the proportion of viable cells were determined by Trypan Blue dye exclusion using a hemocytometer. The final concentration of test compounds and positive controls was 2 μΜ. Incubations were carried out in duplicate wells of a 24-well plate out with gentle shaking at 37 °C under a humid atmosphere of 95% air/5% CO2 (v/v). Aliquots (50 μί) were removed after 0,
1, 3, and 6 hours and added to 100 μί quenching solution. Samples were then processed and analyzed in a manner similar to the microsomal stability samples.
Quantification of test compounds and positive controls were performed using analyte/internal standard peak area ratios (PAR) measured on a Q-Exactive mass spectrometer (Thermo Scientific, San Jose, CA) coupled to an Aria Transcend LX-4 multiplex UHPLC system (Thermo Scientific, San Jose, CA). A Hypersil Gold CI 8 UHPLC column (1.9 μιτι particle size, 50 x 2.1 mm) was used with mobile phases A and B consisting of 0.1% formic acid in water and 0.1% formic acid in acetonitrile, respectively. Elution was achieved by a series of linear gradients with increasing proportions of mobile phase B. The mass spectrometer was configured with a heated electrospray source and operated in positive ion mode. Analytes and the MS internal standard peak areas were obtained from full scan high resolution spectra (100- 1400 m/z, resolution 70,000) using the exact masses of the compounds (± 5 ppm). Half-lives of compounds in the incubations were calculated from extracted data using GMSU/QuickCalc (Gubbs, Inc.) and data are summarized in the following Table 2. Table 2: Stability in dog, rat, cynomolgus monkey and human hepatocytes
Figure imgf000224_0001
Rat Dog Cyno Human
Example 33 1.6 5.7 5.6 21.6
Example 5 >39.5 >39.5 20.8 >39.5
These data suggest that compounds of disclosed herein, e.g. Formula (I), (la), (II) and (Ila), having an additional ring nitrogen (Example 5) in place of carbon (Example 33) have improved in vitro metabolic stability. This suggests that compounds disclosed herein, e.g.
Formula (I), (la), (II) and (Ila) may be administered at lower doses and/or less frequently with reduced likelihood of toxic intermediates to treat or prevent an HBV infection.
Biological Example 4: Toxicology study
Human iPSC Neurite Outgrowth Assay
Human induced pluripotent stem cell (iPSC) derived iCell GABAergic Neurons (Cellular Dynamics Inc.) were seeded at a density of 67,500 cells per square centimeter into 384 well plates. The neurons were plated for 1 hour in attachment media before exchange for serum- free growth media (Cellular Dynamics Inc.). The serum-free growth media was exchanged for fresh media and the plated neurons were treated with test compounds and control compounds at 6 concentrations (lnM-100 μΜ) at 4 and 24 hour timepoints in triplicate wells. Optimum neuron cell attachment to the plates was obtained at the 24 hour timepoint. Vincristine was utilized as the positive control for toxic inhibition of neurite outgrowth and 0.1% DMSO treatment was used for control treatment of neurons. Celltracker and DRAQ7 stains were applied prior to fixation of cells to assess nuclear and cell viability. Cells were then fixed for 20 minutes in 4% formaldehyde in PBS containing Hoechst dye and then fixative was replaced with PBS twice. High content imaging was performed with 9 fields of 20x magnification on a CX7 HCS system with an algorithm to enable quantification of neurite lengths and neurite branch points in all treatment groups. The results of the counts and measurements were then analyzed by the strictly standardized mean difference (SSMD) method of analysis to measure effect size for any decreases in mean neurite total length per cell (microns) or changes in mean branch point counts per cell (Pheno Vista Biosciences, San Diego). The results are shown in FIGS. 1 and 2. FIG. 1 depicting plots of mean branch point counts per cell as a function of concentration for
Vincristine, RG783/R07020322, and Compound 73 (free base, purified without addition of TFA). FIG. 2 shows plots of mean neurite total length per cell as a function of concentration for Vincristine, RG783/R07020322, and Compound 73. Vincristine has the following structure:
Figure imgf000226_0001
Compound RG783/R07020322 has the following structure:
Figure imgf000226_0002
No significant changes of effect were observed for neuron counts or neuron viability at any of the tested concentrations for RG7834/R07020322, Vincristine and Compound 73 when compared to 0.1% DMSO control treated iCell neurons by the SSMD analysis. No significant effects were observed for neurite outgrowth lengths or branch point counts for Compound 73 at any concentration in either the 4 or 24 hour treatments when compared to 0.1% DMSO control treated neurons by the SSMD analysis as shown in FIG. 1, FIG. 2, Table 3, and Table 4.
In contrast, for Vincristine and RG7834/R07020322, significant decreases in neurite total length and branch point counts were observed at 4 and 24 hour timepoints when compared to 0.1% DMSO treated neurons. Significant decreases in mean neurite total length per cell occurred at 1, 10 and 100 μΜ for Vincristine and RG7834/R07020322 with a dose response in FIG. 2 and Table 3. In the 4 hour treatments, significant decreases in neurite total length at 10 and 100 μΜ RG7834/R07020322 and from 1-10 μΜ for the Vincristine treatment was observed. Significant decreases in branch point counts for both Vincristine and RG7834/R07020322 at 1, 10 and 100 μΜ in the 24 hour treatments were also observed but were not seen in neurons treated with Compound 73 (FIG. 1, Table 4).
These data suggest that Compound 73 has improved acute neurotoxicity liabilities as shown in an assay of human-derived iPSC neurons over that of RG7834/R07020322 and the neurotoxic chemotherapeutic drug Vincristine. The lack of effect by the SSMD analysis on neurite mo hology at any concentration for Compound 73 is in contrast to observations of neurite changes for RG7834/R07020322 and Vincristine at concentrations up to 100 μΜ for 24 hours. The results distinguish Compound 73 from more potently neurotoxic compounds.
Table 3: Strictly Standardized Mean Difference (SSMD) Values of Neurite Total Lengths.
Figure imgf000227_0001
Table 4: Strictly Standardized Mean Difference (SSMD) Values of Neurite Branch Point Counts Branch Point 0.001 μΜ 0.01 μΜ 0.1 μΜ 1 μ\Ι 10 100 Count SSMD μΜ μΜ Values
0.1% DMSO 24 hr Control
4 hr
Compound 73
NS NS NS NS NS NS
24 hr
4 hr NS NS NS NS NS NS
RG7834/
NS NS NS -3.3 -3.4 -5.0 R07020322 24 hr
NS NS NS NS NS -5.2 4 hr
Vincristine
NS NS NS -3.1 -3.6 -6.0 24 hr
NS NS NS NS -3.0 -3.5 4 hr
NS = no significant effect and > -3 SSMD Values. Values of < -3 considered significant for decreased branching

Claims

Figure imgf000229_0001
(I)
wherein:
A is a 4-7 membered cycloalkyl or heterocyclyl ring substituted with 0-8 R5 groups;
R1 is H or halogen;
R2 is selected from the group consisting of halogen, R2aO-, alkyl, C3-i0 cycloalkyl, 3-7 membered heterocyclyl, -NRaRb, -S(0)o-2Ra, or -CN, wherein each Ci_ 6alkyl, C3-10 cycloalkyl or 3-7 membered heterocyclyl is optionally substituted with 1-5 R groups;
R2a is selected from the group consisting of H, C3-6 cycloalkyl or C1-6 alkyl, wherein each C3-6 cycloalkyl or C1-6 alkyl is optionally substituted with 1-5 R20 groups;
R3 is selected from the group consisting of R3aO, C1-6 alkyl, 5-10 membered heteroaryl, 3-12 membered heterocyclyl, C2-6 alkenyl, C2-6 alkynyl, Ce-w aryl, C3-lo cycloalkyl, -NRaRb, and -S(0)o-2Ra, wherein each Ci^ alkyl, 5-10 membered heteroaryl, 3-12 membered heterocyclyl, C2-6 alkenyl, C2-6 alkynyl, Ce-w aryl, or C3-10 cycloalkyl is optionally substituted with 1-5 R20 groups;
R3a is selected from the group consisting of H, C1-6 alkyl, C1-6 alkoxyC^alkyl, 5- 10 membered heteroaryl, 3-12 membered heterocyclyl, Ce-w aryl and C3-lo cycloalkyl, wherein each
Figure imgf000229_0002
5-10 membered heteroaryl, 3-12 membered heterocyclyl, C6-1o aryl and C3-lo cycloalkyl is optionally substituted with 1-5 R20 groups;
R4 is H or halogen;
each R5 is independently selected from the group consisting of C1-6 alkyl, alkoxy, C2^ alkenyl, C2-6 alkynyl, -NRaRb, halogen, -C(0)Ra, -C(0)ORa, -C(0)NRaRb, -OC(0)NRaRb, -NRaC(0)Rb, -NRaC(0)ORb, -S(O)0-2Ra, -S(0)2NRaRb, -NRaS(0)2Rb, -ORa, Ce-ιο aryl, C3-lo cycloalkyl, 5-10 membered heteroaryl and 3-12 membered heterocyclyl, wherein each Ci^ alkyl, Ci^ alkoxy, C2-6 alkenyl, C2-6 alkynyl, Ce-ιο aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl and 3-12 membered heterocyclyl is optionally substituted with 1-5 R20 groups;
wherein any two R5 groups on the same carbon atom can optionally form a =0; and any two R5 groups can optionally j oin together to form a C3-6 cycloalkyl or 3-6 membered heterocyclyl ring optionally substituted with 1-3 R21 groups;
each Ra and Rb is independently selected from the group consisting H; or Ci-6 alkyl, C3-i0 cycloalkyl, 3-12 membered heterocyclyl, C6-io aryl, 5-10 membered heteroaryl, each of which is optionally substituted with from one to five R21 groups; or Ra and Rb together with the atoms to which they are attached form a 3-12 membered heterocyclyl optionally substituted with one to five R21 groups;
each R20 is independently selected from the group consisting C i^ alkyl, C3-10 cycloalkyl, Ci-6 alkoxy, 3-12 membered heterocyclyl, C6-10 aryl, 5-10 membered heteroaryl, halogen, oxo, -ORa, -C(0)Ra, -C(0)ORa, -C(0)NRaRb, -OC(0)NRaRb, - NRaRb, -NRaC(0)Rb, -NRaC(0)ORb, -S(O)0-2Ra, -S(0)2NRaRb, -NRaS(0)2Rb, -N3, - CN, or -NO2, or two R20 groups appended to the same group can j oin together to form a fused, spiro or bridged C3-10 cylcloalkyl or 3-12 membered heterocyclyl ring, wherein each Ci-6 alkyl, C3-10 cycloalkyl, Ci-6 alkoxy, 3-12 membered heterocyclyl, C6-10 aryl, 5- 10 membered heteroaryl is optionally substituted with from one to five halogen, oxo, - ORa, -C(0)Ra, -C(0)ORa, -C(0)NRaRb, -OC(0)NRaRb, -NRaRb, -NRaC(0)Rb, - NRaC(0)ORb, -S(0)o-2Ra, -S(0)2NRaRb, -NRaS(0)2Rb, -N3, -CN, or -N02; and
each R21 is independently selected from the group consisting C i^ alkyl, Ci.
6haloalkyl, C3-10 cycloalkyl, Ci^ alkoxy, 3-12 membered heterocyclyl, C6-10 aryl, 5-10 membered heteroaryl, hydroxyl, amino, Ci^ alkylamino, -CN or halogen;
or a pharmaceutically acceptable salt thereof.
2. The compound of claim 1, wherein R2 is selected from the group consisting of halogen, C3-10 cycloalkyl, 3-7 membered heterocyclyl, C3-10 cycloalkoxy, Ci^ alkyl, Ci_ 6alkoxy, or -CN, wherein each C3-10 cycloalkyl, C4-10 cycloalkoxy, 3-7 membered heterocyclyl, Ci-6 alkyl, d^alkoxy is optionally substituted with halo, C^alkoxy or a pharmaceutically acceptable salt thereof.
3. The compound of claim 1 or 2, wherein R2 is selected from the group consisting of chloro, methoxy, ethoxy, methoxy methyl, -OCH(CH3)2 OC(CH3)3i cyclopropyl, -OCF3 -OCHF2 and ° ° , or a pharmaceutically acceptable salt thereof.
4. The compound of any one of claims 1-3, wherein R2 is halogen, or a
pharmaceutically acceptable salt thereof.
5. The compound of claim 4, wherein R2 is chloro, or a pharmaceutically acceptable salt thereof.
6. The compound of any one of claims 1-3, wherein R2 is methoxy, or a
pharmaceutically acceptable salt thereof.
7. The compound of claim 1 or 2, wherein R2 is C3-6cycloalkyl optionally substituted with 1-2 R20 groups, or a pharmaceutically acceptable salt thereof.
8. The compound of claim 7, wherein R2 is cyclopropyl, or a pharmaceutically acceptable salt thereof.
9. The compound of claim 1, wherein R2 is R2aO-, or a pharmaceutically acceptable salt thereof.
10. The compound of claim 9, wherein R2a is C3-6 cycloalkyl optionally substituted with 1-2 R20 groups, or a pharmaceutically acceptable salt thereof.
11. The compound of claim 10, wherein R2a is cyclopropyl, or a pharmaceutically acceptable salt thereof.
12. The compound of claim 1, wherein R2 is methoxymethyl, or a pharmaceutically acceptable salt thereof.
13. The compound of any one of claims 1-12, wherein R3 is selected from Ci-6 alkoxy,
Figure imgf000231_0001
and C3-8cycloalkoxyCi-6alkoxy, wherein each Ci-6 alkoxy,
Figure imgf000231_0002
and C3-8cycloalkoxyCi^alkoxy is optionally substituted with halo, or a pharmaceutically acceptable salt thereof.
14. The compound of any one of claims 1-12, wherein R3 is
Figure imgf000232_0001
or Ci-6haloalkoxyCi^alkoxy, or a pharmaceutically acceptable salt thereof.
15. The compound of any one of claims 1-12, wherein R3 is selected from the group consisting of C3-6 cycloalkyl, C1-6
Figure imgf000232_0002
5-10 membered heteroaryl, C2-6 alkynyl, each optionally substituted with 1-3 R20 groups, or a pharmaceutically acceptable salt thereof.
16. The compound of claim 15, wherein R3 is C3-6 cycloalkyl, or a pharmaceutically acceptable salt thereof.
17. The compound of claim 15, wherein R3 is C3-6 cycloalkoxy, or a
pharmaceutically acceptable salt thereof.
18. The compound of any one of claims 1-12, wherein R3 is R3aO, wherein R3a is optionally substituted with 1-3 R20 groups, or a pharmaceutically acceptable salt thereof.
19. The compound of claim 18, wherein R3a is C3-6 cycloalkyl, or a pharmaceutically acceptable salt thereof.
20. The compound of claim 18, wherein R3a is C3-6 cycloalkylCi-6 alkyl, wherein the C3-6 cycloalkyl is optionally substituted with oxo or 1-3 fluoro groups, or a
pharmaceutically acceptable salt thereof.
21. The compound of claim 18, wherein R3a is 5-10 membered heteroaryl, or a pharmaceutically acceptable salt thereof.
22. The compound of claim 18, wherein R3a is 3-7 membered heterocyclylCi^alkyl, or a pharmaceutically acceptable salt thereof.
23. The compound of claim 18, wherein R3a is Ci-6haloalkoxyCi^alkyl, or a pharmaceutically acceptable salt thereof.
24. The compound of claim 15, wherein R3 is alkoxyCi-6alkyl, or a
pharmaceutically acceptable salt thereof.
25. The compound of claim 15, wherein R3 is C3-6
Figure imgf000233_0001
or a pharmaceutically acceptable salt thereof.
26. The compound of claim 15, wherein R3 is C2-6 alkynyl optionally substituted with 1-3 R20 groups, or a pharmaceutically acceptable salt thereof.
27. The compound of claim 26, wherein R3 is a C2-6 alkynyl group substituted with heteroaryl or
Figure imgf000233_0002
each optionally substituted with 1-3 methyl groups, or a pharmaceutically acceptable salt thereof.
28. The compound of any one of claims 1-12, wherein R3 is selected from the group consisting of:
Figure imgf000233_0003
or a pharmaceutically acceptable salt thereof.
29. The compound of any one of claims 1 -12, wherein R is 0 0 , or a pharmaceutically acceptable salt thereof.
30. The compound of any one of claims 1 -29, wherein R1 and R4 are both H, or a pharmaceutically acceptable salt thereof.
31. The compound of any one of claims 1 or 13-29, wherein R1 and R4 are both H and R2 is cyclopropyl or methoxymethyl, or a pharmaceutically acceptable salt thereof.
32. The compound of any one of claims 1 or 13-30, comprising Formula (la):
Figure imgf000234_0001
la wherein:
A is a 4-7 membered cycloalkyl or heterocyclyl ring substituted with 0-8 R5 groups;
R3 is selected from the group consisting of R3aO, C1-6 alkyl, 5-10 membered heteroaryl, 3-12 membered heterocyclyl, C2-6 alkenyl, C2-6 alkynyl, Ce-w aryl, C3-10 cycloalkyl, -NRaRb, and -S(0)o-2Ra, wherein each Ci^ alkyl, 5-10 membered heteroaryl, 3-12 membered heterocyclyl, C2-6 alkenyl, C2-6 alkynyl, Ce-w aryl, or C3-lo cycloalkyl is optionally substituted with 1-5 R20 groups;
R3a is selected from the group consisting of H, C1-6 alkyl, C1-6 alkoxyCi-6alkyl, 5- 10 membered heteroaryl, 3-12 membered heterocyclyl, Ce-w aryl and C3-10 cycloalkyl, wherein each C -5 alkyl,
Figure imgf000234_0002
5-10 membered heteroaryl, 3-12 membered heterocyclyl, Ce-w aryl and C3-10 cycloalkyl is optionally substituted with 1-5 R20 groups;
each Ra and Rb is independently selected from the group consisting H; or C1-6 alkyl, C3-lo cycloalkyl, 3-12 membered heterocyclyl, C6-1o aryl, 5-10 membered heteroaryl, each of which is optionally substituted with from one to five R21 groups; or Ra and Rb together with the atoms to which they are attached form a 3-12 membered heterocyclyl optionally substituted with one to five R21 groups;
each R20 is independently selected from the group consisting C i^ alkyl, C3-10 cycloalkyl, C1-6 alkoxy, 3-12 membered heterocyclyl, Ce-w aryl, 5-10 membered heteroaryl, halogen, oxo, -ORa, -C(0)Ra, -C(0)ORa, -C(0)NRaRb, -OC(0)NRaRb, - NRaRb, -NRaC(0)Rb, -NRaC(0)ORb, -S(O)0-2Ra, -S(0)2NRaRb, -NRaS(0)2Rb, -N3, - CN, or -N02, or two R groups appended to the same group can j oin together to form a fused, spiro or bridged C3-lo cylcloalkyl or 3-12 membered heterocyclyl ring, wherein each Ci-6 alkyl, C3-10 cycloalkyl, C1-6 alkoxy, 3-12 membered heterocyclyl, Ce-w aryl, 5- 10 membered heteroaryl is optionally substituted with from one to five halogen, oxo, - ORa, -C(0)Ra, -C(0)ORa, -C(0)NRaRb, -OC(0)NRaRb, -NRaRb, -NRaC(0)Rb, - NRaC(0)ORb, -S(0)o-2Ra, -S(0)2NRaRb, -NRaS(0)2Rb, -N3, -CN, or -N02; and
each R21 is independently selected from the group consisting alkyl, C3-lo cycloalkyl, C1-6 alkoxy, C^haloalkyl, 3-12 membered heterocyclyl, C6-1o aryl, 5-10 membered heteroaryl, hydroxyl, amino, Ci^ alkylamino, -CN or halogen;
or a pharmaceutically acceptable salt thereof.
33. The compound of any one of claims 1 or 13-30, comprising Formula (Ic):
Figure imgf000235_0001
Ic wherein:
A is a 4-7 membered cycloalkyl or heterocyclyl ring substituted with 0-8 R5 groups;
R1 is H or halogen;
R3 is selected from the group consisting of R3aO, C1-6 alkyl, 5-10 membered heteroaryl, 3-12 membered heterocyclyl, C2_6 alkenyl, C2-6 alkynyl, Ce-w aryl, C3-lo cycloalkyl, -NRaRb, and -S(0)o-2Ra, wherein each Ci^ alkyl, 5-10 membered heteroaryl, 3-12 membered heterocyclyl, C2-6 alkenyl, C2_6 alkynyl, Ce-w aryl, or C3-lo cycloalkyl is optionally substituted with 1-5 R20 groups;
R3a is selected from the group consisting of H, C1-6 alkyl, C1-6 alkoxyCi-6alkyl, 5- 10 membered heteroaryl, 3-12 membered heterocyclyl, Ce-w aryl and C3-lo cycloalkyl, wherein each
Figure imgf000235_0002
5-10 membered heteroaryl, 3-12 membered heterocyclyl, Ce-ιο aryl and C3-10 cycloalkyl is optionally substituted with 1-5 R20 groups;
R4 is H or halogen;
each R5 is independently selected from the group consisting of Ci-6 alkyl, Ci^ alkoxy, C2^ alkenyl, C2-6 alkynyl, -NRaRb, halogen, -C(0)Ra, -C(0)ORa, -C(0)NRaRb, -OC(0)NRaRb, -NRaC(0)Rb, -NRaC(0)ORb, -S(O)0-2Ra, -S(0)2NRaRb, -NRaS(0)2Rb, -ORa, C6-io aryl, C3-i0 cycloalkyl, 5-10 membered heteroaryl and 3-12 membered heterocyclyl, wherein each Ci^ alkyl, Ci^ alkoxy, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl and 3-12 membered heterocyclyl is optionally substituted with 1-5 R20 groups;
wherein any two R5 groups on the same carbon atom can optionally form a =0; and any two R5 groups can optionally join together to form a C3-6 cycloalkyl or 3-6 membered heterocyclyl ring optionally substituted with 1-3 R21 groups;
each Ra and Rb is independently selected from the group consisting H; or Ci-6 alkyl, C3-10 cycloalkyl, 3-12 membered heterocyclyl, C6-10 aryl, 5-10 membered heteroaryl, each of which is optionally substituted with from one to five R21 groups; or Ra and Rb together with the atoms to which they are attached form a 3-12 membered heterocyclyl optionally substituted with one to five R21 groups;
each R20 is independently selected from the group consisting Ci^ alkyl, C3-10 cycloalkyl, Ci-6 alkoxy, 3-12 membered heterocyclyl, C6-10 aryl, 5-10 membered heteroaryl, halogen, oxo, -ORa, -C(0)Ra, -C(0)ORa, -C(0)NRaRb, -OC(0)NRaRb, - NRaRb, -NRaC(0)Rb, -NRaC(0)ORb, -S(O)0-2Ra, -S(0)2NRaRb, -NRaS(0)2Rb, -N3, - CN, or -N02, or two R20 groups appended to the same group can join together to form a fused, spiro or bridged C3-10 cylcloalkyl or 3-12 membered heterocyclyl ring, wherein each Ci-6 alkyl, C3-i0 cycloalkyl, Ci-6 alkoxy, 3-12 membered heterocyclyl, C6-io aryl, 5- 10 membered heteroaryl is optionally substituted with from one to five halogen, oxo, - ORa, -C(0)Ra, -C(0)ORa, -C(0)NRaRb, -OC(0)NRaRb, -NRaRb, -NRaC(0)Rb, - NRaC(0)ORb, -S(0)o-2Ra, -S(0)2NRaRb, -NRaS(0)2Rb, -N3, -CN, or -N02; and
each R21 is independently selected from the group consisting Ci^ alkyl, Ci_ 6haloalkyl, C3-10 cycloalkyl, Ci^ alkoxy, 3-12 membered heterocyclyl, C6-10 aryl, 5-10 membered heteroaryl, hydroxyl, amino, Ci^ alkylamino, -CN or halogen;
or a pharmaceutically acceptable salt thereof.
34. The compound of any one of claims 1-32, wherein at least one of R is C1-3 alkyl optionally substituted with halo, or a pharmaceutically acceptable salt thereof.
35. The compound of any one of claims 1-32, wherein at least two R5 groups are C1-3 alkyl, or a pharmaceutically acceptable salt thereof.
36. The compound of claim 35, wherein at least two R5 groups are methyl, or a pharmaceutically acceptable salt thereof.
37. The compound of claim 36, wherein at least two R5 groups are methyl bound at the same carbon atom, or a pharmaceutically acceptable salt thereof.
38. The compound of any one of claims 1-32, wherein two R5 groups join together at the same carbon atom to form a C3_6 cycloalkyl or 3-6 membered heterocyclyl ring, or a pharmaceutically acceptable salt thereof.
39. The compound of claim 38, wherein two R5 groups join together at the same carbon atom to form a cyclopropyl group, or a pharmaceutically acceptable salt thereof.
40. The compound of any one of claims 1-39, wherein A is:
Figure imgf000237_0001
wherein:
Z1 is a bond, O, NRa or CR5eR5f;
Z2 is a bond, O, NRa or CR5gR5h;
provided only one of Zxand Z2 is O or NRa;
each of R5a, R5b, R5c, R5d, R5e, R5f R5g and R5h are independently selected from the group consisting of H, Ci^ alkyl, Ci^ alkoxy, C2-6 alkenyl, C2-6 alkynyl, -NRaRb, halogen, C(0)Ra, -C(0)ORa, -C(0)NRaRb, -OC(0)NRaRb, -NRaC(0)Rb, - NRaC(0)ORb, -S(O)0-2Ra, -S(0)2NRaRb, -NRaS(0)2Rb, -N3, -CN, -N02, -ORa, C6.10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl and 3-12 membered heterocyclyl wherein each C -5 alkyl, Ci^ alkoxy, C2-6 alkenyl, C2-6 alkynyl, Ce-w aryl, C3-lo cycloalkyl, 5-10 membered heteroaryl and 3-12 membered heterocyclyl is optionally substituted with 1-5 R20 groups; wherein up to two of R5a and R , R5c and R , R5e and R , or R5g and R5h can form a =0;
wherein any two of R5a, R5b, R5c, R5d, R5e, R5f R5g and R5h can j oin together to form a cycloalkyl or heterocyclyl ring optionally substituted with 1-3 R21 groups;
each Ra and Rb is independently selected from the group consisting H; or C1-6 alkyl, C3-10 cycloalkyl, 3-12 membered heterocyclyl, Ce-w aryl, 5-10 membered heteroaryl, each of which is optionally substituted with from one to five R21 groups; or Ra and Rb together with the atoms to which they are attached form a 3-12 membered heterocyclyl optionally substituted with one to five R21 groups;
each R20 is independently selected from the group consisting C i^ alkyl, C3-lo cycloalkyl, C1-6 alkoxy, 3-12 membered heterocyclyl, Ce-w aryl, 5-10 membered heteroaryl, halogen, oxo, -ORa, -C(0)Ra, -C(0)ORa, -C(0)NRaRb, -OC(0)NRaRb, - NRaRb, -NRaC(0)Rb, -NRaC(0)ORb, -S(O)0-2Ra, -S(0)2NRaRb, -NRaS(0)2Rb, -N3, - CN, or -NO2, or two R20 groups appended to the same group can j oin together to form a fused, spiro or bridged C3-10 cylcloalkyl or 3-12 membered heterocyclyl ring, wherein each Ci-6 alkyl, C3-lo cycloalkyl, C1-6 alkoxy, 3-12 membered heterocyclyl, Ce-w aryl, 5- 10 membered heteroaryl is optionally substituted with from one to five halogen, oxo, - ORa, -C(0)Ra, -C(0)ORa, -C(0)NRaRb, -OC(0)NRaRb, -NRaRb, -NRaC(0)Rb, - NRaC(0)ORb, -S(0)o-2Ra, -S(0)2NRaRb, -NRaS(0)2Rb, -N3, -CN, or -N02; and
each R21 is independently selected from the group consisting C i^ alkyl, Ci_ 6haloalkyl, C3-lo cycloalkyl, Ci^ alkoxy, 3-12 membered heterocyclyl, Ce-w aryl, 5-10 membered heteroaryl, hydroxyl, amino, alkylamino, -CN or halogen;
or a pharmaceutically acceptable salt thereof.
41. The compound of claim 40, wherein Z2 is CR5gR5h, or a pharmaceutically acceptable salt thereof.
42. The compound of claim 41 , wherein R5g and R5h are H or CH3, or a
pharmaceutically acceptable salt thereof.
A compound of Formula (II):
Figure imgf000239_0001
II
wherein:
Z1 is a bond, O, NRa or CR5eR5f;
R2 is selected from the group consisting of halogen, R2aO-, alkyl, or -CN, wherein is optionally substituted with 1 -3 R20 groups;
R2a is selected from the group consisting of H, C3-6 cycloalkyl or C1-6 alkyl, wherein each C3-6 cycloalkyl or C1-6 alkyl is optionally substituted with 1-3 R20 groups;
R3 is selected from C1-6 alk and C3-8cycloalkoxyCi- 6alkoxy, wherein each C -5 alkoxy,
Figure imgf000239_0002
C3-8cycloalkoxyCi^alkoxy is optionally substituted with halo;
each of R5a, R5b, R5c, R5d, R5e, R5f R5g and R5h are independently selected from the group consisting of H, Ci^ alkyl, Ci^ alkoxy, C2-6 alkenyl, C2-6 alkynyl, -NRaRb, halogen, C(0)Ra, -C(0)ORa, -C(0)NRaRb, -OC(0)NRaRb, -NRaC(0)Rb, - NRaC(0)ORb, -S(O)0-2Ra, -S(0)2NRaRb, -NRaS(0)2Rb, -N3, -CN, -N02, -ORa, C6.10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl and 3-12 membered heterocyclyl wherein each C -5 alkyl, Ci^ alkoxy, C2-6 alkenyl, C2-6 alkynyl, Ce-w aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl and 3-12 membered heterocyclyl is optionally substituted with 1 -5 R20 groups;
wherein up to two of R5a and R5b, R5c and R5d, R5e and R5f, or R5g and R5h can optionally form a =0; and wherein any two of R5a, R5b, R5c, R5d, R5e, R5f R5g and R5h can optionally j oin together to form a cycloalkyl or heterocyclyl ring optionally substituted with 1 -3 R21 groups;
each Ra and Rb is independently selected from the group consisting H; or C1-6 alkyl, C3-10 cycloalkyl, 3-12 membered heterocyclyl, Ce-w aryl, 5-10 membered heteroaryl, each of which is optionally substituted with from one to five R21 groups; or Ra and Rb together with the atoms to which they are attached form a 3-12 membered heterocyclyl optionally substituted with one to five R21 groups; each R is independently selected from the group consisting C i^ alkyl, C3-lo cycloalkyl, C1-6 alkoxy, 3-12 membered heterocyclyl, Ce-w aryl, 5-10 membered heteroaryl, halogen, oxo, -ORa, -C(0)Ra, -C(0)ORa, -C(0)NRaRb, -OC(0)NRaRb, - NRaRb, -NRaC(0)Rb, -NRaC(0)ORb, -S(O)0-2Ra, -S(0)2NRaRb, -NRaS(0)2Rb, -N3, - CN, or -N02, wherein each C1-6 alkyl, C3-10 cycloalkyl, C1-6 alkoxy, 3-12 membered heterocyclyl, Ce-w aryl, 5-10 membered heteroaryl is optionally substituted with from one to five halogen, oxo, -ORa, -C(0)Ra, -C(0)ORa, -C(0)NRaRb, -OC(0)NRaRb, - NRaRb, -NRaC(0)Rb, -NRaC(0)ORb, -S(O)0-2Ra, -S(0)2NRaRb, -NRaS(0)2Rb, -N3, - CN, or -N02; and
each R21 is independently selected from the group consisting C i^ alkyl, Ci_ 6haloalkyl, C3-lo cycloalkyl, Ci^ alkoxy, 3-12 membered heterocyclyl, Ce-w aryl, 5-10 membered heteroaryl, hydroxyl, amino, Ci^ alkylamino, -CN or halogen;
or a pharmaceutically acceptable salt thereof.
44. The compound of any one of claims 40-43, wherein Z1 is a bond, or a pharmaceutically acceptable salt thereof.
45. The compound of any one of claims 40-43, wherein Z1 is CR5eR5f, or a pharmaceutically acceptable salt thereof.
46. The compound of claim 45, wherein R5e and R5f are H, halo, or C1-3 alkyl, or a pharmaceutically acceptable salt thereof.
47. The compound of any one of claim 40-43, wherein Z1 is O, or a pharmaceutically acceptable salt thereof.
48. The compound of any one of claims 40-47, wherein R5c and R5d are H, or a pharmaceutically acceptable salt thereof.
49. The compound of any one of claims 40-47, wherein R5c and R5d are C1-3 alkyl, or a pharmaceutically acceptable salt thereof.
50. The compound of claim 49, wherein R5c and R5d are CH3, or a pharmaceutically acceptable salt thereof.
51. The compound of any one of claims 40-47, wherein R c is H and R is CH3, or a pharmaceutically acceptable salt thereof.
52. The compound of any one of claims 40-47, wherein R5c and R5d are taken together to form a C3-6 cycloalkyl or 3-6 membered heterocyclyl ring, each optionally substituted with 1-3 R20 groups, or a pharmaceutically acceptable salt thereof.
53. The compound of claim 52, wherein R5c and R5d are taken together to form a C3-6 cycloalkyl, or a pharmaceutically acceptable salt thereof.
54. The compound of claim 52 or 53, wherein R5c and R5d are taken together to form a cyclopropyl, or a pharmaceutically acceptable salt thereof.
55. The compound of any one of claims 40-54, wherein R5a and R5b are H, or a pharmaceutically acceptable salt thereof.
56. The compound of any one of claims 40-54, wherein R5a and R5b are CH3, or a pharmaceutically acceptable salt thereof.
57. The compound of any one of claims 40-54, wherein R5g and R5h are H, or a pharmaceutically acceptable salt thereof.
58. The compound of any one of claims 40-57, wherein R5g and R5h are CH3, or a pharmaceutically acceptable salt thereof.
Figure imgf000241_0001
Ila wherein: B is a 3-6 membered cycloalkyl or 3-6 membered heterocyclyl ring each substituted with 0-2 R21 groups;
Z1 is a bond, O, NRa or CR5eR5f;
R2 is selected from the group consisting of halogen, R2aO-, Ci^ alkyl, or -CN, wherein is optionally substituted with 1-3 R20 groups;
R2a is selected from the group consisting of H, C3-6 cycloalkyl or C1-6 alkyl, wherein each C3_6 cycloalkyl or C1-6 alkyl is optionally substituted with 1-3 R20 groups;
R3 is selected from C1-6 alkoxy,
Figure imgf000242_0001
and C3-8cycloalkoxyCi. 6alkoxy, wherein each
Figure imgf000242_0002
and C3-8cycloalkoxyCi_6alkoxy is optionally substituted with halo;
each of R5a, R5b, R5e, R5f R5g and R5h are independently selected from the group consisting of H, Ci^ alkyl, C1-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl, -NRaRb, halogen, C(0)Ra, -C(0)ORa, -C(0)NRaRb, -OC(0)NRaRb, -NRaC(0)Rb, -NRaC(0)ORb, -S(O)0. 2Ra, -S(0)2NRaRb, -NRaS(0)2Rb, -N3, -CN, -N02, -ORa, C6.10 aryl, C3-10 cycloalkyl, 5- 10 membered heteroaryl and 3-12 membered heterocyclyl wherein each C -5 alkyl, Ci^ alkoxy, C2-6 alkenyl, C2-6 alkynyl, Ce-w aryl, C3-lo cycloalkyl, 5-10 membered heteroaryl and 3-12 membered heterocyclyl is optionally substituted with 1-5 R20 groups;
wherein up to two of R5a and R5b, R5e and R5f, or R5g and R5h can optionally form a =0; and wherein any two of R5a, R5b, R5e, R5f R5g and R5h can optionally join together to form a cycloalkyl or heterocyclyl ring optionally substituted with 1-3 R21 groups; each Ra and Rb is independently selected from the group consisting H; or C1-6 alkyl, C3-10 cycloalkyl, 3-12 membered heterocyclyl, C6-1o aryl, 5-10 membered heteroaryl, each of which is optionally substituted with from one to five R21 groups; or Ra and Rb together with the atoms to which they are attached form a 3-12 membered heterocyclyl optionally substituted with one to five R21 groups;
each R20 is independently selected from the group consisting Ci^ alkyl, C3-lo cycloalkyl, C1-6 alkoxy, 3-12 membered heterocyclyl, Ce-w aryl, 5-10 membered heteroaryl, halogen, oxo, -ORa, -C(0)Ra, -C(0)ORa, -C(0)NRaRb, -OC(0)NRaRb, - NRaRb, -NRaC(0)Rb, -NRaC(0)ORb, -S(O)0-2Ra, -S(0)2NRaRb, -NRaS(0)2Rb, -N3, - CN, or -N02, wherein each C1-6 alkyl, C3-lo cycloalkyl, C1-6 alkoxy, 3-12 membered heterocyclyl, Ce-w aryl, 5-10 membered heteroaryl is optionally substituted with from one to five halogen, oxo, -ORa, -C(0)Ra, -C(0)ORa, -C(0)NRaRb, -OC(0)NRaRb, - NRaRb, -NRaC(0)Rb, -NRaC(0)ORb, -S(O)0-2Ra, -S(0)2NRaRb, -NRaS(0)2Rb, -N3, - CN, or -N02; and each R21 is independently selected from the group consisting Ci^ alkyl, Ci_ 6haloalkyl, C3-10 cycloalkyl, Ci^ alkoxy, 3-12 membered heterocyclyl, C6-10 aryl, 5-10 membered heteroaryl, hydroxyl, amino, Ci^ alkylamino, -CN or halogen;
or a pharmaceutically acceptable salt thereof.
60. A compound of claim 59, wherein B is oxetanyl, 2,2-dimethyl-l,3-dioxanyl, or cyclopropyl; or a pharmaceutically acceptable salt thereof.
61. The compound of claim 1 selected from:
Figure imgf000243_0001
Figure imgf000244_0001
243
Figure imgf000245_0001
244
Figure imgf000246_0001
245
Figure imgf000247_0001
246
Figure imgf000248_0001
pharmaceutically acceptable salt thereof. The compound of claim 1 selected from:
Figure imgf000248_0002
Figure imgf000249_0001
248
Figure imgf000250_0001
pharmaceutically acceptable salt thereof.
The compound of claim 1 having the formula:
Figure imgf000250_0002
or a pharmaceutically acceptable salt thereof.
The compound of claim 1 having the formula:
Figure imgf000250_0003
or a pharmaceutically acceptable salt thereof.
The compound of claim 1 having the formula:
Figure imgf000250_0004
or a pharmaceutically acceptable salt thereof.
The compound of claim 1 having the formula:
Figure imgf000251_0001
or a pharmaceutically acceptable salt thereof.
68. A pharmaceutical composition comprising a compound or pharmaceutically acceptable salt of any one of claims 1-67, and a pharmaceutically acceptable excipient.
69. The pharmaceutical composition of claim 68, further comprising one or more additional therapeutic agents.
70. The pharmaceutical composition of claim 69, wherein the one or more additional therapeutic agents are selected from the group consisting of HBV DNA polymerase inhibitors, toll-like receptor 7 modulators, toll-like receptor 8 modulators, toll-like receptor 7 and 8 modulators, toll-like receptor 3 modulators, interferon alpha ligands, HBsAg inhibitors, compounds targeting HBcAg, cyclophilin inhibitors, HBV therapeutic vaccines, HBV prophylactic vaccines, HBV viral entry inhibitors, NTCP inhibitors, antisense oligonucleotide targeting viral mRNA, short interfering RNAs (siRNA), HBeAg inhibitors, HBx inhibitors, cccDNA inhibitors, HBV antibodies including HBV antibodies targeting the surface antigens of the hepatitis B virus, thymosin agonists, cytokines, nucleoprotein inhibitors (HBV core or capsid protein inhibitors), stimulators of retinoic acid-inducible gene 1, stimulators of NOD2, recombinant thymosin alpha- 1 and hepatitis B virus replication inhibitors, hepatitis B surface antigen (HBsAg) secretion or assembly inhibitors, IDO inhibitors, KDM5 inhibitors, and combinations thereof.
71. The pharmaceutical composition of claim 66 or 70, wherein the one or more additional therapeutic agents are selected from the group consisting of adefovir
(Hepsera®), tenofovir disoproxil fumarate + emtricitabine (Truvada®), tenofovir disoproxil fumarate (Viread®), entecavir (Baraclude®), lamivudine (Epivir-HBV®), tenofovir alafenamide, tenofovir, tenofovir disoproxil, tenofovir alafenamide fumarate, tenofovir alafenamide hemifumarate, telbivudine (Tyzeka®), Clevudine®, emtricitabine (Emtriva®), peginterferon alfa-2b (PEG-Intron®), Multiferon®, interferon alpha lb (Hapgen®), interferon alpha-2b (Intron A®), pegylated interferon alpha-2a (Pegasys®), interferon alfa-nl(Humoferon®), ribavirin, interferon beta- la (Avonex®), Bioferon, Ingaron, Inmutag (Inferon), Algeron, Roferon-A, Oligotide, Zutectra, Shaferon, interferon alfa-2b (Axxo), Alfaferone, interferon alfa-2b (BioGeneric Pharma), Feron, interferon-alpha 2 (CJ), Bevac, Laferonum, Vipeg, Blauferon-B, Blauferon-A, Intermax Alpha, Realdiron, Lanstion, Pegaferon, PDferon-B, interferon alfa-2b (IFN, Laboratorios Bioprofarma), alfainterferona 2b, Kalferon, Pegnano, Feronsure, PegiHep, interferon alfa 2b (Zydus-Cadila), Optipeg A, Realfa 2B, Reliferon, interferon alfa-2b (Amega), interferon alfa-2b (Virchow), peginterferon alfa-2b (Amega), Reaferon-EC, Proquiferon, Uniferon, Urifron, interferon alfa-2b (Changchun Institute of Biological Products), Anterferon, Shanferon, MOR-22, interleukin-2 (IL-2), recombinant human interleukin-2, Layfferon, Ka Shu Ning, Shang Sheng Lei Tai, Intefen, Sinogen, Fukangtai, Alloferon, and celmoleukin, and combinations thereof.
72. The pharmaceutical composition of any one of claims 69-71, wherein the one or more additional therapeutic agents are selected from the group consisting of entecavir, adefovir, tenofovir disoproxil fumarate, tenofovir alafenamide, tenofovir, tenofovir disoproxil, tenofovir alafenamide fumarate, tenofovir alafenamide hemifumarate, telbivudine and lamivudine.
73. A method of inhibiting the production and/or secretion of HBsAg in an individual infected with HBV comprising administering a therapeutically effective amount of a compound or pharmaceutically acceptable salt of any one of claims 1-67 to the individual.
74. A method of treating or preventing an HBV infection comprising administering to an individual in need thereof a therapeutically effective amount of a compound or pharmaceutically acceptable salt of any one of claims 1-67 to the individual.
75. The method of claim 74, wherein the individual is chronically infected with HBV.
76. The method of any one of claims 73, 74 or 75, further comprising administering one or more additional therapeutic agents.
77. The method of claim 76, wherein the one or more additional therapeutic agents are selected from the group consisting of HBV DNA polymerase inhibitors, toll-like receptor 7 modulators, toll-like receptor 8 modulators, Toll-like receptor 7 and 8 modulators, Toll-like receptor 3 modulators, interferon alpha ligands, HBsAg inhibitors, compounds targeting HBcAg, cyclophilin inhibitors, HBV therapeutic vaccines, HBV prophylactic vaccines, HBV viral entry inhibitors, NTCP inhibitors, antisense oligonucleotide targeting viral mRNA, short interfering RNAs (siRNA), HBeAg inhibitors, HBx inhibitors, cccDNA inhibitors, HBV antibodies including HBV antibodies targeting the surface antigens of the hepatitis B virus, thymosin agonists, cytokines, nucleoprotein inhibitors (HBV core or capsid protein inhibitors), stimulators of retinoic acid-inducible gene 1, stimulators of NOD2, recombinant thymosin alpha- 1 and hepatitis B virus replication inhibitors, hepatitis B surface antigen (HBsAg) secretion or assembly inhibitors, IDO inhibitors, KDM5 inhibitors, and combinations thereof.
78. The method of claim 76, wherein the one or more additional therapeutic agents are selected from the group consisting of adefovir (Hepsera®), tenofovir disoproxil fumarate + emtricitabine (Truvada®), tenofovir disoproxil fumarate (Viread®), entecavir (Baraclude®), lamivudine (Epivir-HBV®), tenofovir alafenamide, tenofovir, tenofovir disoproxil, tenofovir alafenamide fumarate, tenofovir alafenamide hemifumarate, telbivudine (Tyzeka®), Clevudine®, emtricitabine (Emtriva®), peginterferon alfa-2b (PEG-Intron®), Multiferon®, interferon alpha lb (Hapgen®), interferon alpha-2b (Intron A®), pegylated interferon alpha-2a (Pegasys®), interferon alfa-nl(Humoferon®), ribavirin, interferon beta-la (Avonex®), Bioferon, Ingaron, Inmutag (Inferon), Algeron, Roferon-A, Oligotide, Zutectra, Shaferon, interferon alfa-2b (Axxo), Alfaferone, interferon alfa-2b, Feron, interferon-alpha 2 (CJ), Bevac, Laferonum, Vipeg, Blauferon- B, Blauferon-A, Intermax Alpha, Realdiron, Lanstion, Pegaferon, PDferon-B, alfainterferona 2b, Kalferon, Pegnano, Feronsure, PegiHep, Optipeg A, Realfa 2B, Reliferon, peginterferon alfa-2b, Reaferon-EC, Proquiferon, Uniferon, Urifron, interferon alfa-2b, Anterferon, Shanferon, MOR-22, interleukin-2 (IL-2), recombinant human interleukin-2 (Shenzhen Neptunus), Layfferon, Ka Shu Ning, Shang Sheng Lei Tai, Intefen, Sinogen, Fukangtai, Alloferon and celmoleukin.
79. The method of claim 76, wherein the one or more additional therapeutic agents are selected from entecavir, adefovir, tenofovir disoproxil fumarate, tenofovir alafenamide, tenofovir, tenofovir disoproxil, tenofovir alafenamide fumarate, tenofovir alafenamide hemifumarate, telbivudine and lamivudine.
80. An article of manufacture comprising a unit dosage of a compound or pharmaceutically acceptable salt of any one of claims 1-69.
81. A compound or pharmaceutically acceptable salt of any one of claims 1-69 for use in medical therapy.
82. A compound or pharmaceutically acceptable salt of any one of claims 1-69 for use in treating or preventing an HBV infection in an individual.
83. The use of a compound or pharmaceutically acceptable salt of any one of claims 1-69 for the manufacture of a medicament for use in medical therapy.
84. A compound or pharmaceutically acceptable salt of any one of claims 1-69 for use in inhibiting the production or secretion of HBsAg in vitro.
85. The compound of claim 1 selected from:
Figure imgf000254_0001
86. A pharmaceutical composition comprising a compound or pharmaceutically acceptable salt of claim 85, and a pharmaceutically acceptable excipient.
87. The pharmaceutical composition of claim 86, further comprising one or more additional therapeutic agents.
88. The pharmaceutical composition of claim 87, wherein the one or more additional therapeutic agents are selected from the group consisting of HBV DNA polymerase inhibitors, toll-like receptor 7 modulators, toll-like receptor 8 modulators, toll-like receptor 7 and 8 modulators, toll-like receptor 3 modulators, interferon alpha ligands, HBsAg inhibitors, compounds targeting HBcAg, cyclophilin inhibitors, HBV therapeutic vaccines, HBV prophylactic vaccines, HBV viral entry inhibitors, NTCP inhibitors, antisense oligonucleotide targeting viral mRNA, short interfering RNAs (siRNA), HBeAg inhibitors, HBx inhibitors, cccDNA inhibitors, HBV antibodies including HBV antibodies targeting the surface antigens of the hepatitis B virus, thymosin agonists, cytokines, nucleoprotein inhibitors (HBV core or capsid protein inhibitors), stimulators of retinoic acid-inducible gene 1, stimulators of NOD2, recombinant thymosin alpha- 1 and hepatitis B virus replication inhibitors, hepatitis B surface antigen (HBsAg) secretion or assembly inhibitors, IDO inhibitors, KDM5 inhibitors, and combinations thereof.
89. The pharmaceutical composition of claim 88, wherein the one or more additional therapeutic agents are selected from the group consisting of adefovir (Hepsera®), tenofovir disoproxil fumarate + emtricitabine (Truvada®), tenofovir disoproxil fumarate (Viread®), entecavir (Baraclude®), lamivudine (Epivir-HBV®), tenofovir alafenamide, tenofovir, tenofovir disoproxil, tenofovir alafenamide fumarate, tenofovir alafenamide hemifumarate, telbivudine (Tyzeka®), Clevudine®, emtricitabine (Emtriva®), peginterferon alfa-2b (PEG-Intron®), Multiferon®, interferon alpha lb (Hapgen®), interferon alpha-2b (Intron A®), pegylated interferon alpha-2a (Pegasys®), interferon alfa-nl(Humoferon®), ribavirin, interferon beta- la (Avonex®), Bioferon, Ingaron, Inmutag (Inferon), Algeron, Roferon-A, Oligotide, Zutectra, Shaferon, interferon alfa-2b (Axxo), Alfaferone, interferon alfa-2b (BioGeneric Pharma), Feron, interferon-alpha 2 (CJ), Bevac, Laferonum, Vipeg, Blauferon-B, Blauferon-A, Intermax Alpha, Realdiron, Lanstion, Pegaferon, PDferon-B, interferon alfa-2b (IFN, Laboratories Bioprofarma), alfainterferona 2b, Kalferon, Pegnano, Feronsure, PegiHep, interferon alfa 2b (Zydus- Cadila), Optipeg A, Realfa 2B, Reliferon, interferon alfa-2b (Amega), interferon alfa-2b (Virchow), peginterferon alfa-2b (Amega), Reaferon-EC, Proquiferon, Uniferon, Urifron, interferon alfa-2b (Changchun Institute of Biological Products), Anterferon, Shanferon, MOR-22, interleukin-2 (IL-2), recombinant human interleukin-2, Layfferon, Ka Shu Ning, Shang Sheng Lei Tai, Intefen, Sinogen, Fukangtai, Alloferon, and celmoleukin, and combinations thereof.
90. The pharmaceutical composition of any one of claims 85-89, wherein the one or more additional therapeutic agents are selected from the group consisting of entecavir, adefovir, tenofovir disoproxil fumarate, tenofovir alafenamide, tenofovir, tenofovir disoproxil, tenofovir alafenamide fumarate, tenofovir alafenamide hemifumarate, telbivudine and lamivudine.
91. A method of inhibiting the production and/or secretion of HBsAg in an individual infected with HBV comprising administering a therapeutically effective amount of a compound or pharmaceutically acceptable salt of claim 85 to the individual.
92. A method of treating or preventing an HBV infection comprising administering to an individual in need thereof a therapeutically effective amount of a compound or pharmaceutically acceptable salt of claim 85 to the individual.
93. The method of claim 92, wherein the individual is chronically infected with HBV.
94. The method of any one of claims 91, 92 or 93, further comprising administering one or more additional therapeutic agents.
95. The method of claim 94, wherein the one or more additional therapeutic agents are selected from the group consisting of HBV DNA polymerase inhibitors, toll-like receptor 7 modulators, toll-like receptor 8 modulators, Toll-like receptor 7 and 8 modulators, Toll-like receptor 3 modulators, interferon alpha ligands, HBsAg inhibitors, compounds targeting HBcAg, cyclophilin inhibitors, HBV therapeutic vaccines, HBV prophylactic vaccines, HBV viral entry inhibitors, NTCP inhibitors, antisense oligonucleotide targeting viral mRNA, short interfering RNAs (siRNA), HBeAg inhibitors, HBx inhibitors, cccDNA inhibitors, HBV antibodies including HBV antibodies targeting the surface antigens of the hepatitis B virus, thymosin agonists, cytokines, nucleoprotein inhibitors (HBV core or capsid protein inhibitors), stimulators of retinoic acid-inducible gene 1, stimulators of NOD2, recombinant thymosin alpha- 1 and hepatitis B virus replication inhibitors, hepatitis B surface antigen (HBsAg) secretion or assembly inhibitors, IDO inhibitors, KDM5 inhibitors, and combinations thereof.
96. The method of claim 94, wherein the one or more additional therapeutic agents are selected from the group consisting of adefovir (Hepsera®), tenofovir disoproxil fumarate + emtricitabine (Truvada®), tenofovir disoproxil fumarate (Viread®), entecavir (Baraclude®), lamivudine (Epivir-HBV®), tenofovir alafenamide, tenofovir, tenofovir disoproxil, tenofovir alafenamide fumarate, tenofovir alafenamide hemifumarate, telbivudine (Tyzeka®), Clevudine®, emtricitabine (Emtriva®), peginterferon alfa-2b (PEG-Intron®), Multiferon®, interferon alpha lb (Hapgen®), interferon alpha-2b (Intron A®), pegylated interferon alpha-2a (Pegasys®), interferon alfa-nl(Humoferon®), ribavirin, interferon beta-la (Avonex®), Bioferon, Ingaron, Inmutag (Inferon), Algeron, Roferon-A, Oligotide, Zutectra, Shaferon, interferon alfa-2b (Axxo), Alfaferone, interferon alfa-2b, Feron, interferon-alpha 2 (CJ), Bevac, Laferonum, Vipeg, Blauferon- B, Blauferon- A, Intermax Alpha, Realdiron, Lanstion, Pegaferon, PDferon-B, alfainterferona 2b, Kalferon, Pegnano, Feronsure, PegiHep, Optipeg A, Realfa 2B, Reliferon, peginterferon alfa-2b, Reaferon-EC, Proquiferon, Uniferon, Urifron, interferon alfa-2b, Anterferon, Shanferon, MOR-22, interleukin-2 (IL-2), recombinant human interleukin-2 (Shenzhen Neptunus), Layfferon, Ka Shu Ning, Shang Sheng Lei Tai, Intefen, Sinogen, Fukangtai, Alloferon and celmoleukin.
97. The method of claim 94, wherein the one or more additional therapeutic agents are selected from entecavir, adefovir, tenofovir disoproxil fumarate, tenofovir alafenamide, tenofovir, tenofovir disoproxil, tenofovir alafenamide fumarate, tenofovir alafenamide hemifumarate, telbivudine and lamivudine.
98. An article of manufacture comprising a unit dosage of a compound or pharmaceutically acceptable salt of claim 85.
99. A compound or pharmaceutically acceptable salt of claim 85 for use in medical therapy.
100. A compound or pharmaceutically acceptable salt of claim 85 for use in treating or preventing an HBV infection in an individual.
101. The use of a compound or pharmaceutically acceptable salt of claim 85 for the manufacture of a medicament for use in medical therapy.
102. A compound or pharmaceutically acceptable salt of claim 85 for use in inhibiting the production or secretion of HBsAg in vitro.
PCT/US2018/016243 2017-02-02 2018-01-31 Compounds for the treatment of hepatitis b virus infection WO2018144605A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
ES18704797T ES2988184T3 (en) 2017-02-02 2018-01-31 Compounds for the treatment of hepatitis B virus infection
EP18704797.2A EP3577118B1 (en) 2017-02-02 2018-01-31 Compounds for the treatment of hepatitis b virus infection

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201762453982P 2017-02-02 2017-02-02
US62/453,982 2017-02-02
US201762506921P 2017-05-16 2017-05-16
US62/506,921 2017-05-16
US201762536777P 2017-07-25 2017-07-25
US62/536,777 2017-07-25

Publications (1)

Publication Number Publication Date
WO2018144605A1 true WO2018144605A1 (en) 2018-08-09

Family

ID=61193171

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/016243 WO2018144605A1 (en) 2017-02-02 2018-01-31 Compounds for the treatment of hepatitis b virus infection

Country Status (8)

Country Link
US (1) US10442804B2 (en)
EP (1) EP3577118B1 (en)
BR (1) BR102018002164A2 (en)
ES (1) ES2988184T3 (en)
JO (1) JOP20180008A1 (en)
TW (1) TW201840563A (en)
UY (1) UY37581A (en)
WO (1) WO2018144605A1 (en)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020028097A1 (en) * 2018-08-01 2020-02-06 Gilead Sciences, Inc. Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
CN110895281A (en) * 2019-11-19 2020-03-20 苏州市第五人民医院 Reagent kit for detecting antiviral curative effect of interferon on chronic hepatitis B and use thereof
WO2020061435A1 (en) 2018-09-21 2020-03-26 Enanta Pharmaceuticals, Inc. Functionalized heterocycles as antiviral agents
US10729688B2 (en) 2018-03-29 2020-08-04 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
US10738035B2 (en) 2015-05-13 2020-08-11 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
US10934306B2 (en) 2016-03-07 2021-03-02 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
US10952978B2 (en) 2017-08-28 2021-03-23 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
US11058678B2 (en) 2018-01-22 2021-07-13 Enanta Pharmaceuticals, Inc. Substituted heterocycles as antiviral agents
US11198693B2 (en) 2018-11-21 2021-12-14 Enanta Pharmaceuticals, Inc. Functionalized heterocycles as antiviral agents
US11236111B2 (en) 2019-06-03 2022-02-01 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
US11236108B2 (en) 2019-09-17 2022-02-01 Enanta Pharmaceuticals, Inc. Functionalized heterocycles as antiviral agents
CN114591338A (en) * 2022-03-31 2022-06-07 苏州欧康维视生物科技有限公司 Preparation method and application of Syk and VEGFR2 double-target inhibitor
US11472808B2 (en) 2019-06-04 2022-10-18 Enanta Pharmaceuticals, Inc. Substituted pyrrolo[1,2-c]pyrimidines as hepatitis B antiviral agents
US11738019B2 (en) 2019-07-11 2023-08-29 Enanta Pharmaceuticals, Inc. Substituted heterocycles as antiviral agents
US11760755B2 (en) 2019-06-04 2023-09-19 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
US11802125B2 (en) 2020-03-16 2023-10-31 Enanta Pharmaceuticals, Inc. Functionalized heterocyclic compounds as antiviral agents

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110066278B (en) 2017-06-01 2021-06-08 广东东阳光药业有限公司 Fused tricyclic compound and application thereof in medicines
CN110862390B (en) 2018-08-28 2023-05-09 广东东阳光药业有限公司 Fused tricyclic compounds and application thereof in medicines
EP3856740A4 (en) 2018-09-30 2021-12-15 Sunshine Lake Pharma Co., Ltd. Fused tetracyclic compounds and uses thereof in medicine
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
JP2022508953A (en) * 2018-10-22 2022-01-19 アッセンブリー バイオサイエンシズ，インコーポレイテッド A 5-membered heteroarylcarboxamide compound for the treatment of HBV
US11884672B2 (en) * 2019-05-14 2024-01-30 Vertex Pharmaceuticals Incorporated Modulators of alpha-1 antitrypsin
WO2021016543A1 (en) * 2019-07-25 2021-01-28 Romark Laboratories L.C. Antiviral combinations of thiazolide compounds

Citations (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080234251A1 (en) 2005-08-19 2008-09-25 Array Biopharma Inc. 8-Substituted Benzoazepines as Toll-Like Receptor Modulators
US20080306050A1 (en) 2005-08-19 2008-12-11 Array Biopharma Inc. Aminodiazepines as Toll-Like Receptor Modulators
US20090047249A1 (en) 2007-06-29 2009-02-19 Micheal Graupe Modulators of toll-like receptor 7
US20100015178A1 (en) 2008-07-08 2010-01-21 Combs Andrew P 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
US20100029585A1 (en) 2008-08-01 2010-02-04 Howbert J Jeffry Toll-like receptor agonist formulations and their use
US20100143301A1 (en) 2008-12-09 2010-06-10 Gilead Sciences, Inc. Modulators of toll-like receptors
US20110092485A1 (en) 2009-08-18 2011-04-21 Ventirx Pharmaceuticals, Inc. Substituted benzoazepines as toll-like receptor modulators
US20110098248A1 (en) 2009-10-22 2011-04-28 Gilead Sciences, Inc. Modulators of toll-like receptors
US20110118235A1 (en) 2009-08-18 2011-05-19 Ventirx Pharmaceuticals, Inc. Substituted benzoazepines as toll-like receptor modulators
US20120082658A1 (en) 2010-10-01 2012-04-05 Ventirx Pharmaceuticals, Inc. Methods for the Treatment of Allergic Diseases
US20120219615A1 (en) 2010-10-01 2012-08-30 The Trustees Of The University Of Pennsylvania Therapeutic Use of a TLR Agonist and Combination Therapy
US20130079327A1 (en) 2010-05-31 2013-03-28 Shingo Yamamoto Purinone derivative
US8513184B2 (en) 2010-12-10 2013-08-20 Gilead Sciences, Inc. Macrocyclic inhibitors of flaviviridae viruses
US20130251673A1 (en) 2011-12-21 2013-09-26 Novira Therapeutics, Inc. Hepatitis b antiviral agents
US20130267517A1 (en) 2012-03-31 2013-10-10 Hoffmann-La Roche Inc. Novel 4-methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
US20130344029A1 (en) 2012-06-08 2013-12-26 Selcia Ltd. Macrocyclic inhibitors of flaviviridae viruses
US20130344030A1 (en) 2012-06-08 2013-12-26 Selcia Ltd. Macrocyclic inhibitors of flaviviridae viruses
US20140030221A1 (en) 2012-06-08 2014-01-30 Selcia Ltd. Macrocyclic inhibitors of flaviviridae viruses
US20140045849A1 (en) 2011-04-08 2014-02-13 David McGowan Pyrimidine derivatives for the treatment of viral infections
WO2014023813A1 (en) 2012-08-10 2014-02-13 Janssen R&D Ireland Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
WO2014033176A1 (en) 2012-08-28 2014-03-06 Janssen R&D Ireland Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
WO2014033167A1 (en) 2012-08-28 2014-03-06 Janssen R&D Ireland Fused bicyclic sulfamoyl derivatives and the use thereof as medicaments for the treatment of hepatitis b
US20140066432A1 (en) 2011-01-12 2014-03-06 James Jeffry Howbert Substituted Benzoazepines As Toll-Like Receptor Modulators
WO2014037480A1 (en) 2012-09-10 2014-03-13 F. Hoffmann-La Roche Ag 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
US20140073642A1 (en) 2011-05-18 2014-03-13 Janssen R&D Ireland Quinazoline derivatives for the treatment of viral infections and further diseases
US20140088085A1 (en) 2011-01-12 2014-03-27 Array Biopharma, Inc Substituted Benzoazepines As Toll-Like Receptor Modulators
WO2014056953A1 (en) 2012-10-10 2014-04-17 Janssen R&D Ireland Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
US8722054B2 (en) 2011-02-12 2014-05-13 Globeimmune, Inc. Compositions and methods for the treatment or prevention of hepatitis B virus infection
WO2014076221A1 (en) 2012-11-16 2014-05-22 Janssen R&D Ireland Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections
US20140171432A1 (en) 2012-12-19 2014-06-19 Quanticel Pharmaceuticals, Inc. Histone demethylase inhibitors
US20140194469A1 (en) 2012-12-06 2014-07-10 Quanticel Pharmaceuticals, Inc. Histone demethylase inhibitors
US20140213591A1 (en) 2012-12-21 2014-07-31 Quanticel Pharmaceuticals, Inc. Histone demethylase inhibitors
WO2014128189A1 (en) 2013-02-21 2014-08-28 Janssen R&D Ireland 2-aminopyrimidine derivatives for the treatment of viral infections
WO2014131847A1 (en) 2013-02-28 2014-09-04 Janssen R&D Ireland Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
US20140275092A1 (en) 2013-03-13 2014-09-18 Constellation Pharmaceuticals, Inc. Pyrazolo compounds and uses thereof
US20140275167A1 (en) 2013-03-12 2014-09-18 Novira Therapeutics, Inc. Hepatitis b antiviral agents
US20140275084A1 (en) 2013-03-14 2014-09-18 Quanticel Pharmaceuticals, Inc. Histone demethylase inhibitors
WO2014164708A1 (en) 2013-03-12 2014-10-09 Quanticel Pharmaceuticals, Inc. Histone dementhylase inhibitors
US20140330015A1 (en) 2011-11-29 2014-11-06 Ono Pharmaceutical Co., Ltd Purinone derivative hydrochloride
US20140343032A1 (en) 2013-05-17 2014-11-20 Hoffmann-La Roche Inc. Novel 6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
US20140350031A1 (en) 2012-02-08 2014-11-27 Janssen R&D Ireland Piperidino-pyrimidine derivatives for the treatment of viral infections
US20140371195A1 (en) 2012-10-02 2014-12-18 Epitherapeutics Aps Inhibitors of histone demethylases
US20140371214A1 (en) 2013-02-27 2014-12-18 Epitherapeutics Aps Inhibitors of histone demethylases
WO2015113990A1 (en) * 2014-01-30 2015-08-06 F. Hoffmann-La Roche Ag Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis b virus infection
US20160039808A1 (en) 2013-03-15 2016-02-11 Quanticel Pharmaceuticals, Inc. Histone demethylase inhibitors
US20160102096A1 (en) 2014-08-27 2016-04-14 Epitherapeutics Aps Compounds and methods for inhibiting histone demethylases
WO2016057924A1 (en) 2014-10-10 2016-04-14 Genentech, Inc. Pyrrolidine amide compounds as histone demethylase inhibitors
WO2016071215A1 (en) * 2014-11-03 2016-05-12 F. Hoffmann-La Roche Ag Novel 6,7-dihydrobenzo[a]quinolizin-2-one derivatives for the treatment and prophylaxis of hepatitis b virus infection
WO2017017042A1 (en) * 2015-07-27 2017-02-02 F. Hoffmann-La Roche Ag Novel tetracyclic 4-oxo-pyridine-3-carboxylic acid derivatives for the treatment and prophylaxis of hepatitis b virus infection
WO2017140821A1 (en) * 2016-02-19 2017-08-24 Novartis Ag Tetracyclic pyridone compounds as antivirals
WO2017205115A1 (en) * 2016-05-27 2017-11-30 Gilead Sciences, Inc. Compounds for the treatment of hepatitis b virus infection
WO2018022282A1 (en) * 2016-07-29 2018-02-01 Newave Pharmaceutical Inc. Novel therapeutic agents for the treatment of hbv infection

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2016014728A (en) 2014-05-13 2017-03-23 Hoffmann La Roche Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis b virus infection.
WO2016012470A1 (en) 2014-07-25 2016-01-28 F. Hoffmann-La Roche Ag New amorphous and crystalline forms of (3s)-4-[[(4r)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-1, 4-dihydropyrimidin-6-yl]methyl]morpholine-3-carboxylic acid
EP3180319B1 (en) 2014-08-14 2018-10-03 F.Hoffmann-La Roche Ag Novel pyridazones and triazinones for the treatment and prophylaxis of hepatitis b virus infection
US9676793B2 (en) 2014-12-23 2017-06-13 Hoffmann-Laroche Inc. Co-crystals of 5-amino-2-oxothiazolo[4,5-d]pyrimidin-3(2H)-yl-5-hydroxymethyl tetrahydrofuran-3-yl acetate and methods for preparing and using the same
AR103222A1 (en) 2014-12-23 2017-04-26 Hoffmann La Roche PROCEDURE FOR THE PREPARATION OF ANALOGS OF 4-PHENYL-5-ALCOXICARBONIL-2-THIAZOL-2-IL-1,4-DIHYDROPIRIMIDINE
JP6506845B2 (en) 2014-12-30 2019-04-24 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Novel tetrahydropyridopyrimidines and tetrahydropyridopyridines for the treatment and prevention of hepatitis B virus infection
JP2018504891A (en) 2014-12-31 2018-02-22 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ A novel high-throughput method for quantifying HBV cccDNA from cell lysates by real-time PCR
MA41338B1 (en) 2015-01-16 2019-07-31 Hoffmann La Roche Pyrazine compounds for the treatment of infectious diseases
JP6435054B2 (en) 2015-02-11 2018-12-05 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Novel 2-oxo-6,7-dihydrobenzo [a] quinolidine-3-carboxylic acid derivatives for the treatment and prevention of hepatitis B virus infection
PE20171648A1 (en) 2015-03-16 2017-11-13 Hoffmann La Roche COMBINED TREATMENT WITH A TLR7 AGONIST AND AN INHIBITOR OF THE HBV CAPSIDE ASSEMBLY
WO2016177655A1 (en) 2015-05-04 2016-11-10 F. Hoffmann-La Roche Ag Tetrahydropyridopyrimidines and tetrahydropyridopyridines as inhibitors of hbsag (hbv surface antigen) and hbv dna production for the treatment of hepatitis b virus infections
WO2016202721A1 (en) 2015-06-16 2016-12-22 F. Hoffmann-La Roche Ag Salts of (s)-4-[(r)-6-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-3,6- dihydro-pyrimidin-4-ylmethyl]-morpholine-3-carboxylic acid, salt former and methods for preparing and using the same
EP3325477B1 (en) 2015-07-21 2019-05-01 H. Hoffnabb-La Roche Ag Novel tricyclic 4-pyridone-3-carboxylic acid derivatives for the treatment and prophylaxis of hepatitis b virus infection
WO2017016960A1 (en) 2015-07-24 2017-02-02 F. Hoffmann-La Roche Ag Process for the preparation of (6s)-6-alkyl-10-alkoxy-9-(substituted alkoxy)-2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid analogues
WO2017016921A1 (en) 2015-07-24 2017-02-02 F. Hoffmann-La Roche Ag New crystalline forms of (6s)-10-methoxy-6-isopropyl-9-(3-methoxypropoxy)-2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid
CN107835813B (en) 2015-07-28 2020-04-24 豪夫迈·罗氏有限公司 6, 7-dihydropyrido [2,1-a ] phthalazin-2-ones for the treatment and prevention of hepatitis b virus infections
WO2017064156A1 (en) 2015-10-16 2017-04-20 F. Hoffmann-La Roche Ag Novel 6-fused and 2-heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
CA2999944A1 (en) 2015-11-03 2017-05-11 F.Hoffmann-La Roche Ag Combination therapy of an hbv capsid assembly inhibitor and an interferon
WO2017102648A1 (en) 2015-12-15 2017-06-22 F. Hoffmann-La Roche Ag Combination therapy of an hbsag inhibitor and a nucleos(t)ide analogue
WO2017108630A1 (en) 2015-12-21 2017-06-29 F. Hoffmann-La Roche Ag Combination therapy of an hbsag inhibitor and an hbv capsid assembly inhibitor
WO2017114812A1 (en) 2015-12-29 2017-07-06 F. Hoffmann-La Roche Ag Combination therapy of an hbsag inhibitor and an interferon
WO2017216686A1 (en) 2016-06-16 2017-12-21 Novartis Ag 8,9-fused 2-oxo-6,7-dihydropyrido-isoquinoline compounds as antivirals
WO2017216685A1 (en) 2016-06-16 2017-12-21 Novartis Ag Pentacyclic pyridone compounds as antivirals
WO2018019297A1 (en) 2016-07-29 2018-02-01 银杏树药业(苏州)有限公司 Isoquinolinone compound and use thereof in preparation of antiviral drugs

Patent Citations (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080234251A1 (en) 2005-08-19 2008-09-25 Array Biopharma Inc. 8-Substituted Benzoazepines as Toll-Like Receptor Modulators
US20080306050A1 (en) 2005-08-19 2008-12-11 Array Biopharma Inc. Aminodiazepines as Toll-Like Receptor Modulators
US20090047249A1 (en) 2007-06-29 2009-02-19 Micheal Graupe Modulators of toll-like receptor 7
US20100015178A1 (en) 2008-07-08 2010-01-21 Combs Andrew P 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
US20100029585A1 (en) 2008-08-01 2010-02-04 Howbert J Jeffry Toll-like receptor agonist formulations and their use
US20100143301A1 (en) 2008-12-09 2010-06-10 Gilead Sciences, Inc. Modulators of toll-like receptors
US20110118235A1 (en) 2009-08-18 2011-05-19 Ventirx Pharmaceuticals, Inc. Substituted benzoazepines as toll-like receptor modulators
US20110092485A1 (en) 2009-08-18 2011-04-21 Ventirx Pharmaceuticals, Inc. Substituted benzoazepines as toll-like receptor modulators
US20110098248A1 (en) 2009-10-22 2011-04-28 Gilead Sciences, Inc. Modulators of toll-like receptors
US20130079327A1 (en) 2010-05-31 2013-03-28 Shingo Yamamoto Purinone derivative
US20130217880A1 (en) 2010-05-31 2013-08-22 Ono Pharmaceutical Co., Ltd. Purinone derivative
US20120082658A1 (en) 2010-10-01 2012-04-05 Ventirx Pharmaceuticals, Inc. Methods for the Treatment of Allergic Diseases
US20120219615A1 (en) 2010-10-01 2012-08-30 The Trustees Of The University Of Pennsylvania Therapeutic Use of a TLR Agonist and Combination Therapy
US8513184B2 (en) 2010-12-10 2013-08-20 Gilead Sciences, Inc. Macrocyclic inhibitors of flaviviridae viruses
US20140088085A1 (en) 2011-01-12 2014-03-27 Array Biopharma, Inc Substituted Benzoazepines As Toll-Like Receptor Modulators
US20140066432A1 (en) 2011-01-12 2014-03-06 James Jeffry Howbert Substituted Benzoazepines As Toll-Like Receptor Modulators
US8722054B2 (en) 2011-02-12 2014-05-13 Globeimmune, Inc. Compositions and methods for the treatment or prevention of hepatitis B virus infection
US20140045849A1 (en) 2011-04-08 2014-02-13 David McGowan Pyrimidine derivatives for the treatment of viral infections
US20140073642A1 (en) 2011-05-18 2014-03-13 Janssen R&D Ireland Quinazoline derivatives for the treatment of viral infections and further diseases
US20140330015A1 (en) 2011-11-29 2014-11-06 Ono Pharmaceutical Co., Ltd Purinone derivative hydrochloride
US20130251673A1 (en) 2011-12-21 2013-09-26 Novira Therapeutics, Inc. Hepatitis b antiviral agents
US20140350031A1 (en) 2012-02-08 2014-11-27 Janssen R&D Ireland Piperidino-pyrimidine derivatives for the treatment of viral infections
US20130267517A1 (en) 2012-03-31 2013-10-10 Hoffmann-La Roche Inc. Novel 4-methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
US20130344030A1 (en) 2012-06-08 2013-12-26 Selcia Ltd. Macrocyclic inhibitors of flaviviridae viruses
US20130344029A1 (en) 2012-06-08 2013-12-26 Selcia Ltd. Macrocyclic inhibitors of flaviviridae viruses
US20140030221A1 (en) 2012-06-08 2014-01-30 Selcia Ltd. Macrocyclic inhibitors of flaviviridae viruses
WO2014023813A1 (en) 2012-08-10 2014-02-13 Janssen R&D Ireland Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
WO2014033176A1 (en) 2012-08-28 2014-03-06 Janssen R&D Ireland Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
WO2014033167A1 (en) 2012-08-28 2014-03-06 Janssen R&D Ireland Fused bicyclic sulfamoyl derivatives and the use thereof as medicaments for the treatment of hepatitis b
WO2014033170A1 (en) 2012-08-28 2014-03-06 Janssen R&D Ireland Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
WO2014037480A1 (en) 2012-09-10 2014-03-13 F. Hoffmann-La Roche Ag 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
US20140371195A1 (en) 2012-10-02 2014-12-18 Epitherapeutics Aps Inhibitors of histone demethylases
WO2014056953A1 (en) 2012-10-10 2014-04-17 Janssen R&D Ireland Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
WO2014076221A1 (en) 2012-11-16 2014-05-22 Janssen R&D Ireland Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections
US20140194469A1 (en) 2012-12-06 2014-07-10 Quanticel Pharmaceuticals, Inc. Histone demethylase inhibitors
US20140171432A1 (en) 2012-12-19 2014-06-19 Quanticel Pharmaceuticals, Inc. Histone demethylase inhibitors
US20140213591A1 (en) 2012-12-21 2014-07-31 Quanticel Pharmaceuticals, Inc. Histone demethylase inhibitors
WO2014128189A1 (en) 2013-02-21 2014-08-28 Janssen R&D Ireland 2-aminopyrimidine derivatives for the treatment of viral infections
US20140371214A1 (en) 2013-02-27 2014-12-18 Epitherapeutics Aps Inhibitors of histone demethylases
WO2014131847A1 (en) 2013-02-28 2014-09-04 Janssen R&D Ireland Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
US20140275167A1 (en) 2013-03-12 2014-09-18 Novira Therapeutics, Inc. Hepatitis b antiviral agents
WO2014164708A1 (en) 2013-03-12 2014-10-09 Quanticel Pharmaceuticals, Inc. Histone dementhylase inhibitors
US20140275092A1 (en) 2013-03-13 2014-09-18 Constellation Pharmaceuticals, Inc. Pyrazolo compounds and uses thereof
US20140275084A1 (en) 2013-03-14 2014-09-18 Quanticel Pharmaceuticals, Inc. Histone demethylase inhibitors
US20160039808A1 (en) 2013-03-15 2016-02-11 Quanticel Pharmaceuticals, Inc. Histone demethylase inhibitors
US20140343032A1 (en) 2013-05-17 2014-11-20 Hoffmann-La Roche Inc. Novel 6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
WO2015113990A1 (en) * 2014-01-30 2015-08-06 F. Hoffmann-La Roche Ag Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis b virus infection
US20160102096A1 (en) 2014-08-27 2016-04-14 Epitherapeutics Aps Compounds and methods for inhibiting histone demethylases
WO2016057924A1 (en) 2014-10-10 2016-04-14 Genentech, Inc. Pyrrolidine amide compounds as histone demethylase inhibitors
WO2016071215A1 (en) * 2014-11-03 2016-05-12 F. Hoffmann-La Roche Ag Novel 6,7-dihydrobenzo[a]quinolizin-2-one derivatives for the treatment and prophylaxis of hepatitis b virus infection
WO2017017042A1 (en) * 2015-07-27 2017-02-02 F. Hoffmann-La Roche Ag Novel tetracyclic 4-oxo-pyridine-3-carboxylic acid derivatives for the treatment and prophylaxis of hepatitis b virus infection
WO2017140821A1 (en) * 2016-02-19 2017-08-24 Novartis Ag Tetracyclic pyridone compounds as antivirals
WO2017205115A1 (en) * 2016-05-27 2017-11-30 Gilead Sciences, Inc. Compounds for the treatment of hepatitis b virus infection
WO2018022282A1 (en) * 2016-07-29 2018-02-01 Newave Pharmaceutical Inc. Novel therapeutic agents for the treatment of hbv infection

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
"Remington: The Science and Practice of Pharmacy", 2006, LIPPINCOTT WILIAMS AND WILKINS
FOSTER: "Deuterium Isotope Effects in Studies of Drug Metabolism", TRENDS PHARMACOL. SCI., vol. 5, no. 12, 1984, pages 524 - 527, XP025943358, DOI: doi:10.1016/0165-6147(84)90534-0
OP DEN BROUW ET AL., IMMUNOLOGY, vol. 126, 2009, pages 280 - 89
ROWE ET AL.: "Handbook of Pharmaceutical Excipients", 2009, AMERICAN PHARMACISTS ASSOCIATION
SMITH: "March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure", 2013, WILEY-INTERSCIENCE
T. W. GREENE; P. G. M. WUTS: "Protective Groups in Organic Synthesis", 2006, WILEY
WIELAND, S.F.; F.V. CHISARI, J. VIROL., vol. 79, 2005, pages 9369 - 80
WOLTMAN ET AL., PLOS ONE, vol. 6, 2011, pages e15324

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10738035B2 (en) 2015-05-13 2020-08-11 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
US12054493B2 (en) 2016-03-07 2024-08-06 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
US10934306B2 (en) 2016-03-07 2021-03-02 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
US12011425B2 (en) 2017-08-28 2024-06-18 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
US10952978B2 (en) 2017-08-28 2021-03-23 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
US11596611B2 (en) 2017-08-28 2023-03-07 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
US11058678B2 (en) 2018-01-22 2021-07-13 Enanta Pharmaceuticals, Inc. Substituted heterocycles as antiviral agents
US10729688B2 (en) 2018-03-29 2020-08-04 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
WO2020028097A1 (en) * 2018-08-01 2020-02-06 Gilead Sciences, Inc. Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
US10865211B2 (en) 2018-09-21 2020-12-15 Enanta Pharmaceuticals, Inc. Functionalized heterocycles as antiviral agents
WO2020061435A1 (en) 2018-09-21 2020-03-26 Enanta Pharmaceuticals, Inc. Functionalized heterocycles as antiviral agents
US11377450B2 (en) 2018-09-21 2022-07-05 Enanta Pharmaceuticals, Inc. Functionalized heterocycles as antiviral agents
US11198693B2 (en) 2018-11-21 2021-12-14 Enanta Pharmaceuticals, Inc. Functionalized heterocycles as antiviral agents
US12264159B2 (en) 2018-11-21 2025-04-01 Enanta Pharmaceuticals, Inc. Functionalized heterocycles as antiviral agents
US11891393B2 (en) 2018-11-21 2024-02-06 Enanta Pharmaceuticals, Inc. Functionalized heterocycles as antiviral agents
US11236111B2 (en) 2019-06-03 2022-02-01 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
US11760755B2 (en) 2019-06-04 2023-09-19 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
US11472808B2 (en) 2019-06-04 2022-10-18 Enanta Pharmaceuticals, Inc. Substituted pyrrolo[1,2-c]pyrimidines as hepatitis B antiviral agents
US11738019B2 (en) 2019-07-11 2023-08-29 Enanta Pharmaceuticals, Inc. Substituted heterocycles as antiviral agents
US11236108B2 (en) 2019-09-17 2022-02-01 Enanta Pharmaceuticals, Inc. Functionalized heterocycles as antiviral agents
CN110895281A (en) * 2019-11-19 2020-03-20 苏州市第五人民医院 Reagent kit for detecting antiviral curative effect of interferon on chronic hepatitis B and use thereof
US11802125B2 (en) 2020-03-16 2023-10-31 Enanta Pharmaceuticals, Inc. Functionalized heterocyclic compounds as antiviral agents
CN114591338B (en) * 2022-03-31 2023-05-09 苏州欧康维视生物科技有限公司 Preparation method and application of Syk and VEGFR2 double-target inhibitor
CN114591338A (en) * 2022-03-31 2022-06-07 苏州欧康维视生物科技有限公司 Preparation method and application of Syk and VEGFR2 double-target inhibitor

Also Published As

Publication number Publication date
EP3577118C0 (en) 2024-09-04
ES2988184T3 (en) 2024-11-19
US10442804B2 (en) 2019-10-15
EP3577118A1 (en) 2019-12-11
US20180251460A1 (en) 2018-09-06
UY37581A (en) 2018-08-31
JOP20180008A1 (en) 2019-01-30
TW201840563A (en) 2018-11-16
BR102018002164A2 (en) 2018-10-30
EP3577118B1 (en) 2024-09-04

Similar Documents

Publication Publication Date Title
EP3577118B1 (en) Compounds for the treatment of hepatitis b virus infection
WO2017205115A1 (en) Compounds for the treatment of hepatitis b virus infection
EP3534903B1 (en) Substituted pyridinone-containing tricyclic compounds, and methods using same
US8987273B2 (en) Substituted imidazo[1,2-B]pyridazines
JP2019524684A (en) Diazepinone derivatives and their use in the treatment of hepatitis B infection
JP7337086B2 (en) STING MODULATOR COMPOUNDS HAVING SULFAMATE LINKS AND METHODS OF MAKING AND USING
JP2022501316A (en) PRMT5 inhibitor
JP6916796B2 (en) A new 6-membered heteroaromatically substituted cyanoindoline derivative as an NIK inhibitor
WO2011050284A1 (en) Pyrazolylpyridine antiviral agents
TWI826535B (en) Cyclic dinucleotide analogs, pharmaceutical compositions and applications thereof
CA3230542A1 (en) Novel ras inhibitors
CA3202957A1 (en) Substituted pyridotriazine compounds and uses thereof
CN116745292A (en) Substituted pyridotriazine compounds and uses thereof
JP2011529085A (en) Antiviral compounds
US20230108906A1 (en) Substituted bicyclic and tricyclic ureas and amides, analogues thereof, and methods using same
US20230062119A1 (en) Use of biomarkers in identifying patients that will be responsive to treatment with a prmt5 inhibitor
HK40017226B (en) Compounds for the treatment of hepatitis b virus infection
HK40017226A (en) Compounds for the treatment of hepatitis b virus infection
CN117343064B (en) Preparation and application of a pyrimidine derivative with antiviral effect
CN113583020B (en) JAK2 inhibitor and application
US20230108408A1 (en) Oxalamide substituted heterocyclic compounds as modulators of the aryl hydrocarbon receptor (ahr)
AU2023295387A1 (en) 1,8-naphthyridin-2-one heterobifunctional bcl6 degraders
TW201706279A (en) Substituted phosphoramidate derivative, method for preparing thereof, and use thereof definitions of substituent groups in general formula (I) are the same as those defined in the specification
TW201708238A (en) Phosphamide derivative substituted by aryl group and medical applications thereof including a use in manufacturing drugs for treating virus infectious diseases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18704797

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018704797

Country of ref document: EP

Effective date: 20190902